<SEC-DOCUMENT>0001564590-22-018775.txt : 20220509
<SEC-HEADER>0001564590-22-018775.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509130056
ACCESSION NUMBER:		0001564590-22-018775
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22904170

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cbio-10q_20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-08T17:25:16.2712857+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : b481765bcc1e4c2bb9d0981034513db3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cbio="http://www.catalystbiosciences.com/20220331" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
cbio-10q_20220331.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001124105_20220101_20220331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001124105_20220101_20220331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001124105_20220101_20220331">0001124105</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001124105_20220101_20220331">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000248" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331">2023-04-30</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001124105_20220331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001124105_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:PreferredStockValue" contextRef="C_0001124105_20220331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:PreferredStockValue" contextRef="C_0001124105_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20210101_20211231">P7Y5M15D</ix:nonNumeric>
			<ix:nonNumeric id="F_000277" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20220101_20220331">P8Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000280" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">P6Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000281" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P6Y1M6D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="cbio-20220331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001124105_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20220429">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-04-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cbioSegment">
				<xbrli:measure>cbio:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-09</xbrli:startDate>
					<xbrli:endDate>2021-06-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioMosaicBiosciencesIncMember_srtRangeAxis_srtMaximumMember_20200508_20200508">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-08</xbrli:startDate>
					<xbrli:endDate>2020-05-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:DalcinonacogAlfaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IntegrityBioMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:GMPMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20211101_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-01</xbrli:startDate>
					<xbrli:endDate>2021-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cbioEmployee">
				<xbrli:measure>cbio:Employee</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000218 F_000219 F_000222 F_000223"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000224 F_000225"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000002" fromRefs="F_000290 F_000291"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001124105_20220101_20220331">10-Q</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:DocumentQuarterlyReport" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001124105_20220101_20220331" format="ixt:datemonthdayyearen">March 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001124105_20220101_20220331">2022</ix:nonNumeric></ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentTransitionReport" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000015" name="dei:EntityFileNumber" contextRef="C_0001124105_20220101_20220331">000-51173</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001124105_20220101_20220331">Catalyst Biosciences, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001124105_20220101_20220331">56-2020050</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation or Organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityAddressAddressLine1" contextRef="C_0001124105_20220101_20220331">611 Gateway Blvd.</ix:nonNumeric>, <ix:nonNumeric id="F_000018" name="dei:EntityAddressAddressLine2" contextRef="C_0001124105_20220101_20220331">Suite 710</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityAddressCityOrTown" contextRef="C_0001124105_20220101_20220331">South San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000020" name="dei:EntityAddressStateOrProvince" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressPostalZipCode" contextRef="C_0001124105_20220101_20220331">94080</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000022" name="dei:CityAreaCode" contextRef="C_0001124105_20220101_20220331">650</ix:nonNumeric>) <ix:nonNumeric id="F_000023" name="dei:LocalPhoneNumber" contextRef="C_0001124105_20220101_20220331">871-0761</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s Telephone Number, Including Area Code) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered or to be registered pursuant to Section 12(b) of the<span style="letter-spacing:-0.6pt;"> </span>Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title <span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:-0.1pt;">l</span>ass</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trad<span style="letter-spacing:-0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g <span style="letter-spacing:0.05pt;">Sy</span><span style="letter-spacing:-0.1pt;">m</span><span style="letter-spacing:0.05pt;">bo</span>l<span style="letter-spacing:0.05pt;">(</span><span style="letter-spacing:-0.05pt;">s</span>)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Na<span style="letter-spacing:-0.1pt;">m</span>e of<span style="letter-spacing:0.05pt;"> </span>ea<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>exch<span style="letter-spacing:-0.05pt;">an</span>ge<span style="letter-spacing:-0.05pt;"> </span>on <span style="letter-spacing:-0.05pt;">w</span><span style="letter-spacing:0.05pt;">h</span>ich<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gistered</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:Security12bTitle" contextRef="C_0001124105_20220101_20220331">Common Stock</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001124105_20220101_20220331">CBIO</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:SecurityExchangeName" contextRef="C_0001124105_20220101_20220331">NASDAQ</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000013" name="dei:EntityCurrentReportingStatus" contextRef="C_0001124105_20220101_20220331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000024" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001124105_20220101_20220331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:23%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:22.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="bottom" style="width:23%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:22.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="top" style="width:23%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;">&#160;</p></td>
<td valign="top" style="width:22.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="font-size:9pt;">&#160;</span><span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityShellCompany" contextRef="C_0001124105_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 29, 2022, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="U_xbrlishares" id="F_000012" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001124105_20220429" decimals="INF" format="ixt:numdotdecimal">31,477,053</ix:nonFraction>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:7.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page&#160;No.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="5" valign="bottom" style="width:93.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I_FINANCIAL_INFORMATION"><span style="text-decoration:underline;">PART I. FINANCIAL INFORMATION</span></a></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements:</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets as of M</span><span style="text-decoration:underline;">arch 31</span><span style="text-decoration:underline;">, 2022 (unaudited) and December 31, 202</span></a><span style="text-decoration:underline;">1</span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations </span><span style="text-decoration:underline;">and Comprehensive Loss</span><span style="text-decoration:underline;"> for the three months ended M</span><span style="text-decoration:underline;">arch 31</span><span style="text-decoration:underline;">, 2022 and 2021 (unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENT_STOCKHO"><span style="text-decoration:underline;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the </span><span style="text-decoration:underline;">three </span><span style="text-decoration:underline;">months ended M</span><span style="text-decoration:underline;">arch </span><span style="text-decoration:underline;">31, 2022 </span><span style="text-decoration:underline;">and 2021</span><span style="text-decoration:underline;"> (unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows for the t</span><span style="text-decoration:underline;">hree </span><span style="text-decoration:underline;">months ended M</span><span style="text-decoration:underline;">arch</span><span style="text-decoration:underline;"> 31, 2022 and 2021 (unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:underline;">Notes to the Unaudited Interim Condensed Consolidated Financial Statements</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="5" valign="bottom" style="width:93.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II_OR_INFORMATION"><span style="text-decoration:underline;">PART II. OTHER INFORMATION</span></a></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="5" valign="bottom" style="width:93.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXHIBIT_INDEX"><span style="text-decoration:underline;">Exhibit Index</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:8.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:85.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="bottom" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:6.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I. FINANCIAL INFORMATION </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM 1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_FINANCIAL_STATEMENTS"><span style="font-weight:normal;"></span>FINANCIAL STATEMENTS </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">Condensed Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:ShortTermInvestments" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001124105_20220331" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AssetsCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AssetsCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets, noncurrent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001124105_20220331" decimals="-3" scale="3">472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001124105_20220331" decimals="-3" scale="3">857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001124105_20211231" decimals="-3" scale="3">970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:Assets" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:Assets" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,706</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, noncurrent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:Liabilities" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:Liabilities" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and Contingencies (Note 9)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000061">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000062">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000075" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001124105_20220331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000076" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001124105_20211231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000077" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001124105_20220331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001124105_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001124105_20220331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001124105_20211231" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000063">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000064">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000083" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_20220331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000084" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_20211231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal">31,477,053</ix:nonFraction></ix:nonFraction> and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">31,409,707</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2022 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:CommonStockValue" contextRef="C_0001124105_20220331" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:CommonStockValue" contextRef="C_0001124105_20211231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">444,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">443,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">417,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">402,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT">Condensed Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331" decimals="-3" scale="3">794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20220101_20220331" decimals="-3" scale="3">798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:OperatingExpenses" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OperatingExpenses" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">23,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stockholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000108" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20220101_20220331" decimals="2" sign="-">0.46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000109" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20210101_20210331" decimals="2" sign="-">0.79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used to compute net loss per share attributable to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; common stockholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000110" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20220101_20220331" decimals="0" format="ixt:numdotdecimal">31,456,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000111" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20210101_20210331" decimals="0" format="ixt:numdotdecimal">28,385,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENT_STOCKHO">Condensed Consolidated Statements of Stockholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred&#160;Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">31,409,707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">443,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">402,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000117" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">32,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" scale="3">515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from stock grants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000120" name="cbio:StockIssuedDuringPeriodFromStockGrantsShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">34,662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="cbio:StockIssuedDuringPeriodFromStockGrantsValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="cbio:StockIssuedDuringPeriodFromStockGrantsValue" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">31,477,053</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">444,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">417,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred&#160;Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000130" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">22,097,820</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">390,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">10,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000139" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">9,185,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">49,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">49,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from stock grants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000143" name="cbio:StockIssuedDuringPeriodFromStockGrantsShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">38,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="cbio:StockIssuedDuringPeriodFromStockGrantsValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">182</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="cbio:StockIssuedDuringPeriodFromStockGrantsValue" contextRef="C_0001124105_20210101_20210331" decimals="-3" scale="3">182</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000148" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">31,331,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">441,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">337,199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">104,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F">Condensed Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:ProfitLoss" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:ProfitLoss" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:ShareBasedCompensation" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:ShareBasedCompensation" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001124105_20210101_20210331" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bad debt expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,054</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability and right-of-use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" contextRef="C_0001124105_20210101_20210331" decimals="-3" scale="3">26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" scale="3">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" scale="3">651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">24,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">49,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from stock grants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="cbio:ProceedsFromIssuanceOfCommonStockFromStockGrants" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="cbio:ProceedsFromIssuanceOfCommonStockFromStockGrants" contextRef="C_0001124105_20210101_20210331" decimals="-3" scale="3">182</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">49,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">52,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of the period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">83,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">Notes to Condensed Consolidated Financial Statements (Unaudited)</p><ix:nonNumeric id="F_000191" name="cbio:NatureOfOperationsAndLiquidityTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Nature of Operations and Liquidity</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a <span style="color:#000000;">biopharmaceutical company with expertise in protease engineering and several protease assets that may address unmet medical needs in disorders of the coagulation and complement systems. The Company is focused on the monetization of its assets and is exploring several strategic alternatives.</span> The Company is located in South San Francisco, California and operates in <ix:nonFraction unitRef="U_cbioSegment" id="F_000214" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001124105_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20220101_20220331" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">14.5</ix:nonFraction> million for the three months ended March 31, 2022 and an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20220331" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">417.2</ix:nonFraction> million as of March 31, 2022. As of March 31, 2022, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20220331" decimals="-5" scale="6">34.8</ix:nonFraction> million of cash and cash equivalents. <span style="color:#000000;">Its primary uses of cash are to fund operating and business development expenses and general and administrative expenditures. The Company believes that its existing cash and cash equivalents as of March 31, 2022 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. The Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the novel coronavirus disease (&#8220;COVID-19&#8221;) pandemic on its business, operations, and cash requirements.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000192" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000192_dcnt_25481d32-7bb6-4bca-b2e7-a12071979c8f">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.05%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Summary of Significant Accounting Policies </p></td></tr></table></div><ix:nonNumeric id="F_000202" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (&#8220;Annual Report&#8221;). </p></ix:nonNumeric><ix:nonNumeric id="F_000203" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000203_dcnt_bdd8ac78-1adb-4b15-867c-2230d5cb8ac9">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022, and the adoption did not have a material impact on its condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">New Accounting Pronouncements Recently Issued But Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;Measurement of Credit Losses on Financial Instruments</span>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000192_dcnt_25481d32-7bb6-4bca-b2e7-a12071979c8f"><ix:continuation id="F_000203_dcnt_bdd8ac78-1adb-4b15-867c-2230d5cb8ac9">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial statements</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000193" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Fair Value Measurements </p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of the fair value hierarchy and the Company&#8217;s fair value methodology, see &#8220;<span style="font-style:italic;">Part II - Item 8 - Financial Statements and Supplementary Data - Note 3</span> &#8211; <span style="font-style:italic;">Summary of Significant Accounting Policies</span>&#8221; in the Company&#8217;s Annual Report. There were no significant changes in these methodologies during the three months ended March 31, 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000204" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000204_cnt_1">The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (<span style="font-style:italic;">in thousands</span>):</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000204_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000000" xml:lang="en-US">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</ix:footnote> </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000001" xml:lang="en-US">Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.</ix:footnote></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p></ix:continuation></ix:nonNumeric><ix:nonNumeric id="F_000194" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000194_dcnt_635bf041-57a6-407d-ac15-054cf4dfc79b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Financial Instruments </p></td></tr></table></div><ix:nonNumeric id="F_000205" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and short-term investments (debt securities) which are classified as available-for-sale debt securities, consisted of the following (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">34,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="C_0001124105_20220101_20220331" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> material realized gains or losses on available-for-sale debt securities for the periods presented. As of March 31, 2022, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001124105_20220331" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> available-for-sale debt securities.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000194_dcnt_635bf041-57a6-407d-ac15-054cf4dfc79b">
</ix:continuation><ix:nonNumeric id="F_000195" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Lease</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<span style="font-style:italic;">e.g.</span>, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through <ix:nonNumeric id="F_000245" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001124105_20220101_20220331" format="ixt:datemonthdayyearen">April 30, 2023</ix:nonNumeric> and there are <ix:nonNumeric id="F_000246" name="cbio:LesseeOperatingLeaseRenewalTermDescription" contextRef="C_0001124105_20220101_20220331">no stated renewal options</ix:nonNumeric>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commenced in April 2022. Under the terms of the sublease agreement, the Company will receive $<ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" contextRef="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331" decimals="-5" scale="6">0.2</ix:nonFraction> million in base lease payments over the term of the sublease, which ends in <span style="-sec-ix-hidden:F_000248">April 2023</span>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, the Company&#8217;s operating lease expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001124105_20220101_20220331" decimals="-5" scale="6">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001124105_20210101_20210331" decimals="-5" scale="6">0.2</ix:nonFraction> million, respectively. <ix:nonNumeric id="F_000206" name="cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000206_cnt_1">The present value assumptions used in calculating the present value of the lease payments were as follows:</ix:nonNumeric></p><ix:continuation id="F_000206_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000251" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001124105_20220331" format="ixt-sec:duryear">1.1</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000252" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001124105_20211231" format="ixt-sec:duryear">1.3</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000253" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001124105_20220331" decimals="3" scale="-2">4.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000254" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001124105_20211231" decimals="3" scale="-2">4.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000207" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of March 31, 2022 were as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining in 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001124105_20220331" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001124105_20220331" decimals="-3" scale="3">44</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001124105_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000208" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases was as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:OperatingLeasePayments" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:OperatingLeasePayments" contextRef="C_0001124105_20210101_20210331" decimals="-3" scale="3">182</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000196" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000196_dcnt_3dbad6f4-1b37-4c4b-83e2-f77ba7676e45">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Stock Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000262" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction> to a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000263" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609" decimals="INF" format="ixt:numdotdecimal">5,300,000</ix:nonFraction> shares. The amendment became effective immediately upon stockholder approval.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000196_dcnt_3dbad6f4-1b37-4c4b-83e2-f77ba7676e45"><ix:nonNumeric id="F_000209" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">2,603,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20211231" decimals="2">7.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000276">7.46</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000265" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001124105_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">879,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000271" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20220101_20220331" decimals="2">0.52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000266" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001124105_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">658,947</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000272" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20220101_20220331" decimals="2">5.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001124105_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">46,173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000273" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20220101_20220331" decimals="2">9.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; March 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000268" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal">2,777,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20220331" decimals="2">5.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000277">8.00</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; March 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000269" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal">1,305,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001124105_20220331" decimals="2">9.42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Valuation Assumptions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000210" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000210_cnt_1">The fair value of employee stock options was estimated using the following weighted-average assumptions:</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000210_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="4" scale="-2">1.87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="4" scale="-2">0.69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000280">6.1</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000281">6.1</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000282" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="4" scale="-2">91.54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000285" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="4" scale="-2">93.83</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of stock options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000286" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="2">0.39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000287" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2">4.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation><ix:nonNumeric id="F_000211" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.06%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized was as follows (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331" decimals="-3" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" scale="3">369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331" decimals="-3" scale="3">387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331" decimals="-3" scale="3">657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000002" xml:lang="en-US">Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to <ix:nonFraction unitRef="U_xbrlishares" id="F_000294" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001124105_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">32,684</ix:nonFraction> shares of common stock issued to certain board members in lieu of their cash compensation.</ix:footnote> </p></td></tr></table></div></ix:nonNumeric>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, <ix:nonFraction unitRef="U_xbrlishares" id="F_000295" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001124105_20220331" decimals="INF" format="ixt:numdotdecimal">2,937,588</ix:nonFraction> shares of common stock were available for future grant.</p></ix:continuation><ix:nonNumeric id="F_000197" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000197_dcnt_a73c5295-9d61-41f7-b8d2-57b9aa467ca7">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Collaborations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mosaic</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a strategic research collaboration with Mosaic Biosciences (&#8220;Mosaic&#8221;) to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company subsequently amended this agreement in December 2018, December 2019 and May 2020.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the as amended Mosaic collaboration agreement, Mosaic is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMosaicBiosciencesIncMember_srtRangeAxis_srtMaximumMember_20200508_20200508" decimals="-5" scale="6">4.0</ix:nonFraction> million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s prior obligations to pay Mosaic a double-digit percentage of funds the Company </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000197_dcnt_a73c5295-9d61-41f7-b8d2-57b9aa467ca7">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.58%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISU Abxis<span style="font-weight:normal;"> </span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&#38;R ISU Abxis Agreement&#8221;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 <span style="color:#000000;">(the &#8220;Original ISU Abxis Agreement&#8221;)</span>. Under the A&#38;R ISU Abxis Agreement, <span style="color:#000000;">ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)</span>. <span style="color:#000000;">The </span>A&#38;R ISU Abxis Agreement <span style="color:#000000;">eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and</span> p<span style="color:#000000;">rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&#38;R </span>ISU Abxis Agreement<span style="color:#000000;">, the Company will also pay up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">19.5</ix:nonFraction> million in milestone payments to ISU Abxis, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="cbio:RegulatoryAndDevelopmentMilestonePayment" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">2.5</ix:nonFraction>&#160;million in regulatory and development milestone payments and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="cbio:CommercialMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">17.0</ix:nonFraction>&#160;million in commercial milestone payments, if the applicable milestones are met. As of March 31, 2022, <ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="cbio:RegulatoryAndDevelopmentMilestonePayment" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="cbio:CommercialMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> milestones have been met.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company and Biogen International GmbH (&#8220;Biogen&#8221;) entered into a License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company performed certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen was solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131" decimals="-5" scale="6">15.0</ix:nonFraction> million in January 2020. The Company was eligible to receive development milestones and sales milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="cbio:DevelopmentAndSalesMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131" decimals="-5" scale="6">340.0</ix:nonFraction> million. In addition, the Company was eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company also received reimbursements for costs associated with the performance of the Research Services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company received written notice from Biogen to terminate the Biogen Agreement which will be effective in May 2022. As a result of the termination, Biogen will no longer have the Exclusive License to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. In March 2022, Biogen returned full rights to CB 2782-PEG.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, the Company recognized <ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> license revenue from the Biogen Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, respectively, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20220101_20220331" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20210331" decimals="-5" scale="6">1.5</ix:nonFraction> million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, respectively, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331" decimals="-5" scale="6">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331" decimals="-5" scale="6">1.4</ix:nonFraction> million of research and development expense was recorded as cost of collaboration revenue related to the Biogen Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="C_0001124105_20220101_20220331" decimals="-5" scale="6">0.2</ix:nonFraction> million of revenue from the beginning of period deferred revenue balance.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000198" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Net Loss per Share Attributable to Common Stockholders </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000212" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000212_cnt_1">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000212_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000312" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">2,777,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">3,208,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000314" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20220101_20220331" decimals="INF">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000315" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20210331" decimals="INF">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000316" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">2,777,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000317" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">3,208,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:continuation></ix:nonNumeric><ix:nonNumeric id="F_000199" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company signed an agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;) to perform certain manufacturing services related to the Company&#8217;s collaboration agreement with Biogen, which includes firm work orders totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="cbio:CostOfManufacturingServices" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331" decimals="-5" scale="6">0.7</ix:nonFraction> million. The payment obligations were fully paid off as of March 31, 2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for the Company&#8217;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="cbio:CostOfServicesAsPerAgreement" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331" decimals="-5" scale="6">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="cbio:CostOfServicesAsPerAgreement" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331" decimals="-5" scale="6">6.5</ix:nonFraction> million, respectively. The Company can terminate the CFI agreement at its discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB 4332. The agreement covers analytical method qualification to support good manufacturing practices (&#8220;GMP&#8221;) manufacturing. The Company currently has firm work orders related to this agreement totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="cbio:FirmWorkOrderSupportingClinicalTrials" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20220331" decimals="-5" scale="6">0.3</ix:nonFraction> million and the payment obligations remaining as of March 31, 2022 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:ContractualObligation" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20220331" decimals="-5" scale="6">0.1</ix:nonFraction> million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Company provided notice of intent to terminate its MarzAA manufacturing agreements and incurred charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost" contextRef="C_0001124105_20211101_20211130" decimals="-5" scale="6">3.8</ix:nonFraction> million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.4%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#8217;s employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#8217;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under the Company&#8217;s agreements. The Company<span style="Background-color:#FFFFFF;"> is actively monitoring the impact of COVID-19 and the possible effects on its financial condition, liquidity, operations, clinical trials, suppliers, industry and workforce</span>.</p></ix:nonNumeric><ix:nonNumeric id="F_000200" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true" continuedAt="F_000200_dcnt_87a03c2d-11cc-4780-be8c-dc10c38e7d87">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interest and Other Income, Net</p></td></tr></table></div><ix:nonNumeric id="F_000213" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income, net as follows (<span style="font-style:italic;">in thousands</span>):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001124105_20210101_20210331" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain from extinguishment of liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="cbio:GainLossFromExtinguishmentOfLiability" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001124105_20220101_20220331" decimals="-3" sign="-" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001124105_20210101_20210331" decimals="-3" sign="-" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001124105_20220101_20220331" decimals="-3" scale="3">165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000200_dcnt_87a03c2d-11cc-4780-be8c-dc10c38e7d87">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000201" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="C_0001124105_20220101_20220331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Restructuring</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000330" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="C_0001124105_20211101_20211130" decimals="2" scale="-2">35</ix:nonFraction>% of employees were terminated. During the year ended December 31, 2021, the Company recorded charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:SeveranceCosts1" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">0.4</ix:nonFraction> million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">3.8</ix:nonFraction> million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. The remaining restructuring liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="cbio:RestructuringLiability" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million will be paid during the second quarter of 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Board approved a further reduction of its workforce as part of its restructuring plan whereby <ix:nonFraction unitRef="U_cbioEmployee" id="F_000334" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" contextRef="C_0001124105_20220301_20220331" decimals="INF">22</ix:nonFraction> full-time employees were terminated. Following this reduction, the Company will have <ix:nonFraction unitRef="U_cbioEmployee" id="F_000335" name="cbio:RemainingNumberOfFullTimeEmployees" contextRef="C_0001124105_20220301_20220331" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction> full-time employees remaining. As of March 31, 2022, the Company recorded an additional liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="cbio:SeveranceAndOtherCosts" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20220101_20220331" decimals="-5" scale="6">1.0</ix:nonFraction> million for severance and other charges related to the reduction-in-force, recognized as an operating expense within the consolidated statements of operations, which the Company expects to pay in the second quarter of 2022.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="font-weight:normal;"></span>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated, in this Quarterly Report on Form 10-Q, references to &#8220;Catalyst,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; mean Catalyst Biosciences, Inc. and our subsidiary. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and related notes that appear in this Quarterly Report on Form 10-Q (this &#8220;Report&#8221;) and with the audited consolidated financial statements and related notes that are included as part of our Annual Report on Form 10-K for the year ended December 31, 2021 (&#8220;Annual Report&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In addition to historical information, this Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (&#8220;the Exchange Act&#8221;). Forward-looking statements are identified by words such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. For example, forward-looking statements include any statements regarding the strategies, prospects, plans, expectations or objectives of management for future operations, the progress, scope or duration of the development of product candidates or programs, clinical trial plans, timelines and potential results, the benefits that may be derived from product candidates or the commercial or market opportunity in any target indication, our ability to protect intellectual property rights, our anticipated operations, financial position, revenues, costs or expenses, statements regarding future economic conditions or performance, statements of belief and any statement of assumptions underlying any of the foregoing. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part II, Item 1A &#8212; &#8220;Risk Factors,&#8221; elsewhere in this Report and in Part I - Item 1A &#8211; &#8220;Risk Factors&#8221; in the Annual Report. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this Report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with expertise in protease engineering and several protease assets that may address unmet medical needs in disorders of the complement or coagulation systems. Proteases are an important class of enzymes, which are key natural regulators of many biological processes, including the complement system. Our complement pipeline includes the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, first-in-class improved albumin-fused Complement Factor I (&#8220;CFI&#8221;) molecule intended for prophylactic subcutaneously (&#8220;SQ&#8221;) or intravitreal (&#8220;IVT&#8221;) administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential best-in-class component 3 (&#8220;C3&#8221;) degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration (&#8220;AMD&#8221;). We have proteases from our ProTUNE&#8482; C3b/C4b degrader and ImmunoTUNE&#8482; C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. These programs all target diseases caused by deficient regulation of the complement system and inflammation. We have also used our protein engineering platform to develop potential therapies for coagulation disorders, including marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), a SQ administered next-generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders, and dalcinonacog alfa (&#8220;DalcA&#8221;), a next-generation SQ FIX, both of which has shown sustained efficacy and safety in mid-stage clinical trials.<span style="color:#000000;"> </span>As of March this year we ceased the development of our protease programs and are focused on the monetization of our assets.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates generated by our protease engineering platform are designed to have improved functional properties such as longer half-life, improved specificity and targeting, higher potency, and increased bioavailability. These characteristics potentially allow for improved safety and efficacy for SQ administration of recombinant complement regulators, or less frequently dosed intravitreal products than current therapeutics in development.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our current programs</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with their latest stage of development</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzuqpypd2gjn000001.jpg" title="" alt="" style="width:695px;height:391px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, we announced that we had engaged Perella Weinberg Partners as a financial advisor to assist us in exploring strategic alternatives to monetize our assets.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Program Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Complement</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our protease programs are designed to take advantage of nature&#8217;s natural complement regulators that restore complement homeostasis and potentially treat a variety of complement-mediated disorders. We have several protease programs currently in preclinical discovery or early non-clinical development. These programs target diseases caused by aberrant regulation of the complement system including both ocular programs, specifically for dry AMD, and systemic complement disorders, all of which are wholly owned by Catalyst.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The complement system is an enzyme-based <span style="color:#000000;">innate immune </span>defense system with the primary role of protecting the body from pathogens. The system is naturally regulated by proteases which is the basis for our approach to addressing complement-driven diseases. Deficient or excessive activation of the complement system may lead to severe disorders, including microthrombotic, <span style="color:#000000;">autoimmune and/or immune-complex diseases</span>, severe infectious diseases, and degenerative ophthalmic or neurologic diseases affecting a variety of tissues and organ systems. The absence of regulation can cause the complement system to become self-destructive or not provide the necessary protection when needed. The protease therapeutic candidates generated by our platforms are designed to correct or restore the missing balance in the complement system that drives several diseases.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteases are uniquely poised to regulate key biological functions such as the complement system, either by promoting or limiting the cascade of events that leads to eventual clearing of foreign and damaged proteins, inflammation, and formation of the membrane attack complex, which is deposited on the surface of cells and drives their destruction. Compared with antibodies and small molecule inhibitors that generally require a sustained excess of therapeutic compound over that of the target, Catalyst&#8217;s protease therapeutic candidates are based on natural regulatory proteins that are capable of rapidly engaging and modulating large quantities of target molecules, as each protease molecule can degrade many target molecules over their effective lifetime. This means that our proteases are ideal for regulating high abundancy targets such as complement proteins in a way antibodies and small molecule inhibitors cannot.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG is an engineered pegylated C3 degrader previously licensed to Biogen that we designed with a best-in-class anti-C3 profile for geographic atrophy (&#8220;GA&#8221;) in dry AMD. Dry AMD is an ocular disease that leads to vision loss and blindness for which there is currently no approved therapy. CB 2782-PEG degrades C3 in the eye reducing the steady state level of C3 activity. It is expected </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that maintaining low C3 levels in the eye can significantly slow disease progression and vision loss in patients with dry AMD. We have demonstrated in preclinical non-human primate models that we have the potential to reduce C3 levels in humans based on modeling studies for up to 3 months with a single intravitreal injection. In September 2021, Apellis released the results of the DERBY and OAKS phase 3 trials for GA secondary to dry AMD, showing that once-monthly </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pegcetacoplan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a pegylated C3 targeted inhibitor, was safe and efficacious, meeting its primary endpoint in one trial and narrowly missing the primary endpoint in a second trial for reducing GA lesion growth over a 12-month period. Further subpopulation analyses demonstrated a greater effect of reducing GA lesion growth in those subjects with extrafoveal lesions at baseline. CB 2782-PEG provides a differentiated mechanism of action by degrading both C3 and one of its byproducts, C3a potentially offering not only less frequent dosing but a more efficacious mechanism than </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pegcetacoplan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other complement inhibitors in development for GA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In March 2022, Biogen terminated the license agreement and returned full rights to CB 2782-PEG.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 is an engineered albumin-fused version of the CFI protease with an extended half-life that can be dosed subcutaneously or intravitreally in individuals who would benefit from enhanced regulation of complement. CFI is the central regulator of the complement system and CB 4332 has the potential to address several mechanistically related diseases driven by complement imbalance such as: Lupus Nephritis (&#8220;LN&#8221;), Systemic Lupus Erythematosus (&#8220;SLE&#8221;), warm Autoimmune Hemolytic Anemia (&#8220;wAIHA&#8221;), atypical Hemolytic Uremic Syndrome (&#8220;aHUS&#8221;), C3 Glomerulonephritis (&#8220;C3G&#8221;), and Immune Complex Membranoproliferative Glomerulonephritis (&#8220;IC-MPGN&#8221;), dry AMD and complete CFI deficiency (&#8220;CFID&#8221;), a rare immunodeficiency primarily affecting children. These are severe, chronic, life-threatening diseases that result in a significantly decreased quality of life for the afflicted individual.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 can be dosed subcutaneously for systemic diseases and has the potential for infrequent IVT injections for ophthalmic indications. As a key complement regulator, CFI has the potential to be used in several complement dysregulated diseases (<span style="font-style:italic;">e.g.</span>, those associated with hyperactive complement) in which additional upstream regulation may prove more effective than inhibiting specific downstream targets such as C3 or C5, where many of current molecules in development are targeted<span style="color:#000000;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals with complete or significant absence of endogenous CFI may present with a variety of disease manifestations, such as recurrent invasive infections with encapsulated bacteria, but these patients are also at risk of developing autoimmune and/or immune-complex diseases such as chronic inflammation of the blood vessels of the brain, spinal cord, heart, or kidneys. No CFI replacement therapy, including for prophylactic use, has been approved, and patients often receive supportive care with lifelong antibiotic treatment, which may cause a range of additional problems. We have received pre-IND guidance from the FDA as well as Rare Pediatric Disease Designation of CB 4332 for treatment of CFI deficiency in January 2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Low circulating serum CFI levels have been shown to be associated with rare CFI genetic variants and all forms of AMD ranging from early to late-stage manifestations. Studies have estimated the prevalence rates of CFI deficiency in GA to be approximately 20%, suggesting that CFI is a prognostic biomarker for progression of GA. Approximately 1 million individuals globally are predicted to have low serum CFI levels and may potentially benefit from targeted CFI therapy. Gyroscope released interim results from its FOCUS phase 1/2a trial for patients with GA and having rare CFI variants, showing that gene therapy with GT005, an AAV-delivered CFI rebalanced the overactivation of complement observed in the vitreous with sustained expression of CFI. The FOCUS data also showed that AAV-delivered CFI reduced complement biomarkers in the broader GA population who do not have a rare CFI genetic variant.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have additional early-stage complement discovery programs that target different proteins of the complement system including proteases from our ProTUNE<span style="color:#000000;">&#8482; C3b/C4b degrader and ImmunoTUNE&#8482; C3a/C5a degrader platforms. These proteases are designed to target specific disorders of the complement or inflammatory pathways. The ProTUNE&#8482; platform generates optimized, next-generation engineered CFI molecules that are selectively enhanced for potency and target engagement.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coagulation Programs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">MarzAA<span style="font-style:normal;"> </span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA is a potent, subcutaneously administered, next-generation Factor VIIa variant. We commenced enrollment of a Phase 3 registrational trial of MarzAA for episodic treatment of spontaneous or traumatic bleeding episodes in adolescents and adults with congenital hemophilia A or hemophilia B with inhibitors in May 2021. We have discontinued this trial based on a number of factors, including challenges in enrollment resulting from the limited number of potential patients eligible to enroll in this trial, competition from competing approved therapies, delays in enrollment resulting from COVID-19, the capital requirements to complete the trial, and other factors. Patients enrolled in the study returned to their standard of care and completed all required safety assessments. In the patients enrolled to date, we have successfully treated bleeds with SQ MarzAA and have not observed any adverse events. We plan to report these data at an appropriate medical conference in the future. We had also begun enrollment of <span style="color:#000000;">a Phase 1/2 trial of MarzAA for treatment of bleeding in individuals with Factor VII Deficiency, Glanzmann Thrombasthenia, and hemophilia A with inhibitors on emicizumab prophylaxis. We have discontinued this trial as well, in light of the difficulties in identifying and enrolling eligible patients, </span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">the capital requirements to complete the trial and other factors. We </span><span style="color:#000000;">believe that a SQ r</span><span style="color:#000000;">ecombinant </span><span style="color:#000000;">F</span><span style="color:#000000;">actor </span><span style="color:#000000;">VIIa</span><span style="color:#000000;"> therapy, like </span><span style="color:#000000;">MarzAA</span><span style="color:#000000;">, </span><span style="color:#000000;">has the potential to be </span><span style="color:#000000;">an important treatment option for patients with</span><span style="color:#000000;"> various</span><span style="color:#000000;"> bleeding disorder</span><span style="color:#000000;">s and</span><span style="color:#000000;"> </span><span style="color:#000000;">are exploring opportunities to license or sell </span><span style="color:#000000;">MarzAA</span><span style="color:#000000;"> to another party for further development.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DalcA</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DalcA is a next-generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. An open-label, Phase 2b study was completed in 2020, demonstrating that FIX plasma activity levels were raised from severe to mild hemophilia B levels and maintained throughout the course of the study. We have received guidance from the FDA on the design of the registrational Phase 3 clinical trial, have the necessary data to support its initiation, and are exploring opportunities to license or sell DalcA to another party for further development.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Financing</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no drug products approved for commercial sale and have not generated any revenue from drug product sales. From inception to March 31, 2022, we have raised net proceeds of approximately $510.1 million, primarily from private placements of convertible preferred stock since converted to common stock, proceeds from our merger with Targacept, issuances of shares of common stock and warrants, including $84.3 million in total cash receipts from our license and collaboration agreements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and have incurred significant operating losses in each year since inception. Our net losses were $14.5 million and $22.4 million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $417.2 million. As of March 31, 2022, our cash and cash equivalents balance was $34.8 million. Substantially all our operating losses were incurred in our research and development programs and in our general and administrative operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and Collaboration Revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue consists of revenue earned for performance obligations satisfied pursuant to our license and collaboration agreement with Biogen which was entered into in December 2019. In consideration for the grant of an exclusive license and related know-how, we received an up-front license payment of $15.0 million in January 2020, which was recorded in license revenue during the year ended December 31, 2020. We recognized collaboration revenue for reimbursable third-party vendor, out-of-pocket and personnel costs pertaining to the Biogen Agreement of $0.8 million and $1.5 million for the three months ended March 31, 2022 and 2021, respectively. In March 2022, we received notice that Biogen is terminating the license and collaboration agreement. Under the terms of the Biogen Agreement, termination will be effective in May 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue from the sale of any drug products and we do not expect to generate any revenue from the sale of drug products until we obtain regulatory approval of and commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration Revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license and collaboration revenue consists of fees for research and development services payable to third-party vendors, and personnel costs, corresponding to the recognition of license and collaboration revenue from Biogen. Cost of license and collaboration revenue does not include any allocated overhead costs. In connection with the license revenue recognized from Biogen as discussed above in 2020, we paid<span style="color:#000000;"> Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license. We </span>recognized third-party vendor, out-of-pocket and personnel costs, most of which were reimbursable, pertaining to the Biogen Agreement of $0.8 million and $1.5 million for the three months ended March 31, 2022 and 2021, respectively, and recorded such costs as cost of collaboration revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred. Nonrefundable advance payments for goods or services used in research and development are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of the following: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">employee-related expenses, which include salaries, benefits and stock-based compensation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">laboratory and vendor expenses, including payments to consultants and third parties, related to the execution of preclinical, non-clinical, and clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of acquiring and manufacturing preclinical and clinical materials and developing manufacturing processes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical trial expenses, including costs of third-party clinical research organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performing toxicity and other preclinical studies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense and other supplies.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details our internal and external costs for research and development for the period presented (<span style="font-style:italic;">in thousands</span>). See Overview and Program Status for further discussion of the current research and development programs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel and other</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,140</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,624</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complement</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,383</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,650</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hemophilia</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,370</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,703</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,013</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The largest component of our total operating expenses has historically been our investment in research and development activities, including the clinical and manufacturing development of our product candidates. Costs listed for our hemophilia and complement programs above consist of clinical trial, manufacturing and research costs. Our internal resources, employees and infrastructure, identified above as personnel and other, are generally not directly tied to individual product candidates or development programs. As such, we do not maintain information regarding these costs incurred for these research and development programs on a project-specific basis.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we have ceased research and development activities, we expect our aggregate research and development expenses will be minimal during the next year as we continue to explore strategic opportunities for the clinical and manufacturing development of our programs. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, we signed a development and manufacturing services agreement with AGC, pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. We will own all intellectual property developed in such manufacturing development activities that are specifically related to our product candidates and will have a royalty-free and perpetual license to use AGC&#8217;s intellectual property to the extent reasonably necessary to make these product candidates, including commercial manufacturing. As of March 31, 2022, six GMP batches have been manufactured at AGC in addition to an engineering batch.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the agreement is ten years or, if later, until all stages under outstanding statements of work have been completed. Either party may terminate the agreement in its entirety upon written notice of a material uncured breach or upon the other party&#8217;s bankruptcy, and we may terminate the agreement upon prior notice for any reason. In addition, each party may terminate the agreement in the event that the manufacturing development activities cannot be completed for technical or scientific reasons. We had firm work orders with AGC to manufacture MarzAA and DalcA to support clinical trials totaling $15.8 million. The payment obligations were fully paid off as of December 31, 2021. We also have firm work orders with AGC to perform certain manufacturing services related to our collaboration agreement with Biogen totaling $0.7 million and the payment obligations were fully paid off as of March 31, 2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, we entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for our screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. In November 2021, we provided notice of intent to terminate our MarzAA manufacturing agreements and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. We can terminate the CFI agreement at our discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2021, we signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB 4332. The agreement covers analytical method qualification to support GMP manufacturing. We have firm work orders related to this agreement totaling $0.3 million and the payment obligations remaining as of March 31, 2022 were $0.1 million.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have a long-term clinical supply services agreement with Catalent Indiana, LLC (&#8220;Catalent&#8221;). Catalent has facilities in the U.S. and Europe and conducts drug product development and manufacturing for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DalcA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We successfully completed development work for a variety of vial sizes which supports flexible dosing.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. We incur expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), insurance expenses, audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services. We expect such expenses to fluctuate as we continue to explore strategic opportunities for our programs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table set forth our results of operations data for the periods presented (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change (%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,467</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,467</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,480</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(682</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,703</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,013</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,310</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,994</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,412</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(418</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,495</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,905</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,410</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,701</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,438</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,737</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,536</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,438</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,902</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.67%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Not meaningful</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and Collaboration Revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue was $0.8 million and $1.5 million during the three months ended March 31, 2022 and 2021, respectively.&#160;&#160;In the three months ended March 31, 2022 and 2021, revenue consisted primarily of reimbursable collaboration expenses from our Biogen Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license and collaboration revenue was $0.8 million and $1.5 million during the three months ended March 31, 2022 and 2021, respectively. Cost of collaboration for the three months ended March 31, 2022 and 2021 was primarily reimbursable third-party vendor and personnel costs we incurred pertaining to the Biogen Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $9.7 million and $17.0 million during the three months ended March 31, 2022 and 2021, respectively, a decrease of $7.3 million, or 43%. The decrease was due primarily to a decrease of $5.3 million in hemophilia-related costs, a decrease of $1.3 million in complement-related costs, a decrease of $0.5 million in personnel-related costs, and a decrease of $0.2 million in stock-based compensation expense. Research and development expenses for the three months ended March 31, 2022 include approximately $0.6 million of severance and other costs related to our reduction-in-force. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $5.0 million and $5.4 million during the three months ended March 31, 2022 and 2021, respectively, a decrease of $0.4 million, or 8%. The decrease was due primarily to a decrease of $0.6 million in professional services, partially offset by an increase of $0.2 million related to our allowance for doubtful accounts. General and administrative expenses<span style="font-size:12pt;"> </span>for the three months ended March 31, 2022 include approximately $0.4 million of severance and other costs related to our reduction-in-force. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest and Other Income, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $0.2 million increase in interest and other income, net for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily due to a $0.2 million gain recognized upon the extinguishment of a liability.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to &#8220;Accounting Pronouncements Recently Adopted&#8221; included in Note 2, <span style="font-style:italic;">Summary of Significant Accounting Policies</span>, in the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; in this Form 10-Q.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, we had $34.8 million of cash and cash equivalents. For the three months ended March 31, 2022, we had a $14.5 million net loss and $12.1 million cash used in operating activities. We have an accumulated deficit of $417.2 million as of March 31, 2022. Our primary uses of cash are to fund operating and business development expenses and general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing capital resources, including cash and cash equivalents will be sufficient to meet our projected operating requirements for at least the next 12 months from the date of this filing. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional asset sales, licensing transactions, collaborations or strategic partnerships with other companies. At the year ended March 31, 2022, we had effective registration statements on Form S-3 that enable us to sell up to $150.0 million in securities subject to limitations under SEC rules. The sale of additional equity or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. Licensing transactions, collaborations or strategic partnerships may result in us relinquishing valuable rights. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.<span style="font-size:12pt;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods presented (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,050</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,356</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,581</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,459</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,530</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,684</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows from Operating Activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the three months ended March 31, 2022 was $12.1 million. The most significant component of our cash used was a net loss of $14.5 million. This included non-cash expense related to stock-based compensation of $0.5 million, bad debt expense of $0.2 million and depreciation and amortization of $0.1 million. In addition, cash inflow of $1.7 million was attributable to the change in our net operating assets and liabilities primarily as a result of a $1.5 million decrease in prepaid and other current assets, a $1.1 million decrease in accounts receivable, and a $1.0 million increase in accrued compensation and other accrued liabilities, partially offset by a $1.7 million decrease in accounts payable and a $0.2 million decrease in deferred revenue related to the Biogen Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the three months ended March 31, 2021 was $24.4 million, due primarily to a net loss of $22.4 million, and the change in our net operating assets and liabilities of $3.0 million. The change in our net operating assets and liabilities is due primarily to a $1.7 million increase in prepaid and other assets, a $3.0 million decrease in accounts payable, and a $0.7 million decrease in deferred revenue related to the Biogen Agreement, offset by a $2.3 million decrease in accounts receivable. Non-cash charges of $1.0 million were recorded for stock-based compensation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows from Investing Activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities for the three months ended March 31, 2022 was $2.5 million, due primarily to proceeds from maturities of investments. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities for the three months ended March 31, 2021 was $27.6 million, due primarily to proceeds from maturities of investments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows from Financing Activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the three months ended March 31, 2022 was due to the issuance of stock grants.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the three months ended March 31, 2021 was $49.5 million, due to $49.3 million in net proceeds from the issuance of common stock related to our public offering in the first quarter of 2021 and $0.2 million in stock grants.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Polices and Estimates </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no significant changes to our critical accounting policies since December 31, 2021. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements, refer to Item 7 &#8220;<span style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; contained in our Annual Report on Form 10-K.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="font-weight:normal;"></span>Quantitative and Qualitative Disclosures About Market Risk </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_CONTROLS_PROCEDURES"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONTROLS</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> AND PROCEDURES </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Controls and Procedures </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to an unremediated material weakness in our internal control over financial reporting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to evaluate our internal control over financial reporting, we may determine that additional measures should be taken to address the identified control deficiency or other deficiencies, and/or that we should modify the remediation plan described below. Notwithstanding the identified material weakness in our internal control over financial reporting, we have concluded that the consolidated financial statements and other financial information included in this Quarterly Report on Form10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows as of, and for, the periods presented.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Material Weakness in Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. In connection with management&#8217;s assessment of our internal control over financial reporting described above, management concluded that, as of March 31, 2022, a material weakness existed in our internal control over financial reporting. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our material weakness related to the following control deficiency: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not design and maintain effective controls related to the review of certain contracts, including the proper application of U.S. GAAP. Specifically, we did not design and maintain controls to properly review the retention bonuses granted to our employees in November 2021 after our reduction in workforce to assess the appropriate accounting treatment under U.S. GAAP.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Remediation Plans </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To address our material weakness, we have implemented internal control activity over our accounting policy for monitoring and reviewing personnel contracts so that contracts with a significant impact are reviewed and U.S. GAAP is properly applied. We have formalized our internal control documentation and strengthened supervisory reviews by our management. While these actions and planned actions are subject to ongoing management evaluation and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period to ensure proper seasoning and implementation, we are committed to continuous improvement and will continue to diligently review our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are taking actions to remediate the material weakness relating to our internal control over financial reporting as described above. Except as described above, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II_OR_INFORMATION">PART II. OTHER INFORMATION </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_LEGAL_PROCEEDINGS"><span style="font-weight:normal;"></span>LEGAL PROCEEDINGS </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not a party to any material legal proceedings.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_RISK_FACTORS"><span style="font-weight:normal;"></span>RISK FACTORS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk factors disclosed in <span style="font-style:italic;color:#000000;">&#8220;Part I - Item&#160;1A - Risk Factors&#8221; </span><span style="color:#000000;">of</span><span style="font-style:italic;color:#000000;"> </span>our Annual Report on Form 10-K for the fiscal year ended <span style="color:#000000;">December 31, 2021, filed with the Securities and Exchange Commission on March 31, 2022, disclose risk and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our common stock, and are incorporated herein by reference. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks and uncertainties disclosed as &#8220;Risk Factors&#8221; in our Annual Report, together with all of the other information in this Report, including the section titled <span style="font-style:italic;">&#8220;Part I - Financial Information - Item 2 - Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; </span>and the condensed consolidated financial statements and related notes.&#160;&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="font-weight:normal;"></span>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="font-weight:normal;"></span>DEFAULTS UPON SENIOR SECURITIES </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="font-weight:normal;"></span>MINE SAFETY DISCLOSURES </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_OR_INFORMATION"><span style="font-weight:normal;"></span>OTHER INFORMATION </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_EXHIBITS"><span style="font-weight:normal;"></span>EXHIBITS </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Exhibits at the end of this Report, which is incorporated by reference here. The Exhibits listed in the accompanying Index to Exhibits are filed as part of this Report. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="EXHIBIT_INDEX">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.12%;">
<tr>
<td valign="bottom" style="width:7.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex311_6.htm"><span style="text-decoration:underline;">Certification of the Chief Executive Officer pursuant to Rule&#160;13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex312_9.htm"><span style="text-decoration:underline;">Certification of the Interim Chief Financial Officer pursuant to Rule&#160;13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex321_7.htm"><span style="text-decoration:underline;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr style="height:6.75pt;">
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex322_8.htm"><span style="text-decoration:underline;">Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following materials from the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i)&#160;the Condensed Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021&#59; (ii) the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021 (unaudited)&#59; (iii)&#160;the Condensed Consolidated Statement of Stockholders&#8217; Equity as of March 31, 2022 and March 31, 2021 (unaudited)&#59; (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited)&#59; and (v)&#160;the Notes to Unaudited Interim Condensed Consolidated Financial Statements.</p></td>
</tr>
<tr style="height:7.65pt;">
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:91.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 9, 2022</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<span style="font-style:italic;">Principal Executive Officer</span>)</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 9, 2022</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seline Miller</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seline Miller</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<span style="font-style:italic;">Interim Financial and Principal Accounting Officer</span>)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>cbio-ex311_6.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex311_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Nassim Usman, certify that:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Catalyst Biosciences, Inc. for the period ended March 31, 2022;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 9, 2022</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>cbio-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex312_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Seline Miller, certify that:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Catalyst Biosciences, Inc. for the period ended March 31, 2022;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 9, 2022</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seline Miller</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seline Miller </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Interim Financial and Principal Accounting Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>cbio-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nassim Usman, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:3.8pt;">
<td valign="middle"  style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 9, 2022</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Principal Executive Officer</font>)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>cbio-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Seline Miller, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:3.8pt;">
<td valign="middle"  style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 9, 2022</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seline Miller</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seline Miller</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Interim Financial and Principal Accounting Officer</font>)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gzuqpypd2gjn000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzuqpypd2gjn000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 3)"'\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8U(^SK.#G&-^:%2,6E)TYVBY<CE%34H0E%R347%J3[^BBBN0Z HHHH ****
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M_=^#V?UC,I9?O:?/R<OMMH\U_9^[\9_891116904444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\,W52,.),%!<D.2K3QU6CFDZ4%.E2H9SA8PG\5*B4445_11_)H4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\,_P#!2W_DQ3]I/_L0X_\
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M_";_ -M_\):WB9<8_P"$*\(?V;_9_P#PCF<YO_M?VSI;?9_W_P#-?_P4R_9
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M<W*[DY-MR;O=MW'",:<8PA&,(0BHPC!*,81BDHQC%648Q22222222T/XX?\
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M3PN#J0C:.DZM7'1J.Z7,^:-&FK-M+EO%)N5_QJ_;1_X*W_\ #(/QVUCX*?\
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MQBX5?K$IJ$:2M.*]])1A]P?L4_\ !7'_ (9;^"?@?X _\,^_\)U_8VN:V_\
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M0#G!Q@''!(R >V1D9'MD9]17\U?QZ_X(A?'WXB?$[4OB'I?[2'P^\>:AX_\
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M;1YOLD46F0WFH?V;IVFV<D.E:38OJ6HS6>EV5G;RW]W)$T[SB'2KY?4J4?\
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MA@Z[_P )(-*&C^(]8T J=;.C^'_MHN/[*^V;O[)L_)\_R,2^5YTGY-?M5?\
M!</P9\-_$_B?X??LZ> -/^*FI:)]HTL?%'Q)KL]G\/E\0VMS&EPVA^'M&@_M
MCQUX?A1;BT_M:/Q/X,AO+V,W6CRZKHOV34M1_4SQ+^S#HNF_LN^(OV7_ ( Z
M\_P*T#4O#.K^$_#VN16NN?$"?PII?B759[[Q.;:+7_%MEK6H76J6NI:W:6UU
M<^*8YM*GU)+RU9DL8+1OQ3^$W_!"'Q!X<^/&CWWQ;^(W@7XC?L\Z/=RWE_8:
M-+XP\(_$'QDD6F[[+2=2T2VLKK3O#.GSZVXBU2XTCXBZCJ,FC6S&PN+&_OU?
M3,IJCB<UKP@Y8/++59T.>[E*$I5+QG.$JM2G+#TO9^SC&JJV(K3?)-QHMS*;
MEA\NC4JVQ6/]HHSC32M!1Y90E"G)4Z55XF;=-NHE1P\*4G72]O3J4OGC_A_-
M^U]_T3C]F[_PD/B?_P#/AK](?V-_^"SGP^^/7B_PW\*?C1X(C^$7COQ$-#T7
M0/%.EZS+KGP_\6>+[P+:7-A);WEC:ZOX#.KZF\">&K"_OO%UD1</8ZIXJM[J
M"TEU;Z1_:(^"G_!+OP)X.\0^$?C5X)_91^$AU/PG>ZO'':Z-\.OAY\47TBP\
MZ1=7\$CP[::;\1-2U!+O3I(;.+PQ!J%WK5Y#+HHL]4-U/IUQ_%>\\>DZVUSH
MM[)/%IFJM/I.H^6T$LT=G=F2PO?*D4/#)(L<4_ER(&C8[64$$5O@J^$JXOZM
M7I2^K-TI5<1!<TH4W6J4:SISA?DQ%%1FU2J<].I*UZ=5T9JGGB*&(6%]O3JQ
MIXA-PA2G?D<W2A5IN491O5H2:2J3IQC5IPE!QE3>(@W_ *.=?"W[:O[?OP=_
M8I\/V0\6+<^,OB9XBL+J^\'?"W0+RWMM7U*VA\Z"+6O$6IS1W4/A+PI+J,)T
MY=:N++4;Z]N([Y= T+7GTC6([#[#\*:T^K^#?#?B*]V0/JGAG1]:N_G_ '<+
M7NE6]]<?O'V_)&97^=\?*-S8YK^"+]JOXVZW^T3^T'\4OBSK%Y=W<?B;Q7J:
M^';>ZD9_[)\(:?<R:?X4T6WCR8X(M/T.WLH7CA55ENC<W4F^XN9I9.*O3K1S
M'^S4^2I2=>6*G!1FZ<:-14(TX74H*=>LY<DI1E&5*AB%%<_+*/1A)TJV 68N
M+E3FL,J-*3<>:>*HU*T93<6GRT84WSQA)-SG37,HN1^H6M?\%Z_VI)]8U2?P
M[\*?@%I?A^74+N31=,UK1_B)K^L6&E/.[6-EJFNV/Q%\-V6KZA;6QCAN]3M/
M#NB6U[.CW$.DV$<BVL7Z#?#+_@MK\)O'7PC^)?B76/AW<>%/C'\/?#,OB;2O
MA7J/C&)=#^)5E:7,$-_%X/\ 'J^&Y)+?5=.M7EU;4]!U/PH+Z#3E\_2)?$-M
M9:W>Z1ZY^PW_ ,$ROV>OA)\$?"E_\6/A1X#^*_Q9\;:!I'B'QMJGQ&\,Z1XV
ML-#N=1MEU&V\+>&=&\1VNIZ/HUMH$5X;&]U33[.+5-?ODN+J_OI;!-)T[2_S
M8_X+!_\ !/[X6_!;PSH?[1OP+\,1^"M&U/Q6GAKXC^"=$1U\)V5YKJW]]HWB
MG0--+M#X6MGO+>30;W0]+6#PY']IT(:/IFD/'>_VCTX]T<"ZV!DM9<V CC(/
MVDL%F%62P^%K1Y^9XJG'%.%*ISJI"JYZQC"7UW#XX+GQWL\7!V22QJP\UR1Q
M>"IQ^L8BG)4[*@ZF'A.=-1=.I3IKW9PJ_P"RU/L_]DO_ (+'?\-1_M ^ /@7
M_P ,Y_\ "#?\)S)XAC_X2G_A;O\ PDW]E_V#X5USQ-G^Q/\ A6'A_P"V_:_[
M&^PX_M>T\C[3]IS-Y/V>7]M))$B1Y972..-&DDDD8(D:("SN[L0JHJ@LS,0%
M )) %?Q*?\$E_P#E(#\ ?^OCXA?^JJ\<5^^W_!9S]H35?@W^RQ'X&\,:A-IW
MB7XZZ])X'GN;9Y(;F#P-9Z?+J/C8P31LNS^THGTGPU=QMGS],\0:@@&066LV
M5/!X/ 5:%-.MB:?(DY3Y:F)K9A4P=!S;<G"E%NG[5TXMQI1G-0G-6E. 4\3F
M&(P]2HU1I8:EB)-1BY0IPAC*V)E#X>>;I8?]W"4E%S48\T%*4CP[]K'_ (+@
M>!OAOKVO^ ?V:O!FG?%C7-(EN-.G^)WB74KFU^&<.K6L]B9#X>T?1VAUWQ_I
M6TZKITNJ)KO@JP^W6MOJ6A7GB?0[B"[N/C/PK_P7O_:3M-?TZY\;_!_X'>(?
M"\4DIU;1_"MMX]\':_>Q&WE6%-.\2:OXT\=:=I<D=TT$TLMSX4UA9K>.6V2*
M"29+NW^5O^"77['WAC]KOX_WNE_$6*\N?A?\./#P\7^,-+LKNYT^7Q+//?P:
M;H/A634K&XM=1TVSU2YDNKW4;O3IH;\Z=I-W9V5U875Y#J%I_2=^TG_P33_9
M8^-/PD\1>#_"OP<^&OPH\9PV%S?>"?'/PX\$^'O!FK:3XDM;63^S3K#^&['2
MQXET&[?_ $+6-&UPWMO+:7,UY8-I^N6VFZO8Q7IK+,'1Q-9RQ52I1GB))1BV
MZ%*K4I3J1I?PE+FI5U3H1BYRC2ASSE.<9NZ52..Q53#4U'#4H5(8=SE)J,*M
M2E1E%3J_Q6N2=.K7K+EITY59/#TE[]*GW/[&G[=_P9_;2\,WEYX%EO/#7CSP
M]9V=QXS^&7B*6U/B#1!<+%%)J>E7-L_V?Q-X5_M!WLK77[.*UG1C9C7='\/W
MFHV=A)]KU_G^_LS_ !J\4?LQ?M!_#_XI:/-=6EUX,\56]OXETZ-I8QJ_AF:Z
M&F^+?#UY#NC\V+4-)>]MU24?Z/>+;7:*ES:PNG]_=K<PWEM;W=NZRV]U!%<P
M2*0RR0SQK+$ZLI*E71E8$$@@Y!(KIQ5"E]7P^-P^E&O*I1E!2<XPJTH49\T)
MMR;HUZ=:$Z?/)RYXUHZQA&4N:E.M3Q-;!8F_M:2YX2E%0E.'/*G4ISBE%>UP
MU2,8U>1*/+5HMJ,I-$]%%>>_%OXAZ9\)/A=\0_BAK2E]+^'W@SQ)XOO(AG=<
M1:!I-UJ7V5,<^9=/;K;1XQ\\J\CK7F5JL*%&K7J75.C3G5FTFVH4XN<FDM6^
M5.R6^QWTJ4Z]6E1II.I6J0I03:2<ZDE"*;>B3DUJ]%NSXN_;8_X*3_!7]C'R
MO#.IV5_\2/BYJ%@FHZ?\-O#=_9Z?_9UI/AK2_P#&WB*XCO8_"EA?QK(U@D&D
MZ]KEW^XN(]"_LR8ZE%^*&M?\%Z_VI)]8U2?PY\*?@#I6@3:A=R:+IFM:-\1-
M?UC3]+>=VL+/5-<L?B-X:LM8U"VMC'#=ZE:>'M#M[V='N(=)L(Y%M8OR9O=2
M\?\ [3/QT6\UB_?6OB-\;/B/8VDEW<N[)+X@\9Z[;Z=901B1SY&GV<M[;65C
M:JXALM/M[>T@"0P1JO\ :#\&?^"<7['OP?\  &D^"C\"OAI\1;^UBBFUKQG\
M4/!'AGQ[XJU_6&M+:WOM1DU+Q-I>I-I-K<O;"6WT+0UTW0[!GEDM-/CN;B[N
M+CJHX6K3P<<;BVO:UI3I4L/&5Z<:L53JUJ2<;WCAZ=6A"KB:O-*K5FI86A3I
MU*].AC6Q%)XJ6#PL7*G3BJLZ\E:<J=YTZ522DKQ>(G"M.EAX)*G3A*.(JU*E
M.E.M^</[,G_!=/PEXQUK0/!W[3/P[L_AQ<:EFSN?BEX'U"^U'P1%JEQ?L+)]
M9\&ZLEWXA\*Z#%I[QP7>K6OBCQM.-0C%U/IVGZ5<SSZ5^_UK=6U[;6]Y9W$%
MW9W<$5U:7=K+'/;75M/&LL%Q;SQ,\4T$T3K)%+&S1R1LKHQ4@G^5G]K#_@C3
M\9S^T-<6O[*7P^M9?@9XG&A7=IJWB'X@^&[73OAW?:E.]IKVF7\6OZZ_CW4]
M#T)XAK$4^G:)XGU5])NX[*U.LZK:O _[V_L+_![XT_ ']G3PE\'OCEXB\'>*
M?$?@2ZU/2/#VL^"M6U[6-/;P29EN] T^[N?$/AKPO?)>:-]HO-)@@2QGMH='
ML]*CBNV*O#!M&6'Q.">(4?JV)C4E>C4M"56*J>SJQ]E&4E"=*I*$J,J2CA\1
MAO:U*<Y>RBZF-2-;#XQ45/ZSAIP5JD;R]E*5/VM.3FU=PG!3A7A.<ZV'Q'LZ
M;CRSE[/V/XW_ !U^%O[.GP^U/XF_%[Q78^$_"NFR1VD<UQOGU'6=6N(YI;+0
M?#VE6XDOM;UR^2WN)8-/L899$M;:\U&Z-MIEA?7EM_/I\9?^"^GC"?5#:?L]
M_!#PWI6BVM_-MU_XRWNJ:_JFN:6UO#]GSX1\$:SX;M/"M_%=?:/.QXV\8V]Q
M;^3L^RR%\?&G_!7;]IO5_CI^U+XC\!V.IO)\.O@7>7G@7PYIT$VZRN/$]N84
M\=>()D4!9+^?6H&T*.0ET33=!L_)V-/=&7]'_P#@E1_P33^$6J_"7PS^TE\?
M?!^D?$?Q%X\2[U7P%X+\5VL.K^#?#GA0F_TFTU75_#=PT^B^*-7\10M/JEM%
MXAM-1T_1K)]&NK*PM-?@>]@Y,OHRQF&J9C5FZ>#M"6'BM.>,Y2G@Y-QM4E5Q
MD:3K1HN4(4\-S1KTW.G5.K'5(8.M2P4(>TQC<XUF]>2<:=J\'&5XPHX24E1J
MU^6<OK,H*C+WZ*G\Z> O^"^GQWT_69IOB?\  _X2>+O#[6$L=OIO@*_\8_#K
M68=3:XMFAO9M;\0ZQ\4;*YL(K5;R*73$T"TN)[B>VN$U>WCM9;:\_?+]E3]L
M[X&_MB>%+OQ%\)=<NX]6T9Q'XI\!>)X+72_''A9I)7CM)]4TJUOM1M+G2]15
M!+I^MZ-J.J:1.6>QDO8-7L]1TVR^8/VQ?^"6G[.GQS^&&MK\*OACX'^#WQ<T
M#2+Z\\":W\//#VD^"=%U;4K>*6ZB\.>+M!T&#2] U/3M<G2.Q;7;JQ?7- =H
M+RQOGL8;[1]3_E+_ &9_CWXV_93^._@_XJ^&IKZTO?"NMK8^+-!2=H(O$OA6
M6ZCM_%7A+58OFAF@U"TCD6'SXY1I^K6^G:O;*E_IMG/%UX.IA<9B)8"M%86M
M%1]GB')1@HUI5(T*M2=U">'55-8MR@L1AU9QE.DJ$:_/BJ6(H8=8VA)UX*4H
MU*"5Y2G&G"3I6:<J52<(R^J.,U2KM57.'/&K[+^Z7X]?%/\ X4A\%OBA\7_[
M"_X2?_A6W@G7_&/_  CW]I_V+_;/]AV$M]_9W]K?V?JW]G?:O*\K[7_9E]Y&
M[?\ 99L;#^.OP$_X+A:)\8?BYX-^''B7X!:=\+_#WB.[U%=;^(.K_&Z#4-+\
M):7I6B:GK=]K.H6EU\+_  _;RV=M;Z;)]H:;6=/CAC9IVGQ'L?\ 1G]M?7-+
M\3?L(_M#^)-$NX[_ $7Q!^S[XNUO2+Z$[H;W2]6\*RW^GW<3#K'<VEQ%,A[J
MX-?PT>#/"^H^./&'A3P7I&W^U?%_B30_#&F;PS(+_7M3M=*LRZIEB@N+N,L%
M&[;G'-<V"I5ZF<5L#.C[2=.&7QAA:MZ5\16Q6/HU*522E2J1YW0I4YIU8>SY
M6XRIR<I&N)G0644<;"K[.-66.D\5#W[8>GAL%5I581E&<'R*M4J1_=RY^9*2
MFE&*_HD_:._X+PW6E^);_P /?LN?#+PWKVAZ3J[VZ_$;XK+X@FLO%>GP1W,$
M\NA^ ]"U#PIJ^C6ES=BVO-*U;7/$SZA<:9NBU/PAH]_.4LZ_[./_  7?U?5/
M%UAX>_:?^&7A31_#>M:M:68^('PI77["'P?:7"^1]LU[P=XDUCQ5>:_I\5Y)
M%<ZE?Z/XCT^_TW2HKI['P[XAOE@LYOU<^%O_  3=_8W^&GPSL/AS/\"/AQX[
ME&F-;:]XU\>^$]&\4>.-=U.[TZ"PU75X_%&K6EUK/AU[MXFN[&Q\,7NC:=H-
MS(\^AVUA<L\[_P ;O[4OPNTKX)_M&?&CX4:#/-<:#X%^(?B30M"DN7>6Y718
M+^2328;F9_GGN;;3Y;>VN)VYGFB>7^.JI5<-A\<L$T\:JE&M6]M.\8UHX:IA
MJ5;ELJ4\.N:O0>'E3A"52'M'7I4Y.=.L3IUL1A'BTOJ?)5I4O8QM*=)XBG7J
M4E-MU(UI<M&LJ\9RG&G/D5&I-*$Z7]-'[97_  65^%/P'U6_^'WP+T;2_CEX
M_@T]C>^)H==6'X6>%=2O;*:738I-3TI+J]\=WUC,;&YUG1= N]%TU;6Z.GCQ
MK::[:ZCIVG?GGX1_X+W_ +1]GXAT^Y\=_!WX)>(_"D9N/[5T;PC#X[\%^(;Q
M6M9TM?[/\2ZSXP\?:;II@OFMKBX-SX3U475K#/91BSFN([^U^E/^"0O[ 'P6
M\5?!.#]H[XU_#_P_\2]?\<ZOKMCX'T'QOIMIXA\):#X3T.[N_#USJ#>%=2CN
M-%U/6M;UJUU5_MNN6.H-IUCIVD3Z$NFW%Q?W-[\I_P#!:S]EOX1_ GQY\(?'
MWPC\(Z'\/[+XIZ9XLT_Q'X1\*Z?#HWAB/5_!+>&A;ZWI.A621:7H<FHZ=XB@
MM-0LM'MK'3IY]+CU(V8U.^U2]OG7C'+<5A\/7;Q%7$2A2J2:7L\/6J8>IB%A
MW2=N7V<5.C5D[XBEBK4I2FJ:K4S#MYC2KRI15*-"-=PBG)3Q,<.XPQ%6-2_-
M%KDJU8+FC3=&E*=*TJBC4_I&_9D_:7^&G[6'PITKXM?"^[O#I-W=7.DZSHFK
M1V\'B#PKXBL%A>_T#7;6UN;NWAO8H;FTO;>2WN9[:]TV^L;^WE:*Y4+\Y?\
M!0']O?\ X86TCX9ZK_PJC_A:7_"Q=2\3:?Y'_"=?\(1_8_\ PCMMH]SYWF_\
M(=XN_M#[9_:VSR_+L?L_V?=OG\W;'^67_!O_ .(]3'B']I+PD;F9M&?1OA[X
MC2T,@-O#J<5]XETR6Y2(QEA-<6LT,4LBRJ&2UA5XY"D;1]Y_P<!?\BC^S/\
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M])\)^+/#DNE2:O'H#2R2O8Z#K<&N6M_8Z&7-MHUW!JEKI MM#73M)TK]-O\
M@AC\?=;\?_ _Q]\%?$=[-J$WP5US2;KPK<7,K230>#/&ZZK<0:*C2.SO;Z-K
MNC:Q);C&VVM=6M;)-D%O;QKU8;V.8X'$8BE3]CB<'SRK0Z3C3Q$,+6I\JT52
ME.<:M.<(QA6PO/5DE)1<^7$QJX'$T(SJ>UPN+5/V<[/]W*M&4Z<N=_9E54L)
M4A*4_98SEHTIRAHOSU_X*N?M^?\ "_+SQ5^R[_PJ;_A%/^%*?'GQ!'_PG/\
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MW^QM\1/CK\6_@#X.^)O[0GASPCX/\<>-UN=?L/"_A#0_$6@6^D>$;ID'AO\
MM:S\3^)/$VHG6=4LXSK4I%W:Q0V.I6%HUC%=6US+,8:==9?BZL:5.C1KPC0K
M0JQE"M'GQ='%4G&,9<BJXB6&E5Y9.514H8CVU.E5226*C2^NX6E.I*K6HSE6
MI2I3C4I-PPE7#58RG9N5+#QKJBZD/W+JRH*C5JTI)R_DP_X*P_\ )_GQ]_Z_
M? __ *K;P?7]$'_!&73(;#]@_P !7,1R^L^,?B/J=QPXQ,GBN]TI1\TC@XM]
M+@Y18E]8R^^23^=__@K#_P G^?'W_K]\#_\ JMO!]?T9?\$=/^3!_A7_ -A_
MXE?^I_X@K')-.'&UN\MRVF_\$JV&FU\YTJ;OO[MD[.2>^=?\C?"^6,;7K_9>
M*7Y-GZ@U_';_ ,%MO^3WK[_LE?P__EK-?V)5_';_ ,%MO^3WK[_LE?P__EK-
M>96_WO*O^PZK_P"JO,3NP_\ NV9_]@5/_P!667GZX?\ !"K_ ),^\5_]ER\7
M?^HIX$KX(_X+[?\ );_@3_V2K5__ %+KVOO?_@A5_P F?>*_^RY>+O\ U%/
ME?!'_!?;_DM_P)_[)5J__J77M>CGW_(XR7UR_P#]9.N<.2_\BW-_3'?^M+1/
M>_\ @W\CC_X0W]IF7RT\T^)OAE&9=B^88UTKQBRQE\;BBLS,%)VAF8@9)K]^
M?&?_ ")_BS_L6M=_]-=U7X$_\&_O_(D_M,?]C3\-/_33XPK]]O&?_(G^+/\
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M,15T?_!OO_Q]?M4_]>_P;_\ 1GQ-K\8/VL?VA/B=^U;\5-3^/7Q"TB?1]/\
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MEDK&$3M8Z?XFEAU+R@SBX,8GU'3#-Y,;0AO),[(_V</[9_P<!?\ (H_LS_\
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MFMHM0OO@;X@CTR.;:L]P8/&7@>YO(;1F&6=;>/SY8HVWM#"\I5D@=D_K3K^
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M=Y9@J+52=+ZJY36L$L-CGF>)D^O)3E46#C.*E">(E2E&7LJBJ+\F_P#@NO\
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MZ+OC/_D3_%G_ &+6N_\ IKNJ_P Z*W_X^(/^NT7_ *&M3D7_ "4J_P .0_\
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M>BENLNRJHU_<C[&FY?*=6G&V_O7M9-K^AK_@CI_R8/\ "O\ [#_Q*_\ 4_\
M$%8/_!:3_DQ3Q=_V/OPY_P#3^M?%G_!-O_@I%^RK^S_^R#H?PR^*OC#6]!^(
M/@W7O&TEOX5M/"'B76+GQ7;:SK5SXBTN;0M9T[39?"EF;MM5;2 OBGQ#X=6V
MU"QN9KV2VTM[;49OM#_@L_(LW["'BJ5.4E\=?#:1#P<J^NHRG()'0CH2/0D5
M'$J<JL*\4Y4:F8Y H58ZTY26,RJ4H*:]WVE-2C[6G?GI2?+4C&6@\B:A[6E+
MW:CH<15%3EI/V?)F+53D?O<DE.#A.W+-23@VM3\#/^"0/_)_?P<_[!WQ'_\
M5<^**_1;_@X&AO3#^RW<]=.67XNP<(?W=ZZ_#N3YY/+P/-@C_=H9LMY,K+&
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M-:O4INE.C:<8TZJY84ZM-J+==QE*5*G-SG*#H^WHJ'LG)1C2E"H?SB_LG_\
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M7-3KT*6$JPC_ ,N8XB"Q+A&T56]E)V<J4VO8Z_/;_@J7X+\9?$+]B+XM^$_
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M?6FF65YJ6H7$5I8:?:W%]>W<[!(+6TM(7GN;B9SPD4,,;R2,>%123TK^.O\
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MU.*:TC^AO%__  4:_;\TCXL^'Y_BA\9O'D/B+X.^,W@UOX?VZ:7\.-#U'4-
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M:8;W[)X@L/#>FVNLVWVRVN;VVN_(U&*YB^TV]Y=P3[/-BN9XW65_YDOV-/\
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M];-)_)G_  2Q_P"3^/V=_P#L/^)__4 \65_<+7\/7_!+'_D_C]G?_L/^)_\
MU /%E?W"UZV._P!QR[_%C?\ TY2//H?[_B_^P7 _^G<>%%%%>2>@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8144W=V6LI.UY2>\YNWO3DW*3U;;/YWO^#@+_D4?V9_^QC^)?_IL\'U\D_\
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M3[2_^"$.HWUK8M,[6EO>:A;_ !:TN"_NX8#''<7D&F:=#=3*\\=A:(ZV\?\
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M7NK:AK$K:E=:3I6B:=-*MSJ,\<;6NEV:"!(E9'D5Y7\&_;#_ &$/A%^VU%X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>%?M&_!+2?C[\+-;\#WQ\G6(?,U[P7J#7]S86VE^-+#3]0MM$N]1>WM;_P [
M2)OM]SINM0/IM_)_9-_>3:?##J\.G7UI[K17DY]D>5\39+FG#^=X2GCLISC!
M8C+\?A:L5*-7#XFFZ<[<R?)5A=5*-6-IT:T*=:FXU(1DO3R7.,QX?S;+L[RG
M$U,'F658RACL%B:;:E3KX>:G"]FN>G*SA5IRO"K2E.E44H3DG_)EXN\(^)?
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MS7I8>E6CRS<JM/ YS4PTZ-%T_P!U1S#-,1[2G##5%6_9*BBBO]+S_*T****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-3]BJ***!A1110 445Y1\>/%?CGP)\$/C%XW^&/AO_A,OB3X/^%WC[Q1\/\
MPC_8^L>(?^$I\:Z#X5U75/"_AW^P/#]Q9Z]K?]M:W:V.G?V1HMW:ZMJ/VG['
MIUQ#=S0R+E6JQH4:M>:DX4:52K-0BYS<:<'.2A!:RDTGRQ6LG9+5FM"E+$5J
M-"#BIUZM.C!SDH04JDU"+G-Z1BG).4GI%7;V/5Z*_'3_ ()8_MA?\% _VI-9
M^,MG^VU^RW_PSIIW@W3/!=U\/;O_ (4C\:_A%_PE5[K5WXCB\16_G_%KQ/XA
M@US^R8-.TB3RM$6UEL/M^^^:5+JU"?L7775HSH^RYG!^UI0K1Y)*=HS<DE*W
MPS]UWB]5IW.6G6C5=6,5).C45*7-%Q3DZ5.K>#?Q1Y:L5S+3F4H[Q84445B:
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^K:M
MI6@:5J>NZ[J>GZ+HFBZ?>ZMK.LZM>6VG:5I.E:=;27FH:GJ>H7DD-I8:?86D
M,UU>WMU-%;6MM%)//(D2,PY_P3\0_ 'Q*TJXUWX<^./!_C_1+34)=)NM9\$^
M)M%\5:5;:K!;6EY/IEQJ&A7M_:0ZA#:7]C=2V4DRW,=M>VD[QB*XA9_G?]O.
M[N[+]CG]H>:SN;BTF?X;ZO:/+;3202/:W\EM8WULSQ,C-;WMC<W%G=PDF.YM
M9YK>97AE=&^-_P#@BE_R:QX^_P"S@/%7_JNOA50!^P%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !17RO^UYXA\0>&OAMHE]X<US6
M/#]]+XXTVTEO-$U.]TJZEM9-!\2S/;27%C/!,]N\T$$KPLYC:2&)RI:-"/JB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^5_
MC[XA\0:-\2?V=K'2-<UC2K'6_'$EIK5GINIWMC:ZO:C7O \(MM4M[6>*&_MQ
M#=W40ANTEC\NYN$V[9I WU10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%?*_BSQ#X@MOVL?ACX<M]<UB#P]?^![^[OM!AU.]B
MT:]NDLOB$R7-WI:3K8W-PC65FRS30/(K6EL0P,$6SZHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BOE?X!>(?$&L_$G]HFQU?
M7-8U6QT3QQ'::+9ZEJ=[?6ND6IU[QQ";;2[>ZGEAL+<PVEK$8;1(H_+MK=-N
MV&,+]44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !17RO\ LA^(?$'B7X;:W?>(]<UCQ!?1>.-2M(KS6]3O=5NHK6/0?#4R6T=Q
M?3SS);I-//*D*N(UDFE<*&D<GZHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>?!:_#R[U2'4O#/C6RFL8-(31;/1+>3PKKI&[3(;;3WF$.S]K_C?_P $_/\
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M698VAA*E7VD\._K&$^H?6&ZF*CAZ4%.K6JTU4?GUJ^)PW#N68BK"/UU\0XW
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M;.$FI?N98+!4N3_9??\ U@_X*S?\%:?'G_!/CX>_!OX8^!O#_ACQ/^U1\3O
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MT^TVFE7\OVJ334LH?(\N>XBEEA23W_\ X*F?\$._&W[0?QDO/VO/V,/'&C^
M?CA>7EIXH\8^"M;UG5/"%MK_ (O\,Z>;G1_&WPV\:Z':74GA7XBW]_I6C6K6
MFKKI.@7VM3#Q7<>,O"]W;7[:M_2Q16^)G+$K+7S.A6RK#SPV#Q6';A7A3J8G
M$8JHIRESPJ*=3$/FA*FZ5Z.&JJFL1AZ5:*I-4ZF92<8UJ>;8CZSC,/67-0E4
M5*A1BH1CRU(*$:$7&2J>UM.M3=1T:U2E+^+?Q]^QG_P<9?MD>&- _9V_:.\1
MC0/@Y<2VK:MJGC7XE_L[Z-X4D'AS3Y+O1A\2+KX 2>(OBG\0H)=0L+!K2VUK
M0O&L,GBPZ3XEU>*WNK!O$.G_ -(G_!./_@GQ\./^"=_P*/PN\*:FWC+QKXIU
M!/$?Q6^)-UIYTRX\:>(HX9+6QBM-*:\U$:/X;\/6$C:=H.CB]N3&);_4[J:7
M4M7OY'_02BM57<:6+I1ITH/'V^OU5"]7&J,H32Q,Y.7.N:E1OHN?V%'GYO9Q
M.=T(RGA92E4E#!*?U2BY?N,/*I"5.52E322C-TY3IZ/E4)S48IR;?\A7[4G_
M  1"_;*_9R_:7O\ ]J__ ()<>-;#?-XON/%7AKX<6/B3P_X \??#J\\1WMY<
M:YX9T>7QI)8?"WQO\*K5))+9M'\5:WIMQ<^'=0A\'ZIX2\76UC>ZUJOF'Q$_
MX)[?\%[_ /@HCJ_@KX<?MK^*] \&_##P?J5SXFM->\8^(_V?K3PS8:A=/I^E
MWUS!X-_9ECO]5\7^,H=%FU!_"_\ PEFFVFD6,(UO3H?%OA<>(+Q]1_M$HKFP
M\(T:.'P]1?6\-A&GA*&+E*K##**2IQI.+IU$Z;C&<:DJDJ\II2JU:C.FO.=:
MO7Q4)/"XK%*7UK$851IU<1*<90JSJ\T9PDZU.<Z=6*@J;ISE&,(J3/D[X"_L
M@?#O]G[]D3P_^QYX5OM6O/ ^D?#KQ)X#U#7;PQQZUK5SXUBUB;QCXDECB)M[
M.]UG6O$&L:O%90,UMIQN8[.!WBMT=OY&_A-_P2^_X+C?L _&/XA:E^QOH^BW
MT.LZ<GA.7XG^$_&O[..H>&O&_A5KJQURT/\ PA_Q]U.UU72[ZPO(8H+J6]\'
M6-_8W\&IVVCZIJ.B78O]3_N5HK252K+,\1FTJU3ZYBZ4Z.+E%JG#$TYSK3M4
MC34'!)8K&4^2A*E3G1Q=:G5A4BJ*I9QA2C@*66^QIRPN'K1KX>,U*I.C67LG
M*K&<Y2<ZE2=##U9U*WM:GMJ$*T9QJN<Y_P HO_!5S_@CA^UW^T=XZ^'G[6WP
M'U'P_P"+OCK)\,?A9HWQI^'\?C'3/!GB*X^*O@W3]'TB3QQ\+_%.JKX4\$"P
M2-#<W]G?ZIX%ETL^'(M4\-0ZM>ZZNBZ3YWKG_!/+_@N?^W;\*_$G@;]M[XY6
MG@?P'\/]"U;6O OPPOM1^#.H:[\6?'^D:";CP3IFM3_ _P"Q>&KS1KG6;2VL
M;SQ=\4_&FI:IX9U"<Z[IGA;5I;B]U&+^OZBHE&$J.,PZA".'Q.+Q..HX>,(_
M5\NQ>(Q#Q4*V P\E*A"6#Q#]I@HUZ>(IT.6G#DE2I4X0N+E&I@ZSG.=;"83"
MX&I7G*7M\?A,+AXX7V&.KQ<:LHXG#15'%/#SPTZRYI\T:M2I4G_.9_P0^_8>
M_:A_9I^%7[4_[/G[9G[/<?A3X<_%]])U+3)KSQY\)O&^C^*;36/#NK>"O'_A
M'5['P%XZ\3:M:+>:(VC26TEW:1:?<6SZK%]JM[I(([O\_O$O_!&O_@J#_P $
M_OCOJ/Q7_P""9?Q)C\>>'];FUC1M(:U\4?#KPMXYTSPA?PK<IH?Q8\&_&-].
M^$OC>RL+B6.UTO4K"[\027FL:5:^+D\)>"KY;"&Q_LTHK:O6J5\9#'QG+#8N
M.!P^75:N&DZ;Q.#PM%X:G1Q$9.<9+ZLYX>3A&FW2JUDFI5ZTJF5&E3HX6K@G
M%5\+4Q=7'4Z.(2J1PV*K35:I6PTDHU(.>(_?RC.=2$JBI<T7#"X2&'_C%OO^
M"4G_  6*_P""CGQ:\&ZS_P %&OB!I?P]\$_#NWM=)@UC6-<^#FJZJ/#6K7UY
M?^((OAG\//V>UN_!#>*[F>UL+?6M>\;R^%;BYLGT+.I>)K;PW:Z':?U!?&KX
M#-9?L*?%C]F;X)Z!+>26_P"RMXY^"7PI\,SZI8VT]Y,OPIU3P3X+T:?6M:NM
M.TR">ZE_LZTFU/5;VQL8Y)&NKVYMH!)(GUQ16.)4<1EF)RE0AAL)C'6EB%AH
MJG.K5KTJU*5>3ESQ=6/UC$3@W#E53$5IRC)U&;8:4\-F6&S7GGB,5A'06'^L
M2=2G2IT*E*JJ,8Q<)*E.5"BJBY^;EI4X0E",(I?S6_\ ! O]@']K;]BKQ+^T
MS?\ [3GPE'PULOB%H/PQL?",I\=_#/QF-8N/#U_XUFUF(Q> /&7BN2P%I%J^
MGL6U2.RCN/M&VU:=HIQ'\N?M2?\ !$+]LK]G+]I>_P#VK_\ @EQXUL-\WB^X
M\5>&OAQ8^)/#_@#Q]\.KSQ'>WEQKGAG1Y?&DEA\+?&_PJM4DDMFT?Q5K>FW%
MSX=U"'P?JGA+Q=;6-[K6J_UZT5MB*U6OB<'C(SEAL3@<*L%2JX9N$IX;GYYT
MJO,YJ7M))<TX*%2"35*5-5*O/C1I4Z5''8>4(UZ&88BEBJ]*O&,X1Q%"A##T
M:M*RBXNE"#<5)SBY5)N<9+D4/XN_B)_P3V_X+W_\%$=7\%?#C]M?Q7H'@WX8
M>#]2N?$UIKWC'Q'^S]:>&;#4+I]/TN^N8/!O[,L=_JOB_P 90Z+-J#^%_P#A
M+--M-(L81K>G0^+?"X\07CZC_5W^R;^S9X*_9"_9Y^&'[.OP_NM0U'PW\-="
MDTY=8U7RUU+7]8U/4;W7O$OB"]AA)@M9M=\1:IJFJ?8;=FM[!+I+*!WBMT=O
MHFBJC7<,-4PM*G2HTJ]>&)Q/LH<LL37I1JPI5:S;?O4X5JD%R*"FG%U54E3I
MRC,J//6I5ZM2K6EAZ<Z.%C5GS4\+3J2YZL:,$DE[2?--RESR@ZE94G"->M&9
M1116!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_\
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M?8%?'_[1_P#R53]F+_LH$G_J1_#^OL"@ HHHH **** "OX/_ /@XJLM2U/\
MX*:>!M-T:[_L_5]0^!_P?L=*O_M%Q:?8M2N_&WCV"QN_M5JDEU;?9KJ2*;[1
M;1O/#L\R%&D50?[P*_C/_P""X?[+O[3/Q9_X*6_#'QY\*_V=OCK\3/ ^G_#7
MX,6%_P",OA_\(_'_ (S\*65]I?CSQ?>:G9W?B+PYX?U+2+:[TZTN;:ZO[>:\
M2:SMKB">X2.*6-F6'I0K9]PI3JN4*,N(:,*]2,G3=*C4R_,:<ZGM5;V5N=)5
M+KEDXM.]AXBK*CD?$U2FHRK1R*K*C3E%5%5JPQV7U(4_9N_M;\CO3L^:*DK6
MN=-XC_X(U_\ !<KQAH&L^%/%W_!1O1?%/A?Q'IE[HOB'PWXC_:]_:^UO0->T
M;4K=[34=)UG1]3^%UUIVJ:9?VLLMM>V%];3VMU;R/#/%)&[*?T__ ."5_P#P
M16\$?\$_M>E^-/Q#\=6WQ>_:'U+PVNB6FHZ3H\^C>!/AA:ZQIUFOBO2O!L=_
M<SZOXGU&]O5OM,_X3W6+3PW<WWAEX[*U\&>&I+W6AJ7[ET5T4<14P[JRHJ$*
MM:E*A.LH+VOL)TZM*I14GHH5(5JD9-+G493A"485*L9X5:$*RIQJN<Z=*K&M
M"DY/V?MH3I3IU7%6O.G.C3E%7Y7*,92C*5.DX,D_U<G^XW_H)K^&+_@WQ_Y2
ME?%__LDOQL_]6/X(K^YV3)1P!DE&  [\&OXUO^"&?[+W[3'PD_X*0_%/QS\5
MOV=OCI\,O!.H?##XOZ?I_C'XA?"3Q_X+\+7U_J?C[P?>:;96?B#Q)X?TW2;F
M[U"SM;FZL;:&[>:[MK>>>!)(HI&7+*?=XCE.7NP_U8XBASO2/// UE"',].>
M3:48WO)M))MFN8>]D%:"UF^(^%IJ*UER4\9B'4GRK7E@FG.5K133DU<_8G_@
MOO\ &5OA+_P3<^*.D6=W'::Q\9/$G@OX2:<3-%'/)::MJX\2>)8X(94D-PMQ
MX5\+:SI]PL:J\4%\TRR1NB-7TK_P2@^#$OP%_P"">7[+/@.\MI;75[OX:V7C
M[7K>X1DN;?6_BA>WOQ$O[.Z5X+>19]-?Q,NF/'(C-"+-8!+*D:2-^8'_  7D
M^#GQY_:I^*G[#/[.'PR^$7Q?\7_#>\^(=QXB^*WCWPA\._''B;P#X.7Q3X@\
M,>!](U#Q5XCT31Y?#6BOX=T&3QKK%_+JNM6<NFZ1>"\N&L+&Z^U3_LA^V?XS
M^)_P,_8W^,?B']G'P-XF\:?%7PG\.5\/_"3PAX(\*ZQXX\0KX@U&33O"/A^^
MTOPKHEAJNIZTOA0:C'XAN+9+&X@%EHT\NH;+".ZE3"A7^IY)GV82A.M/'YU&
MGA:4%_M4L)P]E_U>>$<':2IXK-<?6J8&'O4ZL_:U_=]I%RVKT7B\VR'+H3A3
MAA<OE6Q+J7]A3S'/<<H8;$\ZYHNI2RK"TX8GE=\/2JQIV56>(BOQG_X+%?\
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MB@ HHHH ^/\ ]G#_ )*I^T[_ -E C_\ 4C^(%?8%?'_[.'_)5/VG?^R@1_\
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MDL;89=T<BAT;:P##*D'# ,,X(!XJ2OH6FFTTTT[--6::W37<^7=UHU9K1I]
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M)QC)-!1116QRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\NKW]GK$]BMQING:)I5QX?\ B?J%O!>-;#5H8O"1LHA9OJ4CR:99M?I]V_\
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M:197"Q1-<W,<GZ,_\%,D2/\ 8F^+T<:JD:2?#M$1%"JB+\3?!JJJJ,!54
M    #BORM_X)2%_'/[87Q \;:W(\^L+\/?'7BUI9"9GDU?Q#XP\,6=].\KD.
M9&BUR^!D.6?S&W#YLC]5/^"FO_)E/QA_Z[?#S_U9W@VOXSX5G7SCZ._BOQUF
M*Y\YX^GQAGN.K2DI3AA\-"65X'+8M-I87+5@\3#!T[OV5.O*G!^R5-+^^?$;
M"TN%/I#?1H\*\N7LLG\.,5X88.G1C90K9WG/%>"Q^?9J[))XC-:D,'6Q4TK3
MK4Y3LKV7YX_\$U/V1/V>/V@/@QXP\6?%SX>_\);X@TOXE:AH%A?_ /"6>.-!
M\C2(/#7AG4(K3[+X9\2Z-92[;O4+R;SYK:2Y;SO+:8Q1Q(GZ*K_P30_8D5@R
M_!3#*0P/_"Q_BV<$'(.#X\QU]:_%C]CC]G#]K_XQ?#KQ!XB_9]^//_"K/"6G
M^,;O1]5T+_A:/Q/\$?;?$$6C:+>3ZI_9G@G0M3TRY\S3[W3K7[=<SI>O]D\A
MXA!! S?HM\!/V1/V^O ?Q@\!^+_BA^T__P )GX T'63>>)_"_P#PNKXS^(O[
M9T\V5W"+7^Q/$/AJST74?](E@E\C4+F&#]WYF[S$0'3PKIY/C,AX#P.,^CO1
MQT,7A,APF)XVQ.0<+8C#U85_J]&MQ%B*U;"SQ]6C&,Y8^K.;EB94XR=W49[G
MCG4S[!<;>(>89?\ 2MK\-3P=?'XS!^'N%XFXUP6*P=7#8"%:CD6&P^"QE/+:
M%?%5(*G1C2C&@JF(BY67.UH?\%=/A!'XF^ GA;XEZ7:;K_X2>(X+6\=0SO'X
M1\7?9=&NPS?,[BWUVV\-,ID+".*2ZD+ LY/5_P#!)GXJ2^.?V:IO!-_/YNI_
M"7Q5J/A^$/*LDQ\-Z[GQ'HDLF6\U4BO+W7-+ME=?+2UTN"*%V6,QP_H=\2/
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MT57_ ,L?X;__ #'T?\3X^$/_ $3GB1_X9^&/_HP#_B3/Q0_Z'W 7_ATXA_\
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M_M7?]%5_\L?X;_\ S'T?\3X^$/\ T3GB1_X9^&/_ *, _P"),_%#_H?<!?\
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M -& ?\29^*'_ $/N O\ PZ<0_P#T+']&E%?SE_\ #>/[5W_15?\ RQ_AO_\
M,?1_PWC^U=_T57_RQ_AO_P#,?1_Q/CX0_P#1.>)'_AGX8_\ HP#_ (DS\4/^
MA]P%_P"'3B'_ .A8_HTHK^<O_AO']J[_ **K_P"6/\-__F/H_P"&\?VKO^BJ
M_P#EC_#?_P"8^C_B?'PA_P"B<\2/_#/PQ_\ 1@'_ !)GXH?]#[@+_P .G$/_
M -"Q_1I17\Y?_#>/[5W_ $57_P L?X;_ /S'T?\ #>/[5W_15?\ RQ_AO_\
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MO_EC_#?_ .8^C_B?'PA_Z)SQ(_\ #/PQ_P#1@'_$F?BA_P!#[@+_ ,.G$/\
M]"Q_1I17\Y?_  WC^U=_T57_ ,L?X;__ #'T?\-X_M7?]%5_\L?X;_\ S'T?
M\3X^$/\ T3GB1_X9^&/_ *, _P"),_%#_H?<!?\ ATXA_P#H6/Z-**_G+_X;
MQ_:N_P"BJ_\ EC_#?_YCZ/\ AO']J[_HJO\ Y8_PW_\ F/H_XGQ\(?\ HG/$
MC_PS\,?_ $8!_P 29^*'_0^X"_\ #IQ#_P#0L?T:45_.7_PWC^U=_P!%5_\
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M_P"HYX4K[ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OPI_X*=_\ )>_"/_9(= _]3/Q_7[K5^%/_  4[_P"2]^$?^R0Z
M!_ZF?C^OY+^FK_R8W'_]E)P]_P"I%8_IGZ)7_)X,'_V(,\_],TC\Y:_=;_@F
M)_R03Q=_V5[7_P#U#/ %?A37[K?\$Q/^2">+O^RO:_\ ^H9X K^)_H5?\GRP
M'_9-\0_^H]$_K?Z6G_)G\;_V/LC_ /3]0_1JBBBO]C#_ "O"OYFOC]=_M#_L
M5?MH6/QD\17GC3XC>&K/6-1/P_\ $?C+7O$.NZ5XC^&NNRZO+<?#0>*=6DU?
M^S=1T.QU34[-],;S)M*U)+7Q9!HTMC?6$EY_3+6?JNE:7KVEZCHFN:9I^LZ+
MJ]C=:9JVD:K9V^HZ7JFFWT#VU[I^HV%Y'-:7MC>6TLEO=6ES%+!<02/%+&\;
MLI_+O$[PZQ/'E#(<7E'$6+X7XEX4S/\ M?(,UHT5C<+'$_NG.CC\NJ5*='%4
M:KP]%*<_:>Q2G&=#%8:MB<)B/V3P:\6*7A;FN>O-.%\!QAPQQ9DF(X=XER+%
MU?J5?$9=BHSISJ8',HT*]7"5XT:V(HSC&'L\30KU*<G1K+#XK#?D3>_\%E_@
M<GAF2ZT[X6_%:X\9?V5'+%H=ZGA"S\,G7# C2V$GBJ#Q+?:JNE1W)DBCU=?!
MK7DT").VB022-;1?*_\ P36^$/Q(^,'[36J?M5^)-'.D>$M+U?QUXFGU9-/G
MTW1O$?C;QO'KEA<:-X6C=@L]EHTFM:E?7SVTUU!I1L[#3+MFFODQ^W<7[+_[
M-,$L<\'[._P,AFAD26&:+X2> 8Y8I8V#QR1R)X?#I(C@,CJ0RL RD$ U[G7R
MN \+.,LZXOX9XL\2N,\OSQ<&U:^+X?R7(LE65X-9E6=&2S'&XJ=65>I.E.A0
MG'#QI.+J8;#SA6HP6*HXS]#Q7C=X<\)\'<:\+^#OAUFW#F-\0LMGDG$/$'$W
M$DLYQ&%R2<*U&KEN58*-%TX_6*&,QE-XJ>)I5:,IPJ5(XR<,,\)^+_\ P5 _
M8M\8_%"_T[X]_"/0KKQ-XDTW2+7P_P"._!^B6)N=>UC3K![A])\3:19VX-WK
M>HV,,PT?4--MHKG4YM.ATJ2Q@EAL+I5^9=$_X*2Z7XX_9K\7?L^?'^T^)&A>
M(K_P@/!-C\4OA7I_AC6=5U.R"/:R)XK\+^*=8\*V\.ZRM[72O$2:9K)G\4Z;
M>ZO!#-X3O6BU!_Z.J\R\7_!3X-?$+54UWQ]\)/AEXXUN.TAT^/6?%_@+PKXE
MU5+"WDFE@L4U'6M*O;M;2"6XN)(;99A#')/,Z(K2N6X>)O!+-UGO%6>>'_%5
M'A^AQ[AL1A>->&<VR^KCLDSEXNGB88G&4JV%Q.&QN"Q-2>+Q59NDY8A5\?CY
M4,=AL+B*N"JUP5](;(Z?"7"W!?BEP56XNPW .8X;,^ N)LHS.GEG$?#E3"8B
MEB*&#E#%87%8#-,$G1HT51Q:6&^JX?#4<3@L;/#X2OA?Y&?&G[3/QG\6_#RY
M^"VL_%+Q=XU^%MKXE@UG1HO&$<+^(9K?21=6VCQ7]])?:YJMO8"WEMKO_A%I
M/$NMZ)H]_:VHTN9A:BYG_>3_ ()5>(_@#;?!-/ ?PY\7+JWQ696\;_%K1=4T
MZ\T77+?4;^Z;2K<Z?;7;36>K^'=#M+;3-+34M U#4+:.2[L[_6H=!U3Q)'I"
M?H%;?!7X.V/A#6?A]I_PI^'&F^!/$4_VO7O!NF>"?#>G>&-8O!]DV7NHZ'9:
M;!IMW?1FPL&AO9[9[J%[&RDBE1[6!H_-?@%^R5\&/V:-4\=ZI\*='U/3'\?7
M.ER7MOJNK3:Y'HMAI$,R6FB:!>7\<FKPZ2US=76H7*:GJ>K7MU>S*9KY[:ST
M^VL_*\-?!KC?@'CW"\1YGQ'E/&6$QV02R?-LSS2&:O/LFIX>DI8/ 9&\3CL5
M1JX.57#X'#SQ6(J0JPP=.K1I8.@G)U_L/%;Z1?AOXF^&'$/!N6\(Y_P#CZ>?
MX+B+)<)D=3(8Y'Q3F#J4</C\7Q;'!Y9@IT*ZP]7$XY8;!TJM/%8_"8'$5LP4
MZ5.@OI>OP*_X+4?\C#^S[_V!OB+_ .EW@^OWUK@/&OPH^%OQ)DT^;XB_#7P!
MX^ETA+F/2I?&O@[P[XJDTR.\:%KN/3WUW3K]K)+IK>W:Y6V,:SM!"90QB3;^
MH^+O >+\2."<;PK@<?ALMQ&*QF7XF.+Q5*K5HPC@L3"O*+A1]]N:CRQ:T3=W
MH?@'@?XBX+PH\2\@XZS'+L5FV$R>EG%.I@,%5I4<16>9Y+F&5TW"I7_=15*I
MC(U9\V\(2BM6C\E?VK/AX?%G_!+3X)ZZ+-VU'X;>"?@IXOA;8B3QV-]X=T_P
MOJ )D7S3:O:^(XKV6.-E$AM+:=@ZPK7QO_P2N\*7_P 1OVL+7QEKC2ZFGPQ^
M'E_J,-W<>2ZPSPZ1IOP[\,VC*R?-]BT2^F2R9 )8SID4QD\R,LW])]QX0\)W
M?A?_ (0>[\+^';GP5_9$/A__ (1"XT339O"_]@VUO':6^B?\(_);-I/]D6]I
M%%;0Z;]D^QQ6\4<*0K&BJ,+P5\)_A9\-I=0G^'7PT\ > 9]6CMXM5F\%>#?#
MOA674XK1I7M(M0DT+3;![R.U>>=K=+DR+"TTK1A3(Y/Q>8>"+QOB]PYXCK-<
M/#+,IP>5SS'*71JO%8W.\DR_'8++,PI54_J\84+Y5*'M(.M2^K8ETZG[VG&'
MZUDWTF(93X2>)7ATLBQM3,N,LWXKQ&2YNL305#)\FXPJX.6:Y96@X^WDY1AC
MZEZ$E3JUL32=2*5+F/YSOVA[=[;_ (*M6T<A4L_QT^!-P"A)&RZL/AW<Q@Y5
M3N6.50XP0'#!68 ,;G_!5*W\7:3^UQI.O^/-(OM<^'4_AWPC/X*T^2\O;+2=
M6\.:283XN\/VFIP1NNG:C-KSZJ=4-H'O[&WU?2M0DB\J[T_S/Z&-3^"OP;UK
MQ8OCW6/A+\,]6\<K>Z=J2^--3\!^%K_Q8NHZ1':Q:3?KXCNM*EU@7NEQ65G'
MIUT+SS[*.TM4MI(EMX@G4^*O!WA'QWHTWAWQOX5\.>,O#]Q-!<7&A>*M#TSQ
M#HT\]K()K6:;3-7M;RREFMI5$L$CP,\,@#QLK &OE\=]'?,\;PKQ%D4>*,)A
M<9F'B77\0LKK++Y8O J^%KX2CE>;X/$RY,524<1.K-N%:BZM.DYX>M#F@_H<
MF^E=E63<1>%><K@W%XZAP3X5T_#7.Z53,:6%QF)<Z&44\1G608NA3G/ XB-3
M*_W4*G)5GA<16PRQ&&G5^L4OYX_CW^UQ\$OBW\"?&GP4_90_9EU7P=+XGL-.
M\6?%/4-,\!>$?#-MHOA?X<ZAIOB>36YXO %WJTFL6UC/:-;WFO>)3I-KI-C/
M(RK/=:H$M?JK_@C'JMC-\(OB_H<<Z-J>G_$?3M5N[8,OF16.L>&;*TT^=E#;
MPEQ<:%J<:,RA6-LX5F*N%_5CPU\*OA?X,T;6?#G@_P"&_@+PIX>\1+,GB#0O
M#7@_P]H6C:ZMQ:M8W"ZSI>EZ=:V.IK/8LUG,+V"<2VK-;N&A)2HO!?PD^%/P
MWN+Z[^'?PR^'O@*[U.&*VU*Z\%^"_#?A:XU"W@=I8(+Z;0]-L9+N&&1WDBBN
M&D2-V9T4,Q)^JX4\)N*LG\1L!X@9YQ/D^;5?]7L3D6-R[+\E62X3 T97GA:.
M38>A*I!X>G6A&K7GBYJM5J8G%5(\D%1H+YCB_P >.!LW\*>+/"[AK@OB/)<-
MG'$.6<28'.<WXFGQ)F.-S+#U,NCCL1GU?&PA53GE^78;+L%1P4YTZ%'"X>I5
ME4FZW/\ SF>(/^4LD/\ V<OX<_\ 3AI=?T0?'#XGV_P7^$?Q ^*=UIDVLQ^"
M?#=]K4>E02)"^H7<86&QM7GD(%O;S7LUNMW<*LLMO:F::&WN9D2WDFD^"7P8
MF\6CQ]+\(OAA+XZ&IQZT/&DG@'PH_BT:S"R/#JP\1MI)U@:G$Z(T=_\ ;/M2
M,B,LH*@CN->T#0?%.CW_ (>\3Z)I'B/0-5@-KJFAZ]IMGJ^CZE;%E<V]_IFH
M0W%E>0%T1S%<021EE5MN5!'K\ >&N?<"<(\<Y)A,]P3SKB3.^(\\R7-*6%JN
MAE6+S;+,+A,NGB*%;F=>6!Q>%AB*L8IPJPM!)ZH^2\3_ !=X>\1\S\)JN)X>
MS&EE/ ?"_#O#.?8&KBZ*K9WALKQ%&68_4JU!Q>%CC<-"K1HRG)5*4IJ;DFKG
M\=FC_%7PI\3?V@G^+?[5%SXR\3Z!JVO/XC\5Z7X)L--OM2UG[*4.E>$;*+7?
M$>AVVC^%8H8K;2F\G49[NQT&U73]/C6XECU"T_>7X=_\%5?V:O%OBCP1\-O"
M_@'XPZ1<>)-<\.>"O#T4_A;P#8:'IDNJWUGHFE1RII_Q$N7LM*LVG@1TLK&=
MK>TC*VUK(42(_9W_  RU^S)_T;G\"/\ PT/P^_\ F>J]IG[-O[.NBZC8:QH_
MP#^"VDZMI5Y;:CI>J:9\+/ UAJ.FZA93)<V=]87MKH45S9WEI<1QSVUU;RQS
MP31I+$Z.JL/B/#GPB\4/#J<Z&7\8<)5L#F6=4LUXCKU\CQN)SK-TZL/K,*F9
MXBM*KSNA[=8;F_=4<1B*^)Y'6Q.)J5?U7Q0\?/!/Q2PV6TLY\/..L,N'<DJY
M1PMEN7\2Y=E^0Y*O9*%"=+*\-AU3=G2PM.L[\\\+A,/AXN-.E3C#\7/^"J/P
M/\=>"?C-X>_:G\'Z3=ZAX;N(/"K>(]6M[ WMGX3\8^$[NSL-"NM>6,,MOI.N
M6\>AV=C=W:I:S:K;S:9-.EQ>Z=#<^I:]_P %E_";?# 2^&/A9XBB^-$NGV\9
ML=>&FW'PPL=59]EU>#5=.\1VOBO5=/BC!N;?3?[&T:YG=_L,FJVRQ_VA+^W)
M 8%6 96!#*1D$$8((/!!'!!X(KQ?3?V;?V=M&U&PUC1_@'\%M*U?2[VVU'3-
M5TWX6>!K'4=.U"RF2YL[^POK70HKJSO;2XCCGMKJWECG@FC26)U=58>QB_"/
MC;)<^XMQ_AQQ[AN&<JXZS"KFV=X''Y)#,L3EV:8NI5J8[,,EQ/M8<M:O/%8F
MK&$HX;V3]C3=6HZ5"M0^3RCQT\/,\X-X(X:\7_#7'<8X[PUH_4>%LURCB">4
M1QV3+V7LLES[">R:J8:A#!X+#^VI5*TJV'II0HX6HL5+,?-/V-_CI\4_VA/A
M/:?$'XF_"RT^&[WAM8]!O;/4[][3QS:FW,UUXHTGP[JEBNH>'?#TSR01:-]K
MUWQ"^JJ+F[AO/L26L]Y_/A^T1JWC30/^"AGCO7_AUIDNM>.M"^-MEK?A31H+
M66^EU?6])GTW4+'2UL+=X[B_&H2VPM&L+9Q<WR3-:V^9ID!_K#K^8KQ!_P I
M9(?^SE_#G_IPTNOD?'O*<Q3\"LDKY_CJ^:SXYRO+JG$WU?!T,P>.JU<LH/-Z
M>%P]&G@J5>E6E]9H453E3@X4X595FIU9_HGT5,]RK%<;^.G$66<+9;D^3/PR
MX@S+"\)4\3CL?EF'P='%X.JLKJ8K&UJF,Q-&O"FX8J;E2A)UJJPN'P>']CAJ
M/TC\>O\ @K1X.\=_ WQ/X'\!?#KQOX>^)7C7P[/X6UV3Q*=#;PQX5M];TZ>P
M\3S:/JFGZM)K'B"]M(Y9[#1FO_#GAI'>==7O8K=K+^Q;WV/_ ()(?L^^)OAY
MX \8?&#QAI=[HUS\4TT.U\'Z?J$=Q:7DO@W2A=WL?B"2RFCC*V?B.[U"*;1I
MY%+7>F6$.IVF=/U.UGN?TRU#X)?!C5O%8\=ZK\(OAAJ?C@7]CJH\9:AX!\*7
MGBL:II@MQINI#Q%<Z3)JXO\ 3Q:6HL;S[9]HM!;6X@DC\F/;Z?7Z-POX7\24
M^/:?B'Q_Q9A.)\ZRG*J^2<.4,LRB.3X'+\-B(UZ>)QM2E[:LY8S$T<9C:,Z<
M>90CBJB>)KTX8>EA_P FXI\:N#*7AAF?ACX6< XW@S+N+,SP.;\8XW-N(:N?
MXS$SP$\/B,/E.7UYX>C5^H4,3A<.Z>(K2IU)T*=6,\&JN-Q-9_RU?%;QBO[.
MG_!2WQ5\1_'&B:O<:3X<^+][XSN;#2H[=M3O_#?B2SDO+*\TE;^>RLKN9]-U
M:.YABFO;6WEN(GLY;RV8/-%]/_\ !0SXU7G[3O[*_P *OB]\*=,\867PAMOB
M3XDTKQS8:Y:V-KJ=CK]G;6NG^%;[7K+0=7U^P@THRRZS;V5W<ZAY2W^J:5#(
MD5YJ%A&_[;^-?A1\+?B3)I\WQ%^&O@#Q]+I"7,>E2^-?!WAWQ5)ID=XT+7<>
MGOKNG7[62736]NURML8UG:"$RAC$FW:T#P9X/\*>'H_"/A;PIX:\->%(8[R&
M'PQH&A:7HWAZ*+4)9I[^*/1=.M;;34COI[FXFO$6V"W,L\TDP=Y7+?%X7P!X
MBH<,^(' ;XUPD.#^+,PQ6>Y9&AE%2.;X'.JF:Y!C<//'U_K488K K 9''+<9
MAJ4Z<<5[:6*A'#MN@OL\1])GA.MF7A#QI/P]QN(X^\,\NRG(,36KY[37#^9Y
M%@,MS3 8J.%PWU.K5PN95Z^/CF6 Q56C6>68F*IRECX4(3J_SR_LW_ML?LW?
M!KX/>$_#WA+]F*ZUK]I[3=+OO#VD>)]/\*^$K^;Q1XDU^^N+&*>3QVMU)\1E
M&K0:CY;>'=.T.ZQF/PQILRV#PWL'&_\ !*\3>$/VS+SPOXGMKC0_$4G@GX@^
M%9-'U*%K/4+;Q%I-WIFH:GI-S:W'ESPWUC;Z#JQN;9D,\+V<RR(OER%/Z(/"
M7P/^"W@'5QX@\"?"#X7>"M>6VGLUUOPEX \)^'-76TN=GVFU&I:/I-G>"VN/
M+3SX!-Y4NQ/,5MHQ+%\%?@Y!XN/Q @^$OPSA\>-J,VKMXVB\!^%H_%QU:X#B
MXU0^)$TH:R=1G$L@FO3>_:91(X>5M[9WRCP2XQP_$7AWQ%F_%N08Q\#5?JU/
M*<LX=IY+@/[,E0AAJ]>C+">]7S?%TTJF(J5J6'PG-A\-2HTJ2]K4GV9S])7P
M^Q&3>+62Y+P)Q5@Y>*F48J&89YF_%M7/LQIYO*IF%;+L/##8V]#!\/Y9B,SQ
MU:EAL-B)XJH\;7BYPC"BH?C+_P %;_V>O&DWBKPM^TAX.TK4M4T.Q\.V?AKQ
MQ/I<=Q>3^%[S0[^^U#0_$E[#$DDEEI%W;7SZ?/J0VZ?87NG6:7;07&J6[76O
MK'_!87PSJ/P-U#3;3P#XUTWX\W_A*ZT:.]MGT)/ .G>);J.33!XHL]<75AX@
M\JT@<>);;1CX41AJ2)X<.JBU7_A)3^Y]>,+^SA^SPFJ+KB? 7X,)K::@-676
M%^%W@==475%N/MBZDNH#0A=KJ"W8%T+P3"X%P//$GF_-7JYOX0\8X'B#C#-/
M#OCG#<-Y;X@S>(XERW,,H685,'F$X5J>(S+(\7"K"I1Q&*^N8VO.#]A*GB)Q
M;Q%:$<''+ODN'/'3@/,>"^".$O%SPZQO&-3PTQ%2?"&:Y1GLLJJ5LNK5:5:I
MDF>86=*5.O@;X3!4)U:-1SJX7"X>E&E0J4\16QOY^_\ !,R;]I3XF?#/QCK?
MQ[\9^+?%7PGUS3[CPYX#TOQPL>H:WXA75)+B;Q-XB/BG5+!O&.JZ&D$Z:+HT
MMUXAO-+9I=4MK*WB72K8Q?F[X1U#XG_\$OOVI;^Y\5>$K_Q#X)UFVUKPY'=+
MBSM/'W@"?4;"]M=:\-:N\$]@GB'1IH-&OM0TQ_WEI<FXT*_DL(-4BU)?ZBZP
M_$GACPWXRT6]\-^+_#VA^*O#NI+"NHZ!XDTFPUS1=06WN(KN!;W2]4M[JQNE
M@NH(+F$3P2".XABF3;)&C#MSKP6Q=;*> JV0<99I@N-O#JCB*>4<59M"6;RS
M.GBTY8O!9K0Q%>51X"I-_5L%1]OB:>5Y7.KE].ABJ,K+/(OI'X7"\6^(^*SK
MP\R/$>'?BI1PV"XCX"R6I#):>"P^#A4HX/'Y9F&#P=%2SFE'$8C%8[&O"X:K
MFN/J?6?;9=5IX:KA?Y_?VP_^"D.D?M)?#F/X&? GP!X\A?Q_JFD6'B&[\3:=
MI7]OZE'#JEO<Z;X5\*^'?#&K>)Y+^\UO5XM-#WK7\5R(X)-)M=(NY-3%[9?H
MW^P1^RQJ'P,_9RU#PM\0;5(/&'Q6EOM=\:Z6IBDET6QU72(M(T[PS/.L8\R[
MT[2@\VHQEI[>UU?4=2MK>2>&(7$_UUX-^#7P?^'6I7&L_#[X4_#;P)J]W9/I
MEWJO@WP+X7\,:E<Z;+/;W4FGW%]HFEV-U-927-I:W#VDDK0//;6\S1F2&-E]
M(.2" =I((!QG!QP<'@XZX[UZ'"7A;F6$XDSGCGQ SZCQ?Q3FF2/ARC3P>7PR
MW*<KR)U)SJX'!T)57.K/%-N3K3>&5)XG&Q:JSQ57$R\;CKQHX>Q/ >"\+?"O
MA'%\$\'0SV'$V<8G,\WEG&?Y]G5.-)8:IBL1&E3I87#X-T,,X4Z3JRJO!8&<
M?JRHU*=?^6/X6>+_ !K_ ,$T/VM]=T[Q]X8U+6/#LEG>^&M:CMHX[>Z\5_#C
M5M5M[S1?''@R:YF33+R[CGT>VO8+6:[CMWNK77/!^HW^B:FM]>:5Z5^W;^W"
MO[6'P\L/#GPI\ >,]&^%/@[7]$U[QSXM\76>G6EW)XKU"'7--\+^'?(T75-<
MTFRM9+0:KJ5J)=9N-5UR:WNW@TO3['PU>7>H]+XN_;2^,GPN^+=Y\&/VW?A=
MX"^.G@?PYXZO]2GD\8_"GPM-XJ'AR2*[TK1O$7P[@/\ 8W@:ZM9K</J6GW>H
M:-<WNH176IZ+/XCL=X?3>-_;#_;8^#/QP^#7A#X _L[?"'7?!&A0^-+?Q!<6
M%SX9\*>%+*TG@748['2?"GA7P-JNN6=U=:[JNO7=[J%T[Z>\,]ND4-CJESK$
MMUIG\;X[.<#@_#/BG@W)O$K%X?A^GCZM/*_#S.^&7@^.OKU3,L%BIY%CL52J
MXRA2P>&QM6M7QM?!UIO&8O"8FBXX6EBJU*/][9?D6<9_XE>&''O$/A#@L_XL
M> R?ZYXK<,\8_6?#IY30PV)E/B=996PN78J>:_4Y5/[,P.,P]..'EB\)*&*S
M"> PM%_I;_P28_Y-(M/^RB^-?YZ77Z9U\:_L"_"#Q#\%/V7OA_X3\7Z?-I'B
MS46UCQ;K^D7*".ZTJZ\2:E/>V.G7D?E12PZA::*-+BU*UN0UQ8ZBMU8NY6V0
M+]E5_H+P!@<5E? 7 ^68ZC/#XW+N#^&,#C</4BXU,/B\)DF!H8JA4B]5.C7I
MU*4_[T';0_S.\:LUP.=^+OB3FN68BEC,OQO&G$-7!XNA.-2ABL/_ &EB(4\1
M0J0;A5H5XQ]I1J0;C4IRC.+<9)G\S?\ P52M_%VD_M<:3K_CS2+[7/AU/X=\
M(S^"M/DO+VRTG5O#FDF$^+O#]IJ<$;KIVHS:\^JG5#:![^QM]7TK4)(O*N]/
M\SI?CW^UQ\$OBW\"?&GP4_90_9EU7P=+XGL-.\6?%/4-,\!>$?#-MHOA?X<Z
MAIOB>36YXO %WJTFL6UC/:-;WFO>)3I-KI-C/(RK/=:H$M?Z'/%7@[PCX[T:
M;P[XW\*^'/&7A^XF@N+C0O%6AZ9XAT:>>UD$UK--IFKVMY92S6TJB6"1X&>&
M0!XV5@#6+X:^%7PO\&:-K/ASP?\ #?P%X4\/>(EF3Q!H7AKP?X>T+1M=6XM6
ML;A=9TO2].M;'4UGL6:SF%[!.);5FMW#0DI7X/C_  !XFGF?B''*^-\NPF1^
M(6-S+,L>\7PWA\;Q%AJF85L5B*F58;-JM5RHY94EB7A*TXN4X8&/)A<-A\3*
M>(G^^9-])OA"APIX78#/?#S-LQXB\*(Y?1R)9=Q=BLHX5S"IEN(R_$8/.<VR
M;#T;8K,\-7R_#Y@J-2-6G7S.BZ];%_5\1+"T/RG_ .",>JV,WPB^+^AQSHVI
MZ?\ $?3M5N[8,OF16.L>&;*TT^=E#;PEQ<:%J<:,RA6-LX5F*N%^,/V>?^4L
M>L_]EX_:$_\ 1/Q'K^B+P7\)/A3\-[B^N_AW\,OA[X"N]3ABMM2NO!?@OPWX
M6N-0MX':6""^FT/3;&2[AAD=Y(HKAI$C=F=%#,2:NG?!7X-Z1XL?Q[I/PE^&
M>E^.I+_4=5D\::=X#\+67BR35-7%R-6U)_$=MI46L-?ZF+R\&HWC7AN+T75R
M+F27SY=WT</!W-WA?!"C5SC+O:>%.9T\7CW3H8EPS:A0Q67SHPP?,E*C5EA\
M!'VGMDXQK5&HN4(\TO*J?2)X?7%?C[Q!0X=SCZOXQ\(8CA_+\-5Q6"]MDN-Q
M633RZMB,9.-X8G#1Q-2=:G&@H5?8\M.2<TY/\I_^"T'_ "3;X*?]CQXC_P#3
M#;U]0?L;P>*;K_@GEX(M? \H@\:7/PQ^(D'A&9I1;B'Q--K/C&/0I?/;"P&/
M5&M7$S$+&0';Y5-?:'C3X;?#OXD6UE9?$3P#X+\>V>F3R76FVGC3PMH?BFVT
M^YFC$4UQ90:Y87T5I/+$!')+ D<CQ@(S%0!6UX=\-^'?"&C6/ASPGH&B^%_#
MVEQR1:9H/AW2K'1-&TZ*6:2YECL=+TV"VL;2.2XFFGD2W@C5YI9)6!>1F/T.
M!\,<9A_$7Q*XRK9O&&!X\R++LEH8?!1JT<SRQX3*,MRRKBHXF5Z7M>;!3KX>
M5-7IRE3<KN+1\#F'B_@,3X)<!>%U')*SS/@WC;%<65LQQDZ%?*<PI5JV>5J>
M!E@URUVF\UI0KJ<E"I"E5BFN>-OY,/V3OBM\%/@;\3_&UY^U#\%[WXG17&EW
MNAC3M8\-Z%XGU;POXHM=7C?5?M_@_P >7.FZ7+J-Q)!+:7NH7MU#K.C36TUO
M!#(-1OPC/VUOC%)^T%X^\,?%30?AEJ_PX^%">%5^&WPI&H:8FGVNMZ!X"U.^
MENY;1;%#H,4^F7/B2.PN](\/75_IV@1K9:9]MN9HGFD_J<\6_!#X+^/]6_M_
MQW\(?A?XUUTVT-D=:\6^ /"GB35OL=L7-O:?VEK.DWMY]F@,LAA@\[RHC(Y1
M%WMG3\6?"KX7^/;'2-,\=?#?P%XTTWP^KIH.G^+/!_A[Q'8Z(LD,-NZZ1::Q
MIUY;Z:KV]M;P.+..$-#;PQ$%(D5?Q:O]&?BZMP7/@9\<Y##)<NS"&/R:GAN%
M:6"Q6/Q'UW%S^L<0YE3JU,=4C@L'F&81P.#A/%Q5;%4Z4L5##8&@I?T51^F'
MP+#CW+/$:IX:<23XBJ99/*LX57C6OBLIRO"/+X4&N&,FJ8>GE]+$8O$X?"+%
MXFM1PB^J4:[6'GC,94Q%.[\/-5L==\ >!]<TN=+K3=9\'^&M5T^YC972XL=0
MT6RN[2=&1F1EE@FCD5D9E(8%6(P:ZV1!)')&>DB,AZ]&4J>A'8^H^M9NAZ%H
MGAC2-/\ #_AK1M*\/:#I-LEGI6B:'IUII.D:9:1Y\NUT_3;"&WL[.VCR=D%M
M#'$N3M49K5K^R*M\5"JL5"FWB8S6(IQ<I4FZR?MH1;49.F^:44VHMQW2>A_
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MEQ49X:3IXW#X9U/:1?/A)8J@FE7DI?C;_P $=/A#.\'Q0_: UVU:>YU.YC\
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M'#=.*I5LU=-4X2E/$8O,<;GV.I2I0A",ZV6JJIO"N1^:G_#G#]F3_H>OCO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9!\/_M.:9^QOJ_QGTNU_:0U>ZTZPLOAROAGQS= ZCJ^A'Q+IFF77C"T\+S^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCGA2OL"OC_\ 8I_Y)7K_ /V4#5?_ %'/"E?8% !1110 4444 %%%% !1110
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MP/J/CFR,2P&S\8WOAC2[GQ-:F!)9DA-OK4M["8EFE6/9L660 .?(?VR/VM_
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M7^,=(NM3T;7M"\9VNJ_$&^EU_2?$.IQ7OQ%N?#5R_P#:IO9'CO;Z^BC^9?\
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MTN.>YD,DJ:?H?[47A_1=(LPQY\C3])T^RT^U3I';6T,8X45]'_%/_E7'L?\
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M66-_X+MM%LH?#%W9^*-0U'5[_P 16MQHJ64MOK=[JNI76J0LE[/?7<LS3O\
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MC_B4;Z0O_1OO_-KX(_\ HE#_ (F<\#O^BW_\UKB__P"<!^0]%?KQ_P .JO\
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M^J\?^8O_ /QB4?\ #JK_ *KQ_P"8O_\ QB4?\2C?2%_Z-]_YM?!'_P!$H?\
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M?^;7P1_]$H?\3.>!W_1;_P#FM<7_ /S@/R'HK]>/^'57_5>/_,7_ /XQ*/\
MAU5_U7C_ ,Q?_P#C$H_XE&^D+_T;[_S:^"/_ *)0_P")G/ [_HM__-:XO_\
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M9SP._P"BW_\ -:XO_P#G ?D/17Z\?\.JO^J\?^8O_P#QB4?\.JO^J\?^8O\
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M ,VO@C_Z)0_XF<\#O^BW_P#-:XO_ /G ?D/17Z\?\.JO^J\?^8O_ /QB4?\
M#JK_ *KQ_P"8O_\ QB4?\2C?2%_Z-]_YM?!'_P!$H?\ $SG@=_T6_P#YK7%_
M_P X#\AZ*_7C_AU5_P!5X_\ ,7__ (Q*/^'57_5>/_,7_P#XQ*/^)1OI"_\
M1OO_ #:^"/\ Z)0_XF<\#O\ HM__ #6N+_\ YP'Y#T5^O'_#JK_JO'_F+_\
M\8E'_#JK_JO'_F+_ /\ &)1_Q*-](7_HWW_FU\$?_1*'_$SG@=_T6_\ YK7%
M_P#\X#\AZ*_7C_AU5_U7C_S%_P#^,2C_ (=5?]5X_P#,7_\ XQ*/^)1OI"_]
M&^_\VO@C_P"B4/\ B9SP._Z+?_S6N+__ )P'Y#T5^O'_  ZJ_P"J\?\ F+__
M ,8E'_#JK_JO'_F+_P#\8E'_ !*-](7_ *-]_P";7P1_]$H?\3.>!W_1;_\
MFM<7_P#S@/R'HK]>/^'57_5>/_,7_P#XQ*/^'57_ %7C_P Q?_\ C$H_XE&^
MD+_T;[_S:^"/_HE#_B9SP._Z+?\ \UKB_P#^<!^0]%?KQ_PZJ_ZKQ_YB_P#_
M !B4?\.JO^J\?^8O_P#QB4?\2C?2%_Z-]_YM?!'_ -$H?\3.>!W_ $6__FM<
M7_\ S@/R'HK]>/\ AU5_U7C_ ,Q?_P#C$H_X=5?]5X_\Q?\ _C$H_P")1OI"
M_P#1OO\ S:^"/_HE#_B9SP._Z+?_ ,UKB_\ ^<!^0]%?KQ_PZJ_ZKQ_YB_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"7W]@4\13_ .??UOZQ_8NOV_8<G]C[?ON;ZQO'V/[W^=7XR_ [XP_M#?\
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M5<>;<37TFK#4/#_]<%%=^-G2S.O6JYC3E7ABJ\Z^+HTJGL(XCGDYSI3:A/\
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MO<7)=$^^O^#BJV\;? SQ7^R?^VG\+WMM/\6Z#8?&3]GO5=7N+>2YCM[/XE>
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MA,XRW-*\HSO%U*6)AEE#"TZ3C!X>\J[J5VW3?X<_\'#_ /RC.\>_]E.^$?\
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M^J_4^;GC;G^L<KY?82_FU_X*0?\ *;/_ ()0?]>\O_J7^(*_4#_@K!_RC?\
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M?#4J5&%6.%<J=IU8THUL3"56>'Q&*<J\Z%JE:G5^2?V#_@/XJ_9C_8]_9[^
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MUZV(J5<554TJ]14Y>S@X*Y11161H%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/\ ^UE_R:Q^
MTO\ ]F__ !E_]5UXCK\__P#@BE_R:QX^_P"S@/%7_JNOA57Z ?M9?\FL?M+_
M /9O_P 9?_5=>(Z_/_\ X(I?\FL>/O\ LX#Q5_ZKKX54 ?L!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\?_ +:W_)*] _[*!I7_
M *CGBNOL"OC_ /;6_P"25Z!_V4#2O_4<\5U]@4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Q_^T?\ \E4_9B_[*!)_ZD?P_K[
MKX__ &C_ /DJG[,7_90)/_4C^']?8% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!\?^,O\ D\KX3?\ 9/\ 4O\ TA^)=?8%?'_C
M+_D\KX3?]D_U+_TA^)=?8% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!\?_ +.'_)5/VG?^R@1_^I'\0*^P*^/_ -G#_DJG[3O_
M &4"/_U(_B!7V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?'_ .Q3_P DKU__ +*!JO\ ZCGA2OL"OC_]BG_DE>O_ /90-5_]
M1SPI7V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?)_QV_;%^&7[/?B[3O!GC/0O'>IZIJ?ART\3P3^&-,\/WM@EA>ZGJ
M^E10S2ZKXGT6X6\6XT6Z>2-+62$0R6[+<.[R1Q?6%?A3_P %._\ DO?A'_LD
M.@?^IGX_K\#^DEXA\2>&'ACBN*N%:N$HYM1SG*,%">-PD<90]AC*U2%=.A.4
M8N3C%<LKWBS]I\ ^!\A\0_$+#\.<24\55RRIE69XR4,)B982LZV$ITY4FJT8
MR:BG)\T;>]W/KS_AYW\!/^A1^+W_ ((/!G_S?U]8? GX[>$?VA/".H^,_!FG
M>(],TO3/$=WX8G@\3V>F65^]_9:9I&JRS0Q:5J^M6[6;6^M6J1R/=1S&:.X5
MK=$2.27^7FOW6_X)B?\ )!/%W_97M?\ _4,\ 5_-?T;?I)>)WB?XG87A7BK%
M9-6RFKDV;XV<,%E%+!U_;X.C3G0:KPJ2DHJ4GS1M[R/W[Q\\ _#WP\\/<3Q)
MPWA\UI9G2S7*\)"6+S.IBZ/L<75G"LG1E"*<FHKEE?W7<_1JBBBO]$#^& HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_IJ_\F-Q_P#V4G#W_J16/Z9^B5_R>#!_]B#//_3-(_.6OW6_X)B?\D$\7?\
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M8VE7KT:<=9>QH5J=!U:G2G3J5IU(49S:C4>%QEG;#5&OHRBOYIM%_P""M?\
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MIQG1S+$8C#82I3DJD:D\-A*>-J2YHWC[-T*L)4ZB;C-NR[GZ!T445F4%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!E C_]2/X@5]@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Q_P#L4_\ )*]?_P"R@:K_ .HYX4K[ KX__8I_Y)7K_P#V4#5?
M_4<\*5]@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7X4_\%._^2]^$?\ LD.@?^IGX_K]UJ_"G_@IW_R7OPC_ -DAT#_U
M,_']?R7]-7_DQN/_ .RDX>_]2*Q_3/T2O^3P8/\ [$&>?^F:1^<M?NM_P3$_
MY()XN_[*]K__ *AG@"OPIK]UO^"8G_)!/%W_ &5[7_\ U#/ %?Q/]"K_ )/E
M@/\ LF^(?_4>B?UO]+3_ ),_C?\ L?9'_P"GZA^C5%%%?[&'^5Y#<?\ 'O/_
M -<9?_0&K^-W_@AY_P %(?V+_P!C/X$_''P%^TG\9?\ A6_BSQ-\?M9\6Z'I
M/_"N_BMXP^W>'I/"?A?1TU#[=X"\#>*=-MLZCI=];_9+N\M[T>1YQMA!+#+)
M_9%<?\>\_P#UQE_] :OY3?\ @WL_9C_9L^-_[./[0'B'XT?L]? [XO:_I7[1
M^M:/I>N?%#X3> O'^L:;I"^"O!]ZNE6&I^*] U:]L]-6\N[J[%C;SQVHN;FX
MG$7FS2.RR[VOU_B#D=-0_P!6LO\ K"FI.;I?ZQ89)46I)1J>W]BVYJ47256*
MBIRA*.F(]G_9V%YU/G_UBPGL7%I153^PN([NJFFY0]C[5)0<9>U=-N7*I1E^
MKWA;_@MY_P $O_&GB?PYX.\,_M.?VEXD\6:]I'AGP_IW_"E_VA;/^T-;U[4+
M?2]*LOMFH?">UL+7[5?W5O!]IO;JVM(/,\VYN(85>1?9/^"F_P"S"G[7?[$7
MQV^#UI8RWWBV3PK-XT^'*6L8DO?^%A^!&_X2?PO9V8,4Q#Z_=:?)X6NO+C,L
MFFZ[>PQ-')(LB^DZ7^P?^P[H>IZ=K>B?L9_LI:/K.CW]GJFD:OI?[._PAT_4
M]+U/3[B.[L-1TZ_M/!\-U8W]C=0Q7-G>6TL5Q;7$4<T,B2(K#ZMK/'8>CB\!
M/#Q=6EB9NHU7?).%"<%1J8&O1IVA+V^%Q4)U[RJ<LG&AR*$HS<C!UZV%QL,0
MU2J4:?LFJ+4TZWO55BZ%=MN$\/B*$H473Y-82KQJ<\9J,?QZ_P""&7[2L?[1
M'_!/SX8Z7J=^UUXZ^ DMU\#/&=M<>:M[;Q^$(K>3P5/,LZK(\=QX#OO#MN;G
MYTDU"PU. OY]K<)'\8?\%KM4UC]J_P#:C_8<_P""8'@R>Z5?B-XXT[XR?&"\
MTXR7$FB>"K2;6M#L[VXMH0JD:-X6TWXE>)9H+FXA5I;;0F_=_:(9@S]DB/3?
M^"?/_!9S]J3]EW5+FV\-_!S]LKP8OQ^^$,<LT\>E6OB'2[CQ#XFN-+A>X46V
MFV]E$?C!I)_?",VWAOP];>82]M"FE_P24T^3]LG]NO\ ;D_X*::[YNJ>$V\7
M77P#_9UN;XWN;3PGID-A]MO[*SNDB73RG@?3_!,0"+N^V>*_%,<L,$[3--Z"
MK1SG,\ES:K17U>6"_P!;<ZP]2U6%/,<IQ'U">68SEC>+QG&<(.BJ24)82C4E
M*,:$:]*'&Z<LHP.=9=1J35>&*AP]DM>+Y*SR_.J?UJAF.'C)KGIX3A:6)A-U
M+U%B(JS59*K#ZE_X+EZ#H_A7_@DS\:_"_A[3K72- \-P_!'0=#TFQA2WLM,T
M?1_BGX T_3-/L[>)5B@M;*RMX+:WAC54BBB1$4*H%7KG_E G%_VC%L/_ %G>
MWJS_ ,%Z_P#E%Q^T/_V$?A'_ .K@\#U6N?\ E G%_P!HQ;#_ -9WMZ\;$SG4
MX8\0ZE24IU*F:9?.<YMRG.<N%<SE*4I.[E*4FW*3;;;;>IZV IPI9YP-2IPC
M"G3IYC3IPBK1A"&<Y!&$8I:*,8I)):)*QH_\$&?^46/[-?\ U\_&'_U=_P 1
MJ^,_^".__*2S_@LW_P!E[N__ %;OQIK[,_X(,_\ *+']FO\ Z^?C#_ZN_P"(
MU?&?_!'?_E)9_P %F_\ LO=W_P"K=^--?48[_DM,V_[$?%?_ *EY&>!0_P"2
M2K_]E?D?_JXSH_I-K^5WX/Z'IW[(_P#P<;^/?ACX"A_X1SX>?M2_#36_$-QX
M4TO$>C+JNN^ G^)VH7']GP@6UL4\>^!/$]_I^(H3IEKKEW961CLKEH9OZHJ_
MEI^#-_9_M??\'%?Q(^+O@&XC\0?#3]DWX;ZCX9O/%FG$OH\VNZ=X$N/AE<Z?
M%?VX>VNYI?&_C/QE#8%Y6CU'3_#.H7MF\EO;QE?'R_\ Y'^7<E_:?V9Q5]8M
MO_9?^KV,^M6OIS?7O[*Y;>_>W_+OVIZ&-_Y$>:\_P^WR3ZI?X/[8_MK!_P!G
M<_VN7V?UWVMO^87ZS;W^0^O/^"D(B_:1_P""A7_!-;]BBV>SO]"\/^.-=_:X
M^,.E7,:S0#PU\-;6Y_X0N"]Q,CB'6[C1_&NA-:-&Z32ZMI\\R-!&0WRA_P %
MQ=0UW]I3]MG_ ()[?\$[8]4N-*\ _$+Q7H7Q'^(,44\MNFIQ>(_%NH>"K2]+
MJJDWWA?PEX=^(;:0D4P:2\\2.LJQLMK*/K/]@9W_ &D?^"GO_!1_]KB\;^T/
M#?PHU'PQ^QQ\)+J>UG"65GX,/VGXCQ:9+(QA2*7Q%H%EJSE"\\W_  E,TA2S
M@F$4_P H?\%O+34?V:OVYO\ @G=_P4,NM)U/5?AUX"\4:1\._B+<:?9S70TF
MW\,^+;SQE:VNY@UJ-2\2^%O%/CYM%MR89KBX\,7067*QO#&!]A"? :QOLOJ>
M8<14.(,V^M\GU=4L[]K/)ECY5/\ 9U3CE.%X4C&FW*%+'*$7.5>]KQ?MI1XS
M^I^U^N8#AZOD65O"\_M76RN*J9R\,XWJSK1S#'<44W4CRWPU.,*,$H1G/^F#
MP;X.\*_#SPGX;\">!M TOPKX.\'Z+IWASPQX;T6UCLM)T30](M8K+3=-L+6(
M!(;:TM88XHUY8A=SLSLS'B/CU\$/A]^TE\'?B'\"_BII3:OX"^)?AN]\-Z];
MP_9DO[1+C9-8:UHUQ=VM[;V/B'P]JD%EKWAW4I+2Y_LS6].L+]89&MPAZWPW
MXF\(_%/P+H_BSP;X@T_Q/X(\>^&[75_#OB;0+N&\T[6?#_B#3UGL=4TR\421
M2Q7-G<I-"[(VTD++&&5T'\YOQ)_X-KOV&/#'@3Q]XPL/BM^UC-J?A[PEXI\2
MV4%YXZ^#\EC+?:3H]]JEM%=10_ FWN'M'N+=$GCBNH)FA++'/&Y$BX9I4E!9
MG+-:51TJ-"O7QLZSG/%3JP=>>,A5I34:L:U-4U-SE4]I*K.2M"=/FEKEM.,W
MEZRRI3C6GB,+3P,**A'#QA+V:PM6E6BW25-2<%",8<BII23<;(_2/QY^S'X/
M_8Z_X)4?M(_L\?#[Q7\0/&/@GP%^S!^TP/#FI_$S5/#^L^*;6RU[P3X[\13:
M5)J'AKPQX1TV73K'4-5O%TR+^QUFM;1X[5IY8H80GQ#_ ,$I?VAO"7[*/_!#
MK1_VAO'%M<7_ (>^%L?QJ\02Z1:7$%I>Z_JDGQ9\1:9X>\-V5U<AK>VO/$?B
M&_TO1+:YE26.WFOTF:&58S&WRA_P20_Y02_M]?\ 7A^UO_ZSKX>KW#_@G7^U
MQX<_8=_X(/\ AC]HWQ'H%SXN/@_Q!\2K#P[X0M+Y-+E\4^+/$OQIU[0O#VD2
M:I);7JZ78&^O5O=8U);*^FL=&LM0NK6PU"[B@L;CT,P57"U>+I5,;-XBOP]P
M576,=!5:WUC,\1CZ])1HRE)8C$^VQ4*,'4<GBL1RU*L6ZDH')AO9XC"<(QAA
M(^PI\6\54IX7VSITY4<%E].E7<J_+'ZM1E3H5*M2:2AA*3D^;DI<QB?"_P ;
M?\' W[>G@W2OVE/@Q\4OV:/V.OA)XUCE;X<_#;Q5X:T[4-4\0>$X[B:XTKQ\
M]QXE^"GQW\0S1ZW;W:Z='J&H:UX.MM<CT5/$.B> M(T+5M.U+6?H#_@G+^WA
M^V?_ ,->_$?_ ()R_P#!0G1_!^K?&OP/X.U+QMX-^+O@ZST?25\>:9;7\&KK
M+J5KX;ATGPCJNEZSX3\0:?J'A#4/#WA/P3JNDZ;X>O-(\<>'9?%LFJS:;XMX
M&M?^#B[]K#P;X6_: \'?'K]D_P#99\'_ !+\/:)XD\*?"*_\+:1=7-AX;U'2
M[2[T7Q#(NN?!']H77;)O%>GSV^NOINM_$BXU73Y+Q[6[T'PU)'_8]K\U?L7_
M  G^)WP3_P""^"?#SXR_M+:]^U5\3M,^ 'BC5/&/Q(\017=M/I>K>)O!L7B5
M_ VG6%[XK\62Z9H?AJ+58O[&T^*3P_9V]C?1"P\*:'8M;P/OAZ2I9E]1G0AA
M<//"YY"> QM26+S&G7P638_,,*WB$I5H5\/7P:GC*CGA\/&<G@JU"G*M0PD.
M;$574R]XN%:6)JPQ.2U(8S!TUA<%*EB\XR[ 5[TGRTZF'K4,=*E0I1A5JU9.
M&-I5YPP]2O/Z0_;)_P""C7[?'P?_ ."JNL?LG_LTZ5H_QEM/%_PI\)6?PF^!
MOB70_!FG>%[7XC^(- L_$.I>-O$WC&&Q\.^.KC0M T33/$FK7^F2_$?0](C0
M":>ZM;.T9:\?_:"_:7_X+F?\$Q;WX<_'?]J[XG_ []J/]G_6?%L/A;QGX9\!
M>%_"FG:=H[7YCNX=.U#7=(^#/P?\:^&]?U;2[;6(O!?B&!_%WA&SUBQ$?BW3
M=0>XTK2=9]V2**3_ (.7YGDBCD>W_9=$T#NBLT$K?#.* RPLP)CD,$\T)="K
M&*:6,G9(X/T1_P '#_\ RC.\>_\ 93OA'_ZE4=>']8J9?E>3YA%1Q&)Q&:XR
MC4^M+VU">#J\=9KDT,+.@_<E*A0565+%76)47A<-S_5<!AZ*]?V,,;F>:X*2
ME1PU#+L'4C&A)TZWUVEP;EV;2Q,:Z]^E3K5:E&-3"02HSJ1Q6*J<^(QM24/M
MW]J>+]K7X\_LS^"/$'_!/?XN> O@[\3?&=WX%\=:=XS^)^F:;J>A7'PTUSP[
M>:K=Z6;6\^&_Q;LUU2_.I:#/#)%X<.Q;6Y6+5[=&*77XH?M :/\ \' /[,7P
MA\;?'#XQ?\%)_P!CWPSX!\!Z4^IZM>MX*\)2WU]<.ZV^F:#H=DW[$T+:IXAU
M_49;;2=#TN*1'OM1N[>$R11F2:/]\/V=O&'A7X??L3_ 3QQXX\0Z1X3\'>$_
MV8_A+K_B;Q-K]_;Z7HNA:+I?PO\ #UWJ&IZGJ%V\=O:6EI;QO+++*ZJ%7 RQ
M /X/>%-"^(/_  7D_:>M_B7XSM]=\(_\$L_V:_&MQ!X#\$WB7FBZA^T?X^TM
M)8Y]9U.-8X;IK>[CEA37KF>9?^$,\'W@\$>&(K/QAXI\<^)+'U<?@O9Y[FV5
M9?5E3C3QN+K8C$XF4L11RC+,/6C@8XF<9.R=5T8TL#A(VEC\QJ573A*V*G3\
MW 8SVN297F>/A&3G@,/"C0H1C0KYOF5:@\8L)2Y4N:7-6<\9BI6IY?EL%.K4
MCRX:G5^W/^")7Q:_X* ?M!? SQE\=/VV/&?_  E'A;Q]J>@']G^/4/!?P_\
M ^O3>&M*AUA/$_BM]*\!>"/"44OAKQ-?76E6_AF^UJ>]O=030M0U*PLK/0[W
M2]3UW\W/V;O^"C7_  5/_:@^(W[5'[*7P!F\+^./B_I'QD\<6^B?'CXH>&?
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MV@-+_:H_X(]?LH?M":/I;:':_%7XW?"SQ+<:&UPMY_8FL-\./C#8^(-%2[0
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MQE]=QF"^L5VU&-/#9CB,'3K8B4(R>E*E&=><8-M\\E"[Y3T&BOYR_P#AFO\
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M*@Z3H.A4H55/#UO;O$4_W3HHHK U"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^?_VLO^36/VE_^S?_ (R_^JZ\1U_)3\#?^13U'_L8KO\
M]-ND5_6M^UE_R:Q^TO\ ]F__ !E_]5UXCK^2GX&_\BGJ/_8Q7?\ Z;=(K^2_
MIJ_\F-Q__92</?\ J16/Z9^B5_R>#!_]B#//_3-(]FHHHK_',_U/"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]2_](?B77V!7Q_XR_P"3ROA-_P!D_P!2_P#2'XEU]@4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_^SA_R53]IW_LH$?_ *D?
MQ K[ KX__9P_Y*I^T[_V4"/_ -2/X@5]@4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'Q_^Q3_R2O7_ /LH&J_^HYX4K[ KX_\
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M5_Y?'PW_ /FPH_X@WXO?]&J\2/\ Q!N)_P#YUA_Q%7PO_P"CD<!?^)AP]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVE_^S?\ XR_^JZ\1U^?_ /P12_Y-8\??]G >*O\ U77PJH _8"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X_P#VUO\ DE>@?]E
MTK_U'/%=?8%?'_[:W_)*] _[*!I7_J.>*Z^P* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#X_\ VC_^2J?LQ?\ 90)/_4C^']?8
M%?'_ .T?_P E4_9B_P"R@2?^I'\/Z^P* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#X_P#&7_)Y7PF_[)_J7_I#\2Z^P*^/_&7_
M ">5\)O^R?ZE_P"D/Q+K[ H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /C_ /9P_P"2J?M._P#90(__ %(_B!7V!7Q_^SA_R53]
MIW_LH$?_ *D?Q K[ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /C_]BG_DE>O_ /90-5_]1SPI7V!7Q_\ L4_\DKU__LH&J_\
MJ.>%*^P* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@!K_2_X/K_2U^;O^&R?V0O^CJOV;O\ P^7PP_\ FHH_X;)_9"_Z.J_9N_\
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M#Z_TM?F[_ALG]D+_ *.J_9N_\/E\,/\ YJ*/^&R?V0O^CJOV;O\ P^7PP_\
MFHKZ1HHNNS^__@!K_2_X/K_2U^;O^&R?V0O^CJOV;O\ P^7PP_\ FHH_X;)_
M9"_Z.J_9N_\ #Y?##_YJ*^D:*+KL_O\ ^ &O]+_@^O\ 2U^;O^&R?V0O^CJO
MV;O_  ^7PP_^:BC_ (;)_9"_Z.J_9N_\/E\,/_FHKZ1HHNNS^_\ X :_TO\
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M]D+_ *.J_9N_\/E\,/\ YJ*^D:*+KL_O_P" &O\ 2_X/K_2U^;O^&R?V0O\
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M]D+_ *.J_9N_\/E\,/\ YJ*^D:*+KL_O_P" &O\ 2_X/K_2U^;O^&R?V0O\
MHZK]F[_P^7PP_P#FHH_X;)_9"_Z.J_9N_P##Y?##_P":BOI&BBZ[/[_^ &O]
M+_@^O]+7YN_X;)_9"_Z.J_9N_P##Y?##_P":BC_ALG]D+_HZK]F[_P /E\,/
M_FHKZ1HHNNS^_P#X :_TO^#Z_P!+7YN_X;)_9"_Z.J_9N_\ #Y?##_YJ*/\
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M'U_I:_-W_#9/[(7_ $=5^S=_X?+X8?\ S44?\-D_LA?]'5?LW?\ A\OAA_\
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M'5?LW?\ A\OAA_\ -17TC11==G]__ #7^E_P?7^EK\W?\-D_LA?]'5?LW?\
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M:BG*,4Y/HG*48IO3FE%;M'NE%<WX0\9>$/B%X9T?QIX!\5>&_''@[Q#:"_\
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M<*5OX<(-2E*I*%/]:J***104444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110 4444 %%%% 'Q_\ LX?\E4_:=_[*!'_ZD?Q
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MKER37PI\</\ @KA^P#\%_A!KWQ6M_P!IKX.?%&ZL=(-WX=^'/PK^(_A/QO\
M$3Q5K-U837>C:##X5\/:GJ6LZ ]_/''9W^K^)K'2='\.22@Z_=V#@1/^)_\
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M5;D45"G3C#\-?^"1G_!*B/\ X*3?"K5?&W[0WQF^*7ASX ?!;Q#X@^&WPJ\
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MQCJ"QM)<F9)P\2P^(_\ !TG%*?@G^RC.(I#!'\4_'T4DP1C%'+-X2TIX8GD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** /C_QE_P GE?";_LG^I?\ I#\2Z^P*^/\
MQE_R>5\)O^R?ZE_Z0_$NOL"@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ^/_P!G#_DJG[3O_90(_P#U(_B!7V!7Q_\ LX?\E4_:
M=_[*!'_ZD?Q K[ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@2?^I'\/Z^P*^/\ ]H__ )*I^S%_V4"3_P!2/X?U]@4 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC<KS+#5,'F&6XO$8#'82LDJN&QF$JSH8G#U4FTJE&M3G3FDVE*+U9^GY7FF
MSK+<!G&58JECLLS3"8?'Y?C:#;HXK!XNE&OA\12;46Z=:E.,X-I/EDKI!17R
MQ^TY^VI^S1^Q]HMAJWQ]^)^E>$;O6H[E_#GA6TM=1\1>-?$AMX+N7=I/A30+
M34=7&G23VC:<WB+4K?3_  M9:G/9V6J:Y82W< ?\P]&_X.(?V&]4UC2M,OO
M_P"TKX<LM1U*QL;SQ#K/@3X>SZ/H5K=W,4%QK.JP>'OBUKVOS:;ID4CWM]%H
M>AZSJ\EM!*FFZ5J%X8;2;ZSA_P -./\ BK RS/A[A'/,URZ+<5CL-@:OU6M*
M+G&<,-7J*G3Q<Z<J<H588:5:5*?+"HHRG!2^4XD\3O#[A#'4\LXEXOR+)\QJ
M153ZABL=3^N4J<HTY4ZF)PU+VE;"4ZT:L9T*F)A1A7@IRHRJ1I57#]XZ*\G^
M"OQT^$?[1?@'3?B?\$_'FA_$/P/JDLEM#K6B27"O:7\,5O/<:1K6E:A!9:UX
M=UVU@N[2>\T'7].TW6;.&[M9;FQBCN8&?X>_;._X*O?L[_L,_$W1/A3\6O!G
MQH\0^(M>\&V'CBSO/AUX=\#ZMHL>DZAJVLZ-#;W-QXE^(OA&^345NM#NY)8H
MM.FME@DMV2[>1Y8H?*ROA'B?.<\GPSEN1YEB.(*;Q$:N3O#3H9A1EA(N>)A6
MPV)]C4HSH1BW5A54)QLTU?0];,N,.%LIX?7%>/S[+*/#3AAJD,\ABJ>)RRI3
MQE:GA\+4HXK"NM2K4Z]:K3ITZE*4X2<E:5KL_3FBOP*_XB+_ -B7_HEW[4__
M (1/PE_^??7UE^RC_P %??V-/VN/&$'PY\):_P"+_AO\0]4O39>%_!OQAT+2
M_#5_XQD$,<I7PUK'A[Q#XN\)75Z\DGV6UT&]\1Z?XFU*>.4Z7HE[!$\X^GS/
MP=\4,GP.)S/,>!\_H8'!TI5\576#]NJ%&&M2M4AAY5:D:-*-YUJO)R4:<9U*
MLH4X3DODLM\:_"C-\?A<LR_CWAVOCL;5C0PE"6,^K^WKSTIT(5,3"C2=:M*U
M.A2=13KUI0HTHSJSA"7ZAT445^:GZB%%?"W[7G_!1O\ 95_8HBCL/C%XWNKW
MQY>:<FK:/\*/ FFCQ/\ $35=/>]M+07;V+76G:!X:M9$N9KVQO/''B+PM9ZW
M;:9JT6@7&JW]A+95\??";_@O=^P;\3O&%IX1UF;XN?!N+4$C2R\6_%GP;X?M
M?!\FI7&H6-A:Z5=ZGX"\:>/[O17G^VO>R:UX@TW2?"FFZ?87USK/B'30ENES
M]SE/AEX@Y]E#S[)^#N(,QRBU65/&X7+<14IXB-'2K/!QY55QT(24J;G@Z=>/
MM85*2;JTJD(_!YUXH^'7#F;QR'/>-.'<KS=NE&>!QF98>E5PSK*+I+&MR]G@
M/:0G"I'Z[.A>C.-;^%)3/VJHKYC_ &I?VL/AI^R7\"]0_:%\>V7BCQ7X"L+S
MPQ:*GPWMM UW5]17Q;?VVGZ1?:8NL^(_#>C7>GNUW#<R7(UI UFWG6JW)*(W
MY3?\1%_[$O\ T2[]J?\ \(GX2_\ S[Z.'/#3CSB[!5\QX:X7S3-\%AL95R^O
MB,+3IN%+&T:5"O5PT_:5(256G2Q-"<ERZ*I'6]TGQ-XG< <&XS"Y?Q/Q5E63
M8S&X"EFF$H8NK/FQ&7UZ^)PM'%TG3IU(RHU*^$Q-.$N;5T9M>ZDW^^M%?AOX
M _X+^_L<_$;QWX*^'NB?#7]IBUUKQWXM\.>#=(NM5\'?"V#2[;4_$^L6>B6$
M^I36GQEOKN&PANKZ*2\EM;*\N([=9'AM;B0+$_ZH_M#?M-? W]E7P&WQ(^/7
MQ TOP%X6:^@TK3Y+JWU'5-8UW5KD@0Z5X=\.:'9ZEK^O7P0FYNH]+TVZ33=/
MBN=6U22RTJSO+V#'._#SCCAS'97EF<\+YO@LQSN<Z>48!X65?&9E5ISI4Y4L
M'AL*Z]:O5]I7I05.G!SE*I&,8MNQKD'B/P)Q1@\VS'(>*LFQ^7Y%2IU\ZQRQ
M<</@\KH5:=>K&OCL5BU0H8:A[+"XBI.M5J1I4Z=&I.I.$8MGN]%?A!H/_!P]
M^PSJ^MZ3I6H>#/VD?"UAJ.HV=E>>)=>\!^ ;C1- MKF>.&;6-6@\,?%7Q'XC
MFT[3HW:ZO(M"T#6M6>"*1=/TN^NC%;2?M%\,/BA\/_C1X"\,?%#X6>*M*\:^
M O&.FQZKX<\2:-)(]G?VCN\,L<D-Q'!>Z?J%C=13V&K:1J5M9ZMH^IVMWI>J
MV5GJ-I<VL4\3>'W&W!M'#XGB?AC-\EPN*J>QH8K&864<+4K\LIJ@L33<Z$:\
MJ<)U(T)5(U9TZ=2<8.,)M'"_B1P)QKB,1@^%>*LGSO&86C]8KX/!XJ+Q<,/S
M0IO$+"U%3KSP\*E2G3J5Z=.5*E4JTJ=2<9U:<9=[17PM^UY_P4;_ &5?V*(H
M[#XQ>-[J]\>7FG)JVC_"CP)IH\3_ !$U73WO;2T%V]BUUIV@>&K61+F:]L;S
MQQXB\+6>MVVF:M%H%QJM_82V5?'WPF_X+W?L&_$[QA:>$=9F^+GP;BU!(TLO
M%OQ9\&^'[7P?)J5QJ%C86NE7>I^ O&GC^[T5Y_MKWLFM>(--TGPIINGV%]<Z
MSXATT);I<]&4^&7B#GV4//LGX.X@S'*+594\;A<MQ%2GB(T=*L\''E57'0A)
M2IN>#IUX^UA4I)NK2J0CCG7BCX=<.9O'(<]XTX=RO-VZ49X'&9EAZ57#.LHN
MDL:W+V> ]I"<*D?KLZ%Z,XUOX4E,_:JBJUG>V>HV=IJ&GW5M?V%_;07EC?6<
M\5U9WEG=1+/;7=I<P,\-Q;7$+I-!/"[Q31.LD;,C FS7P\HRC)QE%QE%N,HR
M34HR3LTT]4T]&GJGHS[J$XU(QG"49PG%3A.#4HSC))QE&2;4HR3333::::=@
MHKX/_;@_X*&?!?\ 8%L?AS?_ !A\,?%#Q)#\3KOQ/9Z OPTT7PIK$MI+X3AT
M*;46U=?%'C7P:MNDR^(+,61LGU!I&BNA.ML$B,WY]?\ $1?^Q+_T2[]J?_PB
M?A+_ //OK[_(/"OQ#XHRNAG7#_">:YKE6*G7AA\=A:=*5"K/"XBIA<1&+E5B
M[TL12JTIWBK2A+=*Y^?\1>*_AUPEF=3)>).+LIR?-*5*C6J8+%U*L:T*6(@J
ME&;4*4URU(-2C[VV]M3]]:*_,#]DW_@KQ^QS^U]XRA^&_@S6_&?P\^(VIW,U
MOX9\%_%SP_IOA[4?& M[07<[^&]6\-^(/&'A.YN47S(XM$OO$6G^)+YX+B33
MM%O+6"2X7Z._;)_;&^&7[#_PHL/C#\6-"\=^(?#.H^,](\#P6/P\TSP_JVNK
MJVLZ9K>JVMQ+;>)/$_A+3UTZ.WT"\2XE34WN5FDMECM)4>62'R\=P+QAEF?X
M+A?,>',UP6?YC.A3R_+,5AI4:^.EB9>SH/"2G:EB(5*BE256E4G356%2E*:J
M4YQCZF6<>\&9UD&/XIRGB3*<QR#*Z6*K9GF>$Q4*U'+Z>"I2Q&*^NPA>MA9T
M</'ZPZ=>E"I+#RIUX0E2J4YR^L:*_ K_ (B+_P!B7_HEW[4__A$_"7_Y]]'_
M !$7_L2_]$N_:G_\(GX2_P#S[Z^M_P"(%>+O_1!9]_X*H?\ R_\ KY,^/_XC
MYX.?]'!R#_P=7_\ E'G_ %9G[ZT5QOPZ\<:3\3?A]X$^).@V^HVFA_$'P;X8
M\<:+::O#;0:M:Z3XLT2QU[3K?5(+*[O[.'48;._ACO8K2^O;:.Y65(+NYB"S
M/\Y?M2_MX_LM?L<6$3_'3XGZ=H?B2_TNZU30/A[HEK>>)_B%XBBBMM1FLOL7
MAC1H;FXTNRUBZTN[TC2_$OBJ7P[X.;6$^PWGB.R997B_.\)D6<YAFO\ 8>7Y
M5C\?G'MZN%_LS X6MC,:Z]"4HUZ<</AX5:DG2<)^T<8N,%&4I-139^D5\_R3
M"Y/#B#&9ME^"R.>%P^.6;X[%T,%EZPF*C3GA\1/%8J=&C3IUHU:;IRJ2CS.<
M8_$TCZ_HK\"O^(B_]B7_ *)=^U/_ .$3\)?_ )]]?K-^SC^UU^SG^UKX?U3Q
M)^S[\4M"^(-IH,\%MXATVW@U70_$_AZ6[$WV)]=\(^)=/T;Q/I=GJ#6MY'I6
MJ7>DQZ5K#V&H#2;Z^%C=&+Z7B'PR\0.%,%_:7$/".>97ERDH3QU?!SG@Z,G*
MG""Q.)H>UHX5U9U84Z/UB=+V\VX4>>4)J/RO#OBKX<\68]97P[QED.:9E*/-
M3P%'&PIXNO%1E.7U;#U_95<4Z<(2G56'C5=*"YJBA%IOZ/HHHKX4_0 HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?\
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MO@O7+I=/U"^\,:)I=U>6*W4,5RMI<RR0">*.81^8BL/LO_@DI^RA^RU\2/\
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MMO\ AS=_P[?OO^%/_P##.W_"R?\ A ?#G_"J?^$/_P"$9_X:6_X3[R$^P?\
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M&G^(?#?PIU>RAOXK6XO+:*]BMKR)+J.WN[J!)U=8KB>,+*WC_P"SA_Q$#_\
M"AOA)_PSW_R0_P#X03P]_P *K_Y,H_Y$C[#'_8/_ ".__%7?\>7E_P#(Q_\
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M/_\ AI?_ (80_P"%N?\ "1_$'^W/^%Z?\,_?\+'^P?\ "8ZM_8?]J_\ "?\
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M/_\ \ZJC_A]9_P %-?\ HY;_ ,PW^S__ /.JK\L:*_T;_P"(6^&7_1N>!/\
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M /$QXB_^>)^IW_#ZS_@IK_T<M_YAO]G_ /\ G54?\/K/^"FO_1RW_F&_V?\
M_P"=57Y8T4?\0M\,O^C<\"?^(AP__P#.\/\ B+'BE_T<KC__ ,3'B+_YXGZG
M?\/K/^"FO_1RW_F&_P!G_P#^=51_P^L_X*:_]'+?^8;_ &?_ /YU5?EC11_Q
M"WPR_P"C<\"?^(AP_P#_ #O#_B+'BE_T<KC_ /\ $QXB_P#GB?J=_P /K/\
M@IK_ -'+?^8;_9__ /G54?\ #ZS_ (*:_P#1RW_F&_V?_P#YU5?EC11_Q"WP
MR_Z-SP)_XB'#_P#\[P_XBQXI?]'*X_\ _$QXB_\ GB?J=_P^L_X*:_\ 1RW_
M )AO]G__ .=51_P^L_X*:_\ 1RW_ )AO]G__ .=57Y8T4?\ $+?#+_HW/ G_
M (B'#_\ \[P_XBQXI?\ 1RN/_P#Q,>(O_GB?J=_P^L_X*:_]'+?^8;_9_P#_
M )U5'_#ZS_@IK_T<M_YAO]G_ /\ G55^6-%'_$+?#+_HW/ G_B(</_\ SO#_
M (BQXI?]'*X__P#$QXB_^>)^IW_#ZS_@IK_T<M_YAO\ 9_\ _G54?\/K/^"F
MO_1RW_F&_P!G_P#^=57Y8T4?\0M\,O\ HW/ G_B(</\ _P [P_XBQXI?]'*X
M_P#_ !,>(O\ YXGZG?\ #ZS_ (*:_P#1RW_F&_V?_P#YU5?TD_\ !''XE?MS
M_M$_#+Q)^T=^U=\7_P#A,/AQXPW^'O@9X6L_#7P?\/\ ]H_\(_X@UC2/'WCK
MQ#;^ _ASHFNVGV37M$B\(^#K2\\66OVC[+XZU#6_!TUG-X"\1R_S&?\ !+C]
MAO4/VXOVE-*\.:S!Y/P:^&/]C^/_ (TZA=V'B=]/UCPQ:Z[8PVWPOLM9\.S:
M7_9'BKXG;-0TW3)YO$OA_4-.\,:7XV\8:%)J^H^#UT+4?[_]"T+1/"^B:-X9
M\,Z-I7AWPWX=TK3]"\/^']"TZTTC1-"T32+2'3]*T;1M*T^&WL-,TK3+"WM[
M+3]/LK>"TLK2"&VMH8H8D1?X^^D[FWAWPMAJ? ?"G!/!N!XCQL<-C<YS7 <,
MY-A<5DV6\RKX;"83$X?!4JU',<RE"G4J5(5$\/EJE!TY2S&E5P_]G_17RCQ)
MXKQ53Q!XNXZXUQW#.!EBL#DF49AQ1G>+PF=YGRNAB<9C,+B<=5HU\MRR,ZE.
ME2G3:Q&9N,U4A'+:M+$:M%%%?Q&?W4%%%% !1110!\?_ +1__)5/V8O^R@2?
M^I'\/Z^P*^/_ -H__DJG[,7_ &4"3_U(_A_7V!0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?'_ (R_Y/*^$W_9/]2_](?B77V!
M7Q_XR_Y/*^$W_9/]2_\ 2'XEU]@4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'Q_P#LX?\ )5/VG?\ LH$?_J1_$"OL"OC_ /9P
M_P"2J?M._P#90(__ %(_B!7V!0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?'_[%/\ R2O7_P#LH&J_^HYX4K[ KX__ &*?^25Z
M_P#]E U7_P!1SPI7V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?Q>?\ !Q?_ ,GM?"[_ +-8\$_^K:^-]?VAU_%Y_P '
M%_\ R>U\+O\ LUCP3_ZMKXWU_2GT4/\ D[N$_P"Q#G?_ *9I'\Q?2Z_Y,WCO
M^Q_D7_J14/P*K^T/_@W0_P"3)?BC_P!G3^-O_52_!"OXO*_M#_X-T/\ DR7X
MH_\ 9T_C;_U4OP0K^L?I7?\ )HL;_P!CW)/_ $_4/Y"^B)_R>/!_]D_GO_IF
MB?OK1117^71_JT%?Q'?M_?\ *<"V_P"R[_LM?^FOX5U_;C17Z;X4>(W_ !#'
MB',L^_L;^V_[0X;S+A[ZI_:']F^Q_M#%9;B?K?M_J.8>T]C_ &?R?5_8P]I[
M;F]M#V?+/\P\7?#?_B*G"F'X8_MG^P?8<099GOU[^SO[4Y_[-HX^C]5^K?7L
MNY?;?7N;V_UA^S]E;V-3GO".:&*XBE@GBCF@GC>&:&5%DBEBD4I)')&P*O'(
MC%71@592000:_P Z7]MKX0^(?V.OVJ?VC_@1X:U#5=$\)7]_+I5E!%,8E\0_
M"?Q)JWA[XD>$M(OI(U1;RSM9=.\-&Z"!(Y-4\/E7&V.2,_Z+U%>EX/>+6)\)
MLXS7'_V-'B#+LXR^CA<9E%3'K+H2Q>#Q=/%9;F'UAX',4ZN OC*=&#PSM]=J
M3C4IR@N;S_&7PEP_BYD.697_ &S/AS,LGS;^TLOSNE@'F-:A1K82OA,PP"PZ
MQV725''QGA:M:<,5"7M,!AKJ<%*#_.#_ ()/?LZR_LU_L._!_P ,:K9I9^,/
M'6G/\6_&R>6T5Q'K?Q BMM4T_3[Y)$21+_0O"B^'/#]]$P(BO=+N$1G7#M^C
M]%%?GO%'$&,XJXBSOB3'Z8O/,TQF95H*3G"B\77G5AAJ<FH_N<-3E##T5RQ4
M:5*$5&*22^\X0X:P7!W"^0<+9>^?"9#E6#RVG6<%3EB9X>C&%?&58*4U&MC:
M_M<772G+]]6F^9[G\Z/_  <?_P#)M_P!_P"RW7O_ *@?B"ONC_@C#_RC;_9S
M_P"O?XC_ /JV?'-?J-17V&*\1OK/A/EOA?\ V-R?V?Q9+BC^W/[0YO;<V$S+
M"_4?[,^HQ]G;^T/:?6?[0G_!Y?J_[SFA\?2\-/9^,&(\5_[:YO;\&RX2_L#^
MS;<O-CL#C?[0_M3Z^^:WU/V7U3^SE_$Y_K/N<DBH+JUMKZUN;*]MX+RSO()K
M6[M+J))[:ZMKB-H9[>X@E5HIH)XG>.6*16CDC9D=2I(J>BOS(_5$VFFKIIW3
M6C36S3[G\<W[1W[!7[7?_!,']IR/]JW]B[P[K_Q!^$>F:KJVMZ2NA:/J7C*?
MPAX;U"RO;_Q-\/?BYX/T,PZU>?#Z#3+?4(#XPM?+TRTTRVTG4+SQ#X9\90:5
M<CLOB'_P<+_'+XK^ Y/A?\$?V:;3P+\9/'$5CX1T3QEIGCK5/B5J46MZ\@T@
MOX$^'EM\/]!NY/%=[J-W"?"$%YKGB2.RU%K6"YTKQ(Y"2?UST5_0L/'#)L\P
MF2OQ,\-,J\0<\X>PU#!Y9Q#6SS,,CQE?"8><JM&CGM##8;&8?/(QJR<Y4\7&
M.&J\^(E5P\ZN+Q-6K_.M?P+SO),QSS$>%OB=FWAOE/$V)KXW..'Z.0Y=Q!E]
M/'8FG&E6Q60RQ>)P=?A^K."DU4P<YXBC+V$<)7PV'P>$P]'^8W_@B_\ \$PO
MB[\-OB4W[8G[3WAS5/!OB*TTO6(/A1X!\6+,GCLZOXLL7LM>^(GC/3[B8WOA
MRX31M0U?0M,\/>(84\37-]JVJZOJ^GZ*--T6;6_B_P#X.)CC]L[X;GT_9[\,
M?^IW\1*_M"HK++OI YY#Q5P_BAG>48?-*N"RS$9/E^0X/&2RO!X#+:E&O3H8
M;#8FIA<SJ*-*KB:^+K2J4:CQ&)KUG'V%*5.E2TQ7T><BI^$F9^%>1YSBLN_M
MG,<)G&:<2X_!PS;'8_-*&.P&+KXK$X6GBLLIR]K2R^A@:%.&(IK#X>G2E4EB
MJZK5<1_*9X>_X.2/[!T#0]#_ .&,OM7]C:1INE?:O^&B?(^T_P!G64-GY_D?
M\*+F\GSO)\SRO.E\O=L\Q\;C^?G[17QL_:H_X+5?M!>"=.^%WP)O-+T/P-96
MWACP_P"'?#\NK>*?#_P[MO%]U#/K?B_XJ?$Q]#TK3-/AU>\T4F/4+O2/#MBF
MEZ'9:/I6EZIKL5W=ZS_=M17I9/XU^'W"F9SXCX/\%,%D_%,*6,C@,WQ_'?$&
M>T,'5QT)4<36_LW%X.E2E*I0J5J+="MA*RI5JM*%>%*I5A/R,V\#?$?BC)8\
M)\6^.>-S;A&J\!#'Y-@/#[AW)*^,PN6UJ.(PF'_M3"XZK7@J.(PV'KQ]O2Q=
M*5:A1JU:%6=.$H^*_LX_!VR_9\^ OPA^"5A?'5(?AA\/_#/@^;5B)4&KZCI.
MF00ZOJZ12N[V\6J:K]LOXK7<5M(KA+:/$<2@>U$XY/0445_/&8X_%YICL=F>
M-JNMCLQQ>)QV+KRBDZV+QE:>(KU91CRQ3J5JDYN,>5:V5D?T;E66X/)<LRW)
M\NI>PR_*<!@\LP-!2E+V.#P&'IX7"TN:3<I>SH4H0YI-MVNVV?YX7_!2#]K7
MQ%^UO^UE\0?'5_?S:AX \(^(-2\$_"KP[/<77]D:;X%\.ZE+9V\\%O!+;/!<
M^+Y[:7Q%K=Q"\5])<:DMJ+I8-/L%M_L'X:?\%X_VG/@YX%\-?#/X7_ +]D#P
M1X#\(:;'I7AWPUH7@#XM6UA86J,\LKL6^.,ES>ZA?74L^H:MJVH3W>JZSJEU
M>:KJU[>ZE>75U-_;Y17]0U/I#<$XKAGA_A/,_!?"9GDO#>&HT,NP>)XRJQH1
MJTJ$:,\;5H4>&:=.MC:]JM6KB:L:E9U<3BIJIS8G$.I_+4_HY<<4N,.)>-\J
M\;,9E&><48NO6QV*PW!=&IB*>$J8AUJ&64,16XGE.C@<+".'P]/#X=4*,J.#
MP5.5+DPF&A1^ ?\ @FA^U5\0OVR_V5O#_P <?B?HW@S0O%FJ^+?&6@W&G^ M
M.US2_#J6?AW5?L-E)#:>(?$7BC4EN98?FNG?5I(GDYBA@7Y*_F=\9QW?[0__
M  7PBTS5YDNH-*_:OT#2_+D79$-#^!263_8-KQP[M]CX#E@(99%FFE;!N(W4
MR?VP45^;\)>*N X,XKXUXER3A"CA:7$^19QD>3Y71S=TZ7#-/-:V%KPJTL1+
M*ZLLPCA9X.C^Y]E@'6BFO;4KGZ1QAX29EQOP+PAP=GO&F(Q>(X?S_)\\SG/*
MV4<];B9951S&C/"5\)#-:2P*Q?U]3=5XG&QHU,/2G["K)1E K^:[_@NA_P $
M]/B]\:O$/@O]JCX!>$M;^(.O^'/#%AX!^(W@3PAI][JWC633M/UJ^OO"OC#P
MSH.GBXU+Q(UK<:[=Z1K^GZ+:3ZQI]G#H^K165WI5MKE[H_\ 2C17QG 7&^<>
M'G%.6\5Y)[&>+R^56%3#8E3EAL;A,33E0Q6$KJG*%11J4IMTZD)*5&O"C7BI
M.GR2^\X]X)R?Q$X4S;A'/556 S6E23KX9QCBL'B<-7IXK"8O#3G&<55H8BC3
MDXSC*G6I>TP]:,Z-:I"7\7_Q!_X+:_M)?&[]FIOV0=/^!8'QR\=Z!%\&?%/Q
M&T+5]=U;Q-XPCU19_"^K:;X>^$EGX6CU+2O'WBNRE@T:]>#Q1K*#5KK5YM&\
M.6$M_IECH?ZY?\$0/V$/B/\ LH?"GQW\4OC3I-UX3^(WQR_X1EK/P#J&^+6?
M!O@CPVFJW.DCQ3:B0IIOB?Q!=:W<:A>:!/&=2\.V%MIEEJ_V'7IM9T32OW.H
MK]$XJ\9,MS#A/.N#^"> LMX"R[BG,J6:<3U</F^+SK$9G6H5Z>*HX?#RQ.&P
M<<LP$<31I5%@<+%T*4(NAA8X:C6Q,*_YAPKX)9GE_%?#O%?&_B'FG'^*X,RZ
MKEO!^%Q.38/):&54JV'G@YXC'2PV*Q=3.L>\-)*6/QCCBJU>G1Q6*JXBKA\.
MZ/\ GA?\%(/VM?$7[6_[67Q!\=7]_-J'@#PCX@U+P3\*O#L]Q=?V1IO@7P[J
M4MG;SP6\$ML\%SXOGMI?$6MW$+Q7TEQJ2VHNE@T^P6W^P?AI_P %X_VG/@YX
M%\-?#/X7_ +]D#P1X#\(:;'I7AWPUH7@#XM6UA86J,\LKL6^.,ES>ZA?74L^
MH:MJVH3W>JZSJEU>:KJU[>ZE>75U-_;Y17V]3Z0W!.*X9X?X3S/P7PF9Y+PW
MAJ-#+L'B>,JL:$:M*A&C/&U:%'AFG3K8VO:K5JXFK&I6=7$XJ:J<V)Q#J?%3
M^CEQQ2XPXEXWRKQLQF49YQ1BZ];'8K#<%T:F(IX2IB'6H990Q%;B>4Z.!PL(
MX?#T\/AU0HRHX/!4Y4N3"8:%'\V/V!?CA>?\%%/V,K#Q]^TI\-?A'XA3Q9XM
M\4Z#KW@2W\'2ZM\.=0L_"/B"'^QI+KPQX]U;QN+NYAN+:VOB]Y>7,4=_;PW5
MK#;/%'M^@/\ AAC]B7_HSK]EC_Q'SX2__,C7U/17\_9IQ3B*F;YMC.&8XWA'
M*,PS"MC<+D.69MB_JN7PJ\D8T(U:2PBQ#IPIPI^VEAZ<I1A!.*44E_0N3\)T
M:.29/@.*JN"XSSC+<##!XGB'-<HPBQ6/E&<ZDJSHUI8UX93E-R=&&(J14KRY
MFY,_ER_X.0].T_1_!7[&ND:1866E:3I5_P#%[3=,TS3;6"QT_3M/L=)^&%M9
M6%A96J16UG96=M%%;VMK;Q1P6\$:11(D:*H_;C_@G#_R8;^R3_V0CX??^F.V
MK[5HKZ'-?$:6:>%W#/AO/*90GP]G^:9[+/99BZTL?+,\3FV(E0EE[P4'0E3>
M:-/$/,,0ZKH\SI0]K:G\]EOAM#+?%7._$RGFT73S?A3!\+PR"&6JC#!PP=7+
M:D<5',(XV4:D7'+U".%67453556KM4[3*_";_@X8_P"3%_"W_9P_@/\ ]0WX
MDU^[-%?,\&\1?ZH\5\/\3_4_[0_L+-L'F?U'ZQ]4^M?5*T:OL/K/L,3[#VG+
MR^U^KUN2]_9RV/KN+\@_UJX4XDX8^M_4/]8<BS7)?KWL/K7U/^T\#7P?UGZM
M[;#_ %CV'MO:>Q^L4/:\O)[6G?F7\4O["_\ P6Q_X8M_9R\*?L__ /#,_P#P
MLK_A&-7\5ZK_ ,);_P +F_X0[[=_PD_B&_UWR/[!_P"%4^*OLWV'[;]E\W^V
M;C[3Y7G^7;[_ "4^OO\ B)=_ZLK_ /-CO_Q#U_4Y17['G/BMX1\09MF.>9OX
M#_6\TS;&5\?F&*_XBAQ-A_K&+Q5256O5]AA<NHX>ESU)2E[.A1ITHWM"$8I(
M_#LB\(/&'AK)\NR')?'_ .I93E.%IX++\)_Q"KA?$_5\-15J=+V^+S.OB:O*
MOMUJU2H_M39\^?!/X@:+^U?^S-X!^(?B7P7:Z7X=^/'PKL=6U_P#?:G_ ,))
M96^B^-]$:/5/#=WJITS1/[8MGL;V>QGN?[*T[[3$['[+#NVC^5/XE?L2?MY_
M\$GOVD;_ ./G[(7ASQ+\6?A%'+>PZ5K6A>'[KX@FX\!WOG:[JW@'XX>!?#JP
M>([32],M]!']K>-]+M],\/%8-$UO2?%GA?Q5>1Z/H_\ 9?17Q/!?BEC>!,VX
MCJ91DV78KA3BA8C"YIP9G,ZV9996RR=:O+!X2>)GR8BKB,!AL15PE/&U(R]O
M3JU98K#U7**I_>\:^%6!\0,@X9P?$&=9C2XJX5G@\;E?&^2T\/E.;X?.J-##
MQQN88;#TU5PV$H9GB\+0QM? T'%4*N'PJPV(I/#0F_Y,/$'_  <G_$.Y\%2V
M'A7]E/P9HWQ%;3].BA\5:_\ %+7/$W@J/58Y+0ZM>R> =.\&^$]<FT^]B2^3
M3M,7XDPW.ER7-I+<ZMK"V4T-_P#'WPE_85_X*1_MV_M.VO[0'Q8^&7B;P?+J
MOCWPGXH\<_$OXR:!)\)M%BTW1[>ROM+B\,^$KW3-/\2>(-/_ +#T.ST+0V\&
M^%=6TF"[DTQ?$&KZ9#<W>KI_<A17W^6>//#O!M+,:WAGX2Y%PAG.9T*^%Q.<
MYCG^:\4XBGAZ\J$I4L)'&4,#4PM%3H0K?5(8AX"IB:6&K5L)55!TZOYQF_T?
M>)N-XX' ^*/C'G_&/#^7UZ.*I9)EO#F4<*4JV(H4J]*G5QE;"5\?'%5?9UZE
M+ZS5PSQT,/6Q5.ABZ-3$>VIE%%%?S:?TZ%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'S_P#M9?\ )K'[2_\ V;_\9?\
MU77B.O\ .\_:#_Y'/3/^Q8LO_3KK5?Z(?[67_)K'[2__ &;_ /&7_P!5UXCK
M_.\_:#_Y'/3/^Q8LO_3KK5?TI]%#_D[N$_[$.=_^F:1_,7TNO^3-X[_L?Y%_
MZD5#PJBBBO\ 40_RD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLH1J4\74E-)/#5H2C["K#G5:J_JM)2Q:E07Z'_'CXG_\*2^"'QB^,O\ 8?\
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M@OQT\_\ Q,];T73+/3VTJT6[^T7URFH*=->WG^W?V6/CQ_PTQ^S;\'OVA/\
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M]2/X?U]@5\?_ +1__)5/V8O^R@2?^I'\/Z^P* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#X_\ &7_)Y7PF_P"R?ZE_Z0_$NOL"
MOC_QE_R>5\)O^R?ZE_Z0_$NOL"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^/_ -G#_DJG[3O_ &4"/_U(_B!7V!7Q_P#LX?\
M)5/VG?\ LH$?_J1_$"OL"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^/\ ]BG_ ))7K_\ V4#5?_4<\*5]@5\?_L4_\DKU_P#[
M*!JO_J.>%*^P* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K^+S_@XO_P"3VOA=_P!FL>"?_5M?&^O[0Z_,;]M+_@E%^SO^
MW5\4M!^+?Q;\9_&CP[XD\.^ -+^'-E9?#GQ%X'TC1)=$TCQ%XJ\36UU=6WB;
MX<^+[]]5>_\ %^I0SSPZE!:-:06,<=C%-%<7%S^S> _&^1>'_B!A^(N(ZF)I
M9;3RO,\)*>$PTL56]MBJ=.-)*E%Q;BW%\TK^Z?B?T@.!<_\ $7P[Q/#7#5/"
MU<TJYME>+A'&8F.$H^QPE6<ZS=::DE)1DN6-KRZ'\ %?VA_\&Z'_ "9+\4?^
MSI_&W_JI?@A1_P 0Z'[$O_14?VI__"V^$O\ \Y"OTY_8M_8M^%O["OPMU[X2
M?"37O'_B+PWXB\?ZI\1KV]^(VJ>'=7UN+6]7\.^%?#-S:VMSX9\*^$+!-*2P
M\(:;-!!-IL]VMW/?227TL,MO;VW[SX\>/'A_X@>'^)X=X=Q&:5<RJYIEF+A'
M%Y95PM'V.%JRG5;JRG)*24ERQM[SN?S[]'_Z/_B)X=>(F&XEXEPV54LKIY3F
MF#G/!YI2Q=95L72IQHI480BW%N+4I7]VQ]>4445_$!_=P5_+C^PE-%^S9_P7
ML_;T^"_CF1+#4/VBK#Q=X_\ AS>73K&FO2:_KFE_&FRT[39&,*7+CPOK/B?S
MHXHIGCN?"U_;F0O:S-)_4=7X^_\ !4+_ ()9Q_MP2>!_C/\ !CXA2? []KOX
M/1VZ_#GXFQ7VMZ5IFKV&G7\^M:-H7B+5_#2R^)/#5SH6O7$VK^&?&_ARUU'5
MO#\UWJ<3Z-K4=W9_V5-"I]3S3!YDZ=2M1AA,URO&4Z24JU/!9QA%AZV+P]*4
MH*OB,'5I4*T<.ZD/;457IP;K2HIW4IQQF78O+I5(T9U,1EV8X2<[JE+'Y3B?
MK&'H8B:4G3P^(IU,11E-1]RO/#SJ5*="-:1^P5?!_P"UC_P4-^"?[('Q.^ 7
MP<\<^'?B;XZ^)/[1WB)?#G@+PI\*=#\,^(=5LY)=:T7P]::KXEM=?\8^%)K#
M1K_5M;CM+"YT^/5KBY;3M8,=IC3Y<_E'I?Q8_P"#ESX<:=/X N/V8/V6_CQ-
MX:O-8TB'XU:IXC^'6EZCX\MHM1O!8>)8-.TS]HGX.6%O9RVCP?V/'?\ PH\'
MZJ=.ALV\1Z$FM-J)E]B_85_X)7_'?2?VCG_;Q_X*/_&+2OCQ^T];V5O;_#KP
MQHCC4?!GPQBETW:FH2RG0?#>AQ:_H1U+5M.T+PKX(\.6'@;PGJ$FJ>*-,U7Q
M/K.M6>H:#T8>E&IBZ$ZE6E'+:%2-?&S;<,3B\.HU'#!X*A-1KPKXFI&G"I5J
MTHQPM.3<U&3<Z/-6J3AA:\8TIO,:M.5'"4XVJ8:AB).,)8K$XB#=&6'PJE*K
M"$)\^*<$J:G;V53]G-(^-?P9\1_$;Q#\'-!^+7PQU[XM^%+!M3\5_"O2/'GA
M75/B-X:TL#3-VH>(? ]GJL_B;1K +K>C;KO4M+MK<#5],S)B_M?-_+K_ (*,
M_P#!,S]B7QE^QK^T'J?AS]G3X'?"'QMX!^&OCCXJ^#_B)\,_AMX/^&FO:1XI
M\">%M;\06?\ :^L^#-)T.YUGPWJ8@N+#7=$UR34=(F@NAJJV*ZWI6CZC8>>?
MM[?\$\/VEX_VH?#W_!17_@G1XL\(^&OVE]#\//HOQ-^&'C4V5EX9^-NAZ9I0
MLK:PM;N^M?[%.O>(=*LM/\'ZQ8>*-5\+Z5<6=KH?B/2_'7@CQ'X;BU+4OF/X
MC_"O_@O7_P %#?#=S^SE^T5X*_9U_8I^!?B1[.3XG^-O VK:7XBU[QEX735=
M-%[X/L],\/?&GXTZWJ%P(P^LIHRWGPRT3Q##IUSH7B+QQ%IU^VEWWG5*%7'X
M'V&':P>;5:53#5JM:?U:CA<1'$U5A<?AL9\,\-"C[',*4(U)8NE6C4P\Z4*_
MLO:>E1KTL#CX5JS>(RR%;#8A0I1E6J8BBJ-.6)P6)PD4Y^V56>(P4I3I+#5J
M,_;1DZ,JO+^C/_!%3XW?$CX^_P#!.OX(^-/BKJU_XC\6Z5-XQ\"-XHU:>\O-
M8\2Z/X)\4ZGH.A:IK&H7TDUQJ>J)I=M;:9?:I+-+-J-QI[W=W+)?373M]J?M
M<ZGXDT;]E/\ :9U?P<TZ>+=*^ 'QBU'PR]JS)<IK]E\//$5SI#VSI)"Z3I?Q
MP-"Z2Q.L@5ED1@&&]^SQ\!_ '[,7P4^'/P%^%]G=V?@?X9^';?P_HQU"=;K5
M-0<2S7NJ:WK%U'%;PW&L:]J]W?ZUJLMO;6MJU_?W'V2TM+40VT7L%S;6][;7
M%G=P17-I=P2VUU;3QK+!<6\\;13031."DD4L;M')&X*NC%6!!(KMXDC'-5G%
M+"RC_MN&Q.'IUJD90C6JU<-*A+&5:<4W2^M5G+%5:4$U1=65.":@C@X>E/+/
M[+JXBF[X/$4,2\.I1DZ-*GB57IX*-1-QJ?5:/+A(U;VJ*DI[2/PX_P"#=O3/
M"5E_P35\&WGAQ-/&LZQ\4OBK>^/)+18!=OXH@\0)IMFNJM%&DK7D?@VQ\*"
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M4=3.H77B72H[CP9JGZ"_\$NOV1/'/PE_X)L>&?V5?VJ_AW;:'K>K0?&+P_\
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MU7"PJ2@Y056%&MF&&HU$TJT:6+]C>$:BC]XU_.[_ ,',7_)AGPV_[.F\ ?\
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MLZ48U<5BI83*Z5/W^>G0S"M;,<9[DH25*AEU'%4*C<H)O&4XQJ*I*G&?RO\
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MHT:3J)+GE["A3J5'9<M6I."O&*;****P-@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^?_VLO^36/VE_^S?_ (R_^JZ\1U_.-^Q)_P $HOV=_P!NKX5>(/BW\6_&
M?QH\.^)/#OQ!U7X<V5E\.?$7@?2-$ET32/#GA/Q-;75U;>)OASXOOWU5[_Q?
MJ4,\\.I06C6D%C''8Q317%Q<_P!'/[67_)K'[2__ &;_ /&7_P!5UXCK\_\
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M  MOA+_\Y"OWUHH_XCKXN_\ 1>Y]_P"#:'_RC^OFP_X@'X.?]&^R#_P37_\
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MU\V'_$ _!S_HWV0?^":__P O_KYL_ K_ (AT/V)?^BH_M3_^%M\)?_G(4?\
M$.A^Q+_T5']J?_PMOA+_ /.0K]]:*/\ B.OB[_T7N??^#:'_ ,H_KYL/^(!^
M#G_1OL@_\$U__E_]?-GX%?\ $.A^Q+_T5']J?_PMOA+_ /.0H_XAT/V)?^BH
M_M3_ /A;?"7_ .<A7[ZT4?\ $=?%W_HO<^_\&T/_ )1_7S8?\0#\'/\ HWV0
M?^":_P#\O_KYL_ K_B'0_8E_Z*C^U/\ ^%M\)?\ YR%'_$.A^Q+_ -%1_:G_
M /"V^$O_ ,Y"OWUHH_XCKXN_]%[GW_@VA_\ */Z^;#_B ?@Y_P!&^R#_ ,$U
M_P#Y?_7S9^!7_$.A^Q+_ -%1_:G_ /"V^$O_ ,Y"OTD_8H_80^"7[!O@CQ?X
M)^#DWBK6_P#A.?%4?BGQ'XM^($GA+4O&]]]DTBRTG2/#DVO>%O!_@_[5X5\/
M^3JFIZ!I%]:7?]DZOXI\5WMK<+_;=Q&/M&BO%S_Q3\0N*<MJY/Q!Q9FV:Y76
MJ4:M;!8JK3="K.A.-6C*<84X.7LZD8U(IMI3BI6NDSV^'O"?PXX3S2EG7#G"
M&493FM"G6I4<=A:515Z5/$4W1K1A*=6:C[2E*5.32YG"4HWM*5RBBBO@#]#"
MBBB@ HHHH **** "BBB@#X__ &C_ /DJG[,7_90)/_4C^']?8%?'_P"T?_R5
M3]F+_LH$G_J1_#^OL"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^/_ !E_R>5\)O\ LG^I?^D/Q+K[ KX_\9?\GE?";_LG^I?^
MD/Q+K[ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /C_P#9P_Y*I^T[_P!E C_]2/X@5]@5\?\ [.'_ "53]IW_ +*!'_ZD?Q K
M[ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C_
M /8I_P"25Z__ -E U7_U'/"E?8%?'_[%/_)*]?\ ^R@:K_ZCGA2OL"@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+E.I9U:M6I4****S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_S8[_\ $/7\L=%?WG_Q+1X)?]$5_P";'Q;_ //X_P ^_P#B:'QT_P"BY_\
M-9X/_P#H?/ZG/^(EW_JRO_S8[_\ $/1_Q$N_]65_^;'?_B'K^6.BC_B6CP2_
MZ(K_ ,V/BW_Y_!_Q-#XZ?]%S_P":SP?_ /0^?U.?\1+O_5E?_FQW_P"(>C_B
M)=_ZLK_\V.__ !#U_+'11_Q+1X)?]$5_YL?%O_S^#_B:'QT_Z+G_ ,UG@_\
M^A\_J<_XB7?^K*__ #8[_P#$/1_Q$N_]65_^;'?_ (AZ_ECHH_XEH\$O^B*_
M\V/BW_Y_!_Q-#XZ?]%S_ .:SP?\ _0^?U.?\1+O_ %97_P";'?\ XAZ/^(EW
M_JRO_P V._\ Q#U_+'11_P 2T>"7_1%?^;'Q;_\ /X/^)H?'3_HN?_-9X/\
M_H?/ZG/^(EW_ *LK_P#-CO\ \0]'_$2[_P!65_\ FQW_ .(>OY8Z*/\ B6CP
M2_Z(K_S8^+?_ )_!_P 30^.G_1<_^:SP?_\ 0^?U.?\ $2[_ -65_P#FQW_X
MAZ/^(EW_ *LK_P#-CO\ \0]?RQT4?\2T>"7_ $17_FQ\6_\ S^#_ (FA\=/^
MBY_\UG@__P"A\_J<_P"(EW_JRO\ \V.__$/1_P 1+O\ U97_ .;'?_B'K^6.
MBC_B6CP2_P"B*_\ -CXM_P#G\'_$T/CI_P!%S_YK/!__ -#Y_4Y_Q$N_]65_
M^;'?_B'H_P"(EW_JRO\ \V.__$/7\L=%'_$M'@E_T17_ )L?%O\ \_@_XFA\
M=/\ HN?_ #6>#_\ Z'S^IS_B)=_ZLK_\V.__ !#T?\1+O_5E?_FQW_XAZ_EC
MHH_XEH\$O^B*_P#-CXM_^?P?\30^.G_1<_\ FL\'_P#T/G]'GQK_ .#@;_A<
M/A73_#/_  R3_P ([]A\06NN_;?^%]?VOYOV;3M5T_[+]F_X4QIFS?\ VGYW
MG_:'V^1Y?DMYN^/V#_B)=_ZLK_\ -CO_ ,0]?RQT4?\ $M'@E_T17_FQ\6__
M #^#_B:'QT_Z+G_S6>#_ /Z'S^IS_B)=_P"K*_\ S8[_ /$/1_Q$N_\ 5E?_
M )L=_P#B'K^6.BC_ (EH\$O^B*_\V/BW_P"?P?\ $T/CI_T7/_FL\'__ $/G
M]3G_ !$N_P#5E?\ YL=_^(>C_B)=_P"K*_\ S8[_ /$/7\L=%'_$M'@E_P!$
M5_YL?%O_ ,_@_P")H?'3_HN?_-9X/_\ H?/ZG/\ B)=_ZLK_ /-CO_Q#T?\
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M[POX3^'O@G2)X#X@\?(=:\.:U:76L#7-$6]GM_#L_@SQ#->77V#^@JOXJ?\
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M.C3J5JU2G1HTH2J5:U:<:5*E3A%RJ5*M6HXPITX13E.I.480BG*3239^>_\
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MM->&G7NDKJ#S^"/$GAJ[O'33]1O;:.&]N+FVC6YE=(5E(<?7^-.0\"\,\=<
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MUJ&C>)/AMX<^(%EXCUF+61J^I^$V\/6NH\O^V3_P4:_;X^#_ /P55UC]D_\
M9ITK1_C+:>+_ (4^$K/X3? WQ+H?@S3O"]K\1_$&@6?B'4O&WB;QC#8^'?'5
MQH6@:)IGB35K_3)?B/H>D1H!-/=6MG:,M*4;_P!F.@UBUF]7&8;!/#>\I8[
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MO#"RJT)SE'EC3Q$X4:GMU1E3J.THKEDX_3M%?RX?#GXF?\' O[>/@2Y_:F^
M/C_X ?LL?!_Q/%JMU\*/@]XAT#PI?>(O&/AK2YKXZ7KFF:EXW^#OQ5U"ZN_$
M#(-&AUWQ5XE^'&@>(+NRC\2:-X7\.>$M4LM2N?TG_P""5G_!0GQU^V=X9^,?
MPX_:!\"Z7\,OVI?V9_&DO@KXQ^&-!M;VQ\.7*3ZEKNG:7JVFV>H:KKLVFZA9
MW_AS6_#_ (FTQ-<U:S34]*CUS3KNWTOQ#9:3I>RH5%]9A64<-BL'0>*Q&!KR
MC'%4\-"K2H5JUHN=&:PU6OAXXNG3K2KX7V]-XBE3BIN&,Z].,:-:#=;"UL0L
M)#&THR>&6(E&<J5.I*:A.E]8=*K3PTYTXT\35IRIT9SDXJ7ZT45_-QX@_;=_
MX*5?\%&_BY\2?!7_  2O7X;?!+]G3X,>*KCPKJW[5GQ:TW3=3B^(_B_1X;X7
MVCZ';:_X.^)%I;^']:M[[3]5TK2-#^&.M>)=.L++0_$/B[QEX1M_&=EX.$&D
M?MM?\%,O^";OQ:^&7A7_ (*E3?"WXZ?LX?&GQ5:>%+']I_X4V>BZ)_PK'Q9J
MXM8K73-8AT?P?\+[6?P]H-G8W^NZ[INO_#/3=8U#3=0U/6_"7CSQ%_PB&H>#
M&C"PEB7A(_[O+,%A_P"SXXJ]*6+^NJ$L HJTGAY8]5*?U2.-^JNI[2E=1]M1
M]IKB;X>6*C9XAX'V_P!>6&3JO"O"*4L;&2]UUI8)1G]96$6(<'3JI<WL:WL_
MZ3JCE<I%(XQE(W89SC*J2,XQQD<\BORG_P""I/\ P49UK]ASP;\*O"OP<\ V
M'Q=_:7_:*\4MX1^"W@6_74KW17E@N-(L[K7=6TW0KJPU?75FU7Q!X?T#0O#V
MG:MHESK>I:R9X=7AM](O(9_A#1;W_@X6_9O\,V_[1OQP\8? 3]ISX=Z!H-OX
MC^)_[+^@:?X)TGXKZ3X5DA@U7Q=_8.L>!/A!X$T2[\<>"M(@U&WMXM!^)/Q"
MT>^OED&DZ!X_S9"3AKSG4P6/K4I_5J5&.)PL,QK?N\(L=3HN52E"K:4I/!2G
M0^NXA4WA,%*M".*KTI0KQI6XN,J$8Q>)KUZ5/$T\%A[5<54PM6I.G2JQIIJ"
M^LRI58X6C*I'$XOV;>%HU8R@Y?;_ /P2!_;T^+_[?_P8^+7Q%^,GAOX;>&M;
M\!_&74?AYI%K\,]'\4:-I5SHMIX8\.:U'=:E!XI\8^,[N;5&NM7N8WGM;ZSM
M#;I BV2R+)++^ME?S8_\&R5REY^RA^T-=Q!UCNOVFM6N(U< .$G^'O@:5 X5
MF4.%8!@K, <X8CFOZ3J]K,:4:%;#PC!4[Y5DE6I%=:]?)L!7Q$W_ 'JE>I4J
M2Z<TG;0YZ=6%:KCYTI*=!9QGE/#-?#]5HYQCJ.%C#KR0P\*4(7UY(J^I\A?M
MI?MO_ ?]@[X3/\6?CGK=]#;7UZVC>#O!OARVM]3\;>/?$ A-R^D>&-*N;RPM
M6^R6H-WJFK:KJ&F:'I-N81?:C%=7NFVM[^-7AS_@H?\ \%QOVD]-@^*?[*W_
M  34^%GA?X,:S;:<?#,'QU\421>+=82?2['4_P#A(]+U3Q=\8/V;Y?$7A+7+
M74;2]\/ZWHOP[?0IX'EMK/Q'K<]K=2Q>6?M3:':?MK?\' _P3_9Q^(JIXA^#
MO[-/@/2O%M[X&U9&NO#FIZI;>#/^%NWWVW2+N1K#48_$NL:IX"T?Q#$UO-!J
MV@Z)!I>H0SVD$J+_ %2* H"J JJ JJHP% &  !P !P . *\["T_:8*CF6(G4
MYL?6Q<LNPL&H4*67X+%U\!3Q]6HHRGC)9I5HXRI"DY4:6'H4<).-*K)_6:^^
M(GR8N6!H0AR8;"X*IC<5-.56IBLPPE#,8X2A!N,<-#!X6O@Y5*G)5J5YUZJ]
MK&G)T*/X:_L8?\%@/$/C_P"/=I^Q;^W;\ ]3_9,_:MN1_9WAPS'41\-/BAK\
M5SJ$1L_#:ZP;J]\-#7TLY&^']U%XF^(/@[QZ+*\31/B =4O_  UHNN]'_P %
M<O\ @H+^TW^Q/XD_9,\$_LP^ ?A'\0/%_P"TEXL\;>#$TCXJ:9XDO%FU[3+[
MX<:7X1L-$OM%^(_PZT[26U34O&UQ;:A=Z_?3V*!;.5KC38(+J6;ZX_;&_P""
M=WP'_;;\4?!#QQ\3]4^(WA'QM\ /%)\4>!/%WPK\0:-X6\1.S:AI&K-HFL:G
MJGAGQ'--HRZKH6FZE:'3/[)UG2[V.>?2-8L&O;W[1^/O_!P1XP\._#WX^_\
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M[.#Q$J4IUJ?L^6=.,ZLJ3^L2HQ4XRYU4I4:BJQBN=T/;.+@TYQ^+/@W^WO\
M&'XA_P#!67]I3]A#6O#?PUM?A%\'/A):^/?#'B/2]'\40_$>^UB>R^#MR]MK
MVKW?C&]\,76FA_B%K06'3_!^EW02UTL&\)ANVO?UQK^;']E__E8\_;M_[-MT
M_P#]-?[,5?TG5C02ED7"V)EK7QF0T\3BJK^*O7>99E2=6;ZR=.C2AI;2"-JW
MNYKG=&.E+#YA0I48+X:=.63Y77E&/9.M6JU'_>G(****D84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\__M9?
M\FL?M+_]F_\ QE_]5UXCK_.\_:#_ .1STS_L6++_ -.NM5_HA_M9?\FL?M+_
M /9O_P 9?_5=>(Z_SO/V@_\ D<],_P"Q8LO_ $ZZU7]*?10_Y.[A/^Q#G?\
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M]@C_ (8=_9[/_":Z=]D_:"^+_P#9?B'XU?9_$_\ PD6D:/\ V)<^(/\ A _
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M\DKU_P#[*!JO_J.>%*^P* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#?BN*#0;32/RXTK_ ((5_MW_ !4OO W@[]I_]LGPYJOP<\#6WV;0=-TKQ_\
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M&'P^\3"$PC5]!N[J"XMYK2]@_P!!U[0K^&?3-;T\JLL<&HV>DZIIOXS^#_\
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MI"$IX?)J$H5JU"6'RIUZU*6(H-1QV)G6Q+;I/#4Z)1117X@?NP4444 %%%%
M!1110!\?_M'_ /)5/V8O^R@2?^I'\/Z^P*^/_P!H_P#Y*I^S%_V4"3_U(_A_
M7V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'
M_C+_ )/*^$W_ &3_ %+_ -(?B77V!7Q_XR_Y/*^$W_9/]2_](?B77V!0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'_P"SA_R5
M3]IW_LH$?_J1_$"OL"OC_P#9P_Y*I^T[_P!E C_]2/X@5]@4 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?\
M]K+_ )-8_:7_ .S?_C+_ .JZ\1U_!)X]_9N_:)^,.L6WB;X2? 3XT?%+PW8Z
M;#H5[X@^'/PM\<^-]$L];MKJ\U"YT:ZU7PSH6IV%OJMO8:GIM[/I\MPEW%::
MA8W,D*PW=N\G][?[67_)K'[2_P#V;_\ &7_U77B.OS__ ."*7_)K'C[_ +.
M\5?^JZ^%5?H/AGX@XSPSXII<48'+\-F>(I8+&8)87%U:M&BX8R,82FYT4Y\T
M%&\5L[ZGYUXH^'>"\4>$ZW"F/S'%95AZV.P6.>+P=*E6K*6"G*<::A6:ARS<
MK2;U70_CN_X88_;:_P"C.OVI_P#Q'SXM?_,C1_PPQ^VU_P!&=?M3_P#B/GQ:
M_P#F1K_21HK^CO\ B<[B?_HB\B_\+\P_^1]?Z6O\T?\ $D?"W_1<<0?^&[+O
M_DO7^EK_ )MW_##'[;7_ $9U^U/_ .(^?%K_ .9&C_AAC]MK_HSK]J?_ ,1\
M^+7_ ,R-?Z2-%'_$YW$__1%Y%_X7YA_\CZ_TM3_B2/A;_HN.(/\ PW9=_P#)
M>O\ 2U_S;O\ AAC]MK_HSK]J?_Q'SXM?_,C1_P ,,?MM?]&=?M3_ /B/GQ:_
M^9&O])&BC_B<[B?_ *(O(O\ POS#_P"1]?Z6I_Q)'PM_T7'$'_ANR[_Y+U_I
M:_YMW_##'[;7_1G7[4__ (CY\6O_ )D:/^&&/VVO^C.OVI__ !'SXM?_ #(U
M_I(T4?\ $YW$_P#T1>1?^%^8?_(^O]+4_P")(^%O^BXX@_\ #=EW_P EZ_TM
M?\V[_AAC]MK_ *,Z_:G_ /$?/BU_\R-'_##'[;7_ $9U^U/_ .(^?%K_ .9&
MO])&BC_B<[B?_HB\B_\ "_,/_D?7^EJ?\21\+?\ 1<<0?^&[+O\ Y+U_I:_Y
MMW_##'[;7_1G7[4__B/GQ:_^9&C_ (88_;:_Z,Z_:G_\1\^+7_S(U_I(T4?\
M3G<3_P#1%Y%_X7YA_P#(^O\ 2U/^)(^%O^BXX@_\-V7?_)>O]+7_ #;O^&&/
MVVO^C.OVI_\ Q'SXM?\ S(T?\,,?MM?]&=?M3_\ B/GQ:_\ F1K_ $D:*/\
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M /C_ /8I_P"25Z__ -E U7_U'/"E?8%?'_[%/_)*]?\ ^R@:K_ZCGA2OL"@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?/_[67_)K'[2__9O_ ,9?_5=>
M(Z_/_P#X(I?\FL>/O^S@/%7_ *KKX55^@'[67_)K'[2__9O_ ,9?_5=>(Z_/
M_P#X(I?\FL>/O^S@/%7_ *KKX54 ?L!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\?\ [:W_ "2O0/\ LH&E?^HYXKK[ KX__;6_
MY)7H'_90-*_]1SQ77V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?'_P"T?_R53]F+_LH$G_J1_#^OL"OC_P#:/_Y*I^S%_P!E
M D_]2/X?U]@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'Q_P",O^3ROA-_V3_4O_2'XEU]@5\?^,O^3ROA-_V3_4O_ $A^)=?8
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\?\
M[.'_ "53]IW_ +*!'_ZD?Q K[ KX_P#V</\ DJG[3O\ V4"/_P!2/X@5]@4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_^Q3_
M ,DKU_\ [*!JO_J.>%*^P*^/_P!BG_DE>O\ _90-5_\ 4<\*5]@4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\7G_  <7
M_P#)[7PN_P"S6/!/_JVOC?7]H=?Q>?\ !Q?_ ,GM?"[_ +-8\$_^K:^-]?TI
M]%#_ ).[A/\ L0YW_P"F:1_,7TNO^3-X[_L?Y%_ZD5#\"J_M#_X-T/\ DR7X
MH_\ 9T_C;_U4OP0K^+RO[0_^#=#_ ),E^*/_ &=/XV_]5+\$*_K'Z5W_ ":+
M&_\ 8]R3_P!/U#^0OHB?\GCP?_9/Y[_Z9HG[ZT445_ET?ZM!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\__ +67_)K'[2__ &;_
M /&7_P!5UXCK\_\ _@BE_P FL>/O^S@/%7_JNOA57Z ?M9?\FL?M+_\ 9O\
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M .*1_J<45_ECT4?\24_]7+_\TW_\:@_XGD_ZM?\ ^;M_^*1_J<45_ECT4?\
M$E/_ %<O_P TW_\ &H/^)Y/^K7_^;M_^*1_J<45_ECT4?\24_P#5R_\ S3?_
M ,:@_P")Y/\ JU__ )NW_P"*1_J<45_ECT4?\24_]7+_ /--_P#QJ#_B>3_J
MU_\ YNW_ .*1_J<45_ECT4?\24_]7+_\TW_\:@_XGD_ZM?\ ^;M_^*1_J<45
M_ECT4?\ $E/_ %<O_P TW_\ &H/^)Y/^K7_^;M_^*1_H\?MK?\DKT#_LH&E?
M^HYXKK[ K_,4^$/PA\=?''QSI?P^^'^E?VCK6H[KBZNKAI(-'\/Z/!)#'?\
MB'Q#?I#/_9VBZ=Y\(GG$,]U=74]GI6E6>HZUJ.FZ;>?Z0?[._P !/A[^R_\
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M$NOL"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*'_)W<)_V(<[_P#3-(_F+Z77_)F\=_V/\B_]2*A^!5?VA_\ !NA_R9+\4?\
MLZ?QM_ZJ7X(5_%Y7]H?_  ;H?\F2_%'_ +.G\;?^JE^"%?UC]*[_ )-%C?\
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MK[CAGP7X3GX_YSX89ECL7G/#N6X+$8JCBJ&*AAL;S2RW 9C2PV*Q&&@J3Q.
MEC)X+&.E3I0J5Z$Y>QP[;H4_S?BCQRXRC]&S#^+.69?@\EXIKU:>'>'JX.IB
MLMJ3I9OB<LJ8K!8;%S==X3'0PRQ&&A6J59TE5=*&(Q=.$,77_M?HK^;KXT_\
M'&WPG\&^/]7\-?!G]GS7_C)X,TF2:RC^(.N_$>+X7Q:]?VM_>VTUWX?\-_\
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M/6G@H8#.,?5PT,72I8C#_7O[.R[%PR^=7#UZ.(C2QTL/5]A5A6<%2DI']/\
M17DOP*^-_P .OVCOA/X,^-/PIUEM=\"^.=-?4-(NYK=[*]MI;6ZN-.U72-5L
M9"7LM7T35K.^TG5+7?+'%?6<_P!GN+FV,-S+^+7[5/\ P< ? [X'_$C5/AO\
M'/A1K/[0DWA;5-3T3Q=XN_X3>V^''@I-4T\VL+VW@W4CX4\<ZGXOAMK_ /M3
M3=2U*?1O#ND^?IT5UX=O_$^DZA#J*>#P]X=\;<5Y[CN&LAX=Q^-SO*Y8B&9X
M*:HX'^S:F%JRH5J>88G,*N%PF!JQKPG0C3Q5>E.I6A*E2C.<7%?0<0>)' W"
MW#N"XKSWB7+L'P_F<,-4RS,82K8V.9PQ=)5\/++L/@*6*Q>/52A)5_\ 9*%;
MDH*5:IRTHRDOTD_;:_;U^$'[!?A;P1XM^+_AOXD^(]-\?:_J/AS1X/AMH_AC
M6+ZVOM,TY=3GEU*/Q/XQ\'P0VKP,$A>UN;R9ILJ\$:?O*]K_ &;?C]X._:B^
M"7@/X\^ --\3:/X0^(=EJE]HNF^,;/2]/\26L.DZ_JWARY75+/1=9\0:7#(]
M]H]U+ +36+U6M9('D>.9I((OY#_^"HW_  4G^#W[?W[.'P)'A+0]?\ ?$WP3
M\2-<N_'7PW\0,NJII]IJ7A*".UUKPUXML;:UT[Q-X=FOA<::ES=6/A[Q!#>6
M<S:CX7T^QN=*O=2_HT_X(]G_ (UN?LP?]B[XU_\ 5I^.J_4>-/".'!/@YE/$
MF>Y3F.4\<5./)\/9E0Q>(4L,LM>7Y[BZ4J-&FZF&J1J?4,+4I8W#UJM&M2YI
M4YSC.Y^3<&>,LN./&[%<+<.9QEF<<!2\,ZW%."K87"N&,6<4L[X=R^4,15K1
MI8O#RI4<RQ,:V7XK#T:]*I*FZM.+C%/]+**_ #]J3_@X$^ OP6\?:A\/_@K\
M+]9_:*F\-ZIJ.D>*?&$7C6R^'?@$W=DEHH7P3K8\,^.M3\90Q7[:GIU_J,N@
M^'M%:33X;[PYJOBC2=1@OX_6OV(?^"VOP _:X\<:)\(_&'@[7/@)\6/%-Y=6
M?A+2];U_3_%W@/Q3?![==*\/:3X[@T_PU?0^+]91[IK+1M:\':/IMW/:Q:3I
M7B#5=>U+3=)NOC*O@GXJ4>'?]:ZO!F:0R3ZH\?*LYX+Z[3P4:<JLL36R=8MY
MS1HPHQE6G.KE\%"BO;3M3:D_N7XY>$\>)?\ 5%\;94L]^N++_J_L\=]3^O.J
MJ*PG]L?5/[&^L>W:H>Q_M#G5?]RU[5.)^TM%?G1_P4?_ &_?^'??PW\ ?$'_
M (5-_P +;_X3GQO-X-_LC_A._P#A O[+\G0=0UO^T?M__"&^-/MN[[!]F^Q_
M8K3'F^=]J.SRG_+SQK_P<??#_0]'\!R^$?V9]4\9>(M:\,QZQX_TN?XN1^'M
M%\#ZY=S%K/PQH_B$_"_6+GQI/%I_EW.LZB^@>%[33;R9-,MDU2:*\EM,.&/!
M[Q'XSRS"9SPSPS5S7+,;B\3@</BZ>8Y/0A]9P=.I5Q"KPQ>88>KA*4%3<%B<
M7"AAJE>='#4JT\1B*%*IT\5^,OAKP1FF*R7BKB>CE&:8/+\-FE;"5<NSFO*6
M#Q>)IX3#RPT\'EV(I8S$3JU.9X+!U*^-AAJ6)QM3#PP>$Q5>C_2U17Y4?M$_
M\%:/@G^S1\ /@S\6/B!X(\<)\2?CQ\.[#Q]X&^ D#Z3%XML+?4=#34K>Y\;:
MS-<BP\+^%1J<]GI#:Z;+4=?G-T]QIW@K4+G2]=TW2OS,T;_@Y8T>?6-*@\0_
ML<ZEI>@3:E8Q:YJ>C?'BUU[6-.TB2YB34K[2M#OOA!X<LM9U*TLS-/8Z5>>(
M="M=0N8XK2XUG3(IGO8.W(O [Q4XEPN)QV2\(XG%X/"XS&8&IB9YCDV#I5<3
M@,16PF,A@YX[,L,LPA0Q-"MAY5\!]9H.M2G3C5E-6.#/_'CPEX7KX'"YYQCA
ML'BLPP&"S3#X:&6YWC<1#!9EAJ&-P-7&T<!EF*J9;/%83$T,32H9C'"XAT*L
M*KI*#N?U%45X#^S+^TO\*/VMOA!X=^-?P;UBYU/PIKQGL[JPU6VCT_Q)X5\0
MV B_M?PGXKTN*YO(M-\0:0\\/VF*VO;_ $V]M;BRU?1-2U70M2TS5+SWZOS3
M,<NQ^48_%Y9F>$Q& S# 8BKA<9@\52E1Q&&Q%&3A5I5:<TI1G"2:::UW3::9
M^G97FF79WE^#S;*,;ALQRW,*$,3@L;A*L:V'Q-"HKQJ4JD&TUNI+24)*4)J,
MXRBBBBBN([PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?\
M]K+_ )-8_:7_ .S?_C+_ .JZ\1U_G>?M!_\ (YZ9_P!BQ9?^G76J_P!$/]K+
M_DUC]I?_ +-_^,O_ *KKQ'7^=Y^T'_R.>F?]BQ9?^G76J_I3Z*'_ "=W"?\
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M_&7_ ">5\)O^R?ZE_P"D/Q+K[ H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /C_ /9P_P"2J?M._P#90(__ %(_B!7V!7Q_^SA_
MR53]IW_LH$?_ *D?Q K[ H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /C_]BG_DE>O_ /90-5_]1SPI7V!7Q_\ L4_\DKU__LH&
MJ_\ J.>%*^P* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&I>(O!O[*&H_"S]E_P""FKVWQ"^(OCF?Q#/XRM]7\2:<]UX6TZ#1O%NH^%O
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MI];JYI5Q>&X@PF=8K+:&88B@J$J=/$57G?\ :BPZKY=@<%BLAC0C5[O_ (.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\__M9?\FL?M+_]F_\
MQE_]5UXCK_.\_:#_ .1STS_L6++_ -.NM5_HA_M9?\FL?M+_ /9O_P 9?_5=
M>(Z_/_\ X(I?\FL>/O\ LX#Q5_ZKKX55^E>%'B'_ ,0PXNH\5?V/_;GLL!CL
M#]0_M#^S.;ZY"$/:_6OJ686]GRWY/J[Y[VYXVN?F/B[X<?\ $5.#:_"7]L_V
M#[;,,!CO[0_L[^U.7ZE4E/V7U3Z]EU_:\UN?ZRN2U^2>Q_"/17^IQ17]1?\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_\
MM'_\E4_9B_[*!)_ZD?P_K[ KX_\ VC_^2J?LQ?\ 90)/_4C^']?8% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\?\ C+_D\KX3
M?]D_U+_TA^)=?8%?'_C+_D\KX3?]D_U+_P!(?B77V!0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?'_ .SA_P E4_:=_P"R@1_^
MI'\0*^P*^/\ ]G#_ )*I^T[_ -E C_\ 4C^(%?8% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\?_L4_P#)*]?_ .R@:K_ZCGA2
MOL"OC_\ 8I_Y)7K_ /V4#5?_ %'/"E?8% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML"OC_P#;6_Y)7H'_ &4#2O\ U'/%=?8% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*-+EDZ5:M.'-'[,N6ZZ,_?6BBBO\SC_40**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /G_P#:R_Y-8_:7_P"S?_C+_P"JZ\1U^?\
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MQ.YPM_T1'$'_ (<,N_\ D?7^GI_I(T5_FW?\-T?MM?\ 1XG[4_\ XD'\6O\
MYKJ/^&Z/VVO^CQ/VI_\ Q(/XM?\ S74?\28\3_\ 1:9%_P"&_,/_ )+U_IZ'
M_$[G"W_1$<0?^'#+O_D?7^GI_I(T5_FW?\-T?MM?]'B?M3_^)!_%K_YKJ/\
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M0 4444 %%%% !1110 4444 %%%% 'Q_XR_Y/*^$W_9/]2_\ 2'XEU]@5\?\
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MX',5B*KH4Z7LYU7C'4QM/ZKAL3BL/2QN%7UB'R&*\:?%+(<GP/'/%7A)3P/
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MX@9)F1 37NM?A7^P?_P17_X8F_:(T+X^?\-*_P#"S/[$\/>*=!_X13_A3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G_ /:R
M_P"36/VE_P#LW_XR_P#JNO$=?YWG[0?_ ".>F?\ 8L67_IUUJO\ 1#_:R_Y-
M8_:7_P"S?_C+_P"JZ\1U_G>?M!_\CGIG_8L67_IUUJOZ4^BA_P G=PG_ &(<
M[_\ 3-(_F+Z77_)F\=_V/\B_]2*AX51117^HA_E(%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445])?LE?LP_$+]K_ ./'@7X'_#S3M5DF\1:K
M93^,/$VGZ3%J]I\.?A[!J5A;>+OB-KMO=:IH5@VE>%["]6>&QN]=TB7Q)K<^
MC>$-&NI?$GB+1;*[XLQS' Y1@,9FF9XJC@LNR_#5L9C<77ER4</AL/3E4K5:
MDM;1A"+=DG)_#%.32?=EF6X_.<QP64Y7A*V.S+,L50P6!P>'CSUL3BL14C2H
MT:<=%S3G)*[:C%7E*48IM?2'[ 7[&.J_'O4-0^-GBN#[-\&?A/XZ\):)?PWV
MB7-W:_$;QO?V6K^)[7P78W&I:1=>%=0T71M.T"VO?B;937=QJ]IH_B;PGI<>
MCK!XSC\0:'_H+5^:_P 3O@)\/?V7_P!D/X1? ?X66VJV_@;X>>*[/3]*?7=3
MEUC6]1N]3L?'7B#Q!KNLZ@Z00RZKXB\2:OJ^O:A#IMGIFB6=WJ4UEH&C:+HE
MOI^E6?Z45_D=XR^*&-\4N+\3FMZM'(<OE5P/#67U5",L-EJG&^)KQA%6QN93
MIK&8M2G6=!RIX*%>M0PE&;_V*\$_"K!>%'!N%RFU&MQ!F,:..XHS&DZDH8K,
MW"5L-0E.3O@<KA4E@L(XPHJNH5<=.A1KXRM!%%%%?DI^P!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'Q_^T?_ ,E4_9B_[*!)_P"I'\/Z
M^P*^/_VC_P#DJG[,7_90)/\ U(_A_7V!0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?'_C+_D\KX3?]D_U+_P!(?B77V!7Q_P",
MO^3ROA-_V3_4O_2'XEU]@4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Q_^SA_R53]IW_LH$?\ ZD?Q K[ KX__ &</^2J?M._]
ME C_ /4C^(%?8% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\?_ +%/_)*]?_[*!JO_ *CGA2OL"OC_ /8I_P"25Z__ -E U7_U
M'/"E?8% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC,=CN(>)<%B*.3.>%>E+#XJ-HXVA.$:U>ICLN^NX>AAZ+J/GE6PU.M]#Q/\
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M(EAOKW]GRXBX:]DN*I89>U_MCZU%^R6;/^TDUF+:]FYG0?\ !4[XYZ-^T?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C_ /:/_P"2J?LQ?]E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OXO/^#B_P#Y/:^%W_9K'@G_ -6U\;Z_M#K^+S_@XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^?\ ]K+_ )-8_:7_ .S?_C+_ .JZ
M\1U_G>?M!_\ (YZ9_P!BQ9?^G76J_P!$/]K+_DUC]I?_ +-_^,O_ *KKQ'7X
M7?\ !-[_ ()Z?L??M9_ [Q5\1OV@?A#_ ,)_XRT7XK:YX)TS6?\ A/\ XH>%
M?LWAC3O"'@;7;+3/[/\ !7C7PWI4WDZKXDUJZ^VW%C+J$GVSR);M[:WM(8/U
MWP2X^R?PVXZH<3Y[ALSQ> I99F."E1RFCA:^,=7%TX0IR5/&8S 4?9Q<7SMX
MA22MRQD?COCIX>YUXG< XGA7(<3E>$S"MF>6XV-;-ZV+P^#5+!U9SJQE4P6"
MS"NJDE)>S2P[BW?FG%:G\C%%?WU?\.4_^"97_1M/_F9/V@/_ )ZM'_#E/_@F
M5_T;3_YF3]H#_P">K7]E?\3B^&7_ $(N._\ PV</_P#T3G\3?\26>*7_ $/^
M /\ PZ<1?_0J?P*T5_?5_P .4_\ @F5_T;3_ .9D_: _^>K1_P .4_\ @F5_
MT;3_ .9D_: _^>K1_P 3B^&7_0BX[_\ #9P__P#1.'_$EGBE_P!#_@#_ ,.G
M$7_T*G\"M%?WU?\ #E/_ ()E?]&T_P#F9/V@/_GJT?\ #E/_ ()E?]&T_P#F
M9/V@/_GJT?\ $XOAE_T(N.__  V</_\ T3A_Q)9XI?\ 0_X _P##IQ%_]"I_
M K17]]7_  Y3_P""97_1M/\ YF3]H#_YZM'_  Y3_P""97_1M/\ YF3]H#_Y
MZM'_ !.+X9?]"+CO_P -G#__ -$X?\26>*7_ $/^ /\ PZ<1?_0J?P*T5_?5
M_P .4_\ @F5_T;3_ .9D_: _^>K1_P .4_\ @F5_T;3_ .9D_: _^>K1_P 3
MB^&7_0BX[_\ #9P__P#1.'_$EGBE_P!#_@#_ ,.G$7_T*G\"M%?WU?\ #E/_
M ()E?]&T_P#F9/V@/_GJT?\ #E/_ ()E?]&T_P#F9/V@/_GJT?\ $XOAE_T(
MN.__  V</_\ T3A_Q)9XI?\ 0_X _P##IQ%_]"I_ K17]]7_  Y3_P""97_1
MM/\ YF3]H#_YZM'_  Y3_P""97_1M/\ YF3]H#_YZM'_ !.+X9?]"+CO_P -
MG#__ -$X?\26>*7_ $/^ /\ PZ<1?_0J?P*T5_?5_P .4_\ @F5_T;3_ .9D
M_: _^>K1_P .4_\ @F5_T;3_ .9D_: _^>K1_P 3B^&7_0BX[_\ #9P__P#1
M.'_$EGBE_P!#_@#_ ,.G$7_T*G\"M?H?_P $U?V"];_;Y^/$G@:YU;5?"'PI
M\"Z5;^+_ (M^-M-TJ[N[NUT1]2M[#3?!GAK49-,OO#>G^/\ QO,UZGAP^)I4
MM++1-#\8>+8-*\5/X0E\*ZQ_6W_PY3_X)E?]&T_^9D_: _\ GJU]H_LY_LO_
M  +_ &3/!&J?#G]G[P/_ ,(!X-UKQ5?>-M3T;_A)O&'BK[3XGU'2-#T*]U/^
MT/&OB#Q)JL/G:5X;T6U^Q6]]%I\?V/SXK1+FXNYI_E>-?I?</XOAK,\)P1E?
M$^!XDQ5%8? 9AF^"R:CA,O\ :R4:V,BL/FV:2K8FC2YGA:4\-[%UW"I5GR4W
M3J?6\#?0TXBP?%&5XSCO->%L?PQA*SQ./R[)L;G5?&9DZ2<J."D\3D^50HX6
MM5Y5BZT,5[94%.G2ASU%5I>T:%H6B>%]$T;PSX9T;2O#OAOP[I6GZ%X?\/Z%
MIUII&B:%HFD6D.GZ5HVC:5I\-O8:9I6F6%O;V6GZ?96\%I96D$-M;0Q0Q(BZ
MM%%?P).<ZDI3G*4YSDYSG-N4IRDVY2E)MN4I-MMMMMMMNY_H9"$:<(TZ<8PA
M",80A"*C"$(I1C&,8I*,8I)1BDDDDDK'Q_\ MK?\DKT#_LH&E?\ J.>*Z^P*
M^/\ ]M;_ ))7H'_90-*_]1SQ77V!4E!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\?\ [1__ "53]F+_ +*!)_ZD?P_K[ KX_P#V
MC_\ DJG[,7_90)/_ %(_A_7V!0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?'_C+_D\KX3?]D_U+_TA^)=?8%?'_C+_ )/*^$W_
M &3_ %+_ -(?B77V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?'_[.'_)5/VG?^R@1_\ J1_$"OL"OC_]G#_DJG[3O_90(_\
MU(_B!7V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?'_[%/_)*]?\ ^R@:K_ZCGA2OL"OC_P#8I_Y)7K__ &4#5?\ U'/"E?8%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!\__M9?\FL?M+_]F_\ QE_]5UXCK\__ /@BE_R:QX^_[. \5?\ JNOA57Z
M?M9?\FL?M+_]F_\ QE_]5UXCK\__ /@BE_R:QX^_[. \5?\ JNOA50!^P%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_P#MK?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'S_P#M9?\ )K'[2_\ V;_\9?\ U77B.OS_
M /\ @BE_R:QX^_[. \5?^JZ^%5?H!^UE_P FL?M+_P#9O_QE_P#5=>(Z_/\
M_P""*7_)K'C[_LX#Q5_ZKKX54 ?L!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\?_MK?\DKT#_LH&E?^HYXKK[ KX_\ VUO^25Z!
M_P!E TK_ -1SQ77V!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?'_[1_\ R53]F+_LH$G_ *D?P_K[ KX__:/_ .2J?LQ?]E D
M_P#4C^']?8% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK[ HOZ?<O\@MZ_>_ZZ?U=GS=_P (O^U]_P!%R_9N_P#$5/B?_P#1DT?\(O\
MM??]%R_9N_\ $5/B?_\ 1DU](T47]/N7^06]?O?]=/ZNSYN_X1?]K[_HN7[-
MW_B*GQ/_ /HR:/\ A%_VOO\ HN7[-W_B*GQ/_P#HR:^D:*+^GW+_ ""WK][_
M *Z?U=GS=_PB_P"U]_T7+]F[_P 14^)__P!&31_PB_[7W_1<OV;O_$5/B?\
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M=GS=_P (O^U]_P!%R_9N_P#$5/B?_P#1DT?\(O\ M??]%R_9N_\ $5/B?_\
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M_P 14^)__P!&37TC11?T^Y?Y!;U^]_UT_J[/F[_A%_VOO^BY?LW?^(J?$_\
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M\@MZ_>_ZZ?U=GS=_PB_[7W_1<OV;O_$5/B?_ /1DT?\ "+_M??\ 1<OV;O\
MQ%3XG_\ T9-?2-%%_3[E_D%O7[W_ %T_J[/F[_A%_P!K[_HN7[-W_B*GQ/\
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M^(J?$_\ ^C)H_P"$7_:^_P"BY?LW?^(J?$__ .C)KZ1HHOZ?<O\ (+>OWO\
MKI_5V?G5^PKI'QOB\+W=YK7Q"^%5_P"!H?'&NKK7AS2_@WXNTCQ9J%TWA/0T
MM)M+\:7?QVUO1]'MX+R33+BXMKOP%KDEU:VE_:1W=G+J-O>Z7^BM?'_[%/\
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MOPQ8WK037MIH>DR^(]:GUCQ=K-K)XC\0ZS>W?ZL?\&\/_)ZGQ/\ ^S7?&O\
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M0#]@Z;0-<AA_;9_9&FFFT?4XHHHOVD?@W))+))93HD<:)XS+.[L0J(H+,Q
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M9:A<?P-Q?M"_M8K_ ,%(S^T<GP.W?M?'XTS>,S\!O^%:?$D_\7%>!TD\)_\
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M=;\/Z-_9G]@?\*I\&>3]M_MW[3]M_MJ7[-]E\G[)<>?YL/[OU_-1_P $F_\
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MC0TN-(O;W2K_ %:)?!/B%I-.8V)72Y=1MM5M/ZHOV9OVB_AM^UC\#OA]\?\
MX2WUW>>"?B'H_P#:5E;ZG#!;:WH>H6MS/IVN>&?$-G;7-Y;VFO>'-9M+[1]4
MBM;R]L7NK1[C3;Z_TV>TOKBEAYRP\L3!PJ4J=6-&LZ<U*5"K-3E"%6&DHN<8
M.49).F_AYU.\3G=>$:U.A/FA4K4IUJ/-%J-:%.2A5]G+9NG*233LY>\X<RIU
M7#W>BBBL#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MG_\ :R_Y-8_:7_[-_P#C+_ZKKQ'7Y_\ _!%+_DUCQ]_V<!XJ_P#5=?"JOT _
M:R_Y-8_:7_[-_P#C+_ZKKQ'7Y_\ _!%+_DUCQ]_V<!XJ_P#5=?"J@#]@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C_ /;6_P"2
M5Z!_V4#2O_4<\5U]@5\?_MK?\DKT#_LH&E?^HYXKK[ H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /C_P#:/_Y*I^S%_P!E D_]
M2/X?U]@5\?\ [1__ "53]F+_ +*!)_ZD?P_K[ H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /C_ ,9?\GE?";_LG^I?^D/Q+K[
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MK\&:_>;_ (-X?^3U/B?_ -FN^-?_ %;'P3KC\:_^35<<?]B2K_Z>HG7X)_\
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MS?\ XR_^JZ\1U^?_ /P12_Y-8\??]G >*O\ U77PJK] /VLO^36/VE_^S?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\__M9?\FL?M+_]
MF_\ QE_]5UXCK\__ /@BE_R:QX^_[. \5?\ JNOA57Z ?M9?\FL?M+_]F_\
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M#-?O-_P;P_\ )ZGQ/_[-=\:_^K8^"=?EWC7_ ,FJXX_[$E7_ -/43]2\$_\
MDZW W_8\H_\ IFL?V54445_E ?ZS!1110 4444 %%%% !1110 4444 %?GG^
MUI_P4K^!7[&_Q&T7X8_$[PG\6==U_7?!.G>/+2[\!Z%X/U/2(](U/7?$GA^W
MMKFX\0>._"]ZFI)>^%]0EFABT^:U6UFLW2\DEDFAM_T,K^33_@N__P G=_#G
M_LW#PA_ZLWXOU^G>$?"N4\8\8T<ESJ%>>!GE^.Q,HX>M+#U/:8>$)4_WD4VH
MWD[JVI^J^#?"63\;<:T,CSV&(J8">78_$RCAJ\L/5=7#PA*G^]BFU&\GS*VI
M^CW_  _?_9$_Z)S^T?\ ^$A\,O\ Y[]?H9^R7^UI\.?VR/ASK7Q.^&.B^-M"
MT#0O&VH^ [NT\>:;H6F:O)J^F:%X;\07%S;6_A_Q)XHLGTU[+Q1I\4,TNH0W
M374-XCV<<4<,UQ_!17]9?_!"#_DT3XC?]G'^+_\ U67P@K]<\6_"/@[@[@ZO
MG62T<PACJ>/P.'C+$8Z>(I^SQ%24:B=.4$FVEH[Z,_9?&/P;X*X*X*KY[D5#
M,:>/IYCE^&C+$YA4Q%+V6(J2A53I2@DY-+1WT9^UM%%%?RJ?R*%%%?SM_P#!
M07_@H)^TAK7[1]Q^QA^R#<3Z)K0U#3O &L^(O#L6DR>,_%GC+Q7I*Q7V@:!K
M^LYL_ NF^'EUF&WN_%%E)H?B#0]?TB^UF/Q5HNF::9I/J>$.$<UXUS=Y1E4L
M+1E2PM?'XS&8ZJZ&"P& PTJ<:V*Q-50J24(SK4H*,(3G*51.RIQJ5(?8\$\$
MYKQUFE?+LMK8+!4<#@JV9YIFF9UWALNRW+L/*$:V)Q-;EF]'4BH4XQ;DE.I-
MT\/1KUZ7]$E%?S*^*_V(O^"Q'P]\(7WQ#LOVLO%/C;4/#-G:>(#X$\-_M(_&
M;6?%%^+6:VN+NSM])\7:3I/@S6YM-@\^[O\ 2+K79[?6+:RNM/TN#7+RZLM-
MU#Z[_P""5'_!1KQW^U#J/B;X)_'673=2^*'AO0I_%_AKQOI^FZ=H)\9^';?4
MK>RUK3]=T;2X;#1;7Q%H-QJNFO83>'].L;35M">X:ZTNTOM!O-4U[ZO-/"ZK
M1R+,^(.'>*.'^+<%D;@\ZI935K0QN HU?X>*>'K0_?86RJ.=6-2/NTJLZ4:T
M*&*EA_IL[\*ZV#X=Q_%7#W%'#_&&4916HT<Y>3U*\,;EOUB4(4:U7!XBFISP
MTI5(IU83YDE4G&G*EA\54H?M?17YM?\ !1/_ (*!Z/\ L4^$-$TWPYI6D^,/
MC1XYBNKCPGX9U>:Y_L71=&LW,%SXN\5P:=<6FI3:5]MQIVE:7:WNEW&NWD>H
M"VU.UBTB_D3\D/A5\-_^"P'[<NE)\8[?]H+Q1\)O"M[IUI#X4U#5?B%XI^"7
MA[Q9IC76H3K=>'/!GP;\/N]]!;></^*M\0^'K1M<LI]/BT_7]=AT]TT_DX<\
M-<PSG)'Q/FN;Y/PKPY*N\-ALSSNM4A+'UU.=.4,OPM*$JF)4*M.<*DG*FKTZ
MKI*JJ%?V4</>%>/S3A^GQ7GN?9'P=P[B:OL,NQN>UZL<1FE7VDJ;_L_!4:<J
ME:E&5.KSSE.G/EIRK4Z57#PJUJ?]2E%?RE^,/C9_P5(_X)H>-=%7XP^-M5^+
MWPUUG7/.BU#QEKVH?%;X?^.YFT4)=:-I?C[Q);0_$OP5?V$3S7=CHCW7A,SZ
MMH\VLGP]XC\/B].J?T6_LM_M)^!OVK_@WX<^,/@-+FQM-4>XTS7O#U_)%+J?
MA3Q3IGE+K'A[4)8,17#6YF@N["]1(1J6CWNG:E]FM#=FT@QXK\.<SX:RS!\0
M8;,<KXCX:Q\XTL/GF25Y5\/2Q$E+_9L;2G"%7"U^:G4CR_O:<)Q5&M4I8IO#
MQX.,O#;-N$<#EV>0Q^5\0\,YLU# <0Y'B)8C RKM5']4Q,9PA4PN+Y:-27LF
MJE/W*E)5GB*.(HT?H>BBOYZ/^"WGQJ^,GPG\7?L]VWPL^+7Q-^&EMK7ASX@S
MZS;^ /'GBGP;!JT]EJ?A6.SFU.+P[JNG1W\MI'<7"6TETLKP)/,L102N&\/@
MWAC$<9<29;PWAL51P5?,OKG)B:\)U*5+ZG@,5CY<T*?OOGAA94XVVE*+>B9Y
M? ?!V)X\XDPO#>$QE# 5\51Q=>.)Q-.I4I06$P\\1*+A2]]N<8.,;:)N[T/Z
M%Z*_F,^&?[$O_!5[XJ_#CP%\3_#W[<NIV>@?$7P;X9\<:)::S^TS^TC;ZQ:Z
M3XJT:RUS3K?5+>Q\)ZC90:C#:7T4=[%::A?6T=PLB07=Q$%F?SOPS^V;^WW_
M ,$Y/C/I_P -_P!JR_\ %/Q2\!ZA/<ZG?:1XU\0P^.K_ %WP]>ZA;:>_C/X:
M?%"^N;OQ 9[6+1W;3/"^O:R-%MDOK^TUSPGX?U[45U33/T./@ZL?7QN6\/<<
M<+YYGV"6(YLBIU,1@\;7GA')8FC0>)A[.=>FX23BW&E%KFK5J4+S7WT/!=YF
ML?AN%..>%>)\[RZE5K5,APM7$8/,*].AS1K1PBQ4%"M6A44:;4G3HQE./ML1
M2<H*?]6]%<UX-\7^'_'_ (1\,^.?">HPZMX8\8:#I7B7P_J<!S%?:1K5E#J&
MGW*CJADMKB,O$V)(GW12!71E'2U^,U:56A5JT*U.=*M1J3I5:52+A4IU:<G"
MI3G"23C.$TXRBTG&2::NC\2E&<)2A.,H3A)PG"<7&<)1=I1E&23C*+34HM)I
MIIJX445\$_\ !3OQCXN\ _L.?'#Q;X$\4^(_!7BK28_AZ=*\3>$M;U/PYX@T
MPWOQ5\#:=>'3]9T>ZL]1LC=Z?=W=C<_9KF/S[.ZN+67?!-(C=N49?/-\WRC*
M*52-&KF^:Y;E5.M43E"C4S+&T,%"K.,?>E"E*NISC'WG&+2U:/7X=R:KQ%Q!
MD7#]"M3PU;/<XRS)Z6(JQE*E0J9GC:."A6J1A[TH4I5E.<8^]*,6EJS[VHK\
M</\ @BM\3_B7\5/V>_B?K7Q/^(?CGXCZSI_QDO-+L-6\>^+=?\8:G9:8O@KP
M?=KIUI?^(=0U&ZMK%;JZN;E;2&5+<7%Q/,(_,ED9OV/KT>+.':_"?$.9\/8C
M$4L76RRK2I5,11A.%*JZN'HXA.$9^^DE647S;N+>S-N*<@K<+<0YMP]B,13Q
M5;*<9/!U,11C.%*M*"BW.$9^_&+YM%+4***\Z^+_ (=\6^+_ (3?%#PGX!UW
M_A%_'7B?X>>-/#W@OQ+_ &GJ>B?\(]XLUKPYJ6G>'=<_MG18+G6-)_LG5[FS
MO_[3TFVN-2L?(^U6,$MU%$C>#2A&I5I4Y5(THSJ0A*K._+3C*2BZDK:\L$^9
MVULF>1A*-/$8K#8>KB*>$I5\11HU,564G2PU.K4C">(JJ/O.G1C)U)J/O.,7
M;4]%HK\U/V /V;/VQ/@%J7Q0N?VI_CY_PNJS\3V7A.#P7!_PM/XH_$?_ (1Z
MYTJ?7Y-=F\KXBZ%HT6D_VE%?Z4GF:2UQ)>?8MMX(UMK8O^E=>KG^68/)\TKX
M# YQ@L^PU*%"4,SR^-6&%KNM0IU9PIQK*-1.A.<J%3F2O.G)K2QZ&?Y;A,HS
M?&9=@<WP>?83#?5_99M@(U88/%^VPM#$5'1C62JKV%6K/"U.=)NK0J->ZT%%
M%%>,>.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M117X'_\ !</XQ?%WX30_LS'X5_%/XC_#,Z])\81KI^'_ (X\3>##K0TQ?AA_
M9HU8^'-4TW^T1I_]H7_V'[9YWV3[;=_9_+^TS;_I.$.&Z_%_$N5<-8;$TL'7
MS6IBX4\37A.I2I/"9?B\PDYPIVG+GA@Y4X\NTIQ;T3/KN!.$<1QUQ3EO"V$Q
ME' 8C,H9A.&*Q%.I5HT_[/RS&9G-3A3:F_:4\'*E&VTYQ;T3/WPHKY._9=\<
MZRW[%7P5^(WBK4=8\6:['^S_ .%O%^O:IK.J76I:YX@O[;P9!JU]<ZCK&HR7
M5Y>:CJ,L4C3WUY+/-+-*9IGD8L3_ #4?!KXH_P#!1?\ X*,?''Q=I7P^_:8\
M0?#C6;+PU?\ C"?3-.^)7CSX3_#?0?#UIK=AIUIHND:+\.+74I[FZ@FUZUM+
M:^U'3-3UB^L[0S>(/$5Y=Q)//]1P[X:8S/L;Q;2JYSE>49;P96G1S?-L?[?V
M-UB,9AZ<J-&G"4Y1F\#7G)SE#V<?9Q7/.:BOHN%?##%<24^*<;B<^RG(<FX2
MQ$,)F6:YE]8=.5>KB*M"DJ5&C3E+D;I7G.I.#4JM"G3A6<ZCI?V$45X;^S5X
M(^)_PW^!?PW\#_&?QO\ \+'^)WAS0FL/%WC3^U=3UW^V[[^T+V:WD&MZWI^E
MZUJ_V33I;.P_M/6+*+5+XVIN;YIKF22:3W*OS['X>EA,=C,+0Q5''4<-BL1A
MZ6.PZFL/C*5&K.G3Q5!5(QJ*CB(Q56FIQC-0G'F2=T?F^+HPP^*Q.'I8BEBZ
M5#$5J-/%45-4<33I5)0AB**J1C45*M&*J4U.,9J$ES1C*Z11117(<X45\M?M
MF_M(Z;^RE^SOX]^,%U%;WNMZ;:0Z)X'T:X9-FM^.=?<V/AZTDB:>V>>PLIFE
MUW7(K>9;O_A'M(U:6T#W$<:-\B?\$BK+XT^)/@!K?QR^.'Q-^)OQ UKXO>*K
M^Y\)6GCOQMXB\1Z9HG@SPW=7>E1W6@Z'J^HW5CX??6_$9\0O-_9]I9QW6D:?
MH'V:-;".W,GU&$X6Q6(X4S7B^MB*6$R[+\QP>3X2%6,G5S7-,5'V]7"X2S44
M\'@KXS$3F[.G[M)3G&HJ?UE+A+%O@W%\:XG$TL)@(9SALBRS#U(2>(S?'SHS
MQ6+^KV:5.A@<+!U*E>2E"I5OAX>_"HX?K!17\?/C7X@?MF_&G_@H%\7?V=OA
M/^U%\7/!MUKGQ_\ C5X<\'6>H?&SXJ^'?!'A_3O#7B#QAJ5MIL=OX;O=5DTG
M2[/2-$>QTVSTO1)H+<K:VT<$%L#)%]E?\.Y_^"NW_1]W_FS_ .TW_P#,/7Z!
MB_"3 97A\JJYWX@<.Y-6S?*\)F^&PN,P^.]K]5Q<+PE>$91:C-5*3DFDY4Y-
M*VWZ5FG@SEN0SP5#/O$GAC)\7CLNPN:4<)C,+F"JO!XMU(4JON1E%Q=6C7IW
MOK*E+1+4_H\HKX;_ &#/@?\ M*_ CX:>+?#7[3_Q?_X7+XQU;QS/KFA:_P#\
M)_X^^(?]F>&GT'0["+1_[5^(6DZ/JEELU2QU*]_L^S@DL%^U_:%F-Q<7")^)
M7[.7[0GQ\US_ (*S3_#C6OCA\7]8^'@_: ^/.C#P'JGQ*\9ZAX,&CZ/;_$=M
M(TH>%[O6IM#&FZ6UC9'3K$6/V6Q-G:FVBB-O#L^>RGP]>=X[B[#97Q!EV,PO
M"F2XC.WF-&CB)8;,Z&&PZKSI85/EG3GS<U'FJJRG!MJQ\IE/AS/.X\>U\LS_
M "[%X+@7*<1F\\;2HXAT<YP^'PV,Q-L%=1E2<XX.<(RK*RE*-U9,_J9HK\-?
M^"PW@G]H[P-X=T?]I?X#_'#XX^#O#>CC3O"WQ5\#^"/BAX^T#P]IT%Q/+%H'
MQ!L=&T;7+33M.1[N:#PWXG^SQ11SW%SX<U%+43MKU_-Z]_P38_;Y\/\ QE_9
MCUVZ^-'C&TT[Q_\ L[Z$_P#PLWQ!KM]/+=:WX$TRSDFT;XD7LMP;B]O[N>QM
M9M)\2RQRW]]=^)-.DU&5(7\2:99'GEP!C:W ]'CC*\=1S7"0Q\<NS7+L-0K+
M'Y1B)R5.#Q$?>C5ISJ5,(H.BW*4<=A9\BYJJI9XGPWS%\$95QSD^-HY[@,;C
MZ>58_ X+#8CZ_D^8U91HT\/BJ7O^T]IBYT<-2E3]ZK+&8"<*<HXR'+^ME%?R
M4^ _CO\ M>?\%%_VV[O1?A?\8_C;\(/A?K6M#5=1T;P%\2O%_A71_AS\'_#L
MEK8S:E-9:'JT6D-XLU6S%M";F2TGBU/QMKD*,(]) %I^]O[?W@'XC:I^Q_X\
M7X+?$'XD>!/'?PKT.U\>>'=9\(>/?&&C^*-;T[P)I]P^O:#K/B'3M4'B/Q*V
MK^%3J\BP:GJ%[/J_BBWT;4+Z2XO8EGKKXA\.:G"V8<+91G.>8##YGQ#'"5<;
MA8TJM3_5VAC*E&C"KF=1249\E6I6C..'Y_=PF(J*3A[!UN[/_#"?#7$G"W"N
M:\1Y93S?B"."^OPHTJM:CP[4S"=&CAJ>8UXSY*KEB*E2,G0TAAZ/UR7[BOAW
M4^Z:*_-/_@EI^UM??M3_ +.EO%XPU";4/BK\)KNT\$^.KZ\F\^^\16ILQ<>%
MO&=S)MW//KVGQ7-CJ<LSO<W6OZ%K-]($BN[<O^EE?(<1Y#C^%\\S/(,RBHXS
M+,3+#U'"_LZL'&-3#XFES)2]CBL/4I8FCS*,_958<\8RO%? 9]DN/X<SG,\B
MS.FJ6/RK&5<'B8Q;<'*E+W:M*32<J->FX5Z$[+VE&I3G9*045\4_\%!/VD]?
M_95_9B\9?%'PA:V5SXTEOM%\)>#WU.W-UINGZYXDNS;C6+VVW*ERNCZ;#J.I
M6MM/NM;K4+:SMKQ)+26:-O)=+^-NJ_LT_P#!/WQM\<K_ ..NC?M=>-/#%GK/
MB"_\=6WB3P]K7@^X^(7C/Q-8V,'@_3+[PI>/;P^#_"7B/Q)9V4.BP:DE]'ID
M,NG:+#X<TZ71/#^B=>"X5S+'Y/ALXH>S<,PX@H\-Y9A;5?;X[,JD,-.HH35/
MZK0I47CL!2<\5B*/MJN+C##QJ^QQ#I>S@."\WS+*\DS+#>Q<^).)8<,9)@G[
M95L;C;8>-:M*O[)X/"X>EB,;@L-#ZSB:=;$5*M>=&E*E@\1./Z845\'?\$]-
M<\1^*_@@/&GC?]IK3OVDO'WCB^T[QCXT_L36?!NI:%\*=:U[P]I5R?AMIMAX
M1#)X=DTFT%N=4T6X-A:)JIO+W3= TAKR^>^_G+M?'_[;'Q^_;7\=?L]_"W]J
MKXO^%-4\0?%SXQZ7X6CUOXY?%G0O!VBZ?X1O/&.OBP*>';S6;C3K*#1O#\UC
MI=KIVBS012_8[;R[:UW30_6Y!X7XG.\YXIRB6?9=@(<)8*>.S/,JV&Q_U-T<
M/%RQE2E&M0PV*]AAE"K-5JF'IJO2IJM2BZ=2#?U7#/A75XBQG&5"7$F699@^
M":2Q.99IBL)F,<)5PD5C)U\73IUJ&&QE*A1I8*K6;Q&'I5)4G&2IJ]C^R6BO
MYEO''["?_!8GP-X;O_%&D?M9>+?B3>Z3Y-ROA'P/^TW\:Y_$FH1)*IGDL+3Q
MSI_A#P_?_9(@UQ-I\NL"]OHHVM=.L=2O98;*;Z1_X)D?\%./'?QP\;O^SA^T
MJUK<?%*6/7+CP9X[72=.\,7?B:[TE[S4=7\'^*_#VFVVF:38^)-*T^.Z;1[K
M1M)TN"]TS1I['5K'^WH#J>N:8_PKJ_V)F.?<,<49!Q?ALFC*MG&%RJI6IYA@
M<*J?M?KCPM>"E5PT(0K2JSYJ<DJ4W0AB/9XGZO6;^$V(H</8_B;AGBCA_C/+
M<GM+.Z>35:T<?EE"47*.+JX.O!2EA(QA4E5J<\*D(0E5A2JT*.*JX;]V****
M_*#\D"BBOYD_^"T7Q[^.GPL_:>^'^@?#'XT?%GX<Z%>_ OPYJ]YHO@/XB^,/
M"&D7>K3^/_B39S:I<Z;X?UC3[.?49K.QL;26]EA>YDMK.U@>4Q6\*I]?P-PA
MB>.>(L+P[A,90P-?%4L35CB<13J5*4%AJ,JTE*-/WVY*+2ML]]#[GP]X&Q?B
M%Q!_J_@\=A\NK?4<3COK&)IU*M+DPTJ,90Y:7O<TO;)I[*SN?TV45C^'999_
M#^A3322333:/IDLLLKM)+++)90/)))(Y+/([$L[L2S,222236Q7RE6#I5:E)
MN[IU)TVULW"3BVO6Q\+%\T5+ND_O5PHHK'\1:_I7A7P_KGBC7;J.QT3PWH^I
MZ]K%]*0(K/2]'LI]0U"ZD)( 2WM+>:5R2 %0\U"3;22<FW9**<I-O9**3;;>
MB23;>B5S2E3J5JE.C1A*I5JSA2I4X1<IU*E22C"$(J[E*<FHQBE=MI(V**_B
M!\:?M=?MI?&3Q1\=/C!X)^-7Q]\,>!-"U>Y\;ZMH/A?XN>.]&\-?#SPKXM\;
M67AOPGH=EI^E:]8Z?;V]I>:[I&BVL5I:1M.(9[V125N):_I&_P""37[1NN_M
M"_LIZ:?&_B/4_%/Q$^&7B35O WBK6]=O[C4]>UFU'EZWX9UG5;^\EFO;^>;1
M-4ATF34KR::ZO[O1+RXN9I;@S.?U_C#P<SK@_AM<18G,L!C50Q.!PN:8#"QJ
M/$956QV'A6C'$5&W2E[*I6PU"7*TYO%4*L$Z<[K]CX^\%\YX"R*EGN)S;+LT
MIQS'#97F6&P$:KJY7B\5@OKM..)E)NFX\DJ,&[QD_K6#J1A*GB(R7Z<45\W_
M +7GAWXM^+/V;?BUX=^!-QKMK\7-5\.16_@:X\,^*(?!>NQ:L-7TV5VTWQ3<
M:OH,&C3_ &&.[!NI-7L5,1DA\XF41O\ DE_P3FU?]J_Q]^SI^W[X/\6_$'XI
M^,_C+X<@\3?#3X?W/B3XKZEX@U?PY\3['P/XTTS^S/"GC35?%-WIVA7EKXHE
MT1TUW2]>M-+CNEL=435!#!'>1_(91PDLVX:SKB-9UEN%>28S+<-7RRO-?7:E
M#,<;@L%''1CSKDPE&IC+U*LX\G[FI%2YMOD\EX*CG'"^+XF?$&4X&.!S_+<D
MQ678FHHXNA1S*I@Z5'-ZW[Q*CE\98BO>K4C&$OJ.+49MTI\G[^T5^#__  2,
MUK]J!/C1^U1\.?VD?B#\2_&&O?"_3/A_I&HZ+XW^*E_\3[#PIXBU6\\1W,EK
M8W__  D_B?0XK^YL[)DO7TB]D97LI+*\=+BT>"/]X*YN,.&GPEG=3)O[2P>;
MQAA,!C:>/P#YL)B*&8X.CCL/4HRYI*=.>'KTJE.I&3A5ISA5IMPG%OS.,>&I
M<(<1X_AZ>887-7@89?5688&_U7$T\QRS!9I1J4&W+FA[#&TTIJ3C42]I!N$H
MA1117RY\P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?/_ .UE_P FL?M+_P#9O_QE_P#5=>(Z_GS_ &!O^"E?P*_8
MW^#WB3X8_$[PG\6==U_7?B5K'CRTN_ >A>#]3TB/2-3\+^#?#]O;7-QX@\=^
M%[U-22]\+ZA+-#%I\UJMK-9NEY)+)-#;_P!!G[67_)K'[2__ &;_ /&7_P!5
MUXCK^#3QE_R%(/\ KPB_]*+JOT[PCX5RGC'C&CDN=0KSP,\OQV)E'#UI8>I[
M3#PA*G^\BFU&\G=6U/U7P;X2R?C;C6AD>>PQ%3 3R['XF4<-7EAZKJX>$)4_
MWL4VHWD^96U/ZGO^'[_[(G_1.?VC_P#PD/AE_P#/?H_X?O\ [(G_ $3G]H__
M ,)#X9?_ #WZ_DTHK^JO^)>O#C_H&S?_ ,.M7_Y#^K^EOZY_XEN\,O\ H%SG
M_P .]7_Y7_5_2W]9?_#]_P#9$_Z)S^T?_P"$A\,O_GOT?\/W_P!D3_HG/[1_
M_A(?#+_Y[]?R:44?\2]>''_0-F__ (=:O_R']7]+'_$MWAE_T"YS_P"'>K_\
MK_J_I;^LO_A^_P#LB?\ 1.?VC_\ PD/AE_\ /?H_X?O_ +(G_1.?VC__  D/
MAE_\]^OY-**/^)>O#C_H&S?_ ,.M7_Y#^K^EC_B6[PR_Z!<Y_P##O5_^5_U?
MTM_67_P_?_9$_P"B<_M'_P#A(?#+_P">_1_P_?\ V1/^B<_M'_\ A(?#+_Y[
M]?R:44?\2]>''_0-F_\ X=:O_P A_5_2Q_Q+=X9?] N<_P#AWJ__ "O^K^EO
MZR_^'[_[(G_1.?VC_P#PD/AE_P#/?H_X?O\ [(G_ $3G]H__ ,)#X9?_ #WZ
M_DTHH_XEZ\./^@;-_P#PZU?_ )#^K^EC_B6[PR_Z!<Y_\.]7_P"5_P!7]+?U
ME_\ #]_]D3_HG/[1_P#X2'PR_P#GOT?\/W_V1/\ HG/[1_\ X2'PR_\ GOU_
M)I11_P 2]>''_0-F_P#X=:O_ ,A_5_2Q_P 2W>&7_0+G/_AWJ_\ RO\ J_I;
M^LO_ (?O_LB?]$Y_:/\ _"0^&7_SWZ/^'[_[(G_1.?VC_P#PD/AE_P#/?K^3
M2BC_ (EZ\./^@;-__#K5_P#D/ZOZ6/\ B6[PR_Z!<Y_\.]7_ .5_U?TM_67_
M ,/W_P!D3_HG/[1__A(?#+_Y[]'_  _?_9$_Z)S^T?\ ^$A\,O\ Y[]?R:44
M?\2]>''_ $#9O_X=:O\ \A_5_2Q_Q+=X9?\ 0+G/_AWJ_P#RO^K^EOZR_P#A
M^_\ LB?]$Y_:/_\ "0^&7_SWZ/\ A^_^R)_T3G]H_P#\)#X9?_/?K^32BC_B
M7KPX_P"@;-__  ZU?_D/ZOZ6/^);O#+_ *!<Y_\ #O5_^5_U?TM_67_P_?\
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MR_\ GOT?\/W_ -D3_HG/[1__ (2'PR_^>_7\FE%'_$O7AQ_T#9O_ .'6K_\
M(?U?TL?\2W>&7_0+G/\ X=ZO_P K_J_I;^LO_A^_^R)_T3G]H_\ \)#X9?\
MSWZ/^'[_ .R)_P!$Y_:/_P#"0^&7_P ]^OY-**/^)>O#C_H&S?\ \.M7_P"0
M_J_I8_XEN\,O^@7.?_#O5_\ E?\ 5_2W]9?_  _?_9$_Z)S^T?\ ^$A\,O\
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MK_\ *_ZOZ6_K+_X?O_LB?]$Y_:/_ /"0^&7_ ,]^C_A^_P#LB?\ 1.?VC_\
MPD/AE_\ /?K^32BC_B7KPX_Z!LW_ /#K5_\ D/ZOZ6/^);O#+_H%SG_P[U?_
M )7_ %?TM_2G\6?^"QW[,GCSQI\'?$>D>!?CO;6/P]\4/K>M1:EX8^'\-U=6
MK:MX7OA'I:6OQ/O(9KCR=$NE*7<]E'YDEN/-VO(\7O'_  _?_9$_Z)S^T?\
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M_9$_Z)S^T?\ ^$A\,O\ Y[]'_#]_]D3_ *)S^T?_ .$A\,O_ )[]?R:44?\
M$O7AQ_T#9O\ ^'6K_P#(?U?TL?\ $MWAE_T"YS_X=ZO_ ,K_ *OZ6_K+_P"'
M[_[(G_1.?VC_ /PD/AE_\]^C_A^_^R)_T3G]H_\ \)#X9?\ SWZ_DTHH_P")
M>O#C_H&S?_PZU?\ Y#^K^EC_ (EN\,O^@7.?_#O5_P#E?]7]+?UE_P##]_\
M9$_Z)S^T?_X2'PR_^>_1_P /W_V1/^B<_M'_ /A(?#+_ .>_7\FE%'_$O7AQ
M_P! V;_^'6K_ /(?U?TL?\2W>&7_ $"YS_X=ZO\ \K_J_I;^LO\ X?O_ +(G
M_1.?VC__  D/AE_\]^C_ (?O_LB?]$Y_:/\ _"0^&7_SWZ_DTHH_XEZ\./\
MH&S?_P .M7_Y#^K^EC_B6[PR_P"@7.?_  [U?_E?]7]+?UE_\/W_ -D3_HG/
M[1__ (2'PR_^>_1_P_?_ &1/^B<_M'_^$A\,O_GOU_)I11_Q+UX<?] V;_\
MAUJ__(?U?TL?\2W>&7_0+G/_ (=ZO_RO^K^EOZ4]?_X+'?LR:K\?O!'Q4M_
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M[1__ (2'PR_^>_7\FE%'_$O7AQ_T#9O_ .'6K_\ (?U?TL?\2W>&7_0+G/\
MX=ZO_P K_J_I;^LO_A^_^R)_T3G]H_\ \)#X9?\ SWZ/^'[_ .R)_P!$Y_:/
M_P#"0^&7_P ]^OY-**/^)>O#C_H&S?\ \.M7_P"0_J_I8_XEN\,O^@7.?_#O
M5_\ E?\ 5_2W]9?_  _?_9$_Z)S^T?\ ^$A\,O\ Y[]'_#]_]D3_ *)S^T?_
M .$A\,O_ )[]?R:44?\ $O7AQ_T#9O\ ^'6K_P#(?U?TL?\ $MWAE_T"YS_X
M=ZO_ ,K_ *OZ6_K+_P"'[_[(G_1.?VC_ /PD/AE_\]^C_A^_^R)_T3G]H_\
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MJ5JLZ&']I*M]7HRG*5.C[::4ZOLH.-/VDTI3Y>:23;"BBBL3$**** "BBB@
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MLM"U+4].U667SO&'AJW\(>&M,UZ&[T?0=)L3>QI]FU/[-HVD:;;:8VJ_</\
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M:K*\YR;^A/'7[(__  UO_P $R_V4M'_X6#_PK_\ X5A\(O!_Q+^T_P#"*?\
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MRPF"P>^J36O+RI?(O[;/[*W_  V+\$I/@[_PG?\ PKKS/%F@>)_^$C_X1?\
MX2[']AK?K]A_LC_A(O#&?M7VW/VG^U!Y'E?\>\V_Y/GGP_\ \$W?["_8-\9?
ML2?\+F^U?\);XBBU_P#X6;_PKOR/[/\ +\<>&/&?V3_A#/\ A.IOM>[_ (1S
M^S?/_P"$LML?;/MGDG[/]EG_ % HK\XR_C'B/*\LPV38#,?89;A,]PG$N'PW
MU3 5?9YU@9T*F%QOMJV%J5Y^RGA:#^K3JRPD^2U2A-2FI?FV7\=<595EV493
M@,T]AE^1<08;BG*L/]1RZK]5SW!RE/#8[VM;!U*]?V<I-_5<34K8.=[5,/)6
M1\(?L$_L3?\ #$'@+QMX(_X69_PL[_A,?%\/BK^T_P#A#/\ A"_[.\G1K+2/
ML'V+_A*_%GVS=]C^T?:OM=KCS/*^SG9YK?S[?L3?\IBH/^RV?M._^HK\7:_K
MXK^0?]B;_E,5!_V6S]IW_P!17XNU^S>&6=9GQ%3\9LYSC$_7,RQWAUG4\5B?
M8X?#^UE2RC&8>F_8X6E0P\.6C2IPM3I03Y>:5Y.4G^T>&V<9CG_"_P!(3.<V
MQ'UO,LPX%QN(QF)]C0H>VK/)N(HN?L<-2HT*>D4N6E2A'3X;W/Z^*_C:^-O_
M !:3_@KS?WGA3_0S8?M4> /$2Q6_^B)(_C'6O"^OZ_8GR/N6VH/X@U.RN-HS
M+;7,N0"Y%?V >,/&7A/X?>&M7\9>.?$FB>$?">@6PN]9\1>(M2M-(T?3;=I8
M[>-[N_O98;>(SW,T%K;1L_F7-W/!:VZ27$T4;_R$_"&"X_;C_P""JT/C?PS8
MS7/A&^^-I^*MW<207/EV_P ,_AIJ=C>:5=:K%>^7<6G]N:=HF@:,\$JQ-!JF
MO6]G'#"/+C3C\ H3PN/XTSK&0G'(,%P;F5',L14BUA%6E7P6)IT9S?N2JO!X
M;&R5.[ER-Z>^K\W@1"IA,J\4,YQT)PX?H\&8["8RO5BUA:V+E2J5:>%BY6A6
MQ'U?VL51@Y5/]II0<4\124_WW_X*=:_^UYIGP*M]*_9(\(^,]5U?6=0N#\0/
M%_P[N;9_'?A/PM:?88+:Q\(:-9W\/C6]USQ+J6HQYU3P3I>JZEH6D:+J\\[:
M8+JWU"'\4O%7_!';XMZ7^R[XF_:7\<?%RWLOB?IOP^UKXO>*_A/K_A+4Y+Z"
MVLXKGQ1KFG:W\0;KQ*^H?\)FGAB.ZU#4;2Y\%R1_\)@)?#=QJ9MM_B<?H]_P
M5H_;_P#B[^RSJ/P^^%/P.NM-\,^+?&.@3^,]<\=7^BZ9XAOM(T:#6VTO3-,T
M#2]?M-2\/&XU.XTS6$U>ZU;2M3:"Q^SIIT5I>2B^@^7?BE^R!XBU/]C_ ,5?
MM%?M3_\ !0WXF_%#PWX@^%%Q\1_ _P /;3Q==Q?#B[^,^J:!<:YX*T'3[KQ!
MXE\6Z)XKTYM9EN-!L]'\+^!_!FH^5+--IEWH-G87%N/:\/<3Q#PQP=P]C(9A
MD7"F!X@XDMA<?1R/&Y]Q-Q1"GB'0J956PT</B,)AL+.4*E/"S6)RZLXT(RI.
MA.K4Q>,^K\-L5Q)PIPOP+%YEP_PE@N)^(E6PSP60X[/N)N-,,\;3IRP&9+ZM
M7P. HQIUU##XJGC<#B(X)TI4U0KT*\L=[)_P1"_:2^+'Q2TGXP_"CXE>,==\
M<:5\/;'P7K?@?4/$NH7.LZSHEAJLFN:7JF@'6=0GN-1N=&B&FZ.^B:?/+)!H
MZ1WMO9F*UFAMX?BO_@N]_P G:?#7_LWKPO\ ^K(^*=>K_P#! ;_DH/[1_P#V
M)O@#_P!/?B*O*/\ @N]_R=I\-?\ LWKPO_ZLCXIU]A@,%A,#])B5/!8:CA:5
M7*WB)TL/3C2I.O5R&#K5%3IJ,(SK33JU6DG4JRG5G><Y2?T?#.!P>7?2<XLP
MN PM#!X99(JT</AJ4*-"%7%9+P]BL3.%*FHP@ZV)K5:]3E2YJM6<W[TFS]M_
MV\_VK=2_9&_9)MO'7A46#_$3Q2GASP'\/?[0CCNK>PU[5]$N+VY\0RZ?+'+%
M?)X=T;3-1U&"WNXGTZ?54TNTU%)K:Z:VG_$/]F__ ()P_';_ (*)>";_ /:<
M^,O[16I:)-XIU+4=-\':GXGT2_\ B?K_ (FLM"U+4].U667SO&'AJW\(>&M,
MUZ&[T?0=)L3>QI]FU/[-HVD:;;:8VJ_>_P#P6P\':WK?['OP=\5Z;%-<:7X)
M^('AF7Q"L<A$=I9>(?!VJ:19:G<0[-CQQ:N;'3%E\U7BFU>)%BE2>5X/H7_@
MCU\4_!?C?]BWP'X+T36M/G\7?"JZ\2Z#XW\.K>6[ZMHK:SXP\3:_X>U&ZL0X
MNXM*U[2;SS-,U"2!+2ZO+#6=/MI[BXT>^\KX+),=B^#O";,^,.%:>'I\28KC
M:IE69YU+!87'8G*LJC2JSC1@L51KT</2J5XX*$G6I2A)YEJG5EA)T?SC(,TQ
M_ 7@=E/%W!E/#X?B'..*IY?G^>?4,)F&*P. I1Q\</@6\70Q%/#X>O/"9=;V
ML'257&M04<3C*%2/QK_P3.\&_P#!0[]GSX[^(/@I\0? WQ!\1?LW>&+R_P#"
M.NZEX@U!;;P-X8F#ZU<>&_&_P5O/'=UH5[XB\,7VI64PUO2_A_;W4":9X@35
MM?T*#7TTB"3[,_X*_?'2'X0?L>^*?#-E??9O%/QJO[;X;:/"F[SSHER1J/C:
MYVCC[*?#=I<:).[, DVOV@ 8N!67\._^"LOPM^(W[5VJ_LQZ!\.?$_B*WNO&
MQ\#_  ]^)W@3Q#X=\6>'_%UQ8?:?^$@\2:E973^'$T7P?I4-C?ZC::WH&L>-
MVUG1K1M3M+...6WBE_)3_@M'\5M2^+_[6_A#X%^%1+JZ?"K0=(\,VFE6A\U[
MOXC_ !+FT[6-2M[4[EA>6?2I/ ^DF/.Z'4+.[AFD#AHH=\MR/B#C7Q7X4QG%
M7#& X=<LLP?$V/6"IQI_VK@LMC#%0S/,:*Q->*JX_,JN$P&*A4IX6I0H58X3
M$PJ8C#5'4]?(.'L]XI\:\GS3B_A;+N$GEV3X7C',<+@XPI4,50R])X/-L;S8
MK$T%7Q6<3PU/&1DL,H4,+5P^)H/&X?&5JWV-_P $K?V0=+\:_L&?'6;Q3:16
MUW^U3#XE\*Z9J%Q"2]AX9\+6.I>'O"^KQ!D9A-IOCFX\0:U;D(T<IL=.FV2A
M5S\<_P#!&?XM:U\%_P!KKQ7\ ?%K2Z3:_%+3-;\*:AHUWM3[!\3?AO)J.J::
ML\A+)#-'IUMXST)H491>ZA?:?%ODDAMHV]?^'_@'_@O%\+/!7AGX=> =%A\.
M^#/!VD6NA>'-%@N/V,;Q-/TRR39!";W4KF]U&]F.6DN+W4+R[OKN=Y+F[N9[
MB625OS&^-GA_]K']EO\ :8\-?%SX]^'CX1^-^K>*;'XYV>H0W'@*YL/$.J1>
M*;B[N]4=?AK=WOA"%M1UO3;U-;T>)+:62*Z::_TT6NJPR7?Z7EN6QXHS3Q.R
MS&\9<"YU@^/J$GDV79/Q%3S/,LOKY71J4<HQ%3!+#TXOZKA*6"KXR=&=;EK9
M=1E348<]1?H&6Y+4XLH^+60XWC/@/B)\=5*V<\/Y?D'$M+-<=EN.P$91RR6)
MPSP]!NAAJ.$R&C7K4ISY8Y=&,73C44H_VP_%OP?XG^('PT\:^"O!GQ!U?X4^
M*/$V@WND:+\1-!T^TU75_"EW=J$&IV-C>2VR2RB/S("]M?:7J=O',]SH^L:/
MJT-EJEIX]\%?V4_!W[.7P)UOX+_!7Q!KWA34]:M?$5[<?%/4(='\1>-;GQUK
M]D]LOCS5X[[3X]$UC4M,=+#['IT^G1:;]ATVUL7CR9[F7W/X=^.-%^)G@'P5
M\1/#DPGT'QSX5T'Q;I$H(8G3_$&F6VJ6JN5R!+'%=+',G5)4=& 92*[*OXVE
MC\UR[#8S(95)8;#O,(5LPP+HT$ZV-P#G1IPQDG3=3$4\+/VGL\)7G4PM.K*I
M5C152I.<OXLIYQFV"P7]C1K.A@J6:0S2M@*F&P[A5S+#05"E+'PJ492QD<+&
M,X4<)C77PN'=;%NE0A+&8MUOEO\ 95_91\$_LJ^$-;TG0];\0^._'7CO6F\6
M_%;XJ^-+G[?XQ^(GC"Y5WO=5U.Z=IIX-/6\N=0N-+TN:\U&>S;4+VYU#5=9U
MF_U36-0^I***Y\RS+'9OCL1F698F>+QN*E&5:O444Y<D(TJ<(PA&%.G2I4H4
MZ-&C2A"E1HTX4J4(4X1BN7,<QQV;8[%9GF6)JXS'XVM*OBL36?-4JU)65W9*
M,8QBHTZ=."C3I4H0I4H0IPC%%%%%<)Q!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'S_\ M9?\FL?M+_\ 9O\ \9?_
M %77B.OX-/&7_(4@_P"O"+_THNJ_O+_:R_Y-8_:7_P"S?_C+_P"JZ\1U_!IX
MR_Y"D'_7A%_Z475?N/T>O^3CX;_L49K_ .FZ9^]_1N_Y.;AO^Q-F_P#Z:IG)
M4445_>Y_H:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116EHVC:QXBU?2O#
M_A_2M2UW7]=U*QT;1-$T:QNM3U?6=7U.ZBLM-TK2M-LHI[W4=2U&]GAM+&QM
M(9KJ[NIHK>WBDED1"I2C",I2:C&*<I2DU&,8I7<I-V222NV]$M6*4HPC*<Y*
M,(IRE*348QC%7E*4G9)))MMNR6K/??V3_P!FKQ?^UI\<?"?P7\(W7]C?VS]M
MU3Q/XNGT?4]9TSP3X0T:W-WK7B/5+;3(_P#KVT308-0O=&TS6/%^L^'/#MWK
MVC?VS'J$']T7P@^%?A#X'_"_P+\(_ =G]B\*?#_PWIWAS2O,M],M[[4/L4(^
MW:]K7]C:=I.FW?B3Q)J3WGB#Q/JEMIME_;'B'4]3U::!)[V7/QU_P3B_8GTC
M]CCX,1IJ0U*?XQ_%/3?"OB'XPW%]>6LMKHVKZ=87LVF?#_1K32-3U70/[-\!
M2Z_K>FRZ_97NHW7BS5[K5=;?44T2?P[X?\._H97\ ^-'B0^-L\_L[*Z\I<,Y
M+4E3P5N50S'&I2AB<T=HJ7LY<SP^"C.<TL+#ZPHT:F,K4H?YU^./B<^.\_\
M[-RJO*7"V1U94\!;E4,RQR4J>)S9VBI^SFI/#8",YS2PD/K*C1J8VO1A\?\
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MW;116T$,,%M%;V.F:7IEC;VNE:'H>E6MCHOA_1;'3]$T33]/TC3[*R@^MO\
M@HC^V[XF_;E_: UGX@>=XITCX3>'-VA?!?X=^(KZPF_X0_PT+;3X-5U6XLM'
MABTNW\4^/=4T[_A)_%$GVC7K^Q\[2/!G_"6>(_#_ (+\-W47P97^G7@7X54?
M#KANGB\QP\'Q;GE"E7SBK)4JE3+J,[5:.2T*T8*488=>SEF"A4JTJ^8QG*%6
MMAZ&$E'_ "_\=O%>MXC<2U,)EM>?^J615ZM#)Z475IPS&M&]*OG6(HRJ.,IX
MB7M(Y?*=*E5H9=*$9TJ.(KXN,BBBBOW,_"@HHHH **** "OWF_X-X?\ D]3X
MG_\ 9KOC7_U;'P3K\&:_>;_@WA_Y/4^)_P#V:[XU_P#5L?!.OR[QK_Y-5QQ_
MV)*O_IZB?J7@G_R=;@;_ +'E'_TS6/[*J***_P H#_68**** "BBB@ HHHH
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M@^W?9/#7_"/?VY_8/]JWOV;S/^/S^S/[9N-G_'O_ &@W^OKX8_8._P""8O\
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M4 %%%% !1110 4444 %%%% !1110 4444 ?/_P"UE_R:Q^TO_P!F_P#QE_\
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M%+@G)J\X9IF-&%3.L52G.$\%EE5<T,%"4'%K$9BK>WO)J&7N=.5.?UZ$Z/\
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M%% !1110 4444 %%%% !7\FG_!=__D[OX<_]FX>$/_5F_%^OZRZ_DT_X+O\
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MZ$%"%7,:"QN+A@(5J]/GAA94Z>.E4PZIPQ'M:\J%6<U@Z$J->KT1HXBI7Q^
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MB$5[7$X:<I73ISG:HHHKE.D**** "BBB@ HHHH **** "BBB@ HHHH ****
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MX@_Z)3)__"W&_P"7K_2U_@6_X8Y_:[_Z-7_:/_\ #'?$W_YEZ/\ ACG]KO\
MZ-7_ &C_ /PQWQ-_^9>O[Z:*/^)G<^_Z)C*?_"S&?Y>O]+4_XFKX@_Z)3)__
M  MQO^7K_2U_@6_X8Y_:[_Z-7_:/_P##'?$W_P"9>C_ACG]KO_HU?]H__P ,
M=\3?_F7K^^FBC_B9W/O^B8RG_P +,9_EZ_TM3_B:OB#_ *)3)_\ PMQO^7K_
M $M?X%O^&.?VN_\ HU?]H_\ \,=\3?\ YEZ/^&.?VN_^C5_VC_\ PQWQ-_\
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M\O7^EJ?\35\0?]$ID_\ X6XW_+U_I:_P+?\ #'/[7?\ T:O^T?\ ^&.^)O\
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M (6XW_+U_I:_P+?\,<_M=_\ 1J_[1_\ X8[XF_\ S+T?\,<_M=_]&K_M'_\
MACOB;_\ ,O7]]-%'_$SN??\ 1,93_P"%F,_R]?Z6I_Q-7Q!_T2F3_P#A;C?\
MO7^EK_ M_P ,<_M=_P#1J_[1_P#X8[XF_P#S+T?\,<_M=_\ 1J_[1_\ X8[X
MF_\ S+U_?311_P 3.Y]_T3&4_P#A9C/\O7^EJ?\ $U?$'_1*9/\ ^%N-_P O
M7^EK_ M_PQS^UW_T:O\ M'_^&.^)O_S+T?\ #'/[7?\ T:O^T?\ ^&.^)O\
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M'_1*9/\ ^%N-_P O7^EK_ M_PQS^UW_T:O\ M'_^&.^)O_S+T?\ #'/[7?\
MT:O^T?\ ^&.^)O\ \R]?WTT4?\3.Y]_T3&4_^%F,_P O7^EJ?\35\0?]$ID_
M_A;C?\O7^EK_  +?\,<_M=_]&K_M'_\ ACOB;_\ ,O1_PQS^UW_T:O\ M'_^
M&.^)O_S+U_?311_Q,[GW_1,93_X68S_+U_I:G_$U?$'_ $2F3_\ A;C?\O7^
MEK_ M_PQS^UW_P!&K_M'_P#ACOB;_P#,O1_PQS^UW_T:O^T?_P"&.^)O_P R
M]?WTT4?\3.Y]_P!$QE/_ (68S_+U_I:G_$U?$'_1*9/_ .%N-_R]?Z6O\"W_
M  QS^UW_ -&K_M'_ /ACOB;_ /,O1_PQS^UW_P!&K_M'_P#ACOB;_P#,O7]]
M-%'_ !,[GW_1,93_ .%F,_R]?Z6I_P 35\0?]$ID_P#X6XW_ "]?Z6O\"W_#
M'/[7?_1J_P"T?_X8[XF__,O1_P ,<_M=_P#1J_[1_P#X8[XF_P#S+U_?311_
MQ,[GW_1,93_X68S_ "]?Z6I_Q-7Q!_T2F3_^%N-_R]?Z6O\  M_PQS^UW_T:
MO^T?_P"&.^)O_P R]'_#'/[7?_1J_P"T?_X8[XF__,O7]]-%'_$SN??]$QE/
M_A9C/\O7^EJ?\35\0?\ 1*9/_P"%N-_R]?Z6O\"W_#'/[7?_ $:O^T?_ .&.
M^)O_ ,R]'_#'/[7?_1J_[1__ (8[XF__ #+U_?311_Q,[GW_ $3&4_\ A9C/
M\O7^EJ?\35\0?]$ID_\ X6XW_+U_I:_P+?\ #'/[7?\ T:O^T?\ ^&.^)O\
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MH **** /C_\ 8I_Y)7K_ /V4#5?_ %'/"E?8%?'_ .Q3_P DKU__ +*!JO\
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M ,GJ?$__ +-=\:_^K8^"=?EWC7_R:KCC_L25?_3U$_4O!/\ Y.MP-_V/*/\
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M?[!^ .MZ!XW\,:IX"_X2SQQJGVK0_B-_:O\ PF=C_P )3K7B;4?&D/\ ;/\
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M[X?%4LRFW259_NZGM<%&*]E"4:U"4L5B)<L:E&A5E_-]+\9?V#-?_P""O/\
MP3S\(?L%> /#'A/X(_"'QCX,\!WWC;P]X8N/#S_$KQCXCU>YB.JZAJ_BNSL_
MB'XT&@B^TS03XN^(.HZAK&K7D.JR:1]KTDZ?JFO?W&U\*:O_ ,$S/V$=6E^#
M$\7[-O@CPO-^S[XE_P"$R^$TOPZN_$_PMD\.>+3/X4N9/$VH/\-M?\*-XQUV
M>Y\#^%KBZU3QL?$=[=S:2DMU-,]S>M<_==$:D(99A\#SXBM6I9IG./JXBNU)
MUUF<L%44V^:4H5'5H5Y2H^]3H0E2ITZU5)M-TY2S"MC?9T:-.IEF4X&&'HI\
MM%Y:L93M?EA&HI4:U"3JJ%)U*WMI>PHQY%+\5_\ @X(_Y1??&?\ ['#X-_\
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M^%5 '[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?'_[:W_)*] _[*!I7_J.>*Z^P*^/_P!M;_DE>@?]E TK_P!1SQ77V!0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'_ .T?_P E
M4_9B_P"R@2?^I'\/Z^P*^/\ ]H__ )*I^S%_V4"3_P!2/X?U]@4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_XR_Y/*^$W_9/
M]2_](?B77V!7Q_XR_P"3ROA-_P!D_P!2_P#2'XEU]@4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Q_^SA_R53]IW_LH$?_ *D?
MQ K[ KX__9P_Y*I^T[_V4"/_ -2/X@5]@4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'Q_^Q3_R2O7_ /LH&J_^HYX4K[ KX_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** /C_ ,9?\GE?";_LG^I?^D/Q+K[
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M%K+,1^>W_! CQW?SZ!^T9\,[BX9M,TG5_ ?CK2;4R)LBOM?L]>T#Q!<)$2)
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M@+MN+*Y\0>(;#6C"&^6]\-V,KJ-L>[Z*_P""07[/?@KX6?LH>#?B=::/9O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\__M9?
M\FL?M+_]F_\ QE_]5UXCK\__ /@BE_R:QX^_[. \5?\ JNOA57Z ?M9?\FL?
MM+_]F_\ QE_]5UXCK^#3QE_R%(/^O"+_ -*+JON?#S@S_7WB.GP__:7]E>TP
MF*Q7UOZG]>M]6C&7L_J_UK!WY^:W-[9<MOAD??>&W __ !$+B>EPY_:G]D>T
MP>+Q?USZE]?M]5C&7L_J_P!;P5_:<UN?VZY;7Y9'^B717^</17[W_P 2N?\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^/_V*?^25Z_\
M]E U7_U'/"E?8%?'_P"Q3_R2O7_^R@:K_P"HYX4K[ H **** "BBB@ HHHH
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M%EX,^(VLZA/I7BJ]EE>"*'3XO"WB^P\23S[S''9*\BB4*$?^S&OS%_X*"_\
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MKJA0Q4GB\90H5I5JU2-%4L/@Z-:&'ITHRQ%2K^)G_!)OX?>$O$/[=W@OP_\
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M[%O\W9_I7V+[9L_T;[97ZC?\%OO^$<_X8TL?[8\G^V?^%O>"_P#A$MWE>?\
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M[C;#9KQ/C\3E^-QF*K5*%'#QQN-ESX&M@:CI5Z.-C6IU'44IQDJ--P;BW?\
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MP^'57#TZ5/,J%&G2BJU/DJ8B&+IX25"&%I1I_6)5J;G^PE?R%_$?_E-5:?\
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M&TDVL1F<>2,N:.%POM.3Z]0D4445_)A_'@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Q_^T?\ \E4_9B_[*!)_ZD?P_K[ KX__ &C_ /DJG[,7
M_90)/_4C^']?8% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\?^,O\ D\KX3?\ 9/\ 4O\ TA^)=?8%?'_C+_D\KX3?]D_U+_TA
M^)=?8% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\?_ +.'_)5/VG?^R@1_^I'\0*^P*^/_ -G#_DJG[3O_ &4"/_U(_B!7V!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'_ .Q3
M_P DKU__ +*!JO\ ZCGA2OL"OC_]BG_DE>O_ /90-5_]1SPI7V!0 4444 %%
M%% !1110 4444 %%%% !1110 445_.1_P7-_X*$_\*]\-:O^Q%\+VW^,?B'X
M7TC4?C+XTTWQ)]GF\%>"M5O_ +9;?#:UM?#VKQ:I;^*?'NEZ=%-XTL/%4-KI
M/_"I?$EG8QZ+XGM_B0NI>$_K^!>"\UX^XFR_AK*(VJXJ:J8O%RC&5++LNIS@
ML9F-:,JE)3AA:<^:-%5(3Q%9TL-2?M:T$?'\=\:Y3P!PSF'$N;RO2PD'3PF$
MC*4:N8YC5A/ZGEU&4:=5PGB:D.659TYPP]&-7$U5[*C-GY3_ /!8']OF[_:W
M^.MU\./A]KVJ?\,]_!75-1\/>'["UU[1=4\*_$?X@:/J.MZ5KOQELG\.?:+'
M4]+U.QN%T#X=W-WKOB2*#P?;S^)M&;PU=_$7Q5H$?X_445_K#PKPUE?!^099
MP[DU"-' Y9AXT8-12J8BL_>Q&+KM?'B<77E4Q%>?6I4DHV@HQ7^3'%7$V:\8
M\09GQ'G->5?'YGB95IW;=.A17N8?"4%]C#X2A&GAZ$$M*=.+E>;E)E%%%?0'
MSP4444 %%%% !1110 4444 %%%% !1110 5^\W_!O#_R>I\3_P#LUWQK_P"K
M8^"=?@S7[S?\&\/_ ">I\3_^S7?&O_JV/@G7Y=XU_P#)JN./^Q)5_P#3U$_4
MO!/_ ).MP-_V/*/_ *9K']E5%%%?Y0'^LP4444 %%%% !1110 4444 %%%%
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M,-]:Q#7Q*E[>CA[PC]J7M,137*NC;Z'ZXT444@"BBB@ HHHH **** "BBB@
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M-:\%^"]:\1Z7:ZQ;:??:7?W&EW%]IT$5_!9:GI]W+:O*EO?6LS).G\Z'[/\
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M4;3=6K.E&E!\];F@J33=*-YJ-3VRC2E:U24*L8W=.2/Z.Z*_D^_9E_X*D?\
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M\_\ [67_ ":Q^TO_ -F__&7_ -5UXCK^#3QE_P A2#_KPB_]*+JO[R_VLO\
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M %%%% 'Q_P#M'_\ )5/V8O\ LH$G_J1_#^OL"OC_ /:/_P"2J?LQ?]E D_\
M4C^']?8% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\?^,O^3ROA-_V3_4O_2'XEU]@5\?^,O\ D\KX3?\ 9/\ 4O\ TA^)=?8%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\?_LX
M?\E4_:=_[*!'_P"I'\0*^P*^/_V</^2J?M._]E C_P#4C^(%?8% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\?_L4_\DKU_P#[
M*!JO_J.>%*^P*^/_ -BG_DE>O_\ 90-5_P#4<\*5]@4 %%%% !1110 4444
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M@:]+VD<1AXYEE_$L*U'ZPYRKUHPJY'A:]&I7JU:U*I*HX3BYU95>_ 4HO/\
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M"\FO=3U[X6?&N35+WPC<6#6U_JGA[PM\.?"PO=:N="M+CQCJF@:K=:/]%?\
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MQMX>U6SB\66'C*UTJ'Q,NFZ!-I]WJ=U8V>E0:=_19^R]X\\6?%+]FO\ 9_\
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M,&D:9JU_+J$OC6/2S_3[I! TC3"2 !IMD23P !:QDDD\  =37\M'Q@UC4?\
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M*GA:<\?@XNE#$XFC5^9_VWO^"@'[79_:F\+_ /!-[_@G_P"$?!GB7]HR_P#
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MI=0T62WN3#]J-C;3%8H?RF_9H_:9_P""W7_!1KX)>!/$G[+_ (W^$?P)\+>
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M$XA0A[9Q11117R1\<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?'_ .T?_P E4_9B_P"R@2?^I'\/Z^P*^/\ ]H__ )*I^S%_V4"3_P!2
M/X?U]@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'Q_XR_Y/*^$W_9/]2_](?B77V!7Q_XR_P"3ROA-_P!D_P!2_P#2'XEU]@4
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MS#8W"2_@X_#?5<0EI)TO;T<1:$OLR]IAZ;YET374_&C_ (*/?\$FQ^UUX_\
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M"A#+Z>,I8:,;I0IXY9<J\7OS:97A.1O6/+/5\[/R/^'O[!/Q@\)?\%=?C?\
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M)I_PC<]WJVI>#M(\2I867_"1V/\ ;<L/A*>XMO*NOL%KJ6R'SS]E;]@GXP?
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M^)DNMS>$O%&@K=6NC)X.D\+/I0O-;M)&GE\90W8MH[AQ8F5(X9>Q_P""D?\
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M?P_K[ KX_P#VC_\ DJG[,7_90)/_ %(_A_7V!0 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .T?_P E4_9B_P"R@2?^I'\/Z^P*^/\ ]H__ )*I^S%_V4"3_P!2/X?U]@4
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MJDX4\XSF@TIX=QC)*M@<HK1E2A[2/)6S&%;$04Z6'P6(F4445_5)_*84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?O-_P &\/\
MR>I\3_\ LUWQK_ZMCX)U^#-?O-_P;P_\GJ?$_P#[-=\:_P#JV/@G7Y=XU_\
M)JN./^Q)5_\ 3U$_4O!/_DZW W_8\H_^F:Q_951117^4!_K,%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[S?\&\/_)ZGQ/\
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MM?\ #GB/5/"OP.^"OQ#"6NW6/A#;:SX-\;^,_&_A*\N;OPWXRU33?".E^--
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445_-I_P %W?V^;OP5HL7[%7PFU[5-,\5^+=+TWQ#\
M=?$OAW7M%2*Q^'^M6FL6UG\&M2@L_MWB/3]4\:PMIOBOQ=;2S^%)6^'[^&])
MD7Q;X4^)^NV6G_8\!\%9KX@<3Y?PUE7+3J8J4JN+QE2+G1R[+Z+B\7CJT5*'
M/&C"25.DIP>(Q$Z.'C.$JJDOC>/>-LJ\/N&,PXFS92J4L+&-+"8.G)0K9CF%
M;F6$P-&3C-0E6G%RJ57":P^'A6Q$H3C2<7^27_!57_@H9K?[:GQEO_#7@3Q1
MJDG[+WPYU2./X6Z VDW?AF+Q5K4&EI8:W\4/$VE75Y<7VIZIJ=]<:U9>!I=;
M@TF[\.?#^YL[8>%?"OB?Q#X^36/RGHHK_6+AKAS*>$LCR[A[),-'#9=EF'IX
M>C'EIJK6E%+VN+Q4Z5.E&MC,74YL1BZ_)%UJ]2=1I7LO\EN)N),VXNSS,>(<
M[Q,L3F.9XF>(K2YJCI48R?[K"86%2I4E1P>$I<N'PE#GDJ-"G"FI.UV4445[
MIX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7[S?\ !O#_ ,GJ?$__ +-=\:_^K8^"=?@S7[S?\&\/_)ZGQ/\ ^S7?&O\
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MT-\1?VY/VX_^"7/_  4S\0^-_P!DGQG\'?#7Q&^'GB3PQ^QA^SQJ?P]\5O\
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X+XH?%#X
M?_!;X?\ BKXI_%/Q5I?@KP!X*TN36/$OB76))5M+"T66*V@AA@MHKB^U/5-3
MOKBUTK0]#TJUOM:\0:U?:?HFB:?J&KZA964^M"A7Q5>CAL-1JXC$XBK3H8?#
MT*<ZU>O7K35.E1HTJ:E4JU:M2484Z<(RG.<E&*;:1E7KT,+0K8G$UJ6'PV'I
M5*^(Q%>I"C0H4*,'4JUJU6HXTZ5*E3C*=2I.480A%RDU%-GR3_P41_;=\-?L
M-?L_ZS\0/.\+ZO\ %GQ'NT+X+_#OQ%?:A#_PF'B4W.GP:KJMQ9:/#+JEQX7\
M!:7J/_"3^*)/M&@Z??>3I'@S_A+/#GB#QIX;NI?\_;7-<UOQ/K6L>)?$NL:I
MXA\1^(=4U#7-?U_7-0N]6UK7-:U:[FO]5UC6-5OYKB^U/5-3OKB>]U#4+V>>
M[O;N>:YN9I)I'=OK?]O3]KSQ-^VO^T?XN^,.L+]D\+VGG>"_A+H<FC6&BW_A
MWX2Z+KFN:AX0TW78;#4=:^U^*;O^VM0U_P 67DVO:U"?$NM:K::'=6GA:TT'
M1],^-*_U!\#_  NI>&_"Z>,C&IQ-GL</C,\K;_55&FWA<GH[)4LO56JZTTG*
MOC:V)FZDJ$<+3H_Y<>.7BE5\2N*6L%*5/AC(98C!9'0V^M.51+%YQ6W;JY@Z
M5)48-J-#!4<-!4XXB6*J5BBBBOVH_$PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K]YO^#>'_ )/4^)__ &:[XU_]
M6Q\$Z_!FOWF_X-X?^3U/B?\ ]FN^-?\ U;'P3K\N\:_^35<<?]B2K_Z>HGZE
MX)_\G6X&_P"QY1_],UC^RJBBBO\ * _UF"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_C^_P""W7_!1'_A<7C6]_9$^#^L^*=.^'7PI\4Z[I/QQO-W]CZ3
M\3/B7X;U:SM8/"_]FRZ?!KMWX7^%.NZ/J:_:+[48M \6^-9_[9MO#MW9^!?
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M.MP-_P!CRC_Z9K']E5%%%?Y0'^LP4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD9T^'\J]ACN(L7%U*=L)*JXTLOH5H4YQACLR=.K"@I2@XT*&,Q,'*6%]G/\
M(O&;Q.PWAEPI4QM.4*G$&;>WP/#N$DH5$\7&FI5LPKT9U(2G@<MC4I3KN*FI
M8BO@\--1CBN>/P9^T)\>/B!^TW\9?'GQU^*-QI=QXW^(.J6^H:JFAZ9'I&BZ
M=::9I=AH&@:'H]@CSS1Z7X>\.:3I.A:?-J-YJ>M7EIIT-YKVL:SK5Q?ZK>>-
M445_J;@\)A<OPF%P&!P]+"X+!8>AA,'A:$%3H8;"X:E&CAZ%&G&T84J-*$*=
M.$4E&$5%:(_RMQF,Q688O%8_'5ZN+QN.Q-?&8S%5YRJ5\3BL35E6Q&(K5)-R
MJ5:U6<ZE2<FW*<G)N["BBBN@Y@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K[S_X)N?M1^ /V//VI?#?QO^)FC^,=<\*:/X7\9:)<Z?X%
MT_1=3\0O=>(=&ETZRD@M/$'B#PQIK6\4[AKIY-6BD2++113O\A^#**\W.,JP
MF>Y1FF29A&I+ YOE^,RS&1I3=*I+"X[#U,-75.HKNG-TJLE&:3<96=M#T,IS
M/%9+FV59U@7"..R?,\OS;!2J052G'&99BZ.-PKJ4W95*:KT*;G!M*<;QNKGN
MO[3WQ.T'XU?M%_'#XN^%K/5[#PW\2_BEXV\;Z%8^(+>RM=<M-*\2:_?:K8V^
MK6VG:AJMA!J$5O<QI=Q6>IW]M','6&[G0"1O"J**VR[ 8?*LOP&68136%R[!
MX7 893DYS6'P="&'HJ<W9SFJ=.*E)J\G=]0S;,\5G6:YGG..<)8W-LPQN9XR
M5*'LZ;Q6/Q-3%8ATZ:;4(.K5FX03:C&T4] HHHKL//"BBB@ K]YO^#>'_D]3
MXG_]FN^-?_5L?!.OP9K]YO\ @WA_Y/4^)_\ V:[XU_\ 5L?!.OR[QK_Y-5QQ
M_P!B2K_Z>HGZEX)_\G6X&_['E'_TS6/[*J***_R@/]9@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#5L?!.OP9K]YO^#>'_ )/4^)__ &:[XU_]6Q\$Z_+O&O\ Y-5QQ_V)*O\
MZ>HGZEX)_P#)UN!O^QY1_P#3-8_LJHHHK_* _P!9@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#+US6+3P]HNL:_?PZI<6.AZ7J&L7L&AZ'K?B?6I[33+2:]N8='\->&M/
MU;Q'XAU22&!TT_0] TK4]:U:[:&PTK3[R^N(+:3^'#]O3PU^WS^VO^T?XN^,
M.L?L?_M16GA>T\[P7\)=#D_9F^)&BW_AWX2Z+KFN:AX0TW78;#0]:^U^*;O^
MVM0U_P 67DVO:U"?$NM:K::'=6GA>TT'1],_NCHK]/\ ##Q)_P"(99CC<XPO
M#V SG,\5AU@Z&)Q^(JTU@,-*7/76%A1IMQJXEJ$:U9U.;V4%2@H1G6]I^7>*
M'AK_ ,1.R[ Y/BN(LPR7*\+B7C*^%R_#TJG]H8A1Y:#Q<ZU1*5+"ISE1HJGR
M^VJ.M-SE3H^S_P Y'_AA[]M3_HT#]J+_ ,,!\6/_ )DJ/^&'OVU/^C0/VHO_
M  P'Q8_^9*O]&ZBOV[_B;SB/_HD,D_\ "['_ /R)^(?\2?\ #?\ T6.>?^$.
M _S]?Z6O^<C_ ,,/?MJ?]&@?M1?^& ^+'_S)4?\ ##W[:G_1H'[47_A@/BQ_
M\R5?Z-U%'_$WG$?_ $2&2?\ A=C_ /Y$/^)/^&_^BQSS_P (<!_GZ_TM?\Y'
M_AA[]M3_ *- _:B_\,!\6/\ YDJ/^&'OVU/^C0/VHO\ PP'Q8_\ F2K_ $;J
M*/\ B;SB/_HD,D_\+L?_ /(A_P 2?\-_]%CGG_A#@/\ /U_I:_YR/_##W[:G
M_1H'[47_ (8#XL?_ #)4?\,/?MJ?]&@?M1?^& ^+'_S)5_HW44?\3><1_P#1
M(9)_X78__P"1#_B3_AO_ *+'//\ PAP'^?K_ $M?\Y'_ (8>_;4_Z- _:B_\
M,!\6/_F2H_X8>_;4_P"C0/VHO_# ?%C_ .9*O]&ZBC_B;SB/_HD,D_\ "['_
M /R(?\2?\-_]%CGG_A#@/\_7^EK_ )R/_##W[:G_ $:!^U%_X8#XL?\ S)4?
M\,/?MJ?]&@?M1?\ A@/BQ_\ ,E7^C=11_P 3><1_]$ADG_A=C_\ Y$/^)/\
MAO\ Z+'//_"' ?Y^O]+7_.1_X8>_;4_Z- _:B_\ # ?%C_YDJ/\ AA[]M3_H
MT#]J+_PP'Q8_^9*O]&ZBC_B;SB/_ *)#)/\ PNQ__P B'_$G_#?_ $6.>?\
MA#@/\_7^EK_G(_\ ##W[:G_1H'[47_A@/BQ_\R5'_##W[:G_ $:!^U%_X8#X
ML?\ S)5_HW44?\3><1_]$ADG_A=C_P#Y$/\ B3_AO_HL<\_\(<!_GZ_TM?\
M.1_X8>_;4_Z- _:B_P## ?%C_P"9*C_AA[]M3_HT#]J+_P ,!\6/_F2K_1NH
MH_XF\XC_ .B0R3_PNQ__ ,B'_$G_  W_ -%CGG_A#@/\_7^EK_G(_P###W[:
MG_1H'[47_A@/BQ_\R5'_  P]^VI_T:!^U%_X8#XL?_,E7^C=11_Q-YQ'_P!$
MADG_ (78_P#^1#_B3_AO_HL<\_\ "' ?Y^O]+7_.1_X8>_;4_P"C0/VHO_#
M?%C_ .9*C_AA[]M3_HT#]J+_ ,,!\6/_ )DJ_P!&ZBC_ (F\XC_Z)#)/_"['
M_P#R(?\ $G_#?_18YY_X0X#_ #]?Z6O^<C_PP]^VI_T:!^U%_P"& ^+'_P R
M5'_##W[:G_1H'[47_A@/BQ_\R5?Z-U%'_$WG$?\ T2&2?^%V/_\ D0_XD_X;
M_P"BQSS_ ,(<!_GZ_P!+7_.1_P"&'OVU/^C0/VHO_# ?%C_YDJ/^&'OVU/\
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M_1(9)_X78_\ ^1#_ (D_X;_Z+'//_"' ?Y^O]+7_ #D?^&'OVU/^C0/VHO\
MPP'Q8_\ F2K]J?\ @A)^SG^T)\(?VN?B+XE^+/P(^,OPO\.7W[./B[0[+7_B
M)\+_ !OX*T6\UJY^)OPAO[;1[75?$NAZ98W&J7%CIFI7L&GQ3O=RVFGWMS'"
MT-I.\?\ 6+17SG%_TF<]XNX:SGAK$\,93@Z&<8.6#JXFAB\94JT8RG";G3A4
M7)*7N6M+34^CX0^C'D7"'$V3<38;BC-L97R;&0QE+"U\'@Z=*M*$)1Y*DZ;Y
*XQ?,W>.NWS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cbio-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-08T17:25:16.2712857+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : b481765bcc1e4c2bb9d0981034513db3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:cbio="http://www.catalystbiosciences.com/20220331" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.catalystbiosciences.com/20220331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.catalystbiosciences.com/20220331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Los (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidity" id="Role_DisclosureNatureOfOperationsAndLiquidity">
        <link:definition>100070 - Disclosure - Nature of Operations and Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100120 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborations" id="Role_DisclosureCollaborations">
        <link:definition>100130 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100140 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet" id="Role_DisclosureInterestAndOtherIncomeNet">
        <link:definition>100160 - Disclosure - Interest and Other Income, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuring" id="Role_DisclosureRestructuring">
        <link:definition>100170 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100190 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100200 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables" id="Role_DisclosureLeaseTables">
        <link:definition>100210 - Disclosure - Lease (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100220 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100230 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables" id="Role_DisclosureInterestAndOtherIncomeNetTables">
        <link:definition>100240 - Disclosure - Interest and Other Income, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail" id="Role_DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail">
        <link:definition>100250 - Disclosure - Nature of Operations and Liquidity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>100260 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" id="Role_DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail">
        <link:definition>100270 - Disclosure - Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail" id="Role_DisclosureLeaseAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Lease - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" id="Role_DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
        <link:definition>100300 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" id="Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
        <link:definition>100310 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" id="Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
        <link:definition>100320 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" id="Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails">
        <link:definition>100330 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" id="Role_DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail">
        <link:definition>100350 - Disclosure - Summary of Option Activity Under Company&apos;s Equity Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" id="Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
        <link:definition>100360 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" id="Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
        <link:definition>100370 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" id="Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
        <link:definition>100380 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" id="Role_DisclosureCollaborationsAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" id="Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
        <link:definition>100400 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail" id="Role_DisclosureDetailOfInterestAndOtherIncomeNetDetail">
        <link:definition>100420 - Disclosure - Detail of Interest and Other Income, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" id="Role_DisclosureRestructuringAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Restructuring - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" name="AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_LicenseRevenueMember" name="LicenseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfLicenseMember" name="CostOfLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfCollaborationMember" name="CostOfCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_StockIssuedDuringPeriodFromStockGrantsValue" name="StockIssuedDuringPeriodFromStockGrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_StockIssuedDuringPeriodFromStockGrantsShares" name="StockIssuedDuringPeriodFromStockGrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" name="ProceedsFromIssuanceOfCommonStockFromStockGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_NatureOfOperationsAndLiquidityTextBlock" name="NatureOfOperationsAndLiquidityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" name="SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_LesseeOperatingLeaseRenewalTermDescription" name="LesseeOperatingLeaseRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_SubleaseArrangementMember" name="SubleaseArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" name="TwoThousandEighteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" name="MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MosaicBiosciencesIncMember" name="MosaicBiosciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IsuAbxisMember" name="IsuAbxisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AmendedAndRestatedLicenseAgreementMember" name="AmendedAndRestatedLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_BiogenMember" name="BiogenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ExclusiveLicenseMember" name="ExclusiveLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" name="ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_RegulatoryAndDevelopmentMilestonePayment" name="RegulatoryAndDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_DevelopmentAndSalesMilestonePayments" name="DevelopmentAndSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfManufacturingServices" name="CostOfManufacturingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_CostOfServicesAsPerAgreement" name="CostOfServicesAsPerAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_FirmWorkOrderSupportingClinicalTrials" name="FirmWorkOrderSupportingClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" name="ChargesRelatedToWriteOffOfPrepaidManufacturingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AGCBiologicsIncMember" name="AGCBiologicsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IntegrityBioMember" name="IntegrityBioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MarzeptacogAlfaActivatedMember" name="MarzeptacogAlfaActivatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" name="MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_GMPMember" name="GMPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_DalcinonacogAlfaMember" name="DalcinonacogAlfaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_GainLossFromExtinguishmentOfLiability" name="GainLossFromExtinguishmentOfLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_RestructuringLiability" name="RestructuringLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_RemainingNumberOfFullTimeEmployees" name="RemainingNumberOfFullTimeEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_SeveranceAndOtherCosts" name="SeveranceAndOtherCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cbio-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-08T17:25:16.2712857+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : b481765bcc1e4c2bb9d0981034513db3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="cbio-20220331.xsd#TemplateLink" roleURI="http://www.catalystbiosciences.com/20220331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10160.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:href="cbio-20220331.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_GainLossFromExtinguishmentOfLiability" xlink:type="locator" xlink:label="cbio_GainLossFromExtinguishmentOfLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="cbio_GainLossFromExtinguishmentOfLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cbio-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-08T17:25:16.2712857+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : b481765bcc1e4c2bb9d0981034513db3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="cbio-20220331.xsd#TemplateLink" roleURI="http://www.catalystbiosciences.com/20220331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10090.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfLicenseMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfCollaborationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_StockIssuedDuringPeriodFromStockGrantsShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsShares" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_StockIssuedDuringPeriodFromStockGrantsValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromStockGrantsValue" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromStockGrantsShares" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10770.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureLeaseAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_SubleaseArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_DevelopmentAndSalesMilestonePayments" xlink:type="locator" xlink:label="cbio_DevelopmentAndSalesMilestonePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_MosaicBiosciencesIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IsuAbxisMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_BiogenMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePayments" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_CommercialMilestonePayments" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_DevelopmentAndSalesMilestonePayments" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="11520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_OptionsToPurchaseCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_CommonStockWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_FirmWorkOrderSupportingClinicalTrials" xlink:type="locator" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfServicesAsPerAgreement" xlink:type="locator" xlink:label="cbio_CostOfServicesAsPerAgreement" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfManufacturingServices" xlink:type="locator" xlink:label="cbio_CostOfManufacturingServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceAgreementsMember" xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_GMPMember" xlink:type="locator" xlink:label="cbio_GMPMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MarzeptacogAlfaActivatedMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IntegrityBioMember" xlink:type="locator" xlink:label="cbio_IntegrityBioMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_AGCBiologicsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IntegrityBioMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_MarzeptacogAlfaActivatedMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_GMPMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_DalcinonacogAlfaMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfManufacturingServices" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfServicesAsPerAgreement" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_FirmWorkOrderSupportingClinicalTrials" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SeveranceAndOtherCosts" xlink:type="locator" xlink:label="cbio_SeveranceAndOtherCosts" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RemainingNumberOfFullTimeEmployees" xlink:type="locator" xlink:label="cbio_RemainingNumberOfFullTimeEmployees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RestructuringLiability" xlink:type="locator" xlink:label="cbio_RestructuringLiability" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_RestructuringLiability" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_RemainingNumberOfFullTimeEmployees" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_SeveranceAndOtherCosts" order="10390.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cbio-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-08T17:25:16.2712857+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : b481765bcc1e4c2bb9d0981034513db3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated gross unrealized gain before tax available for sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 100,000,000 shares authorized; 31,477,053 and 31,409,707 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LicenseRevenueMember" xlink:to="cbio_LicenseRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CollaborationRevenueMember" xlink:to="cbio_CollaborationRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of license member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfLicenseMember" xlink:to="cbio_CostOfLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of License [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfCollaborationMember" xlink:to="cbio_CostOfCollaborationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license and collaboration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_StockIssuedDuringPeriodFromStockGrantsValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsValue" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period from stock grants, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockIssuedDuringPeriodFromStockGrantsValue" xlink:to="cbio_StockIssuedDuringPeriodFromStockGrantsValue_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_StockIssuedDuringPeriodFromStockGrantsShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsShares" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period from stock grants, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockIssuedDuringPeriodFromStockGrantsShares" xlink:to="cbio_StockIssuedDuringPeriodFromStockGrantsShares_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from stock grants</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period From Stock Grants Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from stock grants, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period From Stock Grants Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of issuance of common stock for public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in operating lease liability and right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock for secondary public offering, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" />
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock from stock grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bad debt expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Doubtful Accounts</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability and right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability And Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collection Of Shortterm Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from stock grants</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock From Stock Grants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of the period</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_NatureOfOperationsAndLiquidityTextBlock" xlink:type="locator" xlink:label="cbio_NatureOfOperationsAndLiquidityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_NatureOfOperationsAndLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of operations and liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_NatureOfOperationsAndLiquidityTextBlock" xlink:to="cbio_NatureOfOperationsAndLiquidityTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_NatureOfOperationsAndLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations and Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NatureOfOperationsAndLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations And Liquidity [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments All Other Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Other Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income And Expense [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Recently Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:type="locator" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of present value assumptions of lease payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:to="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity Under Company&apos;s Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive Security not Included In Diluted per Share Calculations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Detail of Interest and Other Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Nonoperating Income Expense Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material realized gains or losses on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Realized Gain Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal term description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_SubleaseArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SubleaseArrangementMember" xlink:to="cbio_SubleaseArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SubleaseArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SubleaseArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Arrangement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease renewal term description</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Payments Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining in 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen omnibus incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Omnibus Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Omnibus Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in number of shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Exercisable - March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercisable - March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Exercisable - March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black-Scholes Method Used [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issued to certain board members in lieu of cash compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="cbio_CollaborationAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CollaborationAgreementsAbstract" xlink:to="cbio_CollaborationAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Mosaic Biosciences, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MosaicBiosciencesIncMember" xlink:to="cbio_MosaicBiosciencesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mosaic</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mosaic Biosciences Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ISU Abxis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IsuAbxisMember" xlink:to="cbio_IsuAbxisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ISU Abxis</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Isu Abxis [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AmendedAndRestatedLicenseAgreementMember" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated License Agreement [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_BiogenMember" xlink:to="cbio_BiogenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ExclusiveLicenseMember" xlink:to="cbio_ExclusiveLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exclusive License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursable Out Of Pocket And Personnel Costs Incurred Related To Research Services [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment related to regulatory and clinical development events</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Related To Regulatory And Clinical Development Events</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestonePayments" xlink:to="cbio_MilestonePayments_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory and development milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommercialMilestonePayments" xlink:to="cbio_CommercialMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory and development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory And Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_DevelopmentAndSalesMilestonePayments" xlink:type="locator" xlink:label="cbio_DevelopmentAndSalesMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and sales milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DevelopmentAndSalesMilestonePayments" xlink:to="cbio_DevelopmentAndSalesMilestonePayments_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From License Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Sales Milestone Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Revenue Recognized1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OptionsToPurchaseCommonStockMember" xlink:to="cbio_OptionsToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommonStockWarrantsMember" xlink:to="cbio_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfManufacturingServices" xlink:type="locator" xlink:label="cbio_CostOfManufacturingServices" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfManufacturingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of manufacturing services related company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfManufacturingServices" xlink:to="cbio_CostOfManufacturingServices_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfServicesAsPerAgreement" xlink:type="locator" xlink:label="cbio_CostOfServicesAsPerAgreement" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfServicesAsPerAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of services as per agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfServicesAsPerAgreement" xlink:to="cbio_CostOfServicesAsPerAgreement_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_FirmWorkOrderSupportingClinicalTrials" xlink:type="locator" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Firm work order supporting clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FirmWorkOrderSupportingClinicalTrials" xlink:to="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:label xml:lang="en-US" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Charges related to write off of prepaid manufacturing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AGC Biologics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AGCBiologicsIncMember" xlink:to="cbio_AGCBiologicsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGC Biologics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A G C Biologics Inc [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IntegrityBioMember" xlink:type="locator" xlink:label="cbio_IntegrityBioMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntegrityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrity bio .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IntegrityBioMember" xlink:to="cbio_IntegrityBioMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntegrityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Catalent Indiana, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IntegrityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Integrity Bio [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MarzeptacogAlfaActivatedMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marzeptacog alfa (activated).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MarzeptacogAlfaActivatedMember" xlink:to="cbio_MarzeptacogAlfaActivatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marzeptacog Alfa Activated</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marzeptacog Alfa Activated [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marzeptacog alfa activated and dalcinonacog alfa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marzeptacog Alfa Activated and Dalcinonacog Alfa</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marzeptacog Alfa Activated And Dalcinonacog Alfa [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_GMPMember" xlink:type="locator" xlink:label="cbio_GMPMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_GMPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GMP manufacturing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_GMPMember" xlink:to="cbio_GMPMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_GMPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog alfa.</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_GMPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G M P [Member]</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dalcinonacog alfa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DalcinonacogAlfaMember" xlink:to="cbio_DalcinonacogAlfaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog Alfa</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dalcinonacog Alfa [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceAgreementsMember" xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceAgreementsMember" xlink:to="us-gaap_ServiceAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Service Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfManufacturingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Manufacturing Services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfManufacturingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Manufacturing Services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfServicesAsPerAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of services as per agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfServicesAsPerAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Services As Per Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Firm work order supporting clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Firm Work Order Supporting Clinical Trials</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charges related to write off of prepaid manufacturing cost</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Charges Related To Write Off Of Prepaid Manufacturing Cost</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_GainLossFromExtinguishmentOfLiability" xlink:type="locator" xlink:label="cbio_GainLossFromExtinguishmentOfLiability" />
    <link:label xml:lang="en-US" xlink:label="cbio_GainLossFromExtinguishmentOfLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) from extinguishment of liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_GainLossFromExtinguishmentOfLiability" xlink:to="cbio_GainLossFromExtinguishmentOfLiability_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_GainLossFromExtinguishmentOfLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain from extinguishment of liability</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_GainLossFromExtinguishmentOfLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss From Extinguishment Of Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and other income, net</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RestructuringLiability" xlink:type="locator" xlink:label="cbio_RestructuringLiability" />
    <link:label xml:lang="en-US" xlink:label="cbio_RestructuringLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RestructuringLiability" xlink:to="cbio_RestructuringLiability_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost And Reserve [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of employees terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions Eliminated Period Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs1</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RestructuringLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RestructuringLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Liability</link:label>
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RemainingNumberOfFullTimeEmployees" xlink:type="locator" xlink:label="cbio_RemainingNumberOfFullTimeEmployees" />
    <link:label xml:lang="en-US" xlink:label="cbio_RemainingNumberOfFullTimeEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining number of full time employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RemainingNumberOfFullTimeEmployees" xlink:to="cbio_RemainingNumberOfFullTimeEmployees_lbl" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SeveranceAndOtherCosts" xlink:type="locator" xlink:label="cbio_SeveranceAndOtherCosts" />
    <link:label xml:lang="en-US" xlink:label="cbio_SeveranceAndOtherCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance and other costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SeveranceAndOtherCosts" xlink:to="cbio_SeveranceAndOtherCosts_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions Eliminated</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RemainingNumberOfFullTimeEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining number of full time employees</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RemainingNumberOfFullTimeEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Number Of Full Time Employees</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SeveranceAndOtherCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and other charges</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SeveranceAndOtherCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Severance And Other Costs</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cbio-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-08T17:25:16.2712857+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : b481765bcc1e4c2bb9d0981034513db3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/role/TemplateLink" xlink:href="cbio-20220331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cbio-20220331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfLicenseMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfCollaborationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_StockIssuedDuringPeriodFromStockGrantsShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsShares" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_StockIssuedDuringPeriodFromStockGrantsValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromStockGrantsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromStockGrantsValue" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromStockGrantsShares" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cbio-20220331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidity" xlink:href="cbio-20220331.xsd#Role_DisclosureNatureOfOperationsAndLiquidity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidity">
    <link:loc xlink:href="cbio-20220331.xsd#cbio_NatureOfOperationsAndLiquidityTextBlock" xlink:type="locator" xlink:label="cbio_NatureOfOperationsAndLiquidityTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="cbio_NatureOfOperationsAndLiquidityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="cbio-20220331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments" xlink:href="cbio-20220331.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases" xlink:href="cbio-20220331.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="cbio-20220331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborations" xlink:href="cbio-20220331.xsd#Role_DisclosureCollaborations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="cbio-20220331.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="cbio-20220331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet" xlink:href="cbio-20220331.xsd#Role_DisclosureInterestAndOtherIncomeNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuring" xlink:href="cbio-20220331.xsd#Role_DisclosureRestructuring" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuring">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="cbio-20220331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="cbio-20220331.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables" xlink:href="cbio-20220331.xsd#Role_DisclosureLeaseTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:type="locator" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="cbio-20220331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="cbio-20220331.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables" xlink:href="cbio-20220331.xsd#Role_DisclosureInterestAndOtherIncomeNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureLeaseAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_SubleaseArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:href="cbio-20220331.xsd#Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_li0l2" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_DevelopmentAndSalesMilestonePayments" xlink:type="locator" xlink:label="cbio_DevelopmentAndSalesMilestonePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember_li0l2" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="cbio_CollaborationAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CollaborationAgreementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_MosaicBiosciencesIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IsuAbxisMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_BiogenMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember_li0l2" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePayments" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_CommercialMilestonePayments" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_DevelopmentAndSalesMilestonePayments" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_OptionsToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_CommonStockWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_FirmWorkOrderSupportingClinicalTrials" xlink:type="locator" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfServicesAsPerAgreement" xlink:type="locator" xlink:label="cbio_CostOfServicesAsPerAgreement" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CostOfManufacturingServices" xlink:type="locator" xlink:label="cbio_CostOfManufacturingServices" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceAgreementsMember" xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_GMPMember" xlink:type="locator" xlink:label="cbio_GMPMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_MarzeptacogAlfaActivatedMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_IntegrityBioMember" xlink:type="locator" xlink:label="cbio_IntegrityBioMember" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_AGCBiologicsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IntegrityBioMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_MarzeptacogAlfaActivatedMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_GMPMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_DalcinonacogAlfaMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="cbio_CommitmentsAndContingenciesDisclosureLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfManufacturingServices" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfServicesAsPerAgreement" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_FirmWorkOrderSupportingClinicalTrials" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureDetailOfInterestAndOtherIncomeNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_GainLossFromExtinguishmentOfLiability" xlink:type="locator" xlink:label="cbio_GainLossFromExtinguishmentOfLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="cbio_GainLossFromExtinguishmentOfLiability" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" xlink:href="cbio-20220331.xsd#Role_DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20220331.xsd#cbio_SeveranceAndOtherCosts" xlink:type="locator" xlink:label="cbio_SeveranceAndOtherCosts" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RemainingNumberOfFullTimeEmployees" xlink:type="locator" xlink:label="cbio_RemainingNumberOfFullTimeEmployees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_RestructuringLiability" xlink:type="locator" xlink:label="cbio_RestructuringLiability" />
    <link:loc xlink:href="cbio-20220331.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_RestructuringLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_RemainingNumberOfFullTimeEmployees" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="cbio_SeveranceAndOtherCosts" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904802984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Catalyst Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,477,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-0761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690901748920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="nump">$ 44,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">1,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,322<span></span>
</td>
<td class="nump">2,807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,703<span></span>
</td>
<td class="nump">51,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">40,274<span></span>
</td>
<td class="nump">55,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,706<span></span>
</td>
<td class="nump">6,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,137<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">4,438<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,190<span></span>
</td>
<td class="nump">14,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,190<span></span>
</td>
<td class="nump">14,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 shares authorized; 31,477,053 and 31,409,707 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">444,283<span></span>
</td>
<td class="nump">443,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(417,230)<span></span>
</td>
<td class="num">(402,694)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">27,084<span></span>
</td>
<td class="nump">41,089<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 40,274<span></span>
</td>
<td class="nump">$ 55,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904921864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,477,053<span></span>
</td>
<td class="nump">31,409,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,477,053<span></span>
</td>
<td class="nump">31,409,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690901749112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Los (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,703<span></span>
</td>
<td class="nump">17,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,994<span></span>
</td>
<td class="nump">5,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,495<span></span>
</td>
<td class="nump">23,905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,701)<span></span>
</td>
<td class="num">(22,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (14,536)<span></span>
</td>
<td class="num">$ (22,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">31,456,090<span></span>
</td>
<td class="nump">28,385,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember', window );">Cost of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of license and collaboration</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906732536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 76,069<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 390,803<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (314,761)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for public offering, net of issuance costs</a></td>
<td class="nump">49,250<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">49,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromStockGrantsValue', window );">Issuance of common stock from stock grants</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromStockGrantsShares', window );">Issuance of common stock from stock grants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,438)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">104,089<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">441,252<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(337,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,331,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">41,089<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">443,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,409,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromStockGrantsValue', window );">Issuance of common stock from stock grants</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromStockGrantsShares', window );">Issuance of common stock from stock grants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,536)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 27,084<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 444,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (417,230)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,477,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockIssuedDuringPeriodFromStockGrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period from stock grants, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockIssuedDuringPeriodFromStockGrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockIssuedDuringPeriodFromStockGrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period from stock grants, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockIssuedDuringPeriodFromStockGrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906970744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs of issuance of common stock for public offering</a></td>
<td class="nump">$ 3,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906651832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (14,536)<span></span>
</td>
<td class="num">$ (22,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">2,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="num">(1,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,713)<span></span>
</td>
<td class="num">(2,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation and other accrued liabilities</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset', window );">Operating lease liability and right-of-use asset</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(12,050)<span></span>
</td>
<td class="num">(24,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">27,581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">27,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts', window );">Issuance of common stock for public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants', window );">Issuance of common stock from stock grants</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">49,459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(9,530)<span></span>
</td>
<td class="nump">52,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="nump">$ 83,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in operating lease liability and right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock for secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock from stock grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906792696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_NatureOfOperationsAndLiquidityTextBlock', window );">Nature of Operations and Liquidity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Nature of Operations and Liquidity</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a <span style="color:#000000;">biopharmaceutical company with expertise in protease engineering and several protease assets that may address unmet medical needs in disorders of the coagulation and complement systems. The Company is focused on the monetization of its assets and is exploring several strategic alternatives.</span> The Company is located in South San Francisco, California and operates in one segment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $14.5 million for the three months ended March 31, 2022 and an accumulated deficit of $417.2 million as of March 31, 2022. As of March 31, 2022, the Company had $34.8 million of cash and cash equivalents. <span style="color:#000000;">Its primary uses of cash are to fund operating and business development expenses and general and administrative expenditures. The Company believes that its existing cash and cash equivalents as of March 31, 2022 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. The Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the novel coronavirus disease (&#8220;COVID-19&#8221;) pandemic on its business, operations, and cash requirements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_NatureOfOperationsAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of operations and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_NatureOfOperationsAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906955112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.05%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Summary of Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (&#8220;Annual Report&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022, and the adoption did not have a material impact on its condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">New Accounting Pronouncements Recently Issued But Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;Measurement of Credit Losses on Financial Instruments</span>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial statements</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906941352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Fair Value Measurements </p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of the fair value hierarchy and the Company&#8217;s fair value methodology, see &#8220;<span style="font-style:italic;">Part II - Item 8 - Financial Statements and Supplementary Data - Note 3</span> &#8211; <span style="font-style:italic;">Summary of Significant Accounting Policies</span>&#8221; in the Company&#8217;s Annual Report. There were no significant changes in these methodologies during the three months ended March 31, 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909911896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Financial Instruments </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and short-term investments (debt securities) which are classified as available-for-sale debt securities, consisted of the following (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of March 31, 2022, the Company had no available-for-sale debt securities.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909939272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Lease</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<span style="font-style:italic;">e.g.</span>, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April 30, 2023 and there are no stated renewal options. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commenced in April 2022. Under the terms of the sublease agreement, the Company will receive $0.2 million in base lease payments over the term of the sublease, which ends in <span style="-sec-ix-hidden:F_000248">April 2023</span>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, the Company&#8217;s operating lease expense was $0.5 million and $0.2 million, respectively. The present value assumptions used in calculating the present value of the lease payments were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of March 31, 2022 were as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining in 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,543</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,909</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases was as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">502</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906963592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Stock Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 2,500,000 to a total of 5,300,000 shares. The amendment became effective immediately upon stockholder approval.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000276">7.46</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">879,200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.52</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(658,947</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; March 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,777,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000277">8.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; March 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,305,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Valuation Assumptions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee stock options was estimated using the following weighted-average assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000280">6.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000281">6.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of stock options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.06%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized was as follows (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">387</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to 32,684 shares of common stock issued to certain board members in lieu of their cash compensation. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, 2,937,588 shares of common stock were available for future grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909931752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Collaborations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mosaic</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a strategic research collaboration with Mosaic Biosciences (&#8220;Mosaic&#8221;) to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company subsequently amended this agreement in December 2018, December 2019 and May 2020.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the as amended Mosaic collaboration agreement, Mosaic is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s prior obligations to pay Mosaic a double-digit percentage of funds the Company </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.58%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISU Abxis<span style="font-weight:normal;"> </span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&amp;R ISU Abxis Agreement&#8221;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 <span style="color:#000000;">(the &#8220;Original ISU Abxis Agreement&#8221;)</span>. Under the A&amp;R ISU Abxis Agreement, <span style="color:#000000;">ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)</span>. <span style="color:#000000;">The </span>A&amp;R ISU Abxis Agreement <span style="color:#000000;">eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and</span> p<span style="color:#000000;">rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;R </span>ISU Abxis Agreement<span style="color:#000000;">, the Company will also pay up to an aggregate of $19.5 million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met. As of March 31, 2022, no milestones have been met.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company and Biogen International GmbH (&#8220;Biogen&#8221;) entered into a License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company performed certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen was solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of $15.0 million in January 2020. The Company was eligible to receive development milestones and sales milestones of up to $340.0 million. In addition, the Company was eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company also received reimbursements for costs associated with the performance of the Research Services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company received written notice from Biogen to terminate the Biogen Agreement which will be effective in May 2022. As a result of the termination, Biogen will no longer have the Exclusive License to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. In March 2022, Biogen returned full rights to CB 2782-PEG.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, the Company recognized no license revenue from the Biogen Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, respectively, the Company recognized $0.8 million and $1.5 million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022 and 2021, respectively, $0.7 million and $1.4 million of research and development expense was recorded as cost of collaboration revenue related to the Biogen Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2022, the Company recognized $0.2 million of revenue from the beginning of period deferred revenue balance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690922128936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Net Loss per Share Attributable to Common Stockholders </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,777,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,208,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,777,795</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,208,230</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906805992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company signed an agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;) to perform certain manufacturing services related to the Company&#8217;s collaboration agreement with Biogen, which includes firm work orders totaling $0.7 million. The payment obligations were fully paid off as of March 31, 2022.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for the Company&#8217;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. The Company can terminate the CFI agreement at its discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB 4332. The agreement covers analytical method qualification to support good manufacturing practices (&#8220;GMP&#8221;) manufacturing. The Company currently has firm work orders related to this agreement totaling $0.3 million and the payment obligations remaining as of March 31, 2022 were $0.1 million.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Company provided notice of intent to terminate its MarzAA manufacturing agreements and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.4%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#8217;s employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#8217;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under the Company&#8217;s agreements. The Company<span style="Background-color:#FFFFFF;"> is actively monitoring the impact of COVID-19 and the possible effects on its financial condition, liquidity, operations, clinical trials, suppliers, industry and workforce</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909939272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Interest and Other Income, Net</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interest and Other Income, Net</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income, net as follows (<span style="font-style:italic;">in thousands</span>):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain from extinguishment of liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690908271704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Restructuring</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately 35% of employees were terminated. During the year ended December 31, 2021, the Company recorded charges of $0.4 million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $3.8 million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. The remaining restructuring liability of $0.2 million will be paid during the second quarter of 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Board approved a further reduction of its workforce as part of its restructuring plan whereby 22 full-time employees were terminated. Following this reduction, the Company will have five full-time employees remaining. As of March 31, 2022, the Company recorded an additional liability of $1.0 million for severance and other charges related to the reduction-in-force, recognized as an operating expense within the consolidated statements of operations, which the Company expects to pay in the second quarter of 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690907006536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (&#8220;Annual Report&#8221;). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022, and the adoption did not have a material impact on its condensed consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">New Accounting Pronouncements Recently Issued But Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;Measurement of Credit Losses on Financial Instruments</span>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial statements</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906939112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (<span style="font-style:italic;">in thousands</span>):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909940104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and short-term investments (debt securities) which are classified as available-for-sale debt securities, consisted of the following (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690908401912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock', window );">Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments</a></td>
<td class="text">The present value assumptions used in calculating the present value of the lease payments were as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of March 31, 2022 were as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining in 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,543</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,909</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases was as follows <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">502</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of present value assumptions of lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906981976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Under Company's Equity Incentive Plans</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000276">7.46</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">879,200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.52</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(658,947</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; March 31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,777,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000277">8.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; March 31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,305,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options</a></td>
<td class="text">The fair value of employee stock options was estimated using the following weighted-average assumptions:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.87</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000280">6.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000281">6.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of stock options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Recognized</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.06%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized was as follows (<span style="font-style:italic;">in thousands</span>): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">387</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.67%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to 32,684 shares of common stock issued to certain board members in lieu of their cash compensation. </p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906951784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Security not Included In Diluted per Share Calculations</a></td>
<td class="text">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,777,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,208,145</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,777,795</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,208,230</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909909688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Detail of Interest and Other Income, Net</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income, net as follows (<span style="font-style:italic;">in thousands</span>):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain from extinguishment of liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904542168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Liquidity - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 14,536<span></span>
</td>
<td class="nump">$ 22,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">417,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904838456">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="nump">$ 46,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">34,817<span></span>
</td>
<td class="nump">44,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,817<span></span>
</td>
<td class="nump">46,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | U.S. Government Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="nump">$ 44,347<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904853320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="nump">$ 46,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">34,817<span></span>
</td>
<td class="nump">46,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">34,817<span></span>
</td>
<td class="nump">44,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">34,817<span></span>
</td>
<td class="nump">44,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 34,817<span></span>
</td>
<td class="nump">44,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906870952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Material realized gains or losses on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities current</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909892664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_LesseeOperatingLeaseRenewalTermDescription', window );">Lessee operating lease renewal term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no stated renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember', window );">Sublease Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lease Payments Receivable</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_LesseeOperatingLeaseRenewalTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease renewal term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_LesseeOperatingLeaseRenewalTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690907159768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904230456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturity of Operating Lease Liabilities - (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining in 2022</a></td>
<td class="nump">$ 1,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690919995272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904252904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th"><div>Jun. 09, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember', window );">2018 Omnibus Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock reserved for issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906608376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Option Activity Under Company's Equity Incentive Plans (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares Underlying Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning Balance</a></td>
<td class="nump">2,603,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, Options granted</a></td>
<td class="nump">879,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Underlying Outstanding Options, Options forfeited</a></td>
<td class="num">(658,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Underlying Outstanding Options, Options expired</a></td>
<td class="num">(46,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending Balance</a></td>
<td class="nump">2,777,710<span></span>
</td>
<td class="nump">2,603,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Exercisable - March 31, 2022</a></td>
<td class="nump">1,305,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 7.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options granted</a></td>
<td class="nump">0.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options forfeited</a></td>
<td class="nump">5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options expired</a></td>
<td class="nump">9.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending Balance</a></td>
<td class="nump">5.92<span></span>
</td>
<td class="nump">$ 7.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable - March 31, 2022</a></td>
<td class="nump">$ 9.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 5 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909883752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">91.54%<span></span>
</td>
<td class="nump">93.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690904259064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-Based Compensation Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to 32,684 shares of common stock issued to certain board members in lieu of their cash compensation.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906999912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares of common stock issued to certain board members in lieu of cash compensation</a></td>
<td class="nump">32,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690905387880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 794,000<span></span>
</td>
<td class="nump">$ 1,467,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,703,000<span></span>
</td>
<td class="nump">17,013,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue, recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="nump">1,467,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration | Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_MosaicBiosciencesIncMember', window );">Mosaic | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents', window );">Milestone payment related to regulatory and clinical development events</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember', window );">ISU Abxis | Amended and Restated License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RegulatoryAndDevelopmentMilestonePayment', window );">Regulatory and development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember', window );">ISU Abxis | Maximum | Amended and Restated License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Exclusive License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Maximum | Exclusive License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DevelopmentAndSalesMilestonePayments', window );">Development and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DevelopmentAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DevelopmentAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RegulatoryAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RegulatoryAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_MosaicBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_MosaicBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_IsuAbxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690909882056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Anti-dilutive Security not Included In Diluted per Share Calculations (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">2,777,795<span></span>
</td>
<td class="nump">3,208,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">2,777,710<span></span>
</td>
<td class="nump">3,208,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906529496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost', window );">Charges related to write off of prepaid manufacturing cost</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember', window );">AGC Biologics, Inc | Marzeptacog Alfa Activated and Dalcinonacog Alfa | Service Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfManufacturingServices', window );">Cost of Manufacturing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IntegrityBioMember', window );">Catalent Indiana, LLC. | Dalcinonacog alfa.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_FirmWorkOrderSupportingClinicalTrials', window );">Firm work order supporting clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember', window );">Marzeptacog Alfa Activated | Marzeptacog Alfa Activated and Dalcinonacog Alfa | Maximum | Service Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfServicesAsPerAgreement', window );">Cost of services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember', window );">Marzeptacog Alfa Activated | Dalcinonacog Alfa | Maximum | Service Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfServicesAsPerAgreement', window );">Cost of services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges related to write off of prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services related company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfServicesAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of services as per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfServicesAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_FirmWorkOrderSupportingClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Firm work order supporting clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_FirmWorkOrderSupportingClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_IntegrityBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_IntegrityBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_GMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_GMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_DalcinonacogAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_DalcinonacogAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690910033512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Detail of Interest and Other Income, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_GainLossFromExtinguishmentOfLiability', window );">Gain from extinguishment of liability</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Total interest and other income, net</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_GainLossFromExtinguishmentOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from extinguishment of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_GainLossFromExtinguishmentOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140690906518024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>Employee</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percent of employees terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost', window );">Charges related to write off of prepaid manufacturing cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RestructuringLiability', window );">Restructuring liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees terminated | Employee</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RemainingNumberOfFullTimeEmployees', window );">Remaining number of full time employees | Employee</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SeveranceAndOtherCosts', window );">Severance and other charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges related to write off of prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RemainingNumberOfFullTimeEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining number of full time employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RemainingNumberOfFullTimeEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RestructuringLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RestructuringLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SeveranceAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Severance and other costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SeveranceAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>cbio-10q_20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cbio="http://www.catalystbiosciences.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cbio-20220331.xsd" xlink:type="simple"/>
    <context id="C_0001124105_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="C_0001124105_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-09</startDate>
            <endDate>2021-06-09</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="C_0001124105_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioMosaicBiosciencesIncMember_srtRangeAxis_srtMaximumMember_20200508_20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:DalcinonacogAlfaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IntegrityBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:GMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20211101_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_0001124105_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_cbioSegment">
        <measure>cbio:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_cbioEmployee">
        <measure>cbio:Employee</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001124105_20220101_20220331" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001124105_20220101_20220331" id="F_000004">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001124105_20220101_20220331" id="F_000007">0001124105</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001124105_20220101_20220331" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331"
      id="F_000248">2023-04-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001124105_20220331"
      id="F_000061"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001124105_20211231"
      id="F_000062"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001124105_20220331"
      id="F_000063"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001124105_20211231"
      id="F_000064"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20210101_20211231" id="F_000276">P7Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20220101_20220331" id="F_000277">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      id="F_000280">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000281">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001124105_20220101_20220331" id="F_000000">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001124105_20220101_20220331" id="F_000027">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001124105_20220101_20220331" id="F_000002">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001124105_20220101_20220331" id="F_000003">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001124105_20220101_20220331" id="F_000028">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001124105_20220101_20220331" id="F_000015">000-51173</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001124105_20220101_20220331" id="F_000006">Catalyst Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001124105_20220101_20220331" id="F_000026">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001124105_20220101_20220331" id="F_000016">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001124105_20220101_20220331" id="F_000017">611 Gateway Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001124105_20220101_20220331" id="F_000018">Suite 710</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001124105_20220101_20220331" id="F_000019">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001124105_20220101_20220331" id="F_000020">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001124105_20220101_20220331" id="F_000021">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001124105_20220101_20220331" id="F_000022">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001124105_20220101_20220331" id="F_000023">871-0761</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001124105_20220101_20220331" id="F_000029">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001124105_20220101_20220331" id="F_000005">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001124105_20220101_20220331" id="F_000025">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0001124105_20220101_20220331" id="F_000013">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001124105_20220101_20220331" id="F_000024">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001124105_20220101_20220331" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001124105_20220101_20220331" id="F_000010">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001124105_20220101_20220331" id="F_000011">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001124105_20220101_20220331" id="F_000014">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001124105_20220429"
      decimals="INF"
      id="F_000012"
      unitRef="U_xbrlishares">31477053</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">34817000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">44347000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">2504000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">564000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">1818000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">1322000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">2807000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">36703000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">51476000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">472000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">472000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">2242000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">2744000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">857000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">970000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">40274000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">55662000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">4706000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">6419000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">2137000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">1467000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">230000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">4438000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">4072000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">1909000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">1977000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">13190000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">14165000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">408000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">13190000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">14573000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000075"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000076"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000077"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000083"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000084"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">31477053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">31477053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">31409707</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">31409707</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">444283000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">443752000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">-417230000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">-402694000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">27084000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">41089000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">40274000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">55662000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">1467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">1467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20220101_20220331"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">798000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20210331"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">1480000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">9703000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">17013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">4994000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">5412000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">15495000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">23905000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-14701000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-22438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">165000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">-14536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-22438000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20220101_20220331"
      decimals="2"
      id="F_000108"
      unitRef="U_iso4217USD_xbrlishares">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20210101_20210331"
      decimals="2"
      id="F_000109"
      unitRef="U_iso4217USD_xbrlishares">-0.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20220101_20220331"
      decimals="0"
      id="F_000110"
      unitRef="U_xbrlishares">31456090</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20210101_20210331"
      decimals="0"
      id="F_000111"
      unitRef="U_xbrlishares">28385432</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000112"
      unitRef="U_xbrlishares">31409707</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">443752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-402694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">41089000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000117"
      unitRef="U_xbrlishares">32684</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cbio:StockIssuedDuringPeriodFromStockGrantsShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000120"
      unitRef="U_xbrlishares">34662</cbio:StockIssuedDuringPeriodFromStockGrantsShares>
    <cbio:StockIssuedDuringPeriodFromStockGrantsValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">16000</cbio:StockIssuedDuringPeriodFromStockGrantsValue>
    <cbio:StockIssuedDuringPeriodFromStockGrantsValue
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">16000</cbio:StockIssuedDuringPeriodFromStockGrantsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-14536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-14536000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="INF"
      id="F_000125"
      unitRef="U_xbrlishares">31477053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">444283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-417230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">27084000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000130"
      unitRef="U_xbrlishares">22097820</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">390803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">-314761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">76069000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000136"
      unitRef="U_xbrlishares">10149</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">1026000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">1026000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">3563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000139"
      unitRef="U_xbrlishares">9185000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">49241000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">49250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cbio:StockIssuedDuringPeriodFromStockGrantsShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000143"
      unitRef="U_xbrlishares">38058</cbio:StockIssuedDuringPeriodFromStockGrantsShares>
    <cbio:StockIssuedDuringPeriodFromStockGrantsValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">182000</cbio:StockIssuedDuringPeriodFromStockGrantsValue>
    <cbio:StockIssuedDuringPeriodFromStockGrantsValue
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">182000</cbio:StockIssuedDuringPeriodFromStockGrantsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">-22438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-22438000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000148"
      unitRef="U_xbrlishares">31331027</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">441252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-337199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20210331"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">104089000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">-14536000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-22438000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">515000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">1026000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">113000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">45000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">200000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-1054000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">-2307000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">-1485000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">1671000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">-1713000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">-2969000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">1036000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-31000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">26000</cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
    <cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">26000</cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-230000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-651000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-12050000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-24356000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">2504000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">27581000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">2504000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">27581000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">49277000</cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts>
    <cbio:ProceedsFromIssuanceOfCommonStockFromStockGrants
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">16000</cbio:ProceedsFromIssuanceOfCommonStockFromStockGrants>
    <cbio:ProceedsFromIssuanceOfCommonStockFromStockGrants
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">182000</cbio:ProceedsFromIssuanceOfCommonStockFromStockGrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">16000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">49459000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">-9530000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">52684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">44347000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">30360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">34817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20210331"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">83044000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <cbio:NatureOfOperationsAndLiquidityTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000191">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Nature of Operations and Liquidity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Catalyst Biosciences, Inc. and its subsidiary (the &#x201c;Company&#x201d; or &#x201c;Catalyst&#x201d;) is a &lt;span style="color:#000000;"&gt;biopharmaceutical company with expertise in protease engineering and several protease assets that may address unmet medical needs in disorders of the coagulation and complement systems. The Company is focused on the monetization of its assets and is exploring several strategic alternatives.&lt;/span&gt; The Company is located in South San Francisco, California and operates in one segment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had a net loss of $14.5 million for the three months ended March 31, 2022 and an accumulated deficit of $417.2 million as of March 31, 2022. As of March 31, 2022, the Company had $34.8 million of cash and cash equivalents. &lt;span style="color:#000000;"&gt;Its primary uses of cash are to fund operating and business development expenses and general and administrative expenditures. The Company believes that its existing cash and cash equivalents as of March 31, 2022 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. The Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the novel coronavirus disease (&#x201c;COVID-19&#x201d;) pandemic on its business, operations, and cash requirements.&lt;/span&gt;&lt;/p&gt;</cbio:NatureOfOperationsAndLiquidityTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001124105_20220101_20220331"
      decimals="INF"
      id="F_000214"
      unitRef="U_cbioSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20220101_20220331"
      decimals="-5"
      id="F_000215"
      unitRef="U_iso4217USD">-14500000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20220331"
      decimals="-5"
      id="F_000216"
      unitRef="U_iso4217USD">-417200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20220331"
      decimals="-5"
      id="F_000217"
      unitRef="U_iso4217USD">34800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000192">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:0.05%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Summary of Significant Accounting Policies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and following the requirements of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#x2019;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 (&#x201c;Annual Report&#x201d;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022, and the adoption did not have a material impact on its condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements Recently Issued But Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;span style="font-style:italic;"&gt;&#160;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000202">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and following the requirements of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#x2019;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 (&#x201c;Annual Report&#x201d;). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000203">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022, and the adoption did not have a material impact on its condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements Recently Issued But Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;span style="font-style:italic;"&gt;&#160;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000193">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Fair Value Measurements &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For a description of the fair value hierarchy and the Company&#x2019;s fair value methodology, see &#x201c;&lt;span style="font-style:italic;"&gt;Part II - Item 8 - Financial Statements and Supplementary Data - Note 3&lt;/span&gt; &#x2013; &lt;span style="font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&#x201d; in the Company&#x2019;s Annual Report. There were no significant changes in these methodologies during the three months ended March 31, 2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000204">The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">34817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220331"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">34817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">34817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">34817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">44347000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">44347000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">2504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">2504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">46851000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">46851000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000194">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Financial Instruments &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and short-term investments (debt securities) which are classified as available-for-sale debt securities, consisted of the following (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of March 31, 2022, the Company had no available-for-sale debt securities.&lt;/p&gt;
</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000205">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and short-term investments (debt securities) which are classified as available-for-sale debt securities, consisted of the following (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20220331"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">34817000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20220331"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">34817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">34817000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">34817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20220331"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">34817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">34817000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">44347000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">44347000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">2504000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">2504000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">46851000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">46851000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">44347000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">2504000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">46851000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000195">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (&lt;span style="font-style:italic;"&gt;e.g.&lt;/span&gt;, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April 30, 2023 and there are no stated renewal options. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commenced in April 2022. Under the terms of the sublease agreement, the Company will receive $0.2 million in base lease payments over the term of the sublease, which ends in &lt;span style="-sec-ix-hidden:F_000248"&gt;April 2023&lt;/span&gt;.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2022 and 2021, the Company&#x2019;s operating lease expense was $0.5 million and $0.2 million, respectively. The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of March 31, 2022 were as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining in 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to operating leases was as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;502&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;182&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseExpirationDate1 contextRef="C_0001124105_20220101_20220331" id="F_000245">2023-04-30</us-gaap:LeaseExpirationDate1>
    <cbio:LesseeOperatingLeaseRenewalTermDescription contextRef="C_0001124105_20220101_20220331" id="F_000246">no stated renewal options</cbio:LesseeOperatingLeaseRenewalTermDescription>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="C_0001124105_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331"
      decimals="-5"
      id="F_000247"
      unitRef="U_iso4217USD">200000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001124105_20220101_20220331"
      decimals="-5"
      id="F_000249"
      unitRef="U_iso4217USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001124105_20210101_20210331"
      decimals="-5"
      id="F_000250"
      unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
    <cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000206">The present value assumptions used in calculating the present value of the lease payments were as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001124105_20220331" id="F_000251">P1Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001124105_20211231" id="F_000252">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001124105_20220331"
      decimals="3"
      id="F_000253"
      unitRef="U_xbrlipure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001124105_20211231"
      decimals="3"
      id="F_000254"
      unitRef="U_xbrlipure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000207">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of March 31, 2022 were as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining in 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">1543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">410000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">1953000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">44000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001124105_20220331"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">1909000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000208">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to operating leases was as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;502&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;182&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">502000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">182000</us-gaap:OperatingLeasePayments>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000196">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Stock Based Compensation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2018 Omnibus Incentive Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, stockholders of the Company approved the Company&#x2019;s 2018 Omnibus Incentive Plan (the &#x201c;2018 Plan&#x201d;). The 2018 Plan had previously been approved by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) and the Compensation Committee (the &#x201c;Committee&#x201d;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 2,500,000 to a total of 5,300,000 shares. The amendment became effective immediately upon stockholder approval.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under the Company&#x2019;s 2018 Plan and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&#160;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&#160;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&#160;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000276"&gt;7.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;879,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(658,947&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,777,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000277"&gt;8.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2014; March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,305,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Valuation Assumptions &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#x201c;plain vanilla&#x201d; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#x2019;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee stock options was estimated using the following weighted-average assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Options:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000280"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000281"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of stock options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.06%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense recognized was as follows (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;515&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to 32,684 shares of common stock issued to certain board members in lieu of their cash compensation. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2022, 2,937,588 shares of common stock were available for future grant.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609"
      decimals="INF"
      id="F_000262"
      unitRef="U_xbrlishares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609"
      decimals="INF"
      id="F_000263"
      unitRef="U_xbrlishares">5300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000209">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under the Company&#x2019;s 2018 Plan and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&#160;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&#160;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&#160;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000276"&gt;7.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;879,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(658,947&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,777,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000277"&gt;8.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2014; March 31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,305,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000264"
      unitRef="U_xbrlishares">2603630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20211231"
      decimals="2"
      id="F_000270"
      unitRef="U_iso4217USD_xbrlishares">7.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001124105_20220101_20220331"
      decimals="INF"
      id="F_000265"
      unitRef="U_xbrlishares">879200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20220101_20220331"
      decimals="2"
      id="F_000271"
      unitRef="U_iso4217USD_xbrlishares">0.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001124105_20220101_20220331"
      decimals="INF"
      id="F_000266"
      unitRef="U_xbrlishares">658947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20220101_20220331"
      decimals="2"
      id="F_000272"
      unitRef="U_iso4217USD_xbrlishares">5.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001124105_20220101_20220331"
      decimals="INF"
      id="F_000267"
      unitRef="U_xbrlishares">46173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20220101_20220331"
      decimals="2"
      id="F_000273"
      unitRef="U_iso4217USD_xbrlishares">9.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000268"
      unitRef="U_xbrlishares">2777710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20220331"
      decimals="2"
      id="F_000274"
      unitRef="U_iso4217USD_xbrlishares">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000269"
      unitRef="U_xbrlishares">1305020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001124105_20220331"
      decimals="2"
      id="F_000275"
      unitRef="U_iso4217USD_xbrlishares">9.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000210">The fair value of employee stock options was estimated using the following weighted-average assumptions:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Options:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000280"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000281"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of stock options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="4"
      id="F_000278"
      unitRef="U_xbrlipure">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="4"
      id="F_000279"
      unitRef="U_xbrlipure">0.0069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="2"
      id="F_000282"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="2"
      id="F_000283"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="4"
      id="F_000284"
      unitRef="U_xbrlipure">0.9154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="4"
      id="F_000285"
      unitRef="U_xbrlipure">0.9383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="2"
      id="F_000286"
      unitRef="U_iso4217USD_xbrlishares">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="2"
      id="F_000287"
      unitRef="U_iso4217USD_xbrlishares">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000211">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.06%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense recognized was as follows (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;515&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;margin-right:82.41%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:6.67%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to 32,684 shares of common stock issued to certain board members in lieu of their cash compensation. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">128000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">515000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">1026000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001124105_20220101_20220331"
      decimals="INF"
      id="F_000294"
      unitRef="U_xbrlishares">32684</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001124105_20220331"
      decimals="INF"
      id="F_000295"
      unitRef="U_xbrlishares">2937588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000197">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Collaborations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Mosaic&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, the Company entered into a strategic research collaboration with Mosaic Biosciences (&#x201c;Mosaic&#x201d;) to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company subsequently amended this agreement in December 2018, December 2019 and May 2020.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the as amended Mosaic collaboration agreement, Mosaic is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#x2019;s prior obligations to pay Mosaic a double-digit percentage of funds the Company &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.58%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;ISU Abxis&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#x201c;A&amp;amp;R ISU Abxis Agreement&#x201d;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 &lt;span style="color:#000000;"&gt;(the &#x201c;Original ISU Abxis Agreement&#x201d;)&lt;/span&gt;. Under the A&amp;amp;R ISU Abxis Agreement, &lt;span style="color:#000000;"&gt;ISU Abxis will receive commercialization rights in South Korea to the Company&#x2019;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)&lt;/span&gt;. &lt;span style="color:#000000;"&gt;The &lt;/span&gt;A&amp;amp;R ISU Abxis Agreement &lt;span style="color:#000000;"&gt;eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and&lt;/span&gt; p&lt;span style="color:#000000;"&gt;rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;amp;R &lt;/span&gt;ISU Abxis Agreement&lt;span style="color:#000000;"&gt;, the Company will also pay up to an aggregate of $19.5 million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met. As of March 31, 2022, no milestones have been met.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Biogen&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 18, 2019, the Company and Biogen International GmbH (&#x201c;Biogen&#x201d;) entered into a License and Collaboration Agreement (the &#x201c;Biogen Agreement&#x201d;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#x201c;Exclusive License&#x201d;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company performed certain pre-clinical and manufacturing activities (&#x201c;Research Services&#x201d;), and Biogen was solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of $15.0 million in January 2020. The Company was eligible to receive development milestones and sales milestones of up to $340.0 million. In addition, the Company was eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company also received reimbursements for costs associated with the performance of the Research Services.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Company received written notice from Biogen to terminate the Biogen Agreement which will be effective in May 2022. As a result of the termination, Biogen will no longer have the Exclusive License to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. In March 2022, Biogen returned full rights to CB 2782-PEG.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2022 and 2021, the Company recognized no license revenue from the Biogen Agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2022 and 2021, respectively, the Company recognized $0.8 million and $1.5 million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2022 and 2021, respectively, $0.7 million and $1.4 million of research and development expense was recorded as cost of collaboration revenue related to the Biogen Agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2022, the Company recognized $0.2 million of revenue from the beginning of period deferred revenue balance.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMosaicBiosciencesIncMember_srtRangeAxis_srtMaximumMember_20200508_20200508"
      decimals="-5"
      id="F_000296"
      unitRef="U_iso4217USD">4000000.0</cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000298"
      unitRef="U_iso4217USD">19500000</cbio:MilestonePayments>
    <cbio:RegulatoryAndDevelopmentMilestonePayment
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000300"
      unitRef="U_iso4217USD">2500000</cbio:RegulatoryAndDevelopmentMilestonePayment>
    <cbio:CommercialMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000302"
      unitRef="U_iso4217USD">17000000.0</cbio:CommercialMilestonePayments>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331"
      decimals="INF"
      id="F_000297"
      unitRef="U_iso4217USD">0</cbio:MilestonePayments>
    <cbio:RegulatoryAndDevelopmentMilestonePayment
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331"
      decimals="INF"
      id="F_000299"
      unitRef="U_iso4217USD">0</cbio:RegulatoryAndDevelopmentMilestonePayment>
    <cbio:CommercialMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20220101_20220331"
      decimals="INF"
      id="F_000301"
      unitRef="U_iso4217USD">0</cbio:CommercialMilestonePayments>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131"
      decimals="-5"
      id="F_000303"
      unitRef="U_iso4217USD">15000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <cbio:DevelopmentAndSalesMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131"
      decimals="-5"
      id="F_000304"
      unitRef="U_iso4217USD">340000000.0</cbio:DevelopmentAndSalesMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20220101_20220331"
      decimals="INF"
      id="F_000305"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20210331"
      decimals="INF"
      id="F_000306"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20220101_20220331"
      decimals="-5"
      id="F_000307"
      unitRef="U_iso4217USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20210331"
      decimals="-5"
      id="F_000308"
      unitRef="U_iso4217USD">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20220101_20220331"
      decimals="-5"
      id="F_000309"
      unitRef="U_iso4217USD">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20210331"
      decimals="-5"
      id="F_000310"
      unitRef="U_iso4217USD">1400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_0001124105_20220101_20220331"
      decimals="-5"
      id="F_000311"
      unitRef="U_iso4217USD">200000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000198">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Net Loss per Share Attributable to Common Stockholders &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,777,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,208,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,777,795&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,208,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000212">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,777,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,208,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,777,795&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,208,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000312"
      unitRef="U_xbrlishares">2777710</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000313"
      unitRef="U_xbrlishares">3208145</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20220101_20220331"
      decimals="INF"
      id="F_000314"
      unitRef="U_xbrlishares">85</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20210331"
      decimals="INF"
      id="F_000315"
      unitRef="U_xbrlishares">85</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_20220101_20220331"
      decimals="INF"
      id="F_000316"
      unitRef="U_xbrlishares">2777795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_20210101_20210331"
      decimals="INF"
      id="F_000317"
      unitRef="U_xbrlishares">3208230</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000199">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Manufacturing Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company signed an agreement with AGC Biologics, Inc. (&#x201c;AGC&#x201d;) to perform certain manufacturing services related to the Company&#x2019;s collaboration agreement with Biogen, which includes firm work orders totaling $0.7 million. The payment obligations were fully paid off as of March 31, 2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2021, the Company entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for the Company&#x2019;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. The Company can terminate the CFI agreement at its discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB 4332. The agreement covers analytical method qualification to support good manufacturing practices (&#x201c;GMP&#x201d;) manufacturing. The Company currently has firm work orders related to this agreement totaling $0.3 million and the payment obligations remaining as of March 31, 2022 were $0.1 million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, the Company provided notice of intent to terminate its MarzAA manufacturing agreements and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;COVID-19&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.4%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#x2019;s employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#x2019;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under the Company&#x2019;s agreements. The Company&lt;span style="Background-color:#FFFFFF;"&gt; is actively monitoring the impact of COVID-19 and the possible effects on its financial condition, liquidity, operations, clinical trials, suppliers, industry and workforce&lt;/span&gt;.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <cbio:CostOfManufacturingServices
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331"
      decimals="-5"
      id="F_000318"
      unitRef="U_iso4217USD">700000</cbio:CostOfManufacturingServices>
    <cbio:CostOfServicesAsPerAgreement
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331"
      decimals="-5"
      id="F_000319"
      unitRef="U_iso4217USD">3200000</cbio:CostOfServicesAsPerAgreement>
    <cbio:CostOfServicesAsPerAgreement
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331"
      decimals="-5"
      id="F_000320"
      unitRef="U_iso4217USD">6500000</cbio:CostOfServicesAsPerAgreement>
    <cbio:FirmWorkOrderSupportingClinicalTrials
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20220331"
      decimals="-5"
      id="F_000321"
      unitRef="U_iso4217USD">300000</cbio:FirmWorkOrderSupportingClinicalTrials>
    <us-gaap:ContractualObligation
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20220331"
      decimals="-5"
      id="F_000322"
      unitRef="U_iso4217USD">100000</us-gaap:ContractualObligation>
    <cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost
      contextRef="C_0001124105_20211101_20211130"
      decimals="-5"
      id="F_000323"
      unitRef="U_iso4217USD">3800000</cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000200">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Interest and Other Income, Net&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows the detail of interest and other income, net as follows (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain from extinguishment of liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000213">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows the detail of interest and other income, net as follows (&lt;span style="font-style:italic;"&gt;in thousands&lt;/span&gt;):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain from extinguishment of liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">2000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">17000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <cbio:GainLossFromExtinguishmentOfLiability
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">180000</cbio:GainLossFromExtinguishmentOfLiability>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">-17000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001124105_20210101_20210331"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">-17000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0001124105_20220101_20220331"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">165000</us-gaap:InterestAndOtherIncome>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="C_0001124105_20220101_20220331" id="F_000201">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Restructuring&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately 35% of employees were terminated. During the year ended December 31, 2021, the Company recorded charges of $0.4 million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $3.8 million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. The remaining restructuring liability of $0.2 million will be paid during the second quarter of 2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Board approved a further reduction of its workforce as part of its restructuring plan whereby 22 full-time employees were terminated. Following this reduction, the Company will have five full-time employees remaining. As of March 31, 2022, the Company recorded an additional liability of $1.0 million for severance and other charges related to the reduction-in-force, recognized as an operating expense within the consolidated statements of operations, which the Company expects to pay in the second quarter of 2022.&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_0001124105_20211101_20211130"
      decimals="2"
      id="F_000330"
      unitRef="U_xbrlipure">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000331"
      unitRef="U_iso4217USD">400000</us-gaap:SeveranceCosts1>
    <cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000332"
      unitRef="U_iso4217USD">3800000</cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost>
    <cbio:RestructuringLiability
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000333"
      unitRef="U_iso4217USD">200000</cbio:RestructuringLiability>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_0001124105_20220301_20220331"
      decimals="INF"
      id="F_000334"
      unitRef="U_cbioEmployee">22</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <cbio:RemainingNumberOfFullTimeEmployees
      contextRef="C_0001124105_20220301_20220331"
      decimals="INF"
      id="F_000335"
      unitRef="U_cbioEmployee">5</cbio:RemainingNumberOfFullTimeEmployees>
    <cbio:SeveranceAndOtherCosts
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20220101_20220331"
      decimals="-5"
      id="F_000336"
      unitRef="U_iso4217USD">1000000.0</cbio:SeveranceAndOtherCosts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000222"
          xlink:label="F_000222"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000218"
          xlink:label="F_000218"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000219"
          xlink:label="F_000219"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000223"
          xlink:label="F_000223"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000222"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000218"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000219"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000223"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000224"
          xlink:label="F_000224"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000225"
          xlink:label="F_000225"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in short-term investments on the accompanying condensed consolidated balance sheets and classified as available-for-sale debt securities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000224"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000225"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000291"
          xlink:label="F_000291"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000290"
          xlink:label="F_000290"
          xlink:type="locator"/>
        <link:footnote id="FNT_000002" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in general and administrative stock-based compensation for the three months ended March 31, 2022 is stock-based compensation expense related to 32,684 shares of common stock issued to certain board members in lieu of their cash compensation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000291"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000290"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M)\;;BN]9EIK)%&K'*_@>^ZO%AC4<X_#T.C\!.S:B,9Z8SJ@%&SG!?A&*Y6\
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MRA*5KJW00@D]D(JI1W[^G3:" HT7<R;-+SHWMHZ%XDHJGC?.P"#/BOI)7II
M]!P 9]K!;1S<H8-_Q<%K'#PCM&9F9'TFBFQ6@I^1T-: IE],;(PWJ,D*G<:=
M$O!O!GYJL^5% DFA"8(WR5F6$ 6#G8('9$M)Q _HSY(*HJ,N$2FT90Y;)M6Y
M/%'TE4OT_JD@59*!YP?T$3WM/J/W[SZ@=R@KT/>45Q*\Y,I6P%>O:L<-M_N:
MFWN%FX>^\4*E$OT"')/7_C;H;,6Z%['W[BS@-R)ND8=OD.NX[@2?[=O=\0P=
MKXV]9_"\*WB/]$2+BM[-0/DME&^@_"M07[-89]&D![8$(WM>9PP^-;/(5/1K
MR(6!U)_[:;.,_)5]ZD=D;(/]Q;(U>D4V:,D&L[J;[50<$7TI-6TY%X)%B[J8
M#<$CE92(.#4Q2$ UXZ7>P5/*:Z2@IRI:.MY ^M@(+QWL36M?MBR7LRQ_HP6(
M9X8D2>"#SJ32P3A-9F@YHN!'HQ2-C0(?N],TPY9F.$OS.U= DH\2-44R',<I
M\*-@P')LY7J1$TS3C%J:T?RVYU*B@^#YA2J4J"F*T6CQC]B'9 XX3IBYKN^%
MTR2QT]589Y;FET)10:4R6><JI0(J8\QS>H,*.KE!&\!705U<"1;NU7H\R^,/
M.!8P';*Z3/2KN)Z>)()'!0!"%WB+0>BF[.9BYW:<W;=QA@0CF1(!14XID>TK
M1?:,(L6UDAPJ'?3*^#GE+*%"WNC>GL5U+<A8I8;]HU%7KQWV63NW_DC<I-DR
MNJ*MJ__8F]6VTW(DJG3[K764P%3OB?]1LC?:61XD=.%$SE#UV-(-O3#PO2O%
M!7?="L^WJVV_1<W4?MRU%#S?4][02W'72?!\*_FI;MI@SK?3":/K_11W307/
M=Y4MA^("![7XK7'M^@ ._\->C;O"C><K]X4QNQ;JR1!'$R$.AR$>&V$_= 8A
MMGM'YIR*H[E)2*!0%:H^4+:S[6WEDSFC#^;O]2W&',4[F/H*!,?%8P9'9D8/
M  GU G:PJ&\5]4#QTAS,]US!,=^\IG 3HT(;P/\'SM5EH!=H[W:;?P%02P,$
M%     @ &6BI5.RLJC"N!   ;1,  !@   !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6RU6&UOHS@0_BM6M-*U4E-L8]Y6::1MTN@JW4NUW=Y]=L$)J("SV#3=
M?W^&4 A@"*IZ7Q(;GAD>SPSS&"\./'L1(6,2O"5Q*FYFH93[KX8A_) E5%SS
M/4O5G2W/$BK5--L98I\Q&I1&26Q@"&TCH5$Z6R[*:P_9<L%S&4<I>\B R).$
M9K]N6<P/-S,T>[_P/=J%LKA@+!=[NF./3#[M'S(U,VHO092P5$0\!1G;WLR^
MH:\;7!J4B'\B=A G8U LY9GSEV)R']S,8,&(Q<R7A0NJ_E[9BL5QX4GQ^%DY
MG=7/+ Q/Q^_>-^7BU6*>J6 K'O\;!3*\F;DS$+ MS6/YG1]^9]6"K,*?SV-1
M_H)#A84SX.="\J0R5@R2*#W^T[<J$"<&R!PPP)4!GFI@5@9FQP [ P:D,B =
M V(/&%B5@=5]PM"B[<K +F-_#%89Z365=+G(^ %D!5IY*P9ENDIK%> H+2KK
M46;J;J3LY'+%TT#5"0N &@D>1P&5:O(HU9\J("D WZH9]U]"'@<L$[^!NY]Y
M)'^!BZ>4YD&DT)=@#IX>U^#BRR7X J(4_ AY+F@:B(4A%<?B289?\;D]\L$#
M?'YP26.-V6K<;,631-5I251CO1ZW_A:H=:@ZIS%XH%$POT_!BNXC/9.[,[Y\
M/T_RN(SBWS)DF0ILHE[ZL'@;7QFX3WV>,'#Q!Q?B4N-^,]W]FFTC/Y)M)X8J
M@+H*<%T%N/1*!KS>TIBF/@-4*J?^-3#1%< 00UW^CI[LTE/1MUZ7C@UM;V&\
MGJ:KC\*X#5GW(:8'76BV87=]F-5&;/J(N8F(8Z,:UPJ*60?%G!24"U71(J09
M$Y=3 K0Z>K5:2X>>XQ9H'1]2\R&C?,KBGA=M- "JAI2V"%IV9_96C)DN6:3'
M!4%L=Q)Q!M0B:]5DK<\FN[(T/!#Q]$3LFH@]2N1>B+Q,H^IC_K%+B((;4*H,
M]OES'/GJUI9E4;J[ JG2<@6,WHU\+J2VB]D]KL3#%NR\!7:O,COOR5KKAPQ4
MKE.OV?F_UWQ5E;PN3TZ/LX=<"\*!^G9KUNX'66<\J8:[C*;ZA+C]XG&['6<<
MTR+MU:2]3R(]%E&O1\QTH>7JJ2'8:#L<)?>7RFRL=$8KP[#WS#G&Q'0[S?4\
MKDWN9..!IFK.GS2K6RK2DD6:UD"@VU6="M?2%-0I HTO0A"V.L5RI_'5%1Z-
MJ[EI.L@;Z%FHT6,T39 [VG,N4*O*;:N2D&FJ?NX,4&K4$$V3PXX$ZO/5UT""
M-.DR)Z1+XXJ83C==&PUN3I2,>61@X8WLHG'=G; /T.>BKZMJ6Z)V G H%XVX
MHD]7UUO4EU<+6=UHCX/:=!L)1N,:_)'- .HKHXEM=RB;C32BCVKC%)5!?>U#
MW>W4.*9-N]%&]%GB.*8SJ*^ )K'M 0U$C0BB<14<%9J^N,T1L4R[^P*?Q;4_
M;1H5Q.,J." T6/MQ _O?+0X\J;KJZZ8/ZS4N#880@MW.]\U&@YL3Y&!S8#N%
M&X7%TQ1V1$1T05CAOJP5WU,.M,P.)>/DX*$XB%*N=U$J0,RVRA1>.\I'=CS;
M.4XDWY=G$<]<2IZ4PY#1@&4%0-W?<B[?)\7Q1GW"MOP/4$L#!!0    ( !EH
MJ50!3#6O30(  ,@$   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL?511
M3]M #/XK5H0TD";2)H5-*(U$@6D\("HZMH=I#]?$:4Y<SN'N0N'?SW=)LR*M
MO.1LG_WYL\].MB7S9&M$!Z^-TG8>U<ZU%W%LBQH;84^I1<TW%9E&.%;-)K:M
M05&&H$;%R61R'C="ZBC/@FUI\HPZIZ3&I0';-8TP;PM4M)U'TVAG>)";VGE#
MG&>MV. *W6.[-*S%(THI&]16D@:#U3RZG%XL9MX_./R4N+5[,OA*UD1/7KDM
MY]'$$T*%A?,(@H\7O$*E/!#3>!XPHS&E#]R7=^C?0NU<RUI8O"+U2Y:NGD=?
M(RBQ$IUR#[3]CD,]9QZO(&7#%[:#[R2"HK..FB&8&312]Z=X'?JP%Y!,#P0D
M0T 2>/>) LMKX42>&=J"\=Z,YH50:HAF<E+[1UDYP[>2XUQ^1;KD%F,)+%E2
MLA2.E97C@WOO+%#%&A5/-:D2C?T$-\^==&]P_*A%5TKV/H'CI3#L7*.3A5 G
M< 12PX^:.BMT:;/8,5.?+RX&5HN>57* 50IWQ' 6;IA=^3X^Y@K',I-=F8OD
M0\ [84XAG7Z&9)),'U?7<'QT\@%L.G8O#;#I =BQ37#_ODN[)OV^7%MG>/3^
M?)!M-F:;A6RS ]ENK>V$+A *LOW#R)V%Y8*:AL?<>A; VPIMMU:RX*L*C=2;
M_[U"G^\\Y//K^Y*G9^=I%K_LLXSWIJM!LPD[9#E?IUT_:*-U7-/+?CK_N?<[
MSL^PD=J"PHI#)Z=?SB(P_=[TBJ,VS.J:'$]^$&O^U:#Q#GQ?$;F=XA.,/Z_\
M+U!+ P04    "  9:*E4;&.G_40%  !B$P  &    'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;)58VW*C.!#]%95K'I*J<8P$^))R7)4XF]IYF-G49+/[+(-L
M:P/((PD[V:_?EL#@&*%D7VP!W:W3%_HTFA^$?%%;QC1ZS;-"W0RV6N^N1R.5
M;%E.U978L0*>K(7,J89+N1FIG60TM4IY-B)!,![EE!>#Q=S>>Y2+N2AUQ@OV
M*)$J\YS*MSN6B</-  ^.-W[RS5:;&Z/%?$<W[(GIY]VCA*M18R7E.2L4%P62
M;'TSN,772S(V"E;B+\X.ZF2-C"LK(5[,Q;?T9A 81"QCB38F*/SMV9)EF;$$
M.'[51@?-GD;Q='VT_F"=!V=65+&ER/[FJ=[>#*8#E+(U+3/]4QQ^9[5#L;&7
MB$S97W2H98,!2DJE15XK X*<%]4_?:T#<:( =MP*I%8@YPI1CT)8*X36T0J9
M=>N>:KJ82W% TDB#-;.PL;':X TO3!J?M(2G'/3T8BF*%)+"4@0K)3*>4@T7
M3QK^(%M:(;%&2ZJVZ $RKM#%<T'+E(/,)1JBYZ=[=/'E$GU!O$!_;D6I:)&J
M^4@#,F-_E-0H[BH4I =%B+Z+0F\5^@W0I._U1^!1XQ8YNG5'O :_4WF%0OP5
MD8 0!Y[EY]6Q!T[81#FT]L(>>W_LF*2:%QMT:\J6:\Z4QVS4F(VLV:C'[ ]X
MS3.AG &O-,=6T[S+^\401W$XGH_VIW%PB!$2A=-&[!VPN $6>_V]3?^!TJWJ
M1PMXW1-1)#QCJ*@1F[MFG9C**DWY00&))DJTB=*U)TSC!LW8&Z8G+9*7H7G9
M4Y2('#J@HK:'L%>S9J[P51;CD[C$.#Z+75<&!V3LCMRDP3KQ8KUGT(T37N&#
MEPG17$C-_[4W7$ G71 X/ /:E8EB-\QI W/JA7E'4VB6*^T+X;2S*W"+>]M9
ML^W,6U?++2TV3)T5BU(,ZLP$*^-TQ;,/"P<';7<,O'[>)HDH315#4AC?TU7F
M=+6V\KX4XN@L#0XI$@83=TCP20?'7HR/DNTH3VT A-XR";PA);Q[=62<@'$7
M<#0]+W"'U!"/)[@',6D1D\]%=4??>D-*''M/.J7M$B.S\:P'8MNP<?@11%F>
M]XLVPK1^?%)P3B="1UUT>K!#:ACV!;GE!NPGAY9S,@:MKX'Z9MV09KP9BO40
MFF]5)T[\4;=B.^B],N_!M_R!XP_:X)I!#0-.MF=%Z:Z0V)'Z,#B'YY :QWW1
M;2D%^SGEQY&\UG8L\E&8$WN7.X:8!'$'O4,.Z#GN"W!+,WCB[:3?BCU3GY](
M<$L,V,\,CU(DC*4*K:7(85+5I;3&S1RIML!E0\UD#K$R^]L)P1D?!WG$0:>A
M.J0F\;0ON2W+X-G_2>Y.BCV'N12MWFK<GTCP[%,..*3Z'2 M;9' F]T'7E 8
MN#Z;7=)R#?%SS3>E2K#,3#:A->;0%)69KA!\4*)=N<IX H_@W86]O]H)#P3Y
M42D1RIGN)>D2330CDQYJ)"W1$#_1],,UQ5DM-Y+V%"'I<@L^[WXNF2GIP=VR
M#_&SCZ< UTUJ_05('-33 =^5B691W$.>I*4>\O%W"2\2:7GG(F75ZM(T2.N5
M(2"[8+]*&*JROBY NM0RG,6=%N\0B\EX&O6XT9(0\9/0L@\KHAJMV(87A<D#
MU!;,! @Z/Q>ITXTN!451&$W.W>B*A3 L](S,I*4JXJ<JKQO,C#0?.C#N?"6&
MT11W'.B*3<,@.L_#Z.2T(F=R8P]Q%+(C8?6%W]QM#HIN[?'(V?T[?+VLCGM:
M,]7I$WR_0W843#YK,!E<32"HLCK0J2ZTV-DSD9706N1VN64T9=((P/.U$/IX
M839HCM46_P%02P,$%     @ &6BI5',@8UN&!   QPD  !@   !X;"]W;W)K
M<VAE971S+W-H965T."YX;6RM5E%OVS80?M^O.'C%T &>;"ONDK9)@"1=L0#K
M$C1;]S#L@99.$E&*5$G*2?;K]QTEJTZ1Y&DOMDC=???=Q[NCCF^=_QP:YDAW
MK;'A9-;$V+U9+$+1<*M"YCJV>%,YWZJ(I:\7H?.LRN34FD6^7/Z\:)6VL]/C
MM'?M3X]='XVV?.TI]&VK_/TY&W=[,EO-=AL?==U$V5B<'G>JYAN.?W;7'JO%
MA%+JEFW0SI+GZF1VMGISOA;[9/!)\VW8>R;)9./<9UE<EB>SI1!BPT44!(6_
M+5^P,0($&E]&S-D44ASWGW?H[U/NR&6C E\X\Y<N8W,R.YI1R97J3?SH;G_E
M,9]7@E<X$](OW0ZVAZ]G5/0ANG9T!H-6V^%?W8TZ[#D<+9]PR$>'//$> B66
M[U14I\?>W9(7:Z#)0THU>8.<MG(H-]'CK89?//U=Q=XSN8JN.O9*E JD;$F_
MZ2^]+G6\/UY$Q!'K13%BG@^8^1.8!_3!V=@$^L667#[T7X#?1#+?D3S/GP7\
MH'Q&!ZLYY<L\?P;O8$KZ(.$=/(%WY6ME];\I6[I QL[H<EB=(?5KSX%M'#:N
M*GJOK;*%5H9NL,DHR1CH[[--B!Y%]<\SA-83H74BM/Y?3^%YS%7VW04JPMR'
M2.?:A4*S+3C,Z=(660+72"/TFX  Z$=Z&1NF'[X_RO/EVPO7=LK>I]7J+3D_
MO1@AQS<_D@91VFC7-0I-4G ?=0&EB@$ U1P;XCMD%75@TI8Z[R*CCXAM#<KL
MM:T3G<!;Y&Z^&J@0&!1CHR)*_IY46>)D O6VQ;1JN4R1 %$& 2YU<+YD'T1'
MR:5PJN[-<(P20#B9='P4D *W(:,_8#<F*ZE4#CW')<%#$%IG.>X*!:BBV,@J
M"1@D->-2"COZ4A61:UV0,I&]53)VOHG4J!*J 9N,"XGOB]4Z>X4&-T9"8=BF
M^+'QG%A(-[%T$Z$7BF9JAD1#R7 K^E9RA05FDBYT3*CKU6&63[ JA7J(D-'9
M([OS%'Z?[HN#=78T(<&A4*$99)4'1IUNE9'6R.@2^G1>RY0GR!F^FJ/(HZ.J
MAYL;*GT\_$T?4 S0HH2,QG7IE*1NK/B+1<TVZ9LR+C$*=5(:X@YVZ!+TT#="
M;]AH (Y%),?'=_"3J$_R?U0F%+(Q@$/#5"*OT-ME(K )Q N*'P>$G"%B&I1R
M3&I:OHNTRG?'67G7IGU,'MZ5;*6-<$LK5)?GSOGX,*56[AGR2MI)PDMNWO5U
MLU=YN!6,VKAQDLRIZS<&VV"$8]E*O&J8:;8.LNL0&VR]5[8>Z&=TTR-]"0"C
M.>DJ-1J7\]2*UD410VV51B##TC"5VB*B+%#V+:(. BAC'B:0E"P@@K9]*@>&
M\+V0$@4TC(JXT\,Z5 .,O;-JJWT?I,O3<'BY&TA7GR[?_;1Z/0TDQ"BYE6QM
M.IE=9<UW%9<4F0Y^_\RRQT;Y8N]R;=G7Z1,"!^YZ&X=[=MJ=OE+.ALOYJ_GP
MB8.2PL@+J(D*KLOL\-6,_/#9,"RBZ])5O7$1%W]Z;/"EQ5X,\+YR&(WC0@),
MWVZG_P%02P,$%     @ &6BI5(!=3J]X!0  X0P  !@   !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6RU5UMOVS84?M^O(#Q@2 ''%]EI@MP VTW6=$MK1,V*
M8=@#+=$66XE42:J.__V^0\JRG"59^["7F")YON_<>7*^UN:+S81P[*'(E;WH
M9,Z5I_V^33)1<-O3I5 X66I3<(=/L^K;T@B>>J$B[T>#P>M^P:7J7)[[O;FY
M/->5RZ42<\-L513<;*8BU^N+SK"SW;B3J\S11O_RO.0K$0MW7\X-OOH-2BH+
MH:S4BAFQO.A,AJ?3,=WW%_Z08FU;:T:6++3^0A\WZ45G0 J)7"2.$#A^OHF9
MR',"@AI?:\Q.0TF"[?46_=K;#EL6W(J9SC_)U&47G9,.2\625[F[T^NWHK;G
MB/ 2G5O_EZW#W?&HPY+*.EW4PM"@D"K\\H?:#RV!D\$S E$M$'F] Y'7\@UW
M_/+<Z#4S=!MHM/"F>FDH)Q4%)78&IQ)R[C(.P6!ZR6*Y4G(I$ZX<FR2)KI23
M:L7F.I>)%/:\[\!'4OVDQIX&[.@9[!&[U<IEEEVI5*3[\GWHV2@;;96=1B\"
MWG+38Z-AET6#*'H!;]08/_)XHV?PGK"2_3596&>0+'^_0#!N",:>8/R_>/=E
M[*CWTY1;:0E\;H05RG&?Z!\SP6:Z*+G:_/+S230\/K,LT0B!LB*EE05GRAT^
MEE)QE4B>,PMA@6)SEF7\FV +(11#F9?<X)ZD\DFT27%;($-=QNY[<8^MA!*&
MY_F&CD5)D'QG6VDDP,L<7CT@3:+!V:^3R=POAV>O&%?00.?H"W3;06TCOE;2
MU'K +MJ+15(9Z2@V)'#UD&1<K;R)A;2^.1S0O9HAOIHU!.A94-T)(PM E]J0
M6CTVL:P4II".]*W@& ,B;4%?0=<N2X1Q:&<0UTYI!V+@:'"8EL.D"AV1^%W&
M'8.CF*(M<D=M2,H6&T8V,\0=/FW%@2"#"CV*&-B_-QB>4##+"T$-"1G K=]Y
M''2N5 6T)W'ARBZ%E>1T*169 8<77*$5TY4NM5SJG0P&,9Y^1B_RHEV?0M+Z
M$&N5^^P.AD,$L3)TL">PSF22!0>)1%A+)4&QX6S)I2'+=ME;1_VQ+4\Z?NNY
M78PMFG'(DX3;C"V16S90J4US#<&7.JT#YAJ=9$Y74I0H/11;1;:83E/\Q$,)
MEU#E:../-X(;)B %F]\ J%@@2[8MJDM1WK+7"52Y"KQU:%KY&93R%OD:\N83
MZH^4+AEN1/[H0CM5;::K/"53Z FG# #JYTJ%-])7-IGUWU1+F>.H$7@<KTDP
M\,Y7':4LO:%L.#C\[5^N \QCSPV;AK&'LRWLWEX'-5IAG=1ZW0%*.81RDFK?
MD&X4N^4;C]KUO->-.2V4V,%WW*26335^&O[K23QM^@G:307$)\7N2W+63N_X
MOA$CZL/!N,NNN%&0LFP.4^.,$O#@(ZHO8='KP:LNW+#P-@ZCLUN=^M>"PK)M
M?,1829L%0P_B:N&\\/AX<'A$\A0$I(H7JG%BIY,O>P=;RN/A"40(^0U2[YM/
M^L#T5J0K4-4(,[SA]!Y:2I8KF.UV4?ZPQA8ZG=NTU#D9'AV.!Z].V0VYR^Q2
M8N<V2H%9W67W+<7!ML/[%^#:"&')R206J YG.4??7TJ$XI.A%JK8C)K4AS)@
MO,<L^!T)<A.B.:T<>X\V\"<FX%;.O*N40.2&K^ND01XT\8_O_<GA<-1EMX+;
M*CQ9I.\,'5HZ]KNVE@Q0K6R[41@LJKI0B:@-M%>ZE<\EW]<!^8ZC!- Q0VF,
M>NT''@5(W9G(PAL@L9UX33Q%TU'Q2M@Z5TDKZ7YL)N@]-0SU6V-G(<S*#]>$
M"\>'";39;>;W21A;=]?#\(_)#BEG62Z6$!WTCH\ZS(2!.GP@M?P0N] .([%?
M9FA@PM %G--;O?T@@N:_FLM_ %!+ P04    "  9:*E4W1^L_/@#  !C"0
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MN&^K/6MO=@3(6_[C^R[^&#P4E-'^Z7'/!T%#)$1UUSOKS?'I9K?]KBN*!.S
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MO!V$>:HOG"[]%_6E=DX7_N<:. XG'<#GN<:ICA=DH/D3R_7_ %!+ P04
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M++T8?EC0$XW:;:#U7"F[F3B"]M$?_P!02P,$%     @ &6BI5%A-/M>B P
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MX&5J1S19'K=U%!EGG.T2;6/.JIAA/V8[= A3YZ2X.B]P+(0X>OM=HJHC OF
M"@A?\Y!AYU5R"4B-LY[,!94IR>S\5B8:SJ T>N@=\CBA:K5GTR6'Z-K9V9PR
MD$N['RI4+'-=+5'-VV8%G5:;UZ=XM;]B^$N&K<)A@:J>&^.<DM5.6#UH4=@]
M;"XT;G7V=H5K-$@C@-\70NCM@S'0+.:3_P!02P,$%     @ &6BI5&&M$W4A
M P  MP8  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL?551;]HP$'[G
M5YSRM$F,A "#58 $M-,FK1LJW?8P[<$D!['JV)GM+.7?[^R$-)U:)!3L^.Z[
M[[X[7^:5T@\F0[3PF MI%D%F;7$5AB;),&=FH J4=')0.F>6MOH8FD(C2[U3
M+L(XBMZ'.>,R6,[]NZU>SE5I!9>XU6#*/&?ZM$:AJD4P#,XO[O@QL^Y%N)P7
M[(@[M-^+K:9=V**D/$=IN)*@\; (5L.K]=C9>X,?'"O368/+9*_4@]M\3A=!
MY BAP,0Z!$9_?W&#0C@@HO&GP0S:D,ZQNSZC?_2Y4RY[9G"CQ$^>VFP1S )(
M\<!*8>]4]0F;?"8.+U'"^"=4M>TT"B IC55YXTP,<B[K?_;8Z-!QF+WF$#<.
ML>==!_(LKYEER[E6%6AG36ANX5/UWD2.2U>4G=5TRLG/+K]2W;\H8Z! #;N,
M:825M9KO2\OV L$JV*@\)_UV5B4/F1(I:@-O[MVI>3L/+9%P4&'2!%S7 >-7
M H[@5DF;&;B1*:;/_4,BWV80GS-8QQ<!;YD>P&C8ASB*XPMXHU:1D<<;O8)W
MP[3D\FA@VRKR:[4W5E,#_;Z /V[QQQY__ K^2EK^+N6B=.T(.TQ*S>T)I++P
M62:B)%5H =?.@I9/==DPD92"N68V+^E^.>R.RX3*F:&K9\'D"2IF@-.] .'K
MKPSW]X0N.C A7&"N4CK0:% 2E3ZD#2=)32/.36,\.6X\MF$Y N'21>')2W;_
MH[/:C[O,_457A_I<60K*F8"D;C_O;H#FBK%,IE0ANN^E2"%C).,>D3+I*CN
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MDA%68(C#EE&"1\QB9\X$DR&0M"C(3D,HF#%\P=V#'D<V^(9G<P'G6#>>&R8
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MAJ(P3*CC9T,:.)\&N/^^8_]D@\=@YE3!6!3?6*Y7_> R(#DLZ+K0]V+[&9J
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M;0-H?ZT4OD]LM^A[??8&4$L#!!0    ( !EHJ519K8EU< (  &D%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(U4VT[;0!#]E9'% TAM[-B!(I18
M(DE1D4"-2&D?JCYL[$F\8B_N[IK WW=V[9B4$M07>R]SSIR9V9GQ5IL'6R$Z
M>))"V4E4.5=?Q+$M*I3,#G2-BF[6VDCF:&LVL:T-LC* I(C3)#F+)>,JRL?A
M;&'RL6Z<X H7!FPC)3//4Q1Z.XF&T>[@CF\JYP_B?%RS#2[1W=<+0[NX9RFY
M1&6Y5F!P/8DNAQ>SD;</!M\Y;NW>&GPD*ZT?_.:ZG$2)%X0""^<9&/T><89"
M>"*2\;OCC'J7'KB_WK%?A=@IEA6S.-/B!R]=-8G.(RAQS1KA[O3V"W;QG'J^
M0@L;OK#M;),(BL8Z+3LP*9!<M7_VU.5A#T \;P/2#I"^!HP. +(.D(5 6V4A
MK#ES+!\;O07CK8G-+T)N IJBX<I7<>D,W7+"N7Q)SZ)L!()>P[*I:X%4(L<$
MS)BMX(J*#->J?2P^Z\=S=(P+>P(?X7XYA^.C$S@"KN!;I1O+5&G'L2-9GCPN
M.@G35D)Z0$(&MUJYRL)G56+Y-SZF</J8TEU,T_1=PEMF!I -/T":I.D;>F;_
M#Q^^(R?K4YP%ONP W]<:#65/;> &Z<'!#6<K+KCC:&'!GGV^+<P;A)^7*^L,
M/>Q?[W@=]5Y'P>OH@-=0OYKQ$JAZP*1NO!NN"M%0EGW)7(4@25%C0LW]"Q!!
MH'@1^%8U6[]GP:\?$H_Y:4)I?MS/\+\VP_,7FS:@>._52C2;T,P6"J^T+79_
MVL^+R] FK\ZG-$?:MG^A:8<0E7+#E:6XUD29##Y1%YJVL=N-TW7HC95VU&EA
M6=$L1.,-Z'ZMM=MMO(-^NN9_ %!+ P04    "  9:*E4UN2UW:H"  #M!@
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M@NVF#G8."X_Y.I-ZP9U--F0-3R"_;AZXFKF-EC0O@8J<4<1A-77N\(<%CK6
MV?%7#CMQ-$;Z*$O&ONO)IW3J>)H("DBD5D'4SS,LH"BT)L7QHU;J-#:UX/'X
MH/TW<WAUF"41L&#%MSR5V=2)'93"BFP+^<AVOT-]H%#K2U@AS#?:U7L]!R5;
M(5E9"RN",J?5+WFI'7$DH/1T"_BU@/]*P.\3"&J!P!RT(C/'NB>2S":<[1#7
MNY4V/3"^,=+J-#G5U_@DN7J:*SDY>ZJN#[$5^K(QCKW3CLWE'GVE*7"T8.6&
MT/VO GW\L=7+GV@"5/L>/12$"O3N'B3)B_?H%OV"7"0RPD%,7*G@M DWJ4'F
M%8C? Q*@SXS*3)E19M,.^85='OL6!:[R2N,:_^":N6_5^)GP 0KP#?(]W^\"
MLHO?0]*(8PM.T-Q48/0%/?K^V)9+=1_JHIZ,BZO[*?8Y7:,O6RDDH:D9FVL4
M%HO#QN+06!Q>Q^(-FL,ZIU0OS8F*C02ZPJ"R&1J;.LD\S_R1%XP";^(^=\"&
M#6QX7=AZ@-:<4-D9<?/P##6.QBI!=I..&M+1SR%527L%>0_KZ(SU=A3&XV'4
M#1LUL-'/@8673<Z[4:-SU.$(1T$W:=R0QM<E_5C-+:$:GX=JI#ZX#8 J$73L
MLX7TN#G1^,HG>@&>Y((L"U#96.6O)+,EL/GXC!L'7NCY/=S8:XN*9\U5WTSU
MA/06W3T#5Z\#!S15-'C^VMFG1HXJ%[:ZYRTC%^:CVDI\Y(5HT/.OP7X+Y_]/
MN OR3VU#.[MA\P:AWP/75A(<7 G.FG)J*R=XX:"/KJTZV%YV+J>SY)C:Q@G;
M>!#C'KBVRF![F7D;[NVT4IMXY;>Q_RJKU-LN"\RV^&![];G@ /\RB]0&XQ-/
M#_O"H"T\.+HLAQPX'T&W)=JW"_6BQU4#L"4%^A-XB=[]#82+][:TTI81;*\C
M_\'NS4DZMMV\W72,]EI?Y\NO73*J)%&(RNHE&(<H)?O.MT#WJ%LH@:]-$R50
MPK945HU#L]HT:G>F/7';[567IX)#95B!"E@I46\0J9#E5>-4323;F-YCR:3J
M9,PP4\TF<+U!/5\Q)@\3;:!I7V?_ %!+ P04    "  9:*E4-T".N#8#  #Z
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RE5F%OVC 0_2NG:),V
M:4U"0H%.@ 2TTR:M6E74]L.T#VYR$ LGSFP#Y=_O[(2,;FFV:5\@=NX]OW=G
M^S+>2[71&:*!IUP4>N)EQI3O@T G&>9,^[+$@MZLI,J9H:%:![I4R%('RD40
MA>$@R!DOO.G8S=VHZ5ANC> %WBC0VSQGZC!'(?<3K^<=)V[Y.C-V(IB.2[;&
M)9J[\D;1*&A84IYCH;DL0.%JXLUZ[Q<C&^\"[CGN]<DS6">/4F[LX%,Z\4(K
M" 4FQC(P^MOA H6P1"3C>\WI-4M:X.GSD?V#\TY>'IG&A10//#79Q!MYD.**
M;86YE?N/6/LYMWR)%-K]PKZ.#3U(MMK(O :3@IP7U3][JO-P HCB%P!1#8C^
M%A#7@-@9K90Y6Y?,L.E8R3TH&TUL]L'EQJ')#2]L%9=&T5M..#/]P+B">R:V
MJ$&N8&EDLH$OI4VQABMM.&4*4[C3O%C#7+!D<[9,,BDHW**8J\6U3%' FTLT
MC(NW< 97>2GD ?$9'\V_@@!TQA3J<6!(O=40)+72>:4T>D%I3,L4)B-518KI
M<WQ KAOKT='Z/.HDO&;*A[CW#J(PBEKT+/X>WNN0$S>5B!U?_ +?TN8%YK0E
M4UC(G(ZIKK([4XH5:Z2C8V!^@-.X&W9PT[,]4RG\K"7,-!W+NHJN:G"LVC6:
M3-J"$OSK9]( GPSF^EN'@W[CH.\<]%]P<,OUYFREJ.R\,$A%-J!H][25NINH
MYX^&K]LJT@T+_<'%ZPX?YXV/\TZ>JZ>2+AG*#YG(X0TOX(!,Z;=M1KJ9!A42
M>I#;O0L#2-FA;>\O_I_GF=5!8W7027S)=SS%(H4#1Y&V&>S&AWX8ME;JGV'/
MY \;^<-.GGLIZ(P(;@YMTKNQ%SW_O-^J_0^XV!_%7>)'C?A1)]&#:S&8GK$=
M*NJ8L++G=^?.+UW%VEV=LC[$:[H#S*_77F6S6F7D5K%->T?IC2_&P>[4T^]!
M?7_8Q%3Z@Y,VDJ-:N^ZJ(9';PE37:C/;-/"9ZUN_S,^IL5=]^"=-]55 E^::
MDQV!*Z(,_2'M>U5UVFI@9.F:U:,TU/K<8T8?)ZAL +U?26F. [M \[DS_0%0
M2P,$%     @ &6BI5&]<FW5P P  Z H  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&ULS5;9;MLZ$/V5@="'%DBBS5L"VX"7NP1H@"#N\E#T@9;&%A&)
M]"6I.+E??X>4K-B.[!87?>A#8BYS#L_,4,,9;J5ZU!FB@><B%WKD9<9L;GQ?
M)QD63%_)#0K:64E5,$-3M?;U1B%+':C(_2@(>G[!N/#&0[=VK\9#69J<"[Q7
MH,NB8.IEBKG<CKS0VRT\\'5F[((_'F[8&A=H/F_N%<W\AB7E!0K-I0"%JY$W
M"6_F860!SN(+QZW>&X-U92GEHYW<IB,OL(HPQ\18"D8_3SC#/+=,I..?FM1K
MSK3 _?&._4_G/#FS9!IG,O_*4Y.-O($'*:Y8F9L'N?T;:X>ZEB^1N7;_85O;
M!AXDI3:RJ,&DH."B^F7/=2!^!A#5@.@(0 >W ^(:$!\#.B< G1K0<9&I7'%Q
MF#/#QD,EMZ"L-;'9@0NF0Y/[7-B\+XRB74XX,UY4^0:Y@H61R>/EE(*8PDP6
M=+,T<[EYP$2N!?^7UM_/T3">?X!+^+R8P_MW'^ =< &?,EEJ)E(]] VILMQ^
M4BN850JB$PIBN)/"9!K^$"FFAWB?O&E<BG8NS:*SA'=,74$<7D 41%&+GOG/
MP\,S<N(FPK'CBT]%.&,*+Y=OPSI1BHDUTD=D8/D"^W;W[,4M3[9,I1>'L)G4
M!KY]I%/@UF"AOY_1V&DT=IS&S@F-GZ1A.6AW 2H%R=Z1;3FM^'J.S]:6IW$W
M[ []I_TXO[4)@ZC7&!TH[39*NV>5/J!&II(,Z++1]_U$A6MC0W4F"+V&NO?;
M)JK?:.S_XD15?-W])$2#HT2]M8E[U^UY&C1"!V>%_H4"%4FU:9JD5+BX-HK9
M&G\F"M<-^?5OFZDP>*VLP:_-U?0'A-_"[ZWE-7CSG<6#_E&*6XQZW7Y[CD/[
M>!RN1*].1_]#X_0'J%N1Y"55?_N4K/=N#CNX.2=C"=3_@,F0_A0B%-5[@O8]
M@3M7+7;/ 7!]F@6?[1BIG<F9H4TC(8XN>H,.:'N1M'TD"4#T%0>1Z;*R2U#1
MNRA@*>EV08'%$I6VWN0<2XLC=5Q!PG1V<.95VTWS]Y[S M7:M46:<*4P54UO
M5IO6:^H:CJ/UF6W)6M8G87@S"]MV*%&TX[C\UZ.K'I BN>9"0XXKDA%<]:E@
MJ*JMJB9&;ERCL92&VA8WS*@5164-:'\EI=E-[ %-<SO^#U!+ P04    "  9
M:*E42S%DZ5@"  #F!   &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q]
M5$UOVS ,_2N"3RVPU:F3=D7A&&C:#=NA6Y!@VV'80;;I6*@^,I%NVO[Z4;+C
M9</2BRU1?(^/'U*^<_X!6P 23T9;G"<MT?8Z3;%JP4@\<UNP?-(X;R3QUF]2
MW'J0=009G6:3R65JI+))D4?;TA>YZT@K"TLOL#-&^N<%:+>;)^?)WK!2FY:"
M(2WRK=S &NCK=NEYEXXLM3)@43DK/#3SY.;\>C$+_M'AFX(='JQ%R*1T[B%L
M/M7S9!($@8:* H/DWR/<@M:!B&7\&CB3,60 'J[W[!]B[IQ+*1%NG?ZN:FKG
MR54B:FADIVGE=A]AR.<B\%5.8_R*W> [2435(3DS@%F!4;;_RZ>A#@> [!@@
M&P!9U-T'BBKO),DB]VXG?/!FMK"(J48TBU,V-&5-GD\5XZA8]\T0KA%K<M7#
MVP6G6(M;9[CM*&/E5E"YC54O;#]92@^66B!527TJ3NZ I-*G>4HL)E"FU1!X
MT0?.C@2>BGO'1"C>VQKJO_$I)S%FDNTS662O$MY+?R:FYV]$-LDR;%DGOL(Z
M'>LSC:S3(ZQW"BOML/,@OC3_ED5+BK5"0K$.$<M8O*5\YK%EVX^;$LGSX/U\
M1<EL5#*+2F9'E'SN3 D^-*I/+JPJ9PPKP= YH1 [CDY.5."Y*U:43OI:& A
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M0N&M ;O)<VZ^7:'4NVG @OV+CR);._\BG$T*GN$=ND_%K:%1V%A)1([*"JW
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M&?]BT'H'_CXWAK8;'Z#Z:0W_ E!+ P04    "  9:*E4?6PU"V4#  #+"@
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MCJ-ZXAN48(G\I DW=^&B(^%"<B6%R359B132#ORR'Q\_AU\]$S_J(?#1N];
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MSV4P=]2C SW1$3EGK9RS9\RP98$U0K3"LHIS8O!=/Y#8K^OL#UVC;EEA\/#
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M8&])%"6)'P',KR"*, 3>1AS!%( &#(FB:A_<VX_"S3X5MO]_C7\#4$L#!!0
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M2P$"% ,4    "  9:*E43,O4IN\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  9:*E4F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( !EHJ50EN;LZ3 4   H6   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  9:*E4*ZI/-7X%  !.%0
M&               @(&0#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ &6BI5*6NLM7' @  3PD  !@              ("!1!,  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !EHJ50Z6K0C$ 0
M .<-   8              " @4$6  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  9:*E4[*RJ,*X$  !M$P  &               @(&'
M&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ &6BI5 %,
M-:]- @  R 0  !@              ("!:Q\  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( !EHJ51L8Z?]1 4  &(3   8
M  " @>XA  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  9
M:*E4<R!C6X8$  #'"0  &               @(%H)P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ &6BI5(!=3J]X!0  X0P  !@
M         ("!)"P  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( !EHJ53='ZS\^ ,  &,)   9              " @=(Q  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ &6BI5*5_>KU@ P  =@@
M !D              ("! 38  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  9:*E4KLO+^:X$  #D"@  &0              @(&8.0
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !EHJ532K1?X
M$P<  (X0   9              " @7T^  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ &6BI5,6KO3;G"   ;AD  !D
M ("!QT4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  9
M:*E4,X)^4P$#  "B!@  &0              @('E3@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !EHJ53(M3",7@8  -H.   9
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M970R,"YX;6Q02P$"% ,4    "  9:*E49B%8,2\#    "   &0
M    @(%3:0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M !EHJ51833[7H@,  ,P(   9              " @;EL  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ &6BI5*H2?<OJ!   I L  !D
M             ("!DG   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  9:*E48:T3=2$#  "W!@  &0              @(&S=0  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !EHJ52\X_V@A@(
M (T%   9              " @0MY  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ &6BI5 S%]CG8 @  ?@<  !D              ("!
MR'L  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  9:*E4
M@J""2>H#  !<$   &0              @('7?@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( !EHJ52!^_ \.P,  #L,   9
M      " @?B"  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ &6BI5&"1S2=8 @  , 4  !D              ("!:H8  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  9:*E4]&Y4>.D"   A"0
M&0              @('YB   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( !EHJ53M9F3G2P(  +0%   9              " @1F,  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ &6BI5)T.B-QO
M @  ]P4  !D              ("!FXX  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  9:*E46:V)=7 "  !I!0  &0
M@(%!D0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !EH
MJ536Y+7=J@(  .T&   9              " @>B3  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ &6BI5%-?QAW& P  R@X  !D
M         ("!R98  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  9:*E4-T".N#8#  #Z"   &0              @('&F@  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !EHJ51O7)MU< ,  .@*
M   9              " @3.>  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ &6BI5$LQ9.E8 @  Y@0  !D              ("!VJ$
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  9:*E4(8O(
MV-($   Y%@  &0              @(%II   >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( !EHJ51*>Q\FR (  *0(   9
M  " @7*I  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M&6BI5'5N@YRT P  [ P  !D              ("!<:P  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  9:*E4,]/^GI\"  # !@  &0
M            @(%<L   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( !EHJ51];#4+90,  ,L*   9              " @3*S  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ &6BI5*%I4ITH P
M#!,   T              ( !SK8  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  9:*E4EXJ[',     3 @  "P              @ $AN@  7W)E;',O+G)E
M;'-02P$"% ,4    "  9:*E4+6CRL2,$   H'0  #P              @ $*
MNP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &6BI5.Y)W?^> 0  "!H
M !H              ( !6K\  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ &6BI5*C*A]FK 0  01H  !,              ( !,,$
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #, ,P#<#0  #,,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>79</ContextCount>
  <ElementCount>182</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Los (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Los (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Operations and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidity</Role>
      <ShortName>Nature of Operations and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Interest and Other Income, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet</Role>
      <ShortName>Interest and Other Income, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables</Role>
      <ShortName>Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Interest and Other Income, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables</Role>
      <ShortName>Interest and Other Income, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Nature of Operations and Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations and Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail</Role>
      <ShortName>Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Lease - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail</Role>
      <ShortName>Lease - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail</Role>
      <ShortName>Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Schedule of Maturity of Operating Lease Liabilities - (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Option Activity Under Company's Equity Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail</Role>
      <ShortName>Summary of Option Activity Under Company's Equity Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail</Role>
      <ShortName>Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail</Role>
      <ShortName>Summary of Stock-Based Compensation Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail</Role>
      <ShortName>Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail</Role>
      <ShortName>Collaborations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail</Role>
      <ShortName>Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Detail of Interest and Other Income, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail</Role>
      <ShortName>Detail of Interest and Other Income, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cbio-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Restructuring - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail</Role>
      <ShortName>Restructuring - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cbio-10q_20220331.htm">cbio-10q_20220331.htm</File>
    <File>cbio-20220331.xsd</File>
    <File>cbio-20220331_cal.xml</File>
    <File>cbio-20220331_def.xml</File>
    <File>cbio-20220331_lab.xml</File>
    <File>cbio-20220331_pre.xml</File>
    <File>cbio-ex311_6.htm</File>
    <File>cbio-ex312_9.htm</File>
    <File>cbio-ex321_7.htm</File>
    <File>cbio-ex322_8.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gzuqpypd2gjn000001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="275">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cbio-10q_20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 79,
   "dts": {
    "calculationLink": {
     "local": [
      "cbio-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cbio-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cbio-10q_20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbio-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 313,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 9,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 13
   },
   "keyCustom": 21,
   "keyStandard": 161,
   "memberCustom": 18,
   "memberStandard": 16,
   "nsprefix": "cbio",
   "nsuri": "http://www.catalystbiosciences.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Financial Instruments",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Leases",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Stock Based Compensation",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Collaborations",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Interest and Other Income, Net",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet",
     "shortName": "Interest and Other Income, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Restructuring",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Lease (Tables)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables",
     "shortName": "Lease (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Interest and Other Income, Net (Tables)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables",
     "shortName": "Interest and Other Income, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cbio:NatureOfOperationsAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cbioSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Nature of Operations and Liquidity - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail",
     "shortName": "Nature of Operations and Liquidity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cbio:NatureOfOperationsAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cbioSegment",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "shortName": "Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail",
     "shortName": "Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Lease - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail",
     "shortName": "Lease - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail",
     "shortName": "Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails",
     "shortName": "Schedule of Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Option Activity Under Company's Equity Incentive Plans (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail",
     "shortName": "Summary of Option Activity Under Company's Equity Incentive Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
     "shortName": "Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
     "shortName": "Summary of Stock-Based Compensation Recognized (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
     "shortName": "Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Collaborations - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
     "shortName": "Collaborations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Los (Unaudited)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Los (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
     "shortName": "Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20211101_20211130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20220331",
      "decimals": "-5",
      "lang": null,
      "name": "cbio:CostOfManufacturingServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Detail of Interest and Other Income, Net (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail",
     "shortName": "Detail of Interest and Other Income, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20211101_20211130",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Restructuring - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
     "shortName": "Restructuring - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20211101_20211130",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:NatureOfOperationsAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of Operations and Liquidity",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidity",
     "shortName": "Nature of Operations and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:NatureOfOperationsAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10q_20220331.htm",
      "contextRef": "C_0001124105_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "cbio_AGCBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGC Biologics Inc.",
        "label": "A G C Biologics Inc [Member]",
        "terseLabel": "AGC Biologics, Inc"
       }
      }
     },
     "localname": "AGCBiologicsIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated gross unrealized gain before tax available for sale securities.",
        "label": "Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AmendedAndRestatedLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated license agreement.",
        "label": "Amended And Restated License Agreement [Member]",
        "terseLabel": "Amended and Restated License Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedLicenseAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_BiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen.",
        "label": "Biogen [Member]",
        "terseLabel": "Biogen"
       }
      }
     },
     "localname": "BiogenMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to write off of prepaid manufacturing costs.",
        "label": "Charges Related To Write Off Of Prepaid Manufacturing Cost",
        "terseLabel": "Charges related to write off of prepaid manufacturing cost"
       }
      }
     },
     "localname": "ChargesRelatedToWriteOffOfPrepaidManufacturingCost",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements.",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "xbrltype": "stringItemType"
    },
    "cbio_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration",
        "verboseLabel": "Collaboration"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments.",
        "label": "Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "CommercialMilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CostOfCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration.",
        "label": "Cost Of Collaboration [Member]",
        "terseLabel": "Cost of collaboration"
       }
      }
     },
     "localname": "CostOfCollaborationMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CostOfLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of license member.",
        "label": "Cost Of License [Member]",
        "terseLabel": "Cost of license"
       }
      }
     },
     "localname": "CostOfLicenseMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CostOfManufacturingServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of manufacturing services related company.",
        "label": "Cost Of Manufacturing Services",
        "terseLabel": "Cost of Manufacturing Services"
       }
      }
     },
     "localname": "CostOfManufacturingServices",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CostOfServicesAsPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of services as per agreement.",
        "label": "Cost Of Services As Per Agreement",
        "terseLabel": "Cost of services as per agreement"
       }
      }
     },
     "localname": "CostOfServicesAsPerAgreement",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_DalcinonacogAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dalcinonacog alfa.",
        "label": "Dalcinonacog Alfa [Member]",
        "terseLabel": "Dalcinonacog Alfa"
       }
      }
     },
     "localname": "DalcinonacogAlfaMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_DevelopmentAndSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and sales milestone payments.",
        "label": "Development And Sales Milestone Payments",
        "terseLabel": "Development and sales milestone payments"
       }
      }
     },
     "localname": "DevelopmentAndSalesMilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ExclusiveLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license.",
        "label": "Exclusive License [Member]",
        "terseLabel": "Exclusive License",
        "verboseLabel": "Exclusive License"
       }
      }
     },
     "localname": "ExclusiveLicenseMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_FirmWorkOrderSupportingClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firm work order supporting clinical trials.",
        "label": "Firm Work Order Supporting Clinical Trials",
        "terseLabel": "Firm work order supporting clinical trials"
       }
      }
     },
     "localname": "FirmWorkOrderSupportingClinicalTrials",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_GMPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GMP manufacturing.",
        "label": "G M P [Member]",
        "terseLabel": "Dalcinonacog alfa."
       }
      }
     },
     "localname": "GMPMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_GainLossFromExtinguishmentOfLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InterestAndOtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from extinguishment of liability.",
        "label": "Gain Loss From Extinguishment Of Liability",
        "terseLabel": "Gain from extinguishment of liability"
       }
      }
     },
     "localname": "GainLossFromExtinguishmentOfLiability",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in operating lease liability and right-of-use asset.",
        "label": "Increase Decrease In Operating Lease Liability And Right Of Use Asset",
        "terseLabel": "Operating lease liability and right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_IntegrityBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrity bio .",
        "label": "Integrity Bio [Member]",
        "terseLabel": "Catalent Indiana, LLC."
       }
      }
     },
     "localname": "IntegrityBioMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_IsuAbxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISU Abxis.",
        "label": "Isu Abxis [Member]",
        "terseLabel": "ISU Abxis"
       }
      }
     },
     "localname": "IsuAbxisMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LesseeOperatingLeaseRenewalTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal term description.",
        "label": "Lessee Operating Lease Renewal Term Description",
        "terseLabel": "Lessee operating lease renewal term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTermDescription",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License revenue member.",
        "label": "License Revenue [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marzeptacog alfa activated and dalcinonacog alfa.",
        "label": "Marzeptacog Alfa Activated And Dalcinonacog Alfa [Member]",
        "terseLabel": "Marzeptacog Alfa Activated and Dalcinonacog Alfa"
       }
      }
     },
     "localname": "MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MarzeptacogAlfaActivatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marzeptacog alfa (activated).",
        "label": "Marzeptacog Alfa Activated [Member]",
        "terseLabel": "Marzeptacog Alfa Activated"
       }
      }
     },
     "localname": "MarzeptacogAlfaActivatedMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment .",
        "label": "Milestone Payment Related To Regulatory And Clinical Development Events",
        "verboseLabel": "Milestone payment related to regulatory and clinical development events"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MosaicBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mosaic Biosciences, Inc.",
        "label": "Mosaic Biosciences Inc [Member]",
        "terseLabel": "Mosaic"
       }
      }
     },
     "localname": "MosaicBiosciencesIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_NatureOfOperationsAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of operations and liquidity.",
        "label": "Nature Of Operations And Liquidity [Text Block]",
        "terseLabel": "Nature of Operations and Liquidity"
       }
      }
     },
     "localname": "NatureOfOperationsAndLiquidityTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock for secondary public offering, net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ProceedsFromIssuanceOfCommonStockFromStockGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock from stock grant.",
        "label": "Proceeds From Issuance Of Common Stock From Stock Grants",
        "terseLabel": "Issuance of common stock from stock grants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockFromStockGrants",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_RegulatoryAndDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and development milestone payment.",
        "label": "Regulatory And Development Milestone Payment",
        "terseLabel": "Regulatory and development milestone payment"
       }
      }
     },
     "localname": "RegulatoryAndDevelopmentMilestonePayment",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services.",
        "label": "Reimbursable Out Of Pocket And Personnel Costs Incurred Related To Research Services [Member]",
        "terseLabel": "Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services"
       }
      }
     },
     "localname": "ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_RemainingNumberOfFullTimeEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining number of full time employees.",
        "label": "Remaining Number Of Full Time Employees",
        "terseLabel": "Remaining number of full time employees"
       }
      }
     },
     "localname": "RemainingNumberOfFullTimeEmployees",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "cbio_RestructuringLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring liability.",
        "label": "Restructuring Liability",
        "terseLabel": "Restructuring liability"
       }
      }
     },
     "localname": "RestructuringLiability",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_SeveranceAndOtherCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance and other costs.",
        "label": "Severance And Other Costs",
        "terseLabel": "Severance and other charges"
       }
      }
     },
     "localname": "SeveranceAndOtherCosts",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black-Scholes Method Used [Table]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_StockIssuedDuringPeriodFromStockGrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period from stock grants, shares",
        "label": "Stock Issued During Period From Stock Grants Shares",
        "terseLabel": "Issuance of common stock from stock grants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodFromStockGrantsShares",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_StockIssuedDuringPeriodFromStockGrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period from stock grants, value.",
        "label": "Stock Issued During Period From Stock Grants Value",
        "terseLabel": "Issuance of common stock from stock grants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodFromStockGrantsValue",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_SubleaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease arrangement.",
        "label": "Sublease Arrangement [Member]",
        "terseLabel": "Sublease Arrangement"
       }
      }
     },
     "localname": "SubleaseArrangementMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of present value assumptions of lease payments.",
        "label": "Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]",
        "terseLabel": "Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments"
       }
      }
     },
     "localname": "SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_TwoThousandEighteenOmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen omnibus incentive plan.",
        "label": "Two Thousand Eighteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2018 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenOmnibusIncentivePlanMember",
     "nsuri": "http://www.catalystbiosciences.com/20220331",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r67",
      "r68",
      "r165",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r164",
      "r171",
      "r189",
      "r190",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r310",
      "r312",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r164",
      "r171",
      "r189",
      "r190",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r310",
      "r312",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r112",
      "r178",
      "r179",
      "r287",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r112",
      "r178",
      "r179",
      "r287",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r164",
      "r171",
      "r180",
      "r189",
      "r190",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r310",
      "r312",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r164",
      "r171",
      "r180",
      "r189",
      "r190",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r310",
      "r312",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r67",
      "r68",
      "r165",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r115",
      "r116"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r29"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r38",
      "r39",
      "r42",
      "r43",
      "r44",
      "r70",
      "r71",
      "r72",
      "r239",
      "r313",
      "r314",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r218",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r215",
      "r216",
      "r217",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r191",
      "r193",
      "r221",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance costs of issuance of common stock for public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r193",
      "r213",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r65",
      "r101",
      "r104",
      "r110",
      "r129",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r235",
      "r240",
      "r252",
      "r272",
      "r274",
      "r290",
      "r303"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r34",
      "r65",
      "r129",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r235",
      "r240",
      "r252",
      "r272",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r120",
      "r132"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r118",
      "r121",
      "r132",
      "r294"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r119",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Available-for-sale debt securities current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r194",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r61"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r55",
      "r61",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r253"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r64",
      "r65",
      "r82",
      "r83",
      "r84",
      "r86",
      "r88",
      "r94",
      "r95",
      "r96",
      "r129",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r169",
      "r170",
      "r173",
      "r174",
      "r252",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r152",
      "r295",
      "r307"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "verboseLabel": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized; 31,477,053 and 31,409,707 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation payments"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r50",
      "r287"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of license and collaboration"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Realized Gain Loss",
        "terseLabel": "Material realized gains or losses on available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue Revenue Recognized1",
        "terseLabel": "Deferred revenue, recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r59",
      "r100"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r42",
      "r43",
      "r44",
      "r70",
      "r71",
      "r72",
      "r74",
      "r79",
      "r81",
      "r93",
      "r130",
      "r175",
      "r176",
      "r215",
      "r216",
      "r217",
      "r227",
      "r228",
      "r245",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r313",
      "r314",
      "r315",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r248",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r166",
      "r181",
      "r182",
      "r187",
      "r188",
      "r248",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r181",
      "r182",
      "r187",
      "r188",
      "r248",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r248",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r137",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r139",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued compensation and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r58",
      "r285"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest And Other Income",
        "terseLabel": "Interest and other income, net",
        "totalLabel": "Total interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InterestAndOtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "Remaining in 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor Operating Lease Payments To Be Received",
        "terseLabel": "Lease Payments Receivable"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r65",
      "r105",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r236",
      "r240",
      "r241",
      "r252",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r65",
      "r129",
      "r252",
      "r274",
      "r291",
      "r305"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r65",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r236",
      "r240",
      "r241",
      "r252",
      "r272",
      "r273",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r40",
      "r41",
      "r44",
      "r45",
      "r60",
      "r65",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r80",
      "r81",
      "r85",
      "r101",
      "r103",
      "r106",
      "r109",
      "r111",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r246",
      "r252",
      "r296",
      "r308"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r101",
      "r103",
      "r106",
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r263",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r267",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets, noncurrent"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Other Nonoperating Income And Expense [Text Block]",
        "terseLabel": "Interest and Other Income, Net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_InterestAndOtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r194",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds From License Fees Received",
        "terseLabel": "Up-front payments received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds From Sale Maturity And Collection Of Shortterm Investments",
        "terseLabel": "Proceeds from maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r40",
      "r41",
      "r44",
      "r54",
      "r65",
      "r73",
      "r80",
      "r81",
      "r101",
      "r103",
      "r106",
      "r109",
      "r111",
      "r129",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r234",
      "r237",
      "r238",
      "r242",
      "r243",
      "r246",
      "r252",
      "r297"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r138",
      "r274",
      "r301",
      "r306"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r47",
      "r131"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision For Doubtful Accounts",
        "terseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r224",
      "r286",
      "r335"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring And Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r142",
      "r145",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring And Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring And Related Cost Number Of Positions Eliminated",
        "terseLabel": "Number of employees terminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring And Related Cost Number Of Positions Eliminated Period Percent",
        "terseLabel": "Percent of employees terminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost And Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r176",
      "r218",
      "r274",
      "r304",
      "r316",
      "r317"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfOperationsAndLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r74",
      "r79",
      "r81",
      "r130",
      "r215",
      "r216",
      "r217",
      "r227",
      "r228",
      "r245",
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r98",
      "r99",
      "r102",
      "r107",
      "r108",
      "r112",
      "r113",
      "r114",
      "r177",
      "r178",
      "r287"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Anti-dilutive Security not Included In Diluted per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]",
        "terseLabel": "Cash Equivalents and Short-Term Investments Classified as Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r193",
      "r212",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r193",
      "r212",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule Of Other Nonoperating Income Expense Table [Text Block]",
        "terseLabel": "Detail of Interest and Other Income, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureInterestAndOtherIncomeNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule Of Restructuring And Related Costs [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r194",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r196",
      "r202",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activity Under Company's Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ServiceAgreementsMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.",
        "label": "Service Agreements [Member]",
        "terseLabel": "Service Agreements"
       }
      }
     },
     "localname": "ServiceAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs1",
        "terseLabel": "Severance costs and expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of common stock available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Exercisable - March 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable - March 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r198",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending Balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease",
        "verboseLabel": "Increase in number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Number of Shares Underlying Outstanding Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r192",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r207",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable - March 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Outstanding Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r12",
      "r292",
      "r293",
      "r302"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short Term Investments [Member]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r63",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r64",
      "r65",
      "r82",
      "r83",
      "r84",
      "r86",
      "r88",
      "r94",
      "r95",
      "r96",
      "r129",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r252",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r42",
      "r43",
      "r44",
      "r70",
      "r71",
      "r72",
      "r74",
      "r79",
      "r81",
      "r93",
      "r130",
      "r175",
      "r176",
      "r215",
      "r216",
      "r217",
      "r227",
      "r228",
      "r245",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r313",
      "r314",
      "r315",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r93",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Number of shares of common stock issued to certain board members in lieu of cash compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r65",
      "r117",
      "r129",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureLeaseAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r66",
      "r181",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsClassifiedAsAvailableForSaleDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Shares used to compute net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLosUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r336": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r337": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r338": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r339": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r341": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r342": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(9))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001564590-22-018775-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-018775-xbrl.zip
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M%UIJ$ED.GN>-07JK)W+;+R8419)7;*^/QNYW.73=8.2.DPII2W0.PAZ)%YP
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M]>2)*0K*SV;I)TO4C,4ULQF?QN*:F8$*BVL>R@E:*JXY,Z]?A76-W*"7 P<
ME-)Y%<ZQ-:R]"==((-M"1@?9-@=0(=L>BFV7BC3NPK:[;$T_;^UO:SJR;1;B
M$'"W!:BM2JT!&X2@M+6VG*0;7I@.UT:  +%%S<6"&S(8.&U9'Q-=G62NSE+M
MR^/M)E!J)>5\?SL<<4DEYQ8 *1,($$B9V< )*?,@E+F4*?5XFQ"4>DEI-I R
MH0E107<A $=E[1:$$K_&"L,$N$ "$SRH47=<(,D,5+A DHD3\[BP %>YD*4@
MHX,LE0.HD*4.-5%?RO&^9AG_>C89V.FX?KVZO[-QR*E9F*[O&C_!Z?KRZCV
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M@."M)^#\%P@0A7?N8<" \]^M%DIKL6PBN%(* 32H"H4$(X#@K1-J\NF,NW0
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MZES[2+S%M.9(O)F!"HGW4,3;6MIAO2OQKE[D3T:\5;74/*\C\69"Z-Z??G?
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MBM($M0LENW&6?6T+JK]Q%N/(@&RS\B@A:1^2D3<7?FI"*/Q4J[ZYHRL:M,+
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M"_\F8U"RS)6B+I:YZE]?O5FTLGI>:E5;8(JJ(]<"MQW(M5!@0*[%R5T.<-M
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M_WSD3_)<B">0T6T! 4/1#1<('-!MP:1#D(  J23(&5!@0'4 @ -R!G(&)"!
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M^HZ0I!W_OO7$7+D>WSGY>CRZ .!CO(6W3C!@P!.-<+%!%0$! U(&$"!0'T#
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M3Z;^T#0T_M.(.7QX2L1BGKC0B&[2;/=T1]*1\3&$A3 @XV^+35M55(#@H(Z
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MK30%VX]Y@A&^'S-"-<V>3*GU(G:I6+;''\]%C5"+&+P[CPXU"9<]+XS#N*(
MB6BZRW3QE[3&E*M[E/V$7^YZ_(N)4/K*H49+CHWZQM@<&K+#-$*\4CYUS>=8
M(]-+\[Y5M1EV;^Q$_9O21U8>.HS^*-,1[]X%-7_2%V[7/YQ:8^$;B76-B!>L
M36HCTL=GN4UZ<3WRQ;!=S6"6QMP2X6Q>(?GII71[KF_N>X.'^YN'[LWU9>]Z
MT+L4?PUNOO8O._?\PU7_NG/=[7?./E]+*^G9I#LSA=VX*;R:F<+!S!22=]\M
MRAT@_GMPMB+P0*[]">/^4MSO6DS'>DT]WV$WH[EKQ'VFKP9WK/BS7NYY%[^8
MMO8CV8$=QAVBJ4#,\9ET'SB11B@&  KW(/ L)->&[LFG,^X4:LPTA0/"^6+V
M.71MY.?(60H<&NY,F'3JLHOHCX\D='JJU? XQ\8%F.#B>J517[7==ZT#_V_?
M]8S1RV8)5-JO3.%1->LWWA$K:OK)6J%PCA8-6><""RP.-LBIVIS('J\=Y#D,
M0?<#/1->SES3Y+K43-=F R3=T/5.Z/H!$L/17,GD<:<\D'4XW+Z! <3X&-RV
MN?[0Y6-$G1?R3BS6B<)/:O5C-W LY2?E([&=V0_A(\-?WA.#CS59P&IQ$G+V
MF=O"Z9CR)FG,]PP^GR.AV\K-B3<F[)FCYAG</34LD93/D^?0F<5'E<DJ'[*M
M+GMBTJ&-+J"NRWC[O3'UR(2^$&[&'.:Z?'8\8?P;ILLW62)/IWBPSJ?*PJJY
MT:JD9M-'WY32$BQB\C:9TN 3E_>/3=P*$4YV.!*BGR-;\P5C\#O$$R9\Y#WC
M/\$C1)T_L?(9M$J.KBNZQH="="%J/I]B<UIYY+1!34ZS%K_YB;F1(K]^(:<'
MR4J\_0/;YV,UX*/,9[Z<H?C,NT2Z7%:Y$%@&E6^TI?@SV=\-00-!3@/V*+H:
MBQJHRG)*#W\R9,Z,P*S'\*[4B;;ZUU<+D_VRRS0QX?_)H7&9=?:9C^C2!)^/
MG7SK1J]EA;JN\;PAZVL<_C'5N6*)$I*F[4JI_25I($A5ELXB7S./J[\]85_Y
M0U,?%6XD.BK<Y%3%1WH96#[$INB'*)XI%,H;.TRJE3=VQ08"+OG?J*.-24TI
M$=$0*>5<!?C$UY\(Y>57Z&QD:(:7<H"63H3=,8]RPZ/WJ",.?[B=^:LN@S<E
M7=E*/%AUI5593O4[&RTJA6%Q8"JDL^+;DAS5N$"E&*&5>[>Y(_LJ2-CQNM1Q
M1"3BG]3DKFF*09H-0*U>::_OOZ@DLV[G264S$_4]D?:5OY.S';?D[OQ9W'_@
MDX*1/[.B$>\,?9>+ U= G5MPTYY*@A"498G[Q16/S)*F7<JF/C$L0QIY;M>#
MZ[@#PMV35VPR9*;!'QCREV .]LSO$V]=V[F5R',.-4W^.$[D(R&>HGE13\1C
MY4,<\10GG,T(;>/O-#F+>E) + X34=1(\61E'O&]F!%%;#DRS-E1*$Y,#IO:
MCK?8I8DP@\2A@LG%ZT7?'-M_',=(3\XD^/0B<-)*LY*YCH#E2;QOEHG7%=_:
M_-V\M8XC#E(&<2DR\'GWQ0L,46/7&$F.9WI)>@&6+4YN$?I$#5/.?H1YH4_\
MC>(#9]P)?VLP -0T%SL@1S(*:(M!9'S@?=$H,0(&OTB+8FG\/5P:^,6.;=$G
MP_%=X6 $"70B1^GFG_W+LG(^<Y3X.W0V$;VU)#*19)4BB9,C,@,^CMFBH[\P
M_=PP&U5?:^Z FR&#"PDG'6[6;%_T]/&6SWVYV+C[F(_.1D_O>/-F/.B:Y3VH
MC7I;T6MJN34<-LOUH4;+0Y6URE11JRWEO'6NM4>9F-!6*]7&VQ-:P!.KC>N^
M:2?P.%M_HQ5JTMDZ8 G:>FH^\">2;+G5C!D?,K<^)#(_9-,<?9V-XV;HM8W[
M0EW#O1F]LF\OP7_W%7/;#J/FUK.--1@F7U-*((]RH 0PM]PYX8T)IK';3[%V
M[7/J1;)]S;!DB>O61S?)JAAWHKE;-V1,1"J86-B5DW.Q$.?HLLZA#&E\KPPJ
MD5]HOHB?V50\DL[EGOL[_.%3D_<V\AA^[W1N9]Z"\ -&G*;LG^)JX7(L.'&A
M&S)@FN_(I)KRABCEA.CBQ'!=@6@\JC/H=6<O$&Z@6";D[G#HSO$7R7D$]T8F
MAB?:RYTL)J9F-O=K'-\4P2.-.6*"Q&^WO6#)<>:FS0?,L(*)CB$C)<+7<EB(
M 1^.L".R\(+H,_=W+.&TS7$0CPR:(#TTEVT-1AB:<;E-($,IX=2-SX)FH%/+
M\OG35CZ7#V5)P"KNLZ?<H0]F'5P>:>"%EG@?1B;3I!/)G7ZA&O+6DA2AT)&W
M+5-:OJ#C_!:.51#/BM_ B54+)B 6T[@[*,RE=-&YWVH(OSBFG2'JK_NR<N"C
MD9MC[/IF&)J*5<&0KQ+1IO"R8+-^")@W:Q/737Z)B*G)B4W8D.B9W%<>!K,=
M36I..)]_8=01\WC1YTO^(!%-BDU.^571VT,!\F4@-X0F)I]!HRJ!X_+F.MUV
ML6TU Y9J88$_B9D2(#O,?'5!7"W=L>V;NH#-850:,?[4?_M6$!:05BR(DK[U
M*CXSY#_-;G@MFYT S#MI881Z7O$F$*5:_ON2F/#'O)82968<%YX3&;$*23(C
MXFR^' [[&?,4^&2._ZD%'=NWW[!B;L0O"^9&0UUO4ZW5+BM4'_*YD=(HMYLM
MK:RJM:K>T(;\Q_.DSB%<SR/N_2T,.4=7K#YS4]/1;4&8>?=&^A;Y1E^DH >Q
MNOGR<VR0!AY79^KH+OEB\W]F*G'5&7R)+<.X7+16W_9]*D,Y,U4:?)_=)EY=
MKM9+9-FE7Y"$L\]10)3<<O4<C 5!O+OG[*@1M5E]7^*J.Y1ZJ:@?O]FZ]/3G
M*W&]9]$DWW#'X8KZP!]Z\N9ZJUINB/N%X>#F3=X4/D>64%OX(7IE2VF_#V(E
METP&CL0JBOS\!],YW(_A$[J\(R* *)=$>GQ<O+EENOG)O^*>B/<2:TZ;JUZ]
M^OZ"B+INS)F;L?FX"K/5#;V@Q9[R'R(/3'IH5PYCKD!!W!:\JMPU*??+1@;'
MZE^.<'$LL8ICDINI?$8X;PH"4]Q467HP8/Q='+8(KJAV%>%#&KB=G($UD\O7
MZ"6T_;K/O^5S)^:XHH?"2;4"(9EWBBYV:O*Z,RS>F5&\,RSHC#;OS,^P,YKH
MC!UTAKP;R:=0L;+&/1T9Q_/<]X%/R%U9,83!HTCL47+3T4)KXHU9-30R)AD?
M'R&=3.9<$]Z*]#)XLY@0 .$KBR]&A@@X2_)Q8\F>@I?/>$AIE$+UE$MZ"_Z(
M*UE/OMZ6+NK\@:5P:9,ZPOW7@_&8.];"NPSWU&[_S,5@)0TLY&*O8ZSO2YUW
M!>/^-^74R;W*F>,EKA/69M8PW="EMR<=:LH=7=$DX3"$,<\@8+FGW8/;;SV
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M,>1^(G'4D).TV$B#&^=QW3U!*VI%7'<7>D.DXI#85&GS(GN>-\)?R04UG=L
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MH;'<-9/#@>L=%-N32)Z$0850R^ 0^7=YVU)FA:C72[4ZG.((:'* 6WZD8"!
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MI)@D<M].ER610&;&\8LK([A?__WNZ/S&M[W$X8[E^I;-HJ'%?$?\@V?-52S
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MSEDL:',7)/'0NH,C!@/2M]W(#FK6Y46>%T6OEP@.'KSFAZ&UR*)H=^=8%/"
MCS_';DC&R!6\M;6:'9&/!SCP=6#D>.BPR82C*WUT?C$.7<_J-,G6[TS;M,1C
MQ)[$58M7?J)6;O?=8*XA])W[_(EY6*A]!<9-Z(YQ1RMM!JQU8% Z^5 \S0KH
M*='TNAM6Q3@:U+;PVF8]-O(_B%E!%S,KPI@*LB5["#FI8F)W>#:J=N1Z^K-C
M#<!^E,!#>@ZU( >U1VPOV 9?UK!^A^,00(*<'BF$F'U1<5U/KH>NK,U=\.-_
M6=VG[,TSOX.PR'7?)$#=!Q^  ^E=SO.7#?"*P>W@(H2C?Z"5TWT#9.T[N:G<
MW[*[!K-^Z''J:YX<G3<;[3E./9P"N2P^0<5"C"8E,G6R !=#%VC.?0<AQ2J@
M&CJ]=?=G?>@ZP*WOY*&=*HD7TDX 5S7M?RWC'Z"/.1A'J! C/$/@[&+D@[0?
M!EH+C/OO_W8*W/@>:#-EJBF,?0+(78.?SZ;YN<C)'\73UPX]3;'B\6)6Q%VO
MOO[CF<:&:ZR_I=;?6E^4:J!4HC$8/R#KWJ2Q&+2:1="Z2T; PY/;P3=A[_X#
MS=V+*$I& F-N!T6-@N[))IQ[2X8;N',19TO[ Z,6+6&J% UPEBW)2B*ACM<P
MV86IR3 <Z'G!4_1N&D.71U9R2]Q!Q$?$0UX2^Q#+>L>2.'C_7!SD=&$8Y)6N
M?1V?-;IK7P?>0"YD;Y/BF[J,?;K+T]<&..?2 E:'5L3?CMI'&MSM;?7(]"AS
MN?<52DMF(F^+DHIIF&X;(44R:@3ME&6S\UNLKY'!U>/T]5!@9RMT9M%$,%;0
M<8>MT)[!GLKILROPX]'E+JBTULY5FDX7\_4@5/E;^;LKBY.F]>$:;?^D1W&G
MSA[!'7^8GSK1KEI1F-R'2Y7-(<_V2% TI1=6C%:O]',VE'0\T_FF&/Q20G@A
M9/"[$D'Z(Z9$GLWJ3"=SJ*;)24+,XQR=MQJMF=0-_D7#J=Z5G\.A!QG((ZC8
ML6NG7]M&O993KS,5])M5K[*2?HEZG<V,&_6J \MLT,78F@M?/1?#P3*8Q(^I
ML$N[_H^5]"TT./;*JR8]R'"RH%"[@I;&O.J&G_W0<\=)R O%#3,7AI8:(%=2
M_WT']?>-A_;J-U@Z:;5#O7UTWFV<:M.(U,BWY*%?]:- %9TZ#8Z]8HRO*QE.
MT)\VN+82KLU<S-PLKLU<43>XICT/_3K'FUYX&6NM>C^Q=BPC+BJ3LE<OV\VY
MM=_3-PX^JULQ7UB,%W<G&RO9+%DM78X=]"Z6QOK3D3P_54CZ7"%TX<[:G!OE
MTZ6GUK/7L=[0O:4@B9CO1&]EW?J[Z;IU4WRZE>+3DT9O[>JAPZD5^E_.0NNC
MCV=DJ0H4Y.C=UIVT7VFNNN:8M0>%7)VS1K?DV!E-*KE>0:@N1FA.[KQT2Y>2
MK)V4/&I8DR40YW#559J@Q+L[+ZG'WAH)"%<.EP"Z5F64J >HE"^J7QO%SFD!
MQM<G4U7C4 MNCY9JII1Z].H2IE"D0(C;P;6+@26TTE_6+&QQU\16[;C;T:9I
MHHE7Z5<"HH?#K UE1(\!XQ[OG!"Z9FS,S-Q](=64V?,B<AG+IV#YG*QE^5PE
M_"NLZOZ)>X_\2X ]3-:P>W(MH5M-;5)Q6EZITX;#3 1' R+0:%L0;E7IRIVI
M]BK:N04FHF,B.H9.)JSSNL;-:H4:.>-F>T&<LV,3Q-&.L\H;-?G.X_L?P6EU
M&CV]*8,":[FC<2(:WF(OT6C'&5L3U=$Y5&"B.GM#*A/5*4F_-ZM;/J<K63Z_
MYSS)CS]M^*@HC7E93*=K0CI[P5YOM8CF++-]2@[H/"2BB!#/HMKFR6Z'Y<TS
M@2I((TVC"69D:J5J?<S,U,T'CI[IAI\:3EN,$S7/M(D3F0FI&Y^0NOARV8SE
M?F</N9-X_'9PR:+AM1<\W27CL2?G6.&E2"^(DI!O;B9 R0MF!S&.(W^6E@T'
M; W@A"W7%W**ZB+D'I/#Q*;LL8BF;>S@*MFSY[O"B>[N<MG9SB^7F<D&9K+!
M[G70\OMC)UK<'^LU>F:RP?3E9)S@)*J?\&YF?H+3SB-=NEPJVZL^WX>!*GKK
M-8,Q^M!"KSO*95M^&Q JWG+8_3P=G=(J>I!%#]5WMD;\T SFV1-=6:9]MU&5
M155IYO3H1Y:]N%%PZ$VT,;1LC1GP(H[C9E3]@5.=;2]QQ)!7;+TUX@PCS32V
M.QC,]MO2+H=FFFV;^N%*)H]-G^UU\KXGSTP15S<$UAZ#7BB0.V[.CA'7CY$J
M)LJZ:M0YS;4/6G9UI4/%Q$%+9#.-ME<&MF<F!)8#MI8"MM9R8&N=&F [D#*E
MJ9]WT.]X4:54ZVRF=456"W4[P"[1W(^H@N>[*."Y#*(XNANRD'\ EG<4SV^B
M8LJ2G<.Y<Q%GZ_O#L?WXCX[39\[)H%MO]3N]>M?N]NNG'=ZN#WJ]/NN=]$YX
M]_A(5MZHLQ6*"]E*%LBL68WS7 5.J[FP!"=_TU%\N+O I5A!9JA<;";L-$];
M;B/2-%N=M8M5G#1DV=<"E8@'OYD376N!*XGIPA/-SESL]2X& ;-([JR\:*9G
M0.KHV4[_N..3\1(P?Z8B;L$9R?*\%;:^4MBY=6K=CGRWGT36C8]1=?>16]\\
M.+GIPK_%Q9;SJ7]2>N<K,/8&4>?&M_XS\;F%9U"#30(3#.'L>1A-=?.WV'@<
M!H]893FGQ?^R(WR#7\!/MIOOZ7/X6_JY]?YMP\() NFOK2%SK''(']T@B;R)
MU>?<S][<G\Q]^8> A0XN]\H-N1T'L/;\.^G/ZGT6\[,=*![''T9N''->^&+Z
MV_3+\DCHB7!:2?]?\#XL.\T=G%PN\Z:WUN<V@*'%!P/X$IY.(,^^U:G1QQK6
MK?S-&0U":-7H;:6( L^'A_L.17YS!SA]=N*L8,6N;X=BOCO\UD^H73T\/$+T
MI=?8L/O %V^WX'<\Q,=@\-F-HH0!C;&_#7PK+NYR8CTW94:\HV#]S@QPS:R
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M<XFW1GE4=XNE:"*O]<P=CE:[>'7C^5JQDV:G=M+9W(#& [S2872' 5L-"6'
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M:<+P&M&R9,NPC=#SH"V3-<+TISMNE;UR;+Y=Z_5ZM5Y+GRJX11;90OPP2L?
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M&\0_5E1.QH&?'S67#JK+#T=&&X%-I#X)(IZIGG1:RCAT\:]!X5EC+T&=P:+
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M9U;)!( I'PS/$]LA,X=<;D7#6$EDSK"?$39I=<BWDKNEC@J8*!!U$WA*='!
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M2E-=%$H7)BT8(>(?<N'2%I9 ,:6R'D7O""^0A3A]L-D=*LO!5Z<W\)##\@Z
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M/US'YW@=Y6M 1Q=R<!QL(:HR=II/[\[<>@))KY$:Z'. >Q5V%2B7'D(P /6
MY\KQ,*.$KG.3E%*] IXHZGFL41>A?1=SQ]DM#95-0KK*&\> 6KZH5LD)-;R\
M[U&65D62Y#LQJ<7K-U^OK(?$=<@"D?>1N75]=8'G^L3!!H;_?L<E?:,2%&PY
M?R69Y8HBX^EI*RU-R)2_3#*%N2#;_\G\M$3MT,#J<_!DV6YHJYQ.!/;*B,Y
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MYZ@$;Q$E%V*_#HN94.RX:E5N.F]A&'=V\N]/F2$-J/?#@))T<$*YX!PZ@4Y
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M\:(CEUU3%!.QJ,>R8/7\(^F;V!&8<@\@#6/5$'9ZP);R+*6D^CP6S2K1H\3
M22'=\LMQJ]E(<RZU7.F+;%9-'>NL-#$:B82"_X@]MLASH1D=Y ?'@?T#J\-I
M,B1]0MVN'(VP-R?^O9:M)0TPP]E@?RY2:O= >H:; [<JBA)&LS\P5C,$X9,O
MSYXFVN4RNHU>B('\<MIM='*9)%@&&KDVBX9"KXSCW +2$D%R\CU0H8'4VFG1
MX(%?XTSY&#6Z2%K232?1^RCE5SC@1- Z5XN0313#*PXRZH3W[:B!GN"'E&%%
M,U3D2?EA I5?6MW&<4HN?-TO[7:C6QB$1G[($,BAKB.(TL,B]]-WQ:4#8)>Q
MBK\OFD4G6Z1@.,2VDY&JS*'0 H'N+]U6K]%6ZUCT&&H(A:Q%#(3_0&>*<JM8
MCBWK_A"#?^ET&Z?9X^ZRQLFB01P]:N9 G\2U;WGVKNAPC34>M YQ]3LKHBDT
M(I0?EI=!9> RZRSWF&^GOP4$6C7&L"[_9O.7<F.6%G5J7LN@7&XO;\="_IS3
M2Y<%O?1=PL06S&=M=-+GA5I9@20.$7(C@4GJ=R 3OLJSY3J69SW4\09+[$8T
MT&4,YF="?F]0%@@$3,E2<U&:@X)-,3E1*A"@T*7#A=K-UAG%@VFQCG('E$9[
MH$8J",M83@WP%8D+QMDZ5'GQ#S]XJ@^#)]):J6T,7TO&=4 R/TZ_-683Y33\
MTCIN-/,XF*O(:=9RZT\G<5(P4SQ'':E3:@9VDRSWW+S)^3035WC<41^.7O35
M'[JA4Q>F\2,6LX6H4.-Z,*B/ >*YJ-<'6D8X3]J3LR?&HK4\K4M,OY0DN4@)
MA=MO9MI6P$HKAS,O1Y6I"PAYPOA8QB4C7G)I&#F6=Q/4>99@N(;U.PX#$"OE
MLA1HWH9KV=-S Y&S2LXLV;2A^<>Z*H[,*%]J79/+R42C ?SCE $O!C'((A1Q
MT1E933UP^?.*STH X3U\6M 7PT6R]@?"3Q I$9ECDJZ"ZJ(VVSMW:QW5MH]H
M.'H7MUIM9%.GL%CZYR'<@,MKN0LM/\P(NN@P 0*HF26SZE5V"YK2J#71! =S
MXDY.JTI]KDK)GE\QB8)03=B_I.Q&G0"6C9*6'RJ%'9-M,9H(3+DAMF"BM2H\
M]55K(-65:AJY<FB46Q=F[K(Q.+ 6H1PE)(H9\LM#ME^"B&'7![#G<_ :)7VU
M *"5!&\)JU3"K("9@G&%D\EG4G*+7@L;:P!EXN$2WBELEX/<FA;H69MS0 +;
M<\<SEUGV6/]]SXON54YTY0#Q:!MZ;X>:[OLB5:4&AV%]@KRM((B?NKD4./()
M^I3"JQ5Z167UC],/SUKS3R-GP42591P+5ICR8HQC!5G. \<+ SX.'_0=$1[!
M!I)V:G<+)?T0!(Z8;JB4LKH8M/"-HM)11M-$*(%RLZ@*1,5B[A<6&P6)NF6!
MY0[J2!UU/LIQ$"L1#U?EN?EU44FU<)6P, O[/I"]XE*+%S]0_?/39B^BRA2=
MEYD]*JLS?=/LW*<#JV3H'40EPZH3:W=?RZ"U4I-F6RZ:GDXFE%WEWTT5^CCN
MH]J9()#'!TA(',M.2J9/N?&_'36/1.>X,</<2OKS&.O%Y<_R.>(;=8+0<<3?
MJ7^\MT1+[E83R"G>$,X9_U[LW]UM''=_?0\&!5XT@7?CN3V%;&I*_#KMNTM1
M1UI@>&6L/*4\'H/XU>51K=+GJ#TE1#2L_;DCZC0Z'4V.:(EP_-^I;?_?%YWG
M/*$L)6D.VGUDU8D7?F#VCX<0>P_6\QO9U:86-;HH^7JZ$-%NG[S/"?D"'CI@
M^2D<WP("SV6&^028]L)*$&FFH&PT]H()SP:N9?-K9<].Z7U&S,-+L_#[=* O
M-5O$I*/LI4PESGY$R_[W?SL^>V]-$QO^)\3_0?T-_P45;S2]GIQJ-+W1]$;3
M'Y*FEU&C0$8'1/ LI^YS-QZ5URX"#G@));U^3?$W*MLB+%"H(6-F_">W$Q49
MS?5IK!6&+(@X5UJ!)OLK&L38;XXWB&$0PR#&(2&&J$<6:0=FXV68M.$\\Q.\
M\2+*(/(->0N:'2LJ1;?:7%Q(3 (N?E\.#C<0L-\L;"# 0("!@$."@.(UD;G>
M@L@*4C0_2\VGWTM3>S0X20[[%HK>Z/E]Y5.CYXV>-WK^D/2\K'80Y4\_\:['
M)'>Y/6_@%Z(U^!&CQI>7'NG+ABNK\79+DR,R:KP::EQO^=%/C0]@)YZX?9UI
M[ZQF>%%NUW%IUJ=LKSKU85E@+:=$T,UU[C/9:CE[(5Z=1YQPU2P9JL<+8VGR
MJ\?EUH7WRCV7BO?+(,AAWLRXITF2!("<1F;QF+G8KCD)19-57P;5<+)$*'HV
M1_$S5>]IZP0:]Z.:7P--GV^L+N;W)!$\4C4K>=NP[CA/[P[2VXISX(L7^$4=
M>7Y^L&R@_>S]S!=?PEE4)+BP$%#RUKHFB'CU.Y+TY\R1TX76B-A+9M?,:))K
M^G_OY0+J:#K15M4OOA,[-AN]X]PO[_$\BK_ZD!V:6--)IW':E<MZOAQU\9G+
M'].%%8F ORBK6;=1D;K4SMG=X;<:)Z]S]OGS7-H%X[04 FZ2"K 2U#%_.SHY
MTH BG4ZC>UHADMS3194O 5U4^9A=5!&DZK1J^LG,/ =DBF '0YY9B?E-8L>K
M(T@!+B10JA.. L]U+/%!BW:&$[K]N#IRM%N R:.)(<U*J-/6 75:QXT<Y?"
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M3\!$' 0$92(]:L  >**0+"E*.$.J.-8W)1]^3#"GD&#F"SE7/DEDPV-]Y4N
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M3+?-OEN^W6-'Y0*KE"H5>AO^@(\^EP-N!V+(G5%1J9'ZM^$NT98:K.VY4L@
M'AWX E@ )&1>!WX6_5;H2[0+$],TP(WZ.M309U^$U^4NJW:A^S[PJSC)_^T1
M[9HG YS_3!%?@VAO4)C-=)V,"#4S QH?!,QCP79IO+%$CXEST!-^^Q!\?S!B
M,+DV-(ZO#;@O/=?E#G0N \D>.9Y@#GV?TV^!)5R:GT=#>5;F9V9*)/.5"1U(
M?$[(39J@;*CP]ES/K^>;"0ZL+C]L^=SZ>6AU8'X?+>?1&LDW[/UB(<3RDYP5
M2VR/N?D=*S#-L#<VBELN.:D1JL$%*+SC#5"F6=V8^M_?XT _[Y;Q&YMV.S'M
MR,,]<I^SM^?%LPFK=U8LK=+L%9@%_=N@2F""P?B]/2L>F?8+#,S3\=%O178'
M/41/H7EK@UF.31S8I8E63N)6P)*Q'N][@YYPA'7H<\="ET^&;JKW\OA[6%CG
MD(U[YKU2PAG >Y$]G7H-B##U:B7YJ@P\^^=A"WY5=7W C;'8H\B>Y]W\/@.L
MO!.VP?D-!K[W"^@9 $]P3*?1F&",$CH!L;)YXH8+Y2C,]( #& V!OPAM'"U(
M^2&,PH;ASK!0D3V:S_3/81OF,YP+*,DW[L*T'9ITM=T''R@#],I#'EF'W;(*
MR0E;XQ.>L LG"2M =N&D>+Q6LU"*VR>S\&$9JY 4:]12W^MP*>$3S%ER?PB1
M(.@H1D?"<B@9Z$@>L-8(1HFJDJZT$SH ;WJ/I"RHAKCP$D 2S"S;]D(WD$4V
M!Y6G?:,2B IY?N.25J#FQ^M6\RT(1,:N[[FF63?T]3U7ZOJ>W=%P5)D)CZ.E
M6N#?3]UCM(!70;]E^4I>YGEC,F5!/2;M'1MJ%[(0$#W;Z[I NS8+!Y[*_6'Z
M8&]"(7OD!D&2+<CJK!;X^V"TMH1\?OXM'Z1A]L2JRG*@2;WQ/1?^MBDD6<#Y
M&$',<IIURSL@<,!V/(U?*7V:.6VFZ )R4FU[ S!+]$+YD[%R;93E*R_@K%)@
M*98T:5'>?&Z&?: *+?PT@7*B(VQK@N@>/"G0UY/5+6#S*'9ZG-B3-))>\Y"4
M&+O!7[2%3W;SJW#!KH)38<T OJ!IQ*/&K%RRKT (5BX=_MABB;T4_X2B#5JG
M%H^L 9(9 U;P&C;E4KMD3*L2I6;<]A5P[:1G041T=)Q8,<)E'4NJD)W^X$"H
MH>5PB@B^SFM9H];!-):/$SF'FSP.]+9<*9:CGZB[4"JUT A.(-461EHB +DN
MLC^QT2&Z?0Q3PGZHO'V;@S((,JAOCR'QBTVQE3+S(KN&T$ 9\1%V*.-9^V3/
M.R'ZE7@$\*D52N%"#):>Q^ 3W6>B)9"VT,=)U*)Y3G<5M0AZ)L WV3@]".N(
MZ**/C\!8'WO<10(/+/I%QO%8 6?L\X[#Z4UM .R>Y7;)<V)0Y(6!#&"4BK@J
MV,.F:-V-1F_;?@AOFT:G8Z:%=T8JF=('$*,6=P1P$LAC!405_@OXA22QM3'P
MC3$H:'NM?IRA&^P1) Y:93+LH#"B> ![^YRKYB&<_8_B2<QL']_WM:_ H 6&
MXD",$Q#37)@/*U>,EM%"/GZ/AAJ%@&QQ!T('MQLKADK'Z2>(CRA^9J0&,NP/
M"!!-S;@/D@-#&I*XPZ@?P7%U5=;_B'L)H0-A2P"-_Y>K7&%H"4?M,TR2ATD/
M2(UVP2*AI-58\GHH/W9 @QLX\"-T97OHJL)8R] 6\"G4-DUBU1,^A^1R.6_C
M\'TO[/;@6U0G8H&RXN\QB>$M"/^4#W.[2AL>.3 &HS9P?R[F2PQWHP.53 %A
M@$$2> @/JP5VR@A1C"S*'.#[L75NB4D=:3;O"IMR,)B][(D!RD#0B](1T%Z7
MC%95\7/$+?]I6\D['956 G&[VGIX&!,83XRL)._;/#Q2?.0N,24DORYQIN$
M_WQ;/BDE,E]<KN' &#*C(*(ME$5\S@&;$NAY 9EAX,UZC?FA@P/'&!Q)0X%J
M3#--<@\GZ4(B%@@< I%>"0Z(1N@$V&GBK;9P0IJ.3LUH^:@'/A^(I[K2"_F8
MUD&':"A:H"]D=!\GVJ7.="+,O!88HJ3<3#P\;L@CZ8#GAD ^)"N1,NHC\(6M
ME#86R*+>;'J!<*#*Q8,**5<5[C^8#6"K8$="XB55F2A?!P$>::F C-CU2(M5
MVDL#CF=B;$^LI=KP6WUEW1\Y:0^.#CG _;Y$*\\'@=IL\6 \8.8Z:($LQRFR
M1@??07?H>O"5?HAD"+YN@PB@94FPUR@IO(43;=&B@JU\7!N2\E$!OO_)XXQ<
MDE"27T3+ \:.X_Z.-2+/JH9(^B3#P0!LM4\*BE$;]8QZ*]$1PG@&8$-0!@O&
M#,B0&B81#7%3R"$#Y-(&JM?UK3ZJI3M29A3]IV:GEATTF[Y:6>E9OMH_-0%
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MH=LO,16_8B\@-P3K[R9ZYGHYG[+,J4<9IVH^R#!"-J?6@TT]&)\ZO6)2B:#
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M%,&2DZ 5< ]2C$$&LP><M $RI1D::^FBAA2;-+OH6(%RCPS@ N@_W0+:J\B
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MK'7R]9*[BP_T/_K+UW_^'U!+ P04    "  9:*E4_K;#B> 7  "P>0$ %0
M &-B:6\M,C R,C S,S%?9&5F+GAM;.U=6W/;N))^WZK]#UK/RSFU:UN2XUQ<
MDW-*OF5=I40NVYF<MRF*A&2<4(06(!U[?OTV2(JD)%X B 1!V?.0222AT=T
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M5=)^95-"J9CF+V(Q,8NR=JFD'_=$THVL:B+@1_/MDIB E5GO5&3S#9*8R*J
MAD03GX3-U>_'&XH QGZVC0>Z]XG]\Q'\"T39U?\%($!3(""!GCJ&_"F3:'_@
M(07YEE#X&\8"Y%P&%)8(& U,''YH";_Z0BU04KB.A'A3(-H@WW]8;B 4=9>G
MJ2D>G\M1I+EOZ%?XE62,7HQBF^*%&JY3NDV"[8_=:E]&(=00S%,8[:EM((O(
M:Q%\Y/P[8'YH7!_(R'%PM'_>6MBY\2ZL)08['C(XW63P#H'Y96!XXQ-S)-(=
MLLD\VC6$U[,^7O3,I7!4,XZ,U$S9;JQO :SMJ]+S>Z.U)M24!TZDCZ<NN@6Z
MB%+N+@ SXF $85)Z!'(MMG)SQ%/]9:T[R;8J/$$]B9[E012O($!$$VS+!YTA
M9W66E)_\113T[$&V'2P"?F$CBF:L ?HCIUE>(@FBFC;:W/U,0;!R0IK,[F)!
M/&5#N]58SU6%<&/B\X!XL%;ES50!@0XSK]_,;K#!E$UM/J$WG-@;3JP )R8
M/-A'G)C@PDGUU':.I!PT)F=0B(#]2R5O&U=5BB"K5_"LV.;"K,0V/U+J6D@!
M1;LB9X4/: XHLDZ9Q1WZ+D EI>4O.J(9@Y=L8K/:/E"GXK:=XI;<J H##*0J
M$&(.1E1NAU*3N!M@48' U]J^5!%;W#_(:%Y(.)6R[;5;FY3;X?K] X4VGY?I
M$K948OK+9OQ2M.F^H)L$<[PIZ')?UHQHZGY_()CRJ(S] ?,I &E2X?=E+RR
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M:UBP1)Q_'?[N)9HA2I%S!Z;*"U#RO]7LE4)X"A!K/WY06^1 FS"A%J_!'EV
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M3F[X9P\F6$Y3;NH?M:E^,@\HJR8]DK=2G3@V/:VO^7UJ-II(Y#P 9>*&R7>
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MRIVW8PN.1WQ.-.1#LG8,5*<)<C2'C4 R/&P%P9P7X(SH)J0K@5 14*RKU+F
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M&U;4H>,094$ZYP4HLR*-C[(#]U(PN14"1<.3C7]S>C^T_VIT]L-8#AEE#87
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M(TQFHQX5[S-4JKDA1T\__,O0-Q\V<ZX@9&S=&(>5H,,Z*IP#3*B&$.<(,I9
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MR\+EX&+_UN:C&_ZX"1"Z]4&)0&'4Z=HL9D:JWJ)2OO*'ZS<4O6"'//AX)U*
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M\%6M*#.9&!/W)N!-2?+8EJ#)NO)Y .+D^DVI5H+X*J7): 1>SZ\SRMCLND#
MCZB J"3-#&_,OIQ#_<OL")0#;KL%-/YB9%PLG C&)"^1V42^^^EKWWM]A(M+
M],-=/X0<&[[R%>%%8-E#D[T1RR:'.VSQ$R#OL,6K,::Y5;MK\VJ4=]OFO='R
MJUTS.?"1;BG<P>J[)I!OG6':D+$;Y!.=DE_]N[/GM,._7[I]C, .:N$Y!N4#
M90?*OD#9UR$0@I5%35NTW. [!E*KOC[++)D=FXI*^+GB%IA@Z8]&KD;5=O4Y
M9K'#-CA$K@-E!\H.E'UG]Y_(%WOCWY7F1J E[DEL:R1X3#IW/,KQK2&Y].\8
MOI/'WF9A04W1EAAL\@#VRK]_IO*QH\>'6N!YROC;E\0'U@ZYY4#91I0]FR?"
M/K0'[NT/M#$QWOKUUE;_C/7$"\WU_W[AJ^$H_A7M(BC^Y>T_4$L#!!0    (
M !EHJ539 H>"-P@  &HW   0    8V)I;RUE>#,Q,E\Y+FAT;>U;[V\:.1/^
M?M+]#SZJMTHD8($DU[<DK40)O2*U22^ANKM/K\QZ%JQZUWNV%\K]]>^,O?P(
M(3W2M!*)R(> [;$],\_CF?%N<O;+^65W\-?''GLW^/">??STYGV_RRJU*/KC
MJ!M%YX/S,'!<;S39P/#,2B=UQE44]2XJK#)V+F]'T70ZK4^/ZMJ,HL%5-':I
M.HZ4UA;JPHG*ZY]_.J,^_PE<T*>33@%^B8=2U^#+4;/UOY=U%,*A:#YV%LVE
M?ZG5V,5OK*NS"1@'ADU.ZHUZJ_ZBR6HU$AAJ,<//G\YR9MU,P:M*RLU(9K6A
M=DZG[4;N3LL>IW/?=/#%U60F('/MQG].$YVY6L)3J6;M@4S!L@N8LBN=\BR,
M6?D/M)LTL_+Z>3:T^>E9E+]>V=$OR)4<96TC1^/%AO=380HTMSW42MQ'I] D
M1=J9-BE787%'D"78@;T9!*D)-Y+CCJP4K+SN?1G+H73LJ%EOL;NMBE%/,*M&
M-%OY)C/7[(JUTJ;]K.%_[FU4Z9!2V0?9V>U=#?IO^]W.H']Y@62_NO[4N1BP
MP26[^O2^QYI'O-8\/N"'K'-QSIHGHFQ=OF6#=SUVW>M^NNH/^KUKUONS^ZYS
M\5N/=;J#;?VU-0UVQEUH=_/ET7'UZ5K8N6:=\\N/@][Y#38@TIXA1XW6 OS.
MU9O.1>^Z=OGG^]Y?A#N-M!J-UIIW'N_IZ%?9-2B9 ?L@E0)393$&6YG,F!MS
MUWXR=C;KK,_&? +,P$3"% 0:*"W[O>"46]2,74&NC6,Z8V]Q$FLV:K\SG; N
M=US-K&-OI+:QA"P&6V7]+*XSW!07 9:#D5HP0*L%^\!-/,:@6D6>M%KKZ>+Q
M.K!59V^X10/10>F,?<[T5($8037XT03O"8TZ9=JQ&%?A,F,\F[$B<Z8 = %W
MD*)=Y%;.4FSA)HHE/,8NPW2*V<CI('=+( -TO.5F1B(I_PS>]8LU+?8)5 :W
M5&0S[4$"L31QD:(8X8::"*PCIF.)$-F"?BWG3\% N0@9D$JKL!"1V8A-I1NC
M@3:'V"NX@GFLL39!IPQGJVYX.J@??05U8(G,T*\$T=*/580<Q7'8K(S+C+;B
M5$;B]U@5=%00JQ6G51%G20<Q1U<32X@]2BUI4")@U[9&I@E?GU9)HE H@-AK
M!,AO9[T^,;=CEB@]M7-B&!A)2TYPC%-GT!NUK*[@:^?*W-+VZ4!\7&>#&_YX
M_NR_K>:+4UN"6.8#.@@Z220V#^RA=U:?<0,>%G2S'"KP$1&0"T,E[9AFD%B*
M<8!B ;6%M+'2ML!Y%"&,5@&?W.@8!'9;=H!P"$!\@\][7^(QST; .GCXK@J%
M$KYD.SF H(4OV:@5FI**DRSP@M9G=$)7Z!+@(UVVWBBYL5&"&\TC_RJ)4(+R
MR\-2YDF]>;)#W*!"^!PL5GWH(Q\P_QW *L7RF!=V^RD45(> 8)0[A3"M"X,+
MX$&<2.N/-TI!YM>AVF09&%:#BP'%/;IEG%XB5"T##PU*#!*HB]5*"NZ\HD,K
MA40'D $R9!,?[C):J; 4X?UYL#X=^&" 5UU4""^N?E*.A82,"\4IAJ%97HEE
MIL 9(>^LIDO\-@02Q#"#\T$\+*SL&GN&Z^S9^G#>(M'VQWIK+B'_)E(01;C5
M&:?XQ2W2BTH%X@TW8HXALDKRH532S2A_;-J6&.WA]D@&,MX072DU?)C\4AJ4
M%R9')EF?[^)8&^$5\$7'"#),8PH)A2.0$U-)! NJ0!IDM,PQ4CTMVL2'K#?A
MJO GDWP*28*)7T[0&W9# E\DK"TB36ANSNF>)3@1HX0-E<-0%^YN#;:)A7PA
M#506)?]>/++AO.#RQ(?@"=3GE!9_4D +C _!A[>QH(M#F9#]R$; [Q$5*&/H
M."X,>7PE/&]8-=5XW3- SSEP+1OC0G^':R([N&-*@M3!\[HF72J.Q2?X.P]=
MA[)BH==AT&K,[2*7T4GW5 /A0Z#W1QF>9GBS^0RJO "MR5<?[**'TVN7JMJ3
M!U2U_C&!F!.SNCR0%!]6R;$\FP3O/9+;K>)DH1W' L5I8Q?YQ'?@DBG>CAW
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MB1YWWY@@Y4%<X=62LQB"#*]+MM]E1"&J_]/!?[M!][&YMO!>NX+7Q:7VWL?
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MX[U_E%HOOX?"/LIOOOEJK. DK#AY@+[[&5W^]:GME7^Q^AM02P,$%     @
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MWZEESWVU/'4+0,^-*04+86\/Q1=365>SNS4MF0&,DUM'&2J?PDV/D;9XE^#
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M65=\$%_BOS"]\&NXX!FJ@>'"[^/8S/!G@[#0CYP+6ZW3T++-EQ1B*%>#\'D
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M8YG-&!*ECC^9 9W%_,J:P_>%&4585EH#)L!E<PYK]#B:0X)UV' E<'R;>+8
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MBE<>($2/69UJ[ZOQ6HYY4I*9=8>V-OF^U="AI*+/@8DBV4GD&#AZ'S*VZ//
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M* PU9@?$0SHWC\VB[J-(CK5I%LT36H&*0?4FTJ]%OQ7Q\G#PIB>W2N%ZD(J
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M&*CX*N\9'R3Q7BXT14B5Q/4(DIF\=HMTE#H[HHXVGHV$4J&GX7F8CR90CM#
M/FB;*^;'JX8^A$5#ZX:>X[G>+&?[UK?CR-=?&YCQS]'7%?";R6CO,)$_(-99
MWJ&A/HB@,O@E#S,D'A%>L)S]VENBW3_CRYI!:EK)*FQH,YFR2(8V6K$IR,=,
MSF)O.^88RG.I2=H-FDRA7F--4H(N_Y&$VO$Z/V)HRURS;DV->'5^<L2$:BG=
M^'QTWI5P/Z6FE,OD43#^5N[L=%ZEL1J*MG(W=[/338]2CI*G_JPRQ#X8XXI2
MC6[^L!X5+1&_$IG'>> =1G/_WG.E8LV9\/RMH%U8+-1BN!(P-@KP88JUMU"Z
MH3'S!X$*EB5-)EY'3!KH=P!RJ$9B/?_XVP=D0V>>&DLS)S-HUZV<+8?Q(1J1
MMZ<#]&<"6PW2$I 'LS<=WN6.+IB.->8_V;/KNJ><ZY3A\(VY$2N:KY24XO:O
MOY7&-<="Q2R+M_'7K+/D7CF4+UADA?9:RS[T>++Z]S<\^&'51*278LC9EX\#
MW_9DR8VF&)Q^Q9YH*\$YV9;J'X/V@1N@7!F?SGG521V8$']L'W1<T_#H3$S]
MK ?:%@@-KI@'3 <W5FQ-Q@8;%JV\?T)/^N?JUA0HB=JXC;4ZT]9ZVYX+X&YR
MTMFN*8]W@-Z275!-GY3K2</X5M(-\%DUI:6KN8'C,C-/2W&P&PH36;Q81G7Z
MK)>KE[NE5#=^HK7^QN.#KP:.I<E7@;]J\(5Y'%FT,>]?8U64:B],2&>$.O0;
M^GY\5_# 8G_0M6VL$-#0F4ZW"V!]%]5,;TN-QK?7N"U\_NX[T)02>K@"42(2
M*!K"4+7@_9J#E>5&3G(Q3&COPB&T681>D7Z[9[!Y"Q/?_0E_?AAUI6>M\LN-
M-\5WUC>#BA$M>G7*;WMF$9YNDQ_U;@0%R?WT;DOU>=[UEYH]^VH^V+#J5LF2
MS<EC6@'H*A.[S!6YQI6C/5*UK3_O9V9Z[#Z^5/6\:SAY-<)#6\N>'=S ^U)E
M:H_3#F7[.EH*V8EG\K*O9*>H]<E!AF" ^@IC=Q\DLO6C&U:_R54/ DR@5 MT
M&.L@AIDOX+A0WJ^)*WWN60PS"W4%RDP67),OQOA@X)'O.)9@YC\!%)\M<F\>
M?A\48!.[#_+&SBSP92E+NIO=0X#S/HA9'S6]6!#4OL!,$_Q2<.%H: ZOKMR?
MM ^:@<XL,%, '&9:T%FYA'K, T+!KW,= I(^3D/6L%SI>+85#TN6X%X>(U\#
M#KP'?P9+\E703U]Q@VAI@$4KHG(?%$@22.Y3J PWZ.?<J82?X.-T2N D_EY;
MSZL2%Y$@R#K[A8@I2OY'+U_(B@-%G_L%'_ "&^I.#T$(TP&GBF!BYR^P3AN8
ML7=><J\UN(X1TXZY3<]'4CK")V,K2!F'B\/ TS,_\?=_D"P/M#Z^[/U/9<I?
M1=865V<<$+U7JO=!\0F$8XG)K(8WU>,^[H<"=$9+;T[HWA7\2WB(GW;N7NN*
M-!.I81<6J<RUD/3+GX@3EX)=?N10%UJEMSK9JO.DG/(48PNN)3 B]D&B%<P(
M1T!@1H1_\*4(;+]4).;0/N@>YM<R$*$<+"^KY+L;CIW#)G"5C*6V6O=!#(K2
M.F9Z- SVX$?4A&K!<C>-TK3 E5)='%H/JQ(#37\G866B+A[5(D"XHD4(IQ;I
M#*K[]=>:7Z/Y$C!I2Q^\@HS]N,[L2Z*6TJVQ1H50^]RC6M\FO8=UYF!FXYMM
M\5U>IP#(K\U >)E1EX&TQ:'HOYCQ<>BS;X"<WJ;<@WN;B:U6ATN7!FY9U8V$
MW"[<Z7;[UEQ9(E>##Z3R#%!GR:F31TE#IR^]LU+:!YV"":,EEL1FJMA)S+07
M/Q6>;OSH <N1S]\")Z#M,7F<D6":EIV561=?Y9VK<L*\%3Q@+[M.4\6?/#RL
M<V,,=68YU3O/[OVBDKIDUFG*;#!QR%XB(=D_XJJ%7661=9-*G#;>E71JK%1=
M.#&Z G+O#;\T>[)GJ52NGOT9&/U*.7]AY%OUJL/=E&L6*+0N6A-^0Z72R3[+
MU2%6_Y@9G;O ],+,S.&R\'RYJ,''[J<\VB7GI8'7AJSW'O\N95.--6=[=2H4
M)\+29PZ^:D>^4#ZGR[O/2Z(LUD"/4 (PDI^YEU@Y<8^,A;GVD]JBI-CM 4L8
MB2438^A[->Z -/8-4-3(.!P!D? :8K?#J6W.9HD:F:F#4^931+S;-GPD4HDZ
M!*BJKCM2-^.<*"+R[# @J(;^V#_C.ZE0G74D;IMA1O,JFWIA2IG8,%;F%8+E
M71'Z^A(#P4$1;];<7$;TN_VH'QHC]08[^J: /5ZM\<$!C@I_;.&DL?CW\/F*
M4+_%@E#+";0"30BVGCO$UJXKH\]?8,YUD9S^FH,2M]\%WIP?7+M;9^F_/+ZN
MVD)Z,?1D]E:I 7#!1^E%A;7CA7&<G4-5#ZM"V<(V9OG(-;4(EYZ_JX0=2R],
MIA%7;+/T=<6+7^+C"M7SERR(:AV.%W1*I80)9E?'K'-Q@\6FU15;+5+J=@Y^
M=KKGTS9?D*5Y1$S00C2ESB9^/3Y)>J4')F%HXHV,7-R,;3FTW-9$J'"_M7)#
MFDC3LO;?*&+FQ"J/>QL\67.6=DOYR>@*[?_/W^T'7:[KJ0)VW8@UL\..X67P
M3Z ]60<_S)^9,(3H%= X&?6ZV*["$Q0R<Y!2T7)X&C0!"8$3,9"O=Y;:/"OK
M& 1:/[L*F,7S1Z"-X&Y(DD'W\MR7*!665QE9@=3R"LM1[9"+_)2+B=5Q1VWY
MO-""WB+5QR[%.OJVZ.O;!;UMSG6]5N> L/LT[WRJ)L"ZL4ZJHC=OQZ%2W:$M
M/=_-1L;.8]OWJKE%K!RW;F4Y\VG[8,'# Y^4#PML<:>8"FTBO!:OUE.59,/+
M&LE7[Q"W8]><##3[EW=SDK+8AB&>W^NI@,9'27)_'^5"M?__(6GHKR'IVM'"
M4(2\EKUG'9!$?:<%N]O4=*DSM&(&%7J[J:U D::@TG%->A)B]PO@%LLQPI2'
M:9_=ET*?Z5H=MHG9!\DN9KS79QN+C"-+ID+29.C9L).&:LH_5V(,S7AYQ?)M
M%AV2$0R;3@''E^$0.!GRF/+4N@[C$>=/WA'>KS-V_H4V]'; HJ,D)\E::&VF
M7S<VJ5"'^2T/#_0(+([>\S+4D"F3V]+65H.3B6V]0AV(FMD'_3'F,^R8/KCB
M&6\3&.'4QA_)]K0->;T>DB<VA 4T(5R)'2JL W,8CFDDO:<(NP'2'UNMO*G8
MEX5'F<N5;B@]R<E1>@A4UC_<T%W+4-UG_+\FYD9%B3_K1I$7&5?L.0W/]>4:
MM V2RGR/Z4E5BZ)^]%RMUA*BJ7WL<T'[:@:*56T-VA2V&631.T6<2K)NS\$M
M+CYNTDM>GM#XJ]1&X:9'NL/:7_317-LX)>':"?6);S'.6J<BE-7'O17-34S5
M[6/RF42H 70Q&[J% 3=0>/&_CDTO/Y*DP8DE4-?X0@('J,KB7-\'?<9T[8/V
MGJ'J*6_=MNL6-JZ% G7_B[@W#6=KB_N&<\YIJZHH:BYI:YY;\YQ3BJ*H>4C)
M445)26LH)>24HN938VL\2L2LYAI38C@H2@P5-22HF<00J4Q/^GQ\[OO#^^W]
MD.SK2JZ]]EYK_==O6'OM]4>?!;W=^,H$( 98_RNS,0'6JWU)LO62Q[\GR?[[
M_]NGI+V]K:FM:'\_/"! R3/GQ_;V#X>8)=S2.3^?HI=([S0ASU0W<^^WV1(F
MOB\NL5=6$] X/0(*MUZ,GXU][FOP.MJ84G[(1TX$/VCI.B)\M2U2D>;>_5E;
M6W?"7NN=]Z+K]E:]5.:W[1=M"!X"][7U(B!Q5LWPBTBUFQS^L.OWO+C[HVJ5
M[%V: MS.EYR3JY/K2K42^K"U3NK;TRFRTV<>?/@"F("O-KSZ8H%<:]5JP\.N
MK[TK);)5,VO-=H5E)4;YS\DM&]9<#Y*S[X4O#ZJ\R:#=)3V>>Z:YR';OZ'CL
M=\D,XH!!WL/_)FK,ST]AUCRV*4FNV0%*WDGC8H:#:S9*B>VYPYOUMRD-)/$)
M?%M<G8;5K/U.V\M6(CDS3+*:7O*R1ZHH+&W1+:QQ:B5WKPT556,7$&M##47.
MEOILT"8J#6^2N),?_O1]3Q+D\_&3M4^7](7P2 D-*!QZ?@RWN&T^'N3P+%R>
M*U1&1-U;@UYR<?V:U#\51V;GLQY_4O+6^K)JD=$)VW/JGZLX3K&O?M,_8_O:
MV^Y#,@F(\R6\S@OMH.E]W4?%GYT)!=(L7_J%!IZ+<.\/8P<FE+O01C^AIATP
M4=$ILY);IN._J]2$YK\C$($QQ8!H6<97\1O%F&5..(B.I.?3"U7>A([NO M9
MY@[W&;+KL112:2FT7F$"YL:^NSF]YT(2Q$R'K&8"U:-$[1ACG?=Z:GXE9_T+
ME @4PV&'F #>@Q/0;W#]V9(&$G].?4@.+C<%CH!5;*><PI"N[A[YJ5QBQM;Q
MAXSE@1ZIID^6F16;;JWI_U+JS:>5 _= $30VXL'G90Z:00#>)F&)?[)+ZE_P
M2Q4RI\BX'JQET=C+MYREO[;;7*"+4+=/C=C=DIXYC<CD12];JKH=9/GA2(\W
M LD0?Z;ICC^]O')XC5O*G]0CH?Z%7\5;?_1VM5#5M_<#(T$IO"FR^"V=T7G/
M+?O8H(R"=9KG0)=-"N'+#D\>P:%RZ@4RID^'>F^%^ ]L?C(EZR^D]/>JV;R4
ME]OC08WIBEZ'!WW ;PHKW!C@1?\EL=DN+3^2E@M)*4M@Z0;).56=RMXB],X/
MX=F1T)L<P/LP7*1WOQP]_71M2H,=;@4SF/G437*J.#-,-D@@S.V)$BV=*.=)
M-F"B >FH.;%K++(W(A:R /F^7<2!GM;@". ]L(V,!'/+N"3L"NH&MORQU<K#
M!$!=/*Q0&,UTS<*H,+J!\Y?E%K/=/4^J*5P/PCWPTO<#!8.9R]CQN#RW7X//
M$X+A9BTC:SD<.\#@5+L%3-Z9T(6*$)3KOVCLL96/I<%?3RI+EZ-5C@N)JNG)
MUV[8J_[W45U0_-FQ;\KP]A0ROO3-Q*T1N4=!ESWD48U!J6[/R?-/JV<=B-^V
MG\5DRVO7.!3O@LSJA:HH?@-7B<+CJFUG[XLLA!Y.%5J\2VI633'.#(?O<,:7
M5P6-9"TW#@VF*D=0=#/R4]T^/=5W/K*4?#YV[9\Q$<NK%9.C5]_47WO;D1V^
M9GK>7<S<R>F\J_FY*] ?,"%**$VO6M\VY9O'RUS=2/FQ5NW[*9SYYG)11ZZT
MBC4K!7T5F'Z<.$+)L&):G6Y\#]TSU0(6'5-SP*HHA] MK::5RAO1V(/=\DCH
MJ.B.7E828>IPBJ!SO;VU2/M'S),E.5LQ83,5@MB%N7XWZ-:I,ND*(1+ZYM!M
M:8MG2N=^9+:/5>.]#*,UMM0%KP'9M"=,P-"7?-7*+"_ORW?]C5+*-@F;(ZHI
M6]:JSS>R-=NS+51_V,6UM[]<#82"Z1'_J87^W6^$ C7W/O("^F_UA&M;NH6_
M"5JT>6OX>#4Z(B@C=2'QL! !!A%M;-)%4$,'\\5]9\MOEA@[ TOGT.T43\*8
M![U.!G%E.UH(VYS<K==_@4%UF0TU<&,"G(@]3?B=8E[_CJS6,$&&"NS*V(5B
M&$I4(/>G2E=3!W:_O+'[U=Y^[?<A==7?VL& F(M2[F(674$2ZD&#HY)/_QL9
M.DY@L(=2[R#Z"NDE 5T<-=]?>ERF;-"S5_(/%F%48.I*>SL3$!=<R01\V.PH
MJGY.3G6VG]87)<O"U%-OJE#N,P'X&W.!8VT)?QTR 4V,U.]1-K'Z)J-;CTB&
M$Q*$3\8WAZP<TF>VYOJG4QJ?AEHR#C+2#+ E^G=1+"\OKB7H/M:GRM(6:F=@
MB@_M'C'Y]J!W^)-'1PS.($)!(3:Y$&[-P6W"! 2N/,/&!N4/>%N4*Z=>>E:K
M&*BE\MES"X-SB+- 3(=>M85LES"D_K]DK?U?D]@1)E9L7C47)S(!HM%7X)IS
M^QJB!MP$MOZ#W\-57#LGUUO;9FJ;T5?#BRTG8?OJPP<!&AS:H1<#8-X9X^!J
MCH7P?0&MO%G"K4D0^3T3<%Z)"<B\^G\GF8Q9?M5.C!>=!IOG8%AWDGV9@$8J
M,98)L*?_WOI?95\;;Y7C391U39!(Z'5REDSZEU5MM)Q),^V=#[90&4C.6EO5
M#56K[+,,'Q=2[+#-.+*23M]28UQ3H]Y 3)K1RQ#$>HHG$S >T0GYC56K*TS
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MOS)VOA\BVB/I+C_!$V/^] 3$[Q]17A@BH4A).K7I:NEJ"_@BSK[ZS[5;]1>
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MFL=0??^W1#!70%XP7&[_<@.+ZVRX:1 B(U^\VY,?N9P ]\(G!HJ,P2U7]CS
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M+XO^LAR% /R"J_AW7J,^#84 (\T'5Z-*9)YZ)VL=V5-?(H8WHK'%9#?],"8
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MV29M,>F[P3%N[_6+Q#]^1_KXX3028^6X'&*X->@ZB%YX+0Q(CJ8HO!1&?%R
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MHC7S0?SZBH_$;=5_WE9>[&[*[/=^,$"0TW6I?'2+B-I3VBOP3:AV%C8M6T7
M%!49*$&%T?G()P.6&66\J^LN\!$7-WX)>VX1H40'<ACYX?3.5^3KZHM,P.@[
MPO4&99YF1YBWC*^\/?3;SM$"XU+N"EH8;D1_TZ/$<G>&O"2M-'W[2G?*^>8#
MSG#C.S-P2P+'21/E%3Y_H;5QLAD,7C3="GBZ4K2_UAMP/08G[)O[U+8S_6N>
MPD"]B?/KOQ:24I\:0)%1SRA)CM-1DEL5/<.M+086_(67&JH^E*V.E4X:/K$
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M"G5&%D9FDX+\0 ?R20Q6!Q"N'YPUPV@3"(94!8LQ8M';D^@C R: DE,Z[\"
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M%]YMB=/1?9LB;RYK'="G&ISRH>O,RGZ0X L*4BMYA6*W7$S9CGSZ-*I M+$
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M#.DS<]6A_P;G5SGK*.I&A#(S]4@A(F@RXC3UMB\>+L%2ISN+D64K?.KO?.K
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MBA)EN=*^T."I*@2_1'NRU)N@!7YFKBEV(TRFLCLCV$]?I0*5!>XD-Z]+3_>
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M.T()WN.UAX&YWU>MCV[Y=WY_EUA;6Y[<1U=_R?#E2[<RCOH0=>/_2]%"+7N
MT1P))IM6P/4/I_7=(ZO66L7I#(R&SZ.C#FTMT; M0MD\;.&LQDRE]8.)0*:O
M_LS]R:")K%!@YJ!^99<+6C/J$KI-F,L"J;' \Q%\=+D_Z0=;OX54<9TZ.DX?
M401#2BDR@_R+9]?SQ2:4]\MY(R&\:C&PR._DB$D[*]-0D4IV1F?FUK6[07Y7
M':T9OR>6W<H$GJ^QD<3%NW:/NQ=/CJ_JI@>A?VX'R<FO$=^586'1';8'/T#(
M,"@3C3YC5,TY%W/;Q-7*U<U8V"99Z37SQ7]=5 4B$6)4RSCT>:*!&[7Z)+/9
M_,LPZ^Z'=7.UZ>I-7X"T\L3NG5"/$#_%GA#<NIV8:%-F%OID?5')'!D.FYDU
MGAJVOMWMGRYW<5 0<NL5%2LNUY0.0^#&-9_8>,J;J;_"GFTW>YCKE%PDW]QM
MA:E+_CB"*,GVWK#^M<>,X]:[D\R@"A0&R06<8P >E$@\2PDM/-=ZF8[^6V,G
MGAQ3^7/6N5=[6M\8AZJC+'+Z[DM-D/NZ#TQ:Q_XZTJ]S168GS0I<WU";5O_O
MM7+=J &)^;BE'4%7;Y)DJ\(/]0XT%I745:^5;?\JPJ#"<0X.=J]$V?^CE>9]
MGNS][(Y!DFD(-07=;;U&;LU"5C&#+7YG7DG:?Y(XG^&-O]X/*<Y,"0#_' >7
MRGF/ZY25E^*W#&RSIE-JRR%YP7/WC7'(-AD>WXGAD3@5K9;Q0.KHQ-I//8X6
MLYIS)NCH.M=5N%ZG6S.'EE9BM./WV4[P2& '1X$9@OR($%P_?'48O496:3EH
M;S%A+#RH"8_VPW4$?7*=O8N\9-4?I%>:07+&IPJDJ+4W^<54:4:ZNTA$O4!\
ML*A&WIKJK?;>0.)Z<+UEZVF(PZB\DMYR^ EM^]KIM6 [OQ#IU)/)YS->A/$H
M2:J511IOO%I.-HB>N%2#4U1P7,^J38N>M$7.]Y'!C8^B&E7\]<=EMEH7-!W;
M*TTC6];3*=HE=%=/:C0W+$Z3'IMFE( ND!!\ U?37U"Y(J$7HBYVY0]:1.[C
MP]7+1Y-;HCGNHEDX!T3FUO4VG"-LZI^?(HALR?O7&U*PC^\/%S].,4]/$:Z1
ML3(1=OE("/+6-4O58YAY>P,]+$PSS">S+(UDSO15-Z1;ER-Z"K:>CZ7+:'*M
M4'24_QUX)KR>Q!(L6#S8BJ0FM,HB.$H3AA<B'(GUHQ5!:*$U78."!*(VU<E'
M_ZX/WU!"Q'6#[9B@T,J9M3>F)0[KAYX)>SZ9P_]HFEO\!2,7 TOQ=H(X<;-<
M\L&:>7YN6KJ'Z'@V$>9["P;AIV6/6 6;U)3>[BY^M"51\[U4- V:,I:)L;25
MSGU<*4] X8?^.09PL=*(=(YUBUFX.!0?I< N9MVE;H!.(LGVB8%LH0[X.3SI
M!-P9V72J"%GN5>U?N<ZYR8Q&L-]?WL]%D[5X*=S(7G 2BUV CA9?6XS*Y'"9
MOT:MO7K&WH@&CVM58$93^5]X++K ;28"WT<!UULOC515J1*0>N&2[_;%Z, 8
M?5OA;])V_WY3P8MBE&.^8OXMOL:.,_:!%=.%2Q]6_%I[6%8^$O,Q':F87E:6
MOVXQE!\C-B [5VH$.@>]A14QJC0;JY8@((XDTII];1H5K1E1/Q%W,03;?N&,
M=0A<. <$XM9 .%-.@/NH4Z3N*#GZ4/N.2(3=),%/A.G.N6!@LM!#7GT59*%[
M6>_(KL/A9T4A;><%427@\@XY\(?UU_SM%8&K6'A=:#(&]^.DL'4>+$-$4Z=1
M\6'@&HYQ91U2GKC+R%"TG'CP$,?C6UPH(F;GC35IG1V_#85&10WF7E\3&6,%
MT7M8%X ,:_HQ("7";:G%G7IZZZQ/.7.RR_ *W;?<IP153>G4]6G%4BU@.PZM
MT9:Q&Q2#Y3$[*Q=7\\O%(=I9 <6\$@,!^B^P?N/ 6)# GM^K8P"__FE:1T>#
M;M[V"]K/=JG+-->DT$H+9$"%"R)*?*0R,)PW!4KM[H?4%CS,)(]H-V>.6M8V
M8(*#8R?.]'6V#(AH+"LZH"@*K0\T(E-51&AJY>V!GZ;]CIJ"Y"YNX-_;"I:[
M4+U5PW89#64<N2W<V?')HY^XL^:#"@6JG-&%FLE__,@;'>=1Z"6!&(D=JY&E
MO CUI93?J0:2/5%"&(HTV.G>9-10T*5ZWQ'QE6^$_LN>'?;V_C.N\UX-VIG!
M 3,<7>0"S:\[QK_2.XWISL"-[Z'Y^\/ULU6SJB.DZNBR!#><>AH2688DHSL+
M>*;6#S[W$.1(>-I\PLG^:.DPG[*W@L< 8[R-D6(N5C$D.N-7NM/#].)?6&T(
M9V#,!VG50]8LRL"K6J<O71SX*3^3T2MWN[CB(\XWZ$0];N#?_#+M,1::_>X8
ML)A<4!?R3PO2A([K-'!R8!XM^8A7>=2G=H79O?\8H=G0HOW11]NV@1EZ+GN@
M:[X0-RV/OXDJZ&J5&Y;[@O&!7A8=9!CHX'>F>.0KR^S+[6Z\6IF]\IUR(MU-
MW#(#8G;>*E5_[ I.+\#L!DY<JU"X)D8Q<%FGVY!MKC#0:.9CW-NM/^+K_"8@
MYY70]^C<V4>YR^A^2[(0YZSDD39GI$",!:>7][AJ,>>*F;ANS!IT/5-*B"[W
M]V8$R)=LDE#R0[3#DC!A*+'1E&S&"',AIB6EV/T@]'^EO_OX.!:$/P8\(4VO
MMJ%K)]O5!%AB3'0IL\B!1HI3T^R?D3P&7)Q?TXTE*3=QJD,K757F)A(^HL(A
MJ*6FEDP]-_Z,/V2:NC'$D5,9;&IB(C2#!VA7/"O_W!JW643;A2)&4\.-L3YA
M$K:NY&*DK?.^NRIJT*DT7 ?:U #W5# =_EP]D$I.XYSU.0)Q)HX!PLO,9CJP
M&W@1;REH\<&+<PD)/(&*;H/YQBH'6N*3'.UF7)GA5'-ZB!RY^.ANWH-VIJ7J
MF<\S)/"/BEEW!>L<<%_Z[%I_A>S:8!KF9^ Z1 KCH=!WL_1B?9&=HH@8N,LF
MQE;L>YGUJY9'3<";_\%-;5P':6J'TEI(:Z9DUBU9A'0<9B7N R]:ABZUF-X=
MVW\UMF\  H]ZOE1*%6 &=(B:/WKC-5%]SA+7^ZRV5\_@:_QPC]A;SF0!#5+P
M$EV?E4B4H^XDNLHS<1^\7?EI[*'8O7_U?ZMDFIO7Y'=O6&598YR81./%5!%G
M\V!5V<>F#8V$5T8BL%//'H,BANUAEA?L,KR'R+:%O9LX%<HF;><L/YQ&*?Y1
MO6UX^!:L>+[4+*L14JV-3PXN, A**-".\J;;P@^R? 12T.X[4R$4T*85EKD*
M9MI3@?%A[(9.7K: U02<>JJ2TF(7CMCCC30C#P1VTU9?$14NW327*GWF:[>N
M-QER_X$E3WE%@:MW\/EULF\A=E:CU*_486[M)U'&[G'L[KQY*$SVK;1Q!M3D
M9EW/M=. VAM].6-6\7ZBN$OFC.%2D]NAI>RR&T67]!'-3G,I%[NS-_HR&RZ?
MW'<T<D#/F8EXN/+K=>/+FG8_5:-#Q]-+C@'$H<[OW(+"'_6OUX\EJO;6%;-;
M7X:2.!>7%.^(][31_-\.72/!B3Y+\+,L>9I</#%DR<46#S^%$NLXR-Z))V36
MC@5IC>(M),8&PL,F)#0S&+BP;S.=(Y*1ANTK*U"M-M]-(WM/YZQ4HL@'%I@&
M2C:40I7,FU?S,9<Z=%=?$390'EYR66#ZJ9P ++RRI3V"<0!\TO1F9K! 7^A$
MAN%CX1I-.MRF%)+$2,-)C#_;>W(,"*;?*BF2\@L3M0Y<Z[;,-UQG%GWY,=)!
MM!"?A-R VJR/O6RY[[8*S:GL#9S4_%"<ED3\B ];V!VBDE)!BQA2 R,Z()3^
M!W6GW7*K\O=Y-/\/+DL+)&Q'G6"9?6L=]0DR*/>R!YU?I/EBJ9%R#PJL&\>>
M:K#M[]/A+Q8G2O+-\Q21W4T)M?I"_].WGJAQ&6E!Y\>61SQAIA45W^H_!IR9
M3"2&?W!B(NU?;X_<WZI253,$HM3;#&64?$=ZT$_(?@D5A9E>;F+FH8]'80/,
MTT</T6W:(&^!Z:(NJ6L-!92%Q"CI"*W1:Q-!>6K4AK_U]<I0J1U0E.7]AD3.
MAB/]*4Q?-V6RX]?>AO@Q@.KO0R5\KGU-[;?-,1[7G!/M.7KB%<%W##AIR&XV
MO(2RO$LSC4%[\3T"\3.??T4<ZDL<1',DF?W0^AK3D)<CEN>9/6U-!_'5/ELB
MG %W$4;Y\TS1FTX(AA&OI!,2U=#!=AS-<+ZTRD.XK!.N([]+MBJ7&%<<37?3
MO1T#4U$:9F1!4\#=)1*J5O$.[P:%Z9?2<"=OEWU.K_;8]#32*).3T35+3\,P
MWEJM)!=!%"NHD5SG<7)H).+T8JH0IW^!5__D1R]#X1&B&.V@1RPS2I VG^=>
MC(#)IE %+JQ9(0:0)0[2-V9D.(6%&W7WJ5Q+:34[2TQS!NM-MG -(:F)K]-5
MG%VB#YDX\O';7XC-/B=F7,S>[WZ+8Y(>-C6<Y52SI0Q\!TW<?A80KN@\_,)"
MT.+:!&;N,NCTO5:M4:(279NZ74-M@>WV6S-+J:CJ#S2#5X=A*LLK.2%++6X^
M^L!"F%=PR/VG^G(XUW\8P7Z(8F; G2>8#DC:T1_L>+2'RW6&/O,D9>?51/8K
MB=7XDN8FNF4JR]CGTEO81I3FQ)6Z.&B.)1BC,PD>]5'F.K/[ZETG.P^CWI]<
M'B>*9=G?5(/PB-P0#_ZK)DBXYN).A1EO-K04ZK YKY.[?K2NGB$_DF+VO!,L
M8U?QL4@L+'\H1Q*:KR[V,E94M,,MJI2GU.0F[HS'U!D*POI #2)B6 >)<?AF
MT12X.-.@?*FUZ6.BTI!N.]%Z*6YSC6;.P-"^NEY@SM V[M"W4Q$*!1:1?[HZ
M(,.D=S2+?PY0=H1^-,#\$B+T#RK=$:+%@2ZP?[PSWR3QW7-Q(&;N; 7:#%[(
M7LZUP7B;;2",<>+&.^+=8+-;2=!D#)>M;A7IW)D73'?))CI!1B"W[%UD1)=D
MZBQP1: "4CR(]J=E3%-^H8=V^Q!9K">?9U24?*?4@?FSK>ET9WESSD1>M@)^
MR_3/\2B1'IQCCZ^=D"<7ZPX$S4K06R)VNV)B;<< FM]J]%/"D5X!,&HT2I:N
M'?/6UZ2P" 6BO,Y8C(Q:(Y-MZY @P0U7=68,SD%9+/;LMAWZ[+KL.EG'YU&X
MSA/S?T&%ZTH.-KDB1;(<M=?C0%+XAA5X[>NOH .-[\O+*1\1-CZ]TG.M)TI5
M5)"*$0D^E9B5R>R#D%]W&9[LA&. I]JT&L2+(\#DGQ_J; A["GO22!?H5&^(
M-[R">@G(-%I3T[\3G*C1K&*V!*D;TQ008,*&.CBB658-B0P5'O&BE*SU0WD<
MM-*L=J54QP+;5XU_E.-]/O' [61(_QGLQ?EAL!#/LY)&-Q'AN;G,VC3"LAQQ
M96L'8M%G:3<#RMMAWN;E& .G"SC=H 3TX5-:9,1_0V:=F):TC26_9!#",O88
M(!(A@V6.MD5=85I_Z"CU:BHS$PM#55WWBW0+1ZK4%Q5[3T BMO0<1WPW"2Y:
MBRI=*<O$]5J!5M+B%_B9*&66(XVTN>]'JZ:@.RT3TGXT'0,Z%0CO#(%,N<[6
M6SG@V ,(K<RQO[2',J .#3^S/3]/4<E?>^1(/IMY;46.=PE-N^?W@B1I*!SA
MQ!POC8 R#>B6E*J\,I;.\-/ YF, D&5(]XNN("A-$2WX.NN#Q5ROC6C\4%,M
M^EN\N*$! X9>>?SXC+;UOTNGE2=$TD/EV)\K#80;:T,_P1CC@WU\R"%?^Z]O
M/&\5C-=F@?OS!52;2Q8T? H&H235LK$%C6K&Y86FP:+N IK?P<L@@?/S+A$&
M;"S1DF+)>[_^&.#VC06GC3Z@SS<BY&-.3G^AJZ8NJ<75V[_I?RZ-&9&AM137
MUV]=)AZ(C70?/&?_.KJ$;KM)\N22QS'@83V]ZAVYNI.4E%0B\Y89MR2OL6?!
M$YX$JD5"4:<[@I\1&EX5CH^O)*PVC^F;4ITB=5=V3.'"X)(%;]&#@B*\-<Z5
M(-\GO&ZF:/7L^3Q..;WH=EEMBT.W?WJAE0D"DING\_/.;@PL< -L5GQ=*3(]
M'6%0.6!R"5\\FNB_$KV,64DIGN'A\!P#_-1^Z>^0 SC]IJ^/ 7L' ?!Y+%IX
MH;Y@L_SH(:J<@6=_C !34J=)2PL)^GJ5+"=Z"?;C!EF@[;\9--U)Y6N3L*[.
M^H9#UU(<,YC:S>E;T7*\TH3/=Y UDM(1OZ_YWW] A,^8NF7'8 \Q):_<&AWS
M1+_'Y.1L)X*8SWMR-F>@RV3C_5(M(\LNX]R 5N:6G'S)H8[T@>FF=ML"4P[]
MC^6,.D. _8[@=Y&\[GJ.^1X;<2O<0I(:$FV<TMHH\X5$/V$G89JD[.?CJQSA
M1)G16U.ISNS[[K"168Z4>1U-=?E]!CI^<C4+9<_A.Z15EI!PSLP%1@']='R$
MFC FS\F45MU>J==&9F^:S-O&:.P(>G/TZ!-YV-[+HW<T:F>9U@Z.E4N9T]=>
M@C';"_MHSMDC2JH@4YVASBZ(4%L2$$#F"].UDA8?XR?T]:@NLL< H\G G)KR
M=0P[RWI$TSS<Q:A]J1^CHY]3CBJ>^G$47)O&4 G7B4Y1GM',.RW"\SY3%YN!
M S>]*_N9<=_(>2RM7*&O>/E,-5)'-^UYVHI^\FF#!]4J,<B?=]7:1IN=,Z"O
M)=*%9:#Z!'A=LOL9!?"1?)?1I5('^M +$*!5)&J )! X% L_HZ^$H*#/3=T_
M"#'F=5X_Y-3I/^L*IP(%UW\^^0F;5,.<N9ZYN]8W0W::7@L+U(*9%."F8$>7
MA>U%S A*$%O%WL& D'1L\P\B!BPC7%$D_!$#OEZ6>]6,1YA:=&:^-[1^)M*Y
M>":]>'M9=EEVYBG3C\&U>R]#HKZB"0/DC6/ !99:&0K=TW\9V\!2KHYK2FF(
MT_?P=W_BYK 99$<<)13PHV)!=4X=;B>'XEEZY>LPGY>\+A)'%LEOT(K57 I;
M,!=7JY8>!2$EFRTTM[>!EG@2\RI_423RT:@>S&G>6_08((K_HK9-^;OG<M=W
MB2=Y?&-]/WO<O%[7<YG:5,,ND/II8=KU;&,_1F57P<;;VCOOEU!ZEIZWTD(&
MF&6KJ(/4Z?OHO//^4[NBA9PAS-__5>C6X-(9S3,X)7F3\TS$J!6KE9U)6L1P
MR>$8L#E:Z16EVUP_P;D1 1D6,FWY3#?M%/KK4"".98YSZF54AK2UGAVM_&M4
MHZ'@X5M-%1FB)=?)(CO$M'1]NA.HO)%&9!^CC?U3B4K>A/6)!GP.)N77%4S,
M[0#'?DRN,*+C?7D_1NG]^O;^39Q9GM*NR:#=2MKS].6^2BE$;]_SVN$ \/33
MJ*"H"1#M0?7?QX!ZM<Y(;6I<YX(HR_D;@:W6GHV.KMQDG:U&:3\87G@P&J0"
MMWD96LFZLP@4FB<<S2*UP<JEGTQ]O_7XEB(E*S#FFPNUVINAM"'&39II/.LD
MC>1,GV@I8A9TJ5%GC@J WF&G2DOOEAIFX+Q6>'6(!I147EB/!\/GUND+ Y[^
MH/R?-QMOUAH#Q_=LH.F?K,M-D@+7)E89GU^/,M[%).8= [KB$\NXWK_9R\6F
M?# /1B*6FJ=-]SEU3']#>3FQ-"2+24T++D:M=_^;@?*(%+U0'Q>M03H7\<#"
M'3RAKQX0$KFX(\ET#=?SN\!\OG(H7]12;_W)T5M4]W5"F202M!5Y;7N&+0V[
MHY(QGX/F:V$!7:T<;7!<P^*]9J:>!+%*]SR%%3?Q][;"($U%\S>>#&-UTW!R
M\GK:XG?F%.3$N[JMTA_G>H@;XT<M@(.7<2S)->^LX&KTD:.S\Q2V4R74#T'3
MTE-J3C)^:]&IU9 6X3)V%?\E\_P:WUB]6,W,O_U*9.>RB_"#!0JPPT!H<:@#
M^'N$/&V<4U?*1%-V8@.K>;P:.%=S+!LGM@,'I*95E!>LOXS@YX"6^9MW)*1K
MR6N95O_:AV NUA@F&0<2C3W!WP+8HZ42M2^3[37OFSQ[53P"C7A;:F6L-1:Z
M0DU+S^F8&K6U]87/RYMA,KYOG>V[E0[URP@P._\<X>K\UH(@XM<C0([FG&DY
M D4$TF7_:Z3(EYLP_(W9XSIF=PQPJ1_&FX-$(_1)V:$[VT$^1@(G+#\Q@X],
M)S1UMGWN^ AU-:%CMQ[5RJKQ:BXO#VR$QK6AF5=VVM1.HUX0"E) HOK6=!R$
MD#_HH]V>K1;7TY['LPS5&R/5TXV[LA)8+E07.S(%^SF[GW-AX3Q*:Z7/22%F
M8!!W<N>MSU&+L6=<6KO)S0YRKEO_YI+'[9&'R]]3Y ? T%<ZUPHAV<G7A9<N
M?FJ4PX93+V$=&\W@ET:?Y<[X-$("9SUU,3Z-8VD!.2&Y[W\U')FCVY2/ 4\6
MR.C.5CZZ6,*^6CQ)@$(3^SNP.G;^(HW4'K[S.Q/>#O.+U7"Q=!C7. J/!-HP
MT=3K2&G!#7NM'YGV6O5@!%^%OZ/)FG)=Y-4C14X_7. 8\!@8*\B292(K4#W.
MM._S<N-$A\E6G3$-"W.8Q.L:GQ+RG%&#[NDXHOHCY:)4\P:OZ[J(/)>56\Y]
M%4G D71K'#2P$'8^M^C2W5+%]:TC>_OS-4&79IK3\F441WSFAJ">9VP"/6YW
M$?41W;$)BE9%<8=8^3:3OINX6/970;MD#=-_%@BK+"'<8L$6EEI]EME,S4HT
M5/@AD15-! 506FX) )!1@B.;GC5-8QYCWS,Y:A=0U[OL!>>2$MY?V-KV<3L?
M8_<B5UP ?@2,ZB"=Y293BEJ/KF4[Z3SK[N16ZQ7XC[#77/4ZK^G'MUXW8_G!
M:=UN EFB':<O0[E/2738-X]^WF UW]QD] AEZ_+X2#'1QD/90!'OU0#)B$(C
MS[#4N?F<5#K 47Y@Z\G>C\1?MBD?P]F5,3+D=\,5S%'AN@*\O.@X_CD9]L3A
MNM78YM5Q_-Q=\R\(Z *TIGET%656T<NW3,S<Q5M<NY^D6)SL[OGZ'O]OC]TR
M0$E<WWOB$OO-\'!/IQ_YSW0/_P(QULUNFY?JJ=&+2]?SC:.FALW2 I783Y("
M-SC+X0YK:K,0K)DAO#D/AGF=TYNE8!:X9&;1Y)^^>M$@O:S,OU1F]?9(24&Z
MV'OA\Y7$\S.%C]X87Y)W.IG8^4*XYK<[CX0?Q_QA +ADOY2:!%J,(]6BDR.L
MJ7 Q;_1YDA=*4TV8&>U(ERH\&9=D*&GLSL=H_#2['N+OV.-/RUQ';;GGK]]K
M &_[RMXW4D[KHQ3[3>LJPB!E59,[[A)O; U'8ARM\^XOX)?-<@MR+]Q@SXG$
MQ37?"5>RAO,P;N8J(-C_0OQ=H<C2'I8!S2Z#-OF/*P\SI-#96RQ,[86^ A=:
M3Z^)P?#UH^M9NIZQ>^4N4MV19N%ZYKS@:FQ]7<+V,J&VKB%TFBSI=5U)D&5_
MY,.%4]TH@2@RX_ )@7K9VH$FT"7 C]"6 ,5%746%D0>/ 9'1O9H#51G4!8'Y
MT+-4%_YVQLH*8V1BU);&J?3S]W^62=YJJ1P8QQ\#/J1;5T=8F,*:@Q3[*LJ;
M&OP_E5OF08J]C;L?YHZ;O4W_0%WF28LF>DKW 3>_V7S"0C X"<,!Z;6FA\O/
M</+@VX,7 BGRW6"LO!%R/AG&"2)J'P-.L5%AHRXCVQ&.1U D;"&6TOR:J^RT
MU78E(.]&%@.9QSCTC \"Q>??&-W+*=$S<W5ANCO% *Y6/)[EX?1'#0-K5_\F
M(0I>NB^"4O=)XFNM0D>FL;YP.QJ6$X-C9H.)BG3P7P-!9<P IQ% (RI]03GL
MFM*VVU.54]](X&%[N^(-J]=2Y=9%$GOTF]')3\N'TSW-L"-0HLR9/D56 WCJ
MG9'&1CA*3J*UNPJ8OT5.">J'\:A\P4)U+; #TAB_.3L6B9T+6DR#U^$V2?3P
M#KA$Q!]+EBEAI,0()?Z&4P5N2P(7F&(/O\E:A!N3OE7S+5<ET98Z#I-3+N<7
MZ6=V\]G-RO1U[B9\M(_A>GSYC[GK8Y]*NXMGB\SXA4>/S@?DV8M\7[?);7G<
M)?'L%>YVEX*-?P R]':7D<JO3\4M%WYI'EEQ=UB**W<%9#&'27T_BE*>^R*\
MT\?O:R-QC"CFB5N7.CFNF;"M(K$*F^1(S;$3M8G99,F,=)1YIR'/ZP-H2X[3
MQ*GR3^  F<DN,IPEN5'258K8W8 3@O8YJ9?W*[(K7V?1H OWQZH#Q_*U6O&C
M^TA28M-<U?M(_Z<RL9,/&X<)7LJKJ&W94;6BE$H/3LJGBA_HND_=J<UGGN]:
M<\E"V&7IS&B!QG4(B*?DXX</Z<*AUS[BR^:>S-D/*,"ST>>^S[J++D/UZYY[
M*_S4T0D(@+!VTPMZX;6D30O::8;!MZJ]A5?YDDU9\/$B#/ \ZQ[=HZN$L,15
M*C)A9,[8#5TQ@SCTR'B=]O01WF$/+K &4TU1SK0[C)F+&:SRU13GX*^<OP-X
M>>..^ FI#]%C$C#%];$\S[#:((-Y)W.'3\AM$]"YOZI&7D$3(;W2GI!<!=G2
M+F,='3T_!0,N_!;O$8MG@NW#@&_@>#CK0C3#F3GT:2-*@1D94,WZ@_ZZ_,+;
M1S27UKRR"$W=BH9C *)IW,_P\@*VHI[CDP-VYT];W!%!J=VK5_();@KHRT)&
MTO\Y!D1'M*"1K_66%F5!<*;+:>#;0_N]!&-CV1]8"9]/Y<^[&FYWR9*3W0V]
MNGD8#Q.MK,S.RG<K(*'0<CG=U.SG:>DE(ZNYQ5D:..ETG )L-SW'%V+M,QCP
MG'7(3B<M9@/KU#93JX 2*'5SND!*ZW7ED!M3J".J,2>G8L-0JJ&U]F7_0P*M
M\G5:L1>,_U7#_:S[0;?WRE.%DE0LH2/2]'-DX^\3%H>\QB*5L''D[2-PXW-3
M#$^OT87F+.6KPH4GEA4@9@H!$.O<:ATP$3&",V.]K<O(Y;K[51\Q_>^SJQ[%
MH<6_W+W*I=]8&8N\_6!E+ SX?Z_?=D.V@HXNL6ZQ\?HBE.K?(ZPF(T(^K$F)
MT._3?0L"%B];=ARZ8K6*FR!%1?%JLG2Q6'UKI$S6=)#.]]W%NH:"H?M.6X8P
M(C0JZAC0$8M^K'8H?PS I_YW:MPYT*\A^ZT\X0\9VE:CSJ\KQLU2(AO+GA47
ML]AYBL_V$A6AZ6/",QBL& ^"_4YGL"AQ=S5W>4-NEO7@&!!WCO,O?(^;1@@@
M2XES$?TSO^A_.8.8]/1'I4'Q,>#]V[YF-'R$4S64#GKL-_634K#IOIAZ@<E+
MB6I<J@PWI8,2X5T-!X:&8WM\UM X:*029/BK:  JO$-*E/"Z?Y/\F/]Z]B 5
M;;#B_MS]<2(H#83<84K;_X,FQW7I[G0.\3/CG)AJ=.O. "?GC>SYZ))I9E);
M_I6Q$Q/48X#3))$O**AH2+8%[<9[1^8@CF5-*0]/,3*9U,RYC+3.9C@M3"@J
M(K5=*W7W/13LL!>M<7;;ZBFZSW 0C5\?J<OFF!3YOMSJLV7/5I-SK2%9VPIC
M6+ \M&QEW:BW&UH*M?60+<Y>9:2ECXUCQ<T@*BX%?\-Y28LO"GB)("HJR#()
M+A5A2U?K"/XXCV*I4/Q..K)N(8^^J%5Z(B.1+@5=408M!7>)M8G;[8S^>W$=
MY*%#J(L#*LTR<TJ9A/R?QF<;3A]<2B,UAGSB$)W$$?E!.D/4_H2R;&\*:;>X
MVZ%[2?U'=LSA^A!_$T>6EIJLJHG\LF\_%F0R+I-O8/UP7+,%"9WPT]3;^*4J
MMI>=V#B>=W_DU=R2275]2;J[I"TC"*&(\0>/Y2+LJR&"I5\I/(3K_ Z#X*]7
M+YH54UO6WS "5GR1&%I:LLULNE"&;@#F9:H&Y:S9;B+RN^6T $.=&7HDAG+O
MBN)CNB\!$_*E::M)03-^@K-KI//[?CSK-6NPKW87UK+LL]51?FVM0IA3X\J5
M^!]!PBW(/7_L%*&6_+E1VX"T)7:D$G&>74:\"HQNU4"ICG8&,WX_M.1'3HST
M8YEU[6+D5V?/':;&1MQY MWM-D4I5_GBUP;FHRLL<(B-:H1$):'8;NF'F:)2
M0P)BTK<X'6%R"RUL>\8D0^RLDID@]HR1QJHHCM]F27K$PPIN1_K,GENVLS!]
MLJ&CVP>>NST>4$"(AF@*KY1DIZ=Q0O][6_ 4AZEX!&_ZPHP\>L#$=4B)H;9B
M,E.7U&+#+%\3CD(Q)YQZFNBR"4L"<;"@[P&S";+UB6H\#H1B_LS=@7!IGR U
MV__&?UREA7>0F]>!8AQMY@PU.._D1%80SLM5D-:=0VOJ"\(WAA(,0)U9(;J3
MG2KVT%&"UPG1=S3V,>!5D/F9UG&9UK))H9E^CZ,E8P2$8!:\C D^!A2\37%M
MF"1WA_Q:L-#Z]KY=4PAJX6(<GC(:M0YV'/5'_&C,#DEK3O-IIL/Y6R\Q)2ER
M+UD@V@ZE(5:C^C1*J9UAU'&7QDGY+79P$'AS)=L^!*'JY[=3A<T_LAGW6VT:
MV_<Q6]F CFUO[VQ7J<J0Z6JQ>T!Q5(@S+2LQL-P@I,-59B2(C]=UF'#FU81N
MR=LR<K_')P>7>_<73HY7C'1<.>F@A$FN^(.O24EQ@&J :^ ^3/TJ8W[F('^2
M#">'0Z+\$$,A0P-1R.;Y92B[YWK1499%J34#WLQXGK227-CK:X?=D9/4V(<5
M#.$ZX<PKH(X!ORY[<E:' %FL,Q] RYO<\2&J4%/C)M 7U/#]";+9X$(\70:7
MHG]F=\WJ>H<?[O]A[TVCFLJZ=M%468J(B/0*"*4(2!N5ODVI!0@(D1Y"$Q$1
M0H2H@ 0(I)2^?Z4M04C11H30AR@"D;[$%Q "04*;(""=)"AA"VE._+XS[KCG
MWG/'_;XQ3O?CS<BS?V1D[*RYUISS>>;>:\_,P-<,BYZ?["WFHEQ+K9[';AS\
M@NTV,],].#Z#INT,,B)3XLX#^$$6H@"VNSL27P4X]SHB:-+#NP,9[?#DV^VL
M$PW(%WT1II^WMW4ZX+$(3+9PLETCVLYF7]L2:4N$G<Q3G\C)6!O)^[[0FE<S
M/.\85C-J'O,U3*4<$60)"]\P:O]'^G*-PTM'WQ&-\*)\XX?.R_'+.4XV [-K
M]OCS?_[(\('="T1KCF0RVX];K_\["]HG=F+#0@9X7'SA"T\98SAQS\R4,7Q[
MH&>6YK7&^]7'[OI4AVG#0,%[1(A,12T0]]6WN9E2%SYGZ-%,\4/:0+0"?_ C
M'5&-1-&H'@2:YW%Q*%,E5#5+XE._ F60E3:MEB\9_.ZREU=EEDB=^!'QAF]8
M2PU'E] :7_')'55NT4H+IG5[<^G1:YR6ZZ=E<%K8PYH15^TM)5-;<:<<!TPK
M)4-Y-/11A4R9U'+ T1XE49-@2":V99 C#F$' I8O@P3<CJM'9R]MIX5'W7W%
M&V6=R2JA-R3NR3Y8=_1%N#<#1][MACCP[$2")(:V[5E*F1W7Z"5W[*/WDY-I
MIPE;(9 [^:[2CM*.XE?+-1)=74\)WL=>@@2O0X?2(J2)MKO! Q>?SR0H5)TZ
M7W%TR/NE\\TG&5&?*@ZKSY0Z)IR;N9GFT9-O9.N<$?L]:%5-W6&*K)%7G/,D
M^H7J7\4AE@:C/W$%)'2W(1%'1/7*\T&)<)GPF8V2$RL["Z[CNR$RZZ*0OM)3
M4_?&@PCZVR?6#0V*$HGU%<=E#=WJ2 6R^[%S59/#5=S,R=91<<[O9,%4QVK=
MZ>K(O<&M"]W2FWKS*M9BG ]:3##)W"6DW]A"H*)>>'%@XXOD-TF'%")E_X$H
M"C=TUAP]DUAN,C/(51CSZ-%XONHDDN.JM>Y)//W.ZI+S<PMAET\)9[<4?*"!
M1WN+<S0T$0[."8CAKU:RG]H=;MH/.5PJ>;UT C$2-VQSK=0)!]8KQNKSAA=:
MA!X+[.*#_BBRWMRK6E@O-6?&YK=UGGC!,R*.@;%M@VE?=!HP-@$1U=.(1]%A
M0>Y3[GMK1W)C9"JT8!%O&[LF(LPS'Z@M1PX(XFRANT$6>$ILB(?+<AR9838=
MK\BO)\S4ZM&WE=)@YL]>Y1QI:F$29^?5F'<[JQ#4"R1-+=^SDQU^L8_N)A8Z
M$NWN9BWM%:2UM^3?L^N?"&&HG.IQE7T]>M1RX.1SO_?" T6HZ8$'.=7+ZE>L
MG'(?V&CH*<J5YGG/.5AO\W:<PDHLU;_:.SS,#<O)R=M&&-1E]_-!TV]X1Y\=
MF')^I=9QW%FHOG;REC!#%'P3V0FVH8:;PH]B##+/Y4)?4RHG,9*H&B"+#^HS
MI$;*D-(?G" R9LC"ZVV&*Z-.S(25PZ]R/\098KL5^*" AJP%:0R"%=9GH0:,
MTC-C!F$OJ,02I6Z+LTS58OJ+"+76-E+':\HF,3N)QBX[%*SKU581K3H9ZKHK
M4EMS^V3?VB_8VF^N+K4F.57J0U\2-)RK[I2=LB(UL:D94K=7W=>_F1.L2FQ+
M!W!FN//WRHY27)6EJSRM!!0:\BKLE>?PNX&+['SCLS)ETD[!EVR=R']R3@&>
M51QQP&LQ.Z%=-L7,D1$K\E9.FI34:@X?B(39[Z5\&FO=8:VY1>Y%*Z;3N081
MXW5FF3KOZ.,ASST\:83WWMYU)%T,E*7+;A)(!43<6&&<%O>YQ67.#0!1?T;2
ME;JYRQ5A9#UCD)/;K9(98)'9N<^P/)IA'U3F,T]R+#Q;XJ.=19D?/CA.EA71
M1GJ TM]C:\^R<V9;XG+==VKYH,,_VHK<XB#&NRX"4TN#;Z&'D7"I."6,S91.
MAVL# .]N,XS>SC*396P]9$\3_TY.)!P>(3&TA;RI#?5$@L%!KQLL/LAM)]C-
M9#GI:37"0*Z-D!@]3LB([V] 6DLUG>CTU'RWA#?1[0UKJSI\K!F=ZN#\Q*E6
MSJ7"J<3V'\X+8E9Z3(H'PD2_<7[PHW/Z@^S)LW*UDJ<\!WS'3[KD&]54R?E.
M[MA?^?T@_3?!."_&O<5*T7,'%T0MM#FN+*$G$01WIU?C7O2%?FA2J1;3O./^
MNNZ@16(%<F-13'Q=ML#D]W>J>;"]/EIURTG2I76YROTGP_=_;-77 4XS#['=
M!>=\A-YX"Q'J$/F+8];(RNY32I:Y5%5)*DIZS0BY2^D',V[I-T@@IVB%J9@K
MJK@JQ/YF>W1P=!4P7E=@9V^B:7=XIX+S$V!]X!_W$=NLH*@*()A+#&BZQ>DK
MJ'IO2P;X)Z"P9_X,-3F98XV'AB%KWG;) >ETPGW SD/6RD/_L]Z&N>H7]@KM
M%ZH3 RGB&-JE"U0<!,<M^%YH;II"66CP/L 6DNINET[U^HHQ,PIAX*3-E78O
MF:D[3&PO5P3*'$C8TYWO#JA!OUR]WOJJ/7O3K;V@YKP,]6DO):77K=^Y(JG;
MK<9$HJ'PMLH_9U^Z)DF*)PQ,Q(=S*_H&:7Y.E>L.PUXG)]2&91/E)IB[R-N7
M6NG'&O'952*PBU5F]L>M3CPOJME<2B["IP27)X!9-],_Y4]U"<KK,]_D,Y%L
M-N >*4HND4WZ!DYIWYTMKG1$HOB@HP:ORZNZIWM#WU!#0IYTW23VY/[M!&DM
MXH3_4+L"LL9 #U01<6I #2M'4P25,6]*468NDY-:#PZT;RO]!)B8O@^QVG;H
MF/PV71].N :?(MIIRI?\OF88G?3,/Z *T4@+=M?U"1:6W?1Y=%??3^5QA?
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MI#0C[<4L([],94O'1VF?!0KE^H D[K4\3-PQ0:=0HSA#RE^C8&PB)RQG_L:
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M;F^V4ZG!T,]!>%] *.#^,T;]YW!H"0Q<('/^M-[*YX/NCK&*^:";V@_)_X
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MNO0'A,F>IX-S9_U3Q6TK?1H[!GB[Q(5'W&.A_"/O=P/0O> &F5Z8(GJ4=%
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M>31<KMH#(8(]A[+X0S\P+"\B< 95(D$*+(F'U-UM9J=TS9^=7&1[QV-+N;+
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MLQX/U)R;\ZLEAF.8^U.R?2>M5F3CLK^<WHDDTEB6LHFP<"SY:@':2#K6H:_
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M6>Y1/U8M5(D"WJ!QX+X=@GQ.I9'_PK/B>]B9,@8.8^BTS%7J"DN*('RT61^
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M_AGA><NFY,[05ZJ3&M(7CQ+I;E58W(VR;6!S0=WO@R?[L%_Q4>,TNDMT?F&
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M'D5I562R8<A#3$ P\:7Z]2\LJCO-.H556"?[]9*#@PG*G9K$*U]G"!SGK^O
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M2WNNWY+^OF'8?$NZ5__J:Z?)"\]5V-@HN[*+3T7LS-+8;U2&$1\O&7>GHH;
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MB,@O@%+T'7CTYXRA"<U(Z4(^<"0>Y[W_0$?=TF'F:%Q8):=V7A39JQ3?5NN
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MK 0>(Z2*X%W$PU,A4$ET=,VZL5EY=(#WU%E/LZBWV^%&FRO%"Y0U9&LBYYG
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M@.2!V:%G<R\:HLHRWSQK*95INR"V;B!E1S1Y*J)N,QTL6EQYN-T%>1[;/?S
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M=>,;P?=CNUN?L4'[R*HX+-.K;)M+; 41GV+TL0G&H6>&$11#KA</5D">$V-
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MNO*67UH'$J/LI #W$Z:_,IQP<PO79N] ?\L)\9::-5+RCPE:?FD6ZMB_X-U
M7'=716X.7AK7019NDY8_$%-"*6Z<@U D!\<SV7Y%"<L/Z2:+EF_'DOR!Y]QF
M] 5X FT&Z8X0H[7C'.;YWGY+^#%"#8S"&TMX''_\-N0<]G*N2Z2/JI/:<F<%
M6(Z4])"IOE@316\O=C:(9.1T^ZHKO\U2F<SZN3; I+E4ZPN'4^V@35">(IB*
M;U$;<L],T6_6\F Q%J(I92Z5-U0'[.^4!%$Z:^E[%83)C%LNO<H:;E/(1!S=
MC#2W2!OK(0&!=HN:S*8)9"^B67([G8I"7T7<#5/_=&.?> "PVG2:YKB>C@5+
MHJ(BHBCO_?I>C';EZ-YKD2QRHV/2*=N';&<56A@_L$93RP$LYSB;!U.0!_DA
M,A-@#>E[_$ZZ,U=AW,NJUL^C,$_9OF?B+_]>P.C$^6DC1?'KTG(&Q=3W7RM*
M;31#Q:7BT+;G6]6'1!SPKGD3N>ND(!?G<)V(EE(JP]%R3/0^.#9"%TW,:3L=
M$W$I3D7?9K(\ 7^Q)NMF,S]@!_+'091TA]N,V'H'*O-@&V?CD7?LO3&Z0OMO
MY#3YQK; EF1B,K.X QQ;G"C1P-@&?K[].>+V9XO"F577YQ]_8\"=^BGAGJ63
M&W.%4MD!(\-C6\$#>"7=T\]CGH>.#*MY<XA^P">(^-V&HAJ*= TQ+\#4!LZR
M#3E60 3[4@A&!XCRHQ9YA3G1$8G&4AO>$B\>>C(&4SML B,)[[&T0\E101.&
M@M=GU!*BG[@U>@V&RX9HJYWHZ\S>3H&@Z>ZW]^N?(@\9761+8;N-L/[D!?A
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MW\4I5P@JFK$05,RG0U"!@Z "07SV#S7Q_VVF-/;URK>4,(W8:NRZ4-^+;Y#
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M7PR>75!*-0J@[HBX!34$?7'')%5_7!AXHAZIN3T2="-RV]6N_;F!:ZX&Q25
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MK.2ZA%@H5[N4?ZBT$$4>LCXAD[>!N),EH:WF&'561S9H\N'*PPWQV>GW4E-
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MZ#TVK9H;Q%:L:M'>C)MVT4BZLYA(!])$DB3M'KI9=01'# 2?Y<1^R\2*F6@
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MI$RGW'Q=^T4KSNBOM^:FZ&_KNONG=,@+CLQYZ$QQV&Y#OVD-;2*,8\+P3F+
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MX:2.MU0@E%%*6P"=.^*!S;,XN<"^7 <%DTS](?KOE;;R6NO2]H7ASU/,/A1
M6LN,?2+O>OGIFCWY+ 2-BCCXY,]O*!NMIZ75OI2EV"/7O;WIK#-131):IFX-
M%^000>"P+*QYB%:X #05X\" KE%^]![H0#UY#Q0=+8?<;X=E9)>K/Z6MHTZ_
MW5',T2:944?^):AGFK0W]'#P$5YDE(9Q&@.C @^*C:F/N.UC(.MC%K FZTQJ
MF*3QY9@XKE(6YP\@R!Z8K^2_);9N;;RKYIZ?VNRUJT0=GC67IV_/HN1K'",4
MPCJ[CD40099&X;M);_HBCEC^;A:2@=9<+YDM5&^.XT6:GTN,B*'S5)>@@,;*
M)B" .3@!4(5Q=2!BR#-4AL9P=#JV S<$3:4*HU1K[1)4,HPS=R!"2%<7LY4,
M5\='RAZ</][B-XP_A%(L)HKJ"&O&=P/2(NM#,VKA3:L8Y#Q*P +)N6A=0V(&
MRIH3P'\-:1M-ZTW4"HC '(F#B0 A7BSH8)*D3_[URG^^%%]!'60-#_/;Z.O"
M-?RQ8&"U\:-#@G1W5Q[CN6[]P-H2\UVN\6GDW7C%NB//#,+'&F^^0(N*9_U[
MZP-9^A[.'F>&]W&/U3)Y$611:"^GH^9G*6%GSY\;&V H-7L=#*A2'?<T+K./
MJ6&9<*]#A,J"OHW)X5Q$+,=2S)"F@?RZ224;J+03LG;"]9;M.X%RQ"SL@=C)
MO&KS\RP.^T]>,U>V O!DE_&*HML=%8=+"&G_M#1WL5)*7L73^WROS+9/:+A,
M<TW*-3I88KF[J96-2!5?^&_KG6@U<@AS)./9ZNQ;_![HI5DQ5PK*%TE>(@"G
MHC>?<([Q7^<CSS$.M8&SH[?!*0K$(1@8J6K#1&Q,,/= -L\C8<,8B8Z(34F2
MA\(>*"NJ_0GW/)VP\8 5/YEWE1.G&=4ORBJ;V?8YNHD!3L#OQT^F4IFN,.#4
M)(DJB0J9PX1BQ %54DE(2OQ6-E^]Y%L29K3[3?*2KZ.QRXRAMR%8&F#L@39O
M=Q61P_2*^[5FOE8HW!V.,9"H]/'E:' E74X]Y8NZ"Q#B6NFP?+FI@MSG4S5>
M#.S(KN^$Q"6;G=R0KGO+UL>OA1X/.3"2$D/BF)/.T#._%Z@Y&-"<3KS1=V/&
MU*4,7(U!RMI(:4^1QHMJ5*2#4EW>D8>O[+Y1HZ_1ZYWTRA@:K@?O,[2<'U2Z
MZB[YI6F1S"_7,6*\;ACIV[O73C>]J$@OU&3X_.BK42$V5RALKT]E97.Q'KQV
M@7+"8YF.&$H(#9:*H54L&@&>'%OTY!X($C\!&W1< J?QE9A-&4%TW[H.+X,)
MGR72[E9:OP(*,K/!]:;?J_^R^/N, 48!0'@Q5S)09^;,,*D=HA;^\19!)&*H
MP.L2HQ!YV.:Y-(&$@<BC)%EQ_2IDE"LKT;,-*'MVGCYY("(?H [T0UK?=OAB
MCU@E+$%%@2=<F%[%@2[VP[5N!:^UTQ;O"_ST4W_OE_ZO,8>OC'D9F(W5&\3M
MP>E)P.3^J2:U7S._SIL[3Q[8 W5(_N\)#I<6Q>Q.%!D?>61[0M_6]J"WG<<!
M"6T3>V2CD2N\1"IB-._61OZZ6RWY<]T]0B[M];7 ]&=S+4,<P_*@TV3W)<,,
MTJVW0['O[$OCZS:8[[/'*G/LIV'3C==O,*?P)K6,6OKSGJ.F;QL)KD>ULDX-
MSF:O^GBAK->=ETLN,_CZR :^F&X:_4X&YH8#6(Y[$/"E)6E?R&/H[(%:P:GF
M^C2J)/<\<^6^@6%FY(4WNW 9KA[+8K:N]@-P>PPC SQU:@=HYI>#>J;C]D!B
M8980UCXO0/LR+U.PSC T18*_B&GUO-=O&5ZN3.[56)+?VL$>XEYX:^ =I?[V
M!C>2'E:1[-;-!/I>]$Y'QEF$SZ[ Y]HGSKKV]D_'9?D[&S3@X5Z/QCD!>Z U
M0@[VFPU:#S.OS]KB/^ON0*MB!IY[=E+N<"4QOM/08-_$<^ \C#0T:@6U<9\R
M1RH_6)Z !96U#.5N_N4D17/_<_T*9EU/Y6:*DHQK_O*3?HGJL+$FU2,L^?;6
MM>GUI?HN7_&T7!F5*;BXIN/<"EYSK5)^F$PX?',SWM1]Y+IW4V#AU27[DFHK
M<24CYR.1FLX#KGUFTM49A?G56V:H]F7-_K!Q/.MM%OO7:Y5?N%K,!_"0.D"1
M+\SCF$=@Q'O/'VAI?$CA!@#-;+:9_S\/K__<PF\[1@RH_-XF<6$\")9&2->.
MT;F!5<(,7$8;H?1Y93!:-Z1Y= 0C((X]T(-S=,(] 9L2.I&X(>S[Q=]98+9_
M9V4]_VVW;BGV/5]FJF,"_>/-](ZV=F3)[<([)]%WRK2J>V^-0RA8IK5HQ&36
M+*(3L[E J'2LY\\2V[>RKC%3-F<:F1]Q@[#4ULE*Y(E!XR<?1"TL'5W=WB[=
M/U3H''?8)?%)==YXUT]/]BX3>M]2$+L#:-B?T/U<6V9T"OIWI'8 #_LYV9^9
MEM-K484D#.Y.&\UAVB-WVLVZTG86SO$TG#,7V;.4;X>W=-4O->%IS[-UWHZL
M!6HR3@--^P>M;8HTW?"/&8$^DF[T/,:1I[!)UI6R4\_=7 >MSN"*C(TW2UZZ
MN"M<<:,+M&=$H,D>2-QH+;"RV$&[6NM,7GN1T/'79VX4EY12RDP:/50/9K\.
ML]%R6])!5?W$F3TJI@JXC0\%U#1XRG#^GUL4JSU0*0\M^)*!/S!1D_.>[#E>
M'XR6[\I_C16H(?IU:^9W=A'S0X!^-'#!4A5IS%&!2W"] ;W=$YO /3I8Q*B"
M/?/.\&R93@"^:[[E]I]G?3,P503@SMR&(-=MK#G']T ,0Z[\'NBS'O$ AE8O
M(.']7%%>GP"U_A;GB@,:S#S:)_1)7K4!CB6!T@:B:=2T.D)_,2N"=G4U!P]]
MT![Y>S@>I\MC-D?03=MEBZ]^&-%3IS9Y?=D#-98>?U/_ M,XCVGY5"#EC@A)
MGZV/B7+C%7=X)&>_^&@:>ZO.>CE#H-SFE:PV/IXD-I^%ATW*]TRQ5;ZEZ136
M!WQH\LRT6]3;19<+EG])<$455(%CNXZ5YJKRB@5H!T[QP"H)A!V,<J2#2MHZ
ML#882T>(()VFOC$4)V6!5I/X:+&.3YXD.];!SB=*_6K,SVG/?$+1QUEY6;WG
M Y\A(PT(XERU)F007^PR($E_A38,)RIAKB,H+J,#NXE LB^O?)L@@KP8T7^"
M7#+B6N?UL((+!J!)M1^!*/EK,V)E='!64<D(/J%Z-.@?7&;UBRR;&;37KX>I
M*&4@F26@I $:)-5,=M-B"3JO.H01[]\'A)/IB!'X0?7.W<VT^5[3)<2Y02,)
M #,*.;JC[<S8#+)C>?PM Y4:93?T #I'\>OASA3/^5]CYGUY?2 U(NT%L>/]
M%>&KLQCYFX=,WV B>H.48T>T)P>[Q_5V=]&3TNDCU_O'Q3/=6"8*-\>^^T7M
M2Y&C?5VUP;8-#M98FJ2VN//JRTP#:\=2[.*O"E3WW/UE%Q*=Z1UOWQ[VXNV(
M>]V39>!&Y(W+K"BMZH(&./BOW?8 B:S!:3;19Y@7YLK3XA7N@:*V1/D4;(MQ
M.BR,D.H1"V@/4> IYA@<@!N8Z[IM]K6"N<2XD\R%Q6!B*R?CV#'>ZS+AZE.H
M\Q4!BV$>6$H_9":N)\?!EOSU<]\4'B-*O I?(/)%!1+LH# @:4S*FY\, #!5
M*'LF(MTP@IH-ZT2,8(X LG\PWQ1TY^Q4[X'^XLMP+9G1#RR5(Q:5I@U?Q%G
M7(J'=ONH@Y-2\,C@!I_1NWRI,BZ,<31Z&\H7'A9(! -> >P:8D'H#P'YA@#[
MV9,"V9)-'5D\,<-U9[*I)#L<TG;X+<K@1>ML7([/.@DAA=8<CFU:*TJVFX[V
MX+B1HX-2(JL2-0^^?(Z&\(_BR1N;&%IY]\YR7V^,WQJF'3$4MB/\M_(/5U\
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MUT.9 ;/9T,I"3YKU4'WKB>[&YE<<.X<C]7+'3F:ZV9V(^6Y[HJ'NR#]YTQA
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MPQUC70+CWH\C<H2\,:L&[MQ5 63]__V76S/FF\YKXD;#,&9=?[#F21[GAYC
MR1@_V0.M6[EQ%_[K4?7%[2U 8W2 *+;N(_1 DH$8A6:5;*[<YPNC3 MWI-MF
M#+_H_FG,5YM3G:K(=YM&P>A99? +N>LDBOGLW97,>(L06R;[:>V7AEI_(,N:
M^SJ/!&/>VIQ[@*&CH<-;\XM3=L$89=Q&GD8*7Q&7E7^9/Q_QGB_'JT$\D*",
M2I5<\HU+76*GJ^CFV<1WO&"56AIZ[Q.(B8.9+\BH<X+CK^K,"\BNT?T;6'"D
MI0;I"*6S^O>T"VTS-_HUN6;/R\.^AI0H.AB1%[__0>Q_47+ID:+;?49(:.2;
MR=7<U@%RX>4:;US'H^&K;8WK>B1--9?40ZF7F<^1F#:''R9/KC9X(%^-BSNY
M9F(\LZO/5P5HA<OGF/?,XU))RZ8!EKVTGUI!#9_;ACW*6L3[;IC?+ C5$4E1
M*)^8?L 2.TV(A[R" AI;7*D $E_D(.<L-_ %RS8YCR307+0W>0W N24<*4:F
M^F#NDZ:/H0K3MP-4F;S^%J(G.0YR+. +A=<*1/L][V:!'W0DR;HS^0V)#<-A
M."#+CQL@6+,29L 1<Q7R_@?;B@4?W -1SBZ%<+6)RN$PQ5Y?!L<"S)<F#D_*
M)BPJ3W-U:4E&H\Y\,A/Z5R^\<G1E\<MN-NQ:\16'+_S)SXZ12JY_?..,<B5]
M. XL6ZY4)5_480F\3Z<8 ?Z,D*,XU,_K)-MBASP##%B!"7>B]!TLJS%50.ON
M".;I9)?#/%U;JNK71.P^;.OHQC +QU9E8;(L]?EO8+_Q=8":!?8]5DU.) .1
M@3UL"4%^1W2]VT1!F.RU.;MD;Q8\K</?1M>(\IG]C2$J]]5C5O[KU^!<M4<)
MWC_&M1RDOA]Y4ZAEXOZ4"1:YCOR@AH/^N1XCIE=X*9!JX&;1J96C$VEHDFB&
M]/E&(F<Y5WM__RSN%9(R7N^$OU,8TR6^#%R^^")(JSGU_+TAU_(31JBQ<H6^
MRQ9+E@G3U4X=]H^B&H.G?[ER&*V%V.*Y*<G1!=;9"-YC<T0]Z@[P@G/I/(ZK
MP9SXBQF2*=#^GH.4M'2! ?196!>H?MB(HR*=_33HM^_!_&&L4Z33*<-TW>6Y
M)G-856-)+Z83T>RYP</SQ_9 +7,;/YFB0W.=NVF9ELHH6$LSRXT=JSOS *TU
MLP5%V3%\=8U6CW?)WKW^M"G">/?VD]MO1]5F4O!]0PV?_]WY!MM\)W#.)-Z]
MWDB.%BHR= \4 OU+ ,[QF$-<$]9D'M>094S'D; B*)U9\^,,J#!@C)@VF AQ
MG^D5JD'>7?=GSA0\_6I($%UO7;.$3%?DZ*F3B>T;<3T<B(H "Q,LH5P'@/"K
MXQNY$7V"&A#.I@KS3R%Q=#B)%^1<GMBPROWM6:BEQ)Q!DEY$0T;P(U_$$7]D
MWA7FFYQCWQCD[:/:]E/X)8?$P]8>0N]G<$,F=^V?#;_%/?S\_,5,3*'\\O1Z
MT+=>,8CH*X6HPG"Y#=)I0H!A10:RQ*O6R:31_&;SX(Q^)M[TDU=F[E/23%WI
M\O-05Y<4'^1:P4WY7"/\'5.WG'##FX^/'-02R__GBUN%.QSLN]!K#?MH=NI9
ML^'_D[X9K^ OJ3^E=B <N:8]T/9"E><._O^JO.$3L8; ??P!PRLHM=@#U4GG
MK6*?>7++CT!XZ6<G>6<OL<-//2..GN7!_Y]T!>$%"D#C+OHUC%)LA&B'Y.K$
M96V*@3N'F9.7>B#1+Y(PEV?ZAV.7,IYE?O*>Q_RY&$8I*OR'$NXQ5TQH,."?
M2*7:%ELS/]?5HZ(YVOPWE+1->99X+TQW^7,63:!ZO8?QR$E$1UM)6$5S1.WF
M9IRNUBH^RJ G6GS]:XB"]XQ_X'T2?';G\<9.\K/^O"2>VNIN4NK#P*#J, ^C
MN]>+:[P7PG:CGN(6K((#<>^]+Q3-WC8RNOU*NJ^ZK+HW9B R\D ,Z8!^E?.)
M$UIY7_= %:/W]!G9%$O-& ]1RLVO5AG+=#\U)+E0:2G]Y@PQX?%,<@%.1^:\
M6<2\C5LE7/JI6^4ISYBQ%F3X'FB$:(^5AX@M/V*NI+)03[[&IGUF7':4=78?
M^W;96NW57SA#N4&3WC5)])1S@R;]V[_NV5_JKGOY62L6.%MCZC5^#O[W&4?_
MK4# \_^CEN#_OH &PS'!O'+CX3 ;_]@*0@<R)/*?-_Q+89_JT60B^XK 1D_G
M,0[^S[H__;=N(;]*$=[C^'8!Q%]]6MQ_]6D9+/P?7.;_]/-_[EST,9PK,&#W
MR_9 KQ*9>;Q'ROOW0*XPR-PW!-F3?SD*QA]S$@#5=.;H]N0[;3[\$)@_)+_"
M?U*%OC7WM8LK*<F_I)%%W" (A-UN*G(?4>3_W%5H: ]T@?#3T@O,40<$@M#Y
M"W9V#^0 _WD6H'(@US"[Z(I=0VLI3XX<IO#3K3IDU?F_ HS/ER[I5!U9,K_V
M?8#P"@.<!&_(LC!\X3T0,X@Q1R)DEZL"D0S_Z%&L?#PD_:[U',DB:%CA36'D
MLX] $*E$YW9W 5^3>2=9CSXCLW[IQ4-:1TMON\S6?OSZI2EKV?5@J2]=%VK.
MX&%YRO>K_R(DN9+>C;B.GK=.>L*[6J!8]%5S]+HD;UG+K9KI,F*E?* =O5@N
M*9^<%=V8E H[5GK[ULTBEB"Q_X9D"Z['8PM07QF.7D OT'!YQ.M4922$CAF=
M?' W+:L="CB8A]4!>:3.NU@27"54UN<VL4J/2(>( "1O7\ZYEQG5\W:5O/3W
MR+2A+39'.T/B'%5PU_[,FP\89T-Y^99BZ#<LO]7=H@X: 6P7LQ09;9_PF;Q#
MA0"Y_/6A@+/3VYRL'F6CW17[R$27WO:W5<3F]G['?62'^VN+FH&A<QL*FO2G
M@X&LQ^$JRSJWM>2ZWZW57SC;J]EG>FJFP<6K?KJXQU.&WW)NVBY5E5?3)-$1
M?;=&Y %S&^'D/6Z?[\3=677I5\@)V9H:'/-"&MH[06E80!.[T<7:SW[#R^[7
M0K^ABN[D"85:&K*&J?=P4_%PE36%Q6)Z1!QS,L_<E)'%JET$$DF+FC//PMIY
M*I\5ST<^\\^ JAS^;,1L+Q:W-MX@L$3@@/I5](BJ%S.:JWN0E[N)"2$1E*U\
M!<Y!E"]I@I:VIH5,C]2:FZ&L!/9O8*;26#11\$<7NXZ<_OC+LQ6CY*UN;7GG
M!\W>-;]1UWX.AQNRZOF<.JO]OM":U?&[88$-TX[:BY'PZIQ GSB6]^TS1NQY
M1.=N93@K@"J>.NRVDK? ^RJ1Y=GQK!K2CE(6L/$DK[@7PU% #U,/"Q@?EK%+
M3-[94@0.1:N\:@POWS=MB'<=[%(=AHGW>C)XYF%=B\>9>Z"4G81LLZB>L(,K
ME/9S^LK;=_1?1NE.:3\A*@<+,BP0,Q" %D//0#H(HWGOE]A87K&E^!=$^ZA
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MLX_0_IR<,LG)9&1<_4$DLI]Q]RH?JGF(J;[JFI3=VG%RBS A2&63/GK^6>+
M1"FMX<*]+P[9MS/-]1T&)W0;4QP5!]KQ/E50NG%D?, 831)635!>S<7]B OL
M1H2ZY#,AHPS1YFZ.G6B+'@N;3%8$1MBXM&*5 ;+:#+TWY:H>67D&+=]G$CD?
MTV,][/0JW3.[@RS%)2G0NS8\1D3F7:/)/ZZ>,US<Y3W\S64$RXOC0&=+.'M8
MP[/+G'EWKFT]DY+D>Y9W]]$T^G!+?PQ8T7\4.G.]O.70]$JS5BJK9Q\[AC14
M&Y1:O>2WJ>/9;UB%M\^<=$BN#H6\P]S#%?P<+C+M".FTYU#=$=31MKX:R/P
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MO,U&(\9C=GFZJ&IB A)GT:OS_[#WYD%-;5_;8.YU0$! YAE41&0,,H.!7$5
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M)T-0EZ^%D+<+">>(7V0HK[JR$-^+72PPE<\P0U@I6G/JPD C])YA$;I%X/G
M:L/+LZ[7XC1X)TFR^^ZE,JLC$FMR*6.A)P<B-QGM[_,55KRDTY.B9(K&ZK[-
MNXVI.;EJ&'TAJ!O7<I"&"FU_P)_-+9E<CLQ#7=@GAWF?52"7&:/[J/;B)6;,
M_#NY2\FJ2N[-?^<_8&=PR;,'MM9!32Q;@J]7R91391CFZ [4EZ74,A TZY(:
M)-+]=-S?[LL=X>E4D62Y_15"WV[GIL),&I<+S&+L:QPZFGVE/AFZ-(UJ;4T_
MVYK&+F?2H&QQ/N8A,!,8N@3Z&:_V X7=4G%F,#/?,KH(!*5)YHJ N15?)CTS
M$Z!>30QFME\8+<'&I:'HR)M7NY"D5*?QZVBK*'$;VFOMF\/+S*G%;1ZK28P@
MGJ[R1"=P*H@GHV(>K)C-=IOSN8]H>^1[+O?Q(*:M9<Q7UUV_I;GSZ/"[LV[;
MJG%7*DRY)/Q.W))ZCX(-N?/(/-N0O%T>0'XE(GC50\$$"WW7\/AYFV!*BYJG
M29T+T**N[E9EJ*!M-E3LLD15'\DJU"*PRS9]J9W*M/(_!]M?I]_XTI0.YF6T
M%\*\3Q<%HA24 M,II^M$"_83QFM=DW3'*CVK-5XHZ2:;S7J%/%6U-? 7693G
M\D-Y+OZ3T\Z3$KN0*37:-1+=!G!(!02]$[!=9C.9M:AQ>9ZJ0%N.; ;_^,%5
M0CL!A:EH%;[TYDS9OSN<0YB^AA-L;8+[]W+5B;FPHW;Y=T,WIKG"//Z<-_C[
MK=G7?E&Q' ?ND8FM0J"-^3>GO-,(E=MC(01Z,%+?8O08-?=B(\2^SV@";B4O
MIJWHYF*+W7)38#1%.@XC1C(J/\KM;AJ?T3P LQ<N@:8:JJNUYMF-15Q^=<\#
MGN<(FI3@ID]1V[<XY>R3NY#:68KM+Y@B;4:-[OC4PJ:,<1.1VA]=&SFH+^A4
M=K"QTU7KFK+(H_$<:=GTRHPRVQ8\3?T\MOE5O.FE; T7%4<1ZWR36UQH9)Q
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MMHX&U6..\0HI_ZT9V':(2!U\]I'<)__8[^7FF+>16$I@9O?'WHFW'Z-<-*@
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M F2L):A#3C=")*@"D6[))F=$LQ LE?R 6QB;@H!MH_^"6#VBDO(?=[J=%F(
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M8@XS1RXV#\,2:/%V\B7GYQ+<SE_)5^$<X=R%S]4J-T'9$IH.X]<MI&9#.X7
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MR?K QXNI%L950&T6=ICH_85J[Z=P\O48/L=9VI=4\^]B+-DE0EY3HA<YU*+
M?[="!RXCF1/M<P>0U]>G(MG4U7<LR$.17"U]RQGL0._=%@M"[0.G+W!\6U@&
M[FVSAA/\8R^6H/N%XE@+HW23E:@+$5)])(4NR64O4N>@]#.*R6GK\QQ4DD$5
MS+R2;D6<IT"!2Z3'4 "%W",<5#<'< G-,M2O2!G$B6GP%/L")SJ1K79;)(0
MK:IG$?=O;K9_#$(8 [&A^ )]UEOAX'TO'Y0])M8&EJQSO<31*DOR -GU%? L
MOU?99Z^+KE6XKCL9WB!3H?*D::LI&QN7:O/.-F7A<8E;OI[?LG/BON"L8-:8
M187<N1W.QRCQ^5J2/[\.>\:6.+A\#ES[=/O3>7*[+XS<!W'+7+1M.4D?W](#
M1KC^@CKZ?#E2-5H71+%)G:0IT2:UT4'MLJ3P=3G"F0RV=3(-5/V=L-XJZX5W
M]IH@&%0&,PEH%8=RV'TO;_LC;#8&(>6Y)!++[H,1\ON7ODAC6N_5B(Y$/;'=
M&GFC);(KE\Z77>$J #EIK9($Y,0WOAF9CQ+I;*HWA@CD^0[\@RJU84WK;8LE
M$7>&V^_C]C+U*@K"&%[$Q&BMX'%%E<9XW,847.=(&:9L+@TFS[(<+J^!NF?K
M*<3]2_3H.]I=RPB[7C_!BUU,(KJ5V+Y+]1KS=YXZ>ZO8*WP@^*9L9?D(/M*I
M0!^A8W/?&^I4'N;8M[R6_/EEL>^KKV4.6;KU)Q>5V4?/EOTLLHS>'?T?$3&F
M,Q\M<-\.;8OYB2BR9[6KB/ GR%KHPPK\6=2D5O5/P5 @!GNGHD@:?6$HMV.]
M"RKS<^WVA).*47+( AC'@B9Z=:>T:M3%M)NUJHS [,V\1EE;9D))M @AD'6"
MA!) NP,21Y*B$=/IM/3N"KTZ@,JR2MU7$HD+4.N<4#F2R$;++C7M:EE,@GTU
MXMNI,H-\]P)C+545"W+%*UP9?'+'EW$#^R1RQP%E$>H$>Q98GC/R0'*?7^5<
M'HZMSO1W^([/=8X5T'2.\G0=MT:9';8'$BW<R<X*MAA6R</2B@5$0Z&:7W5M
M;+!SUVCF,$K:2S:]NF)?A%?%%D5+WRMKUQ:4L\ F\G6,'D$/M!X7K<.V6(?]
MMIAD'BLRO?6PZ,M)08D@64#?%MN#C(M RQ&O;HO=( 8NSTVAF:0ITE7AD+!O
MM+5K45"VJA2-?J(=(VR#TA;Y9LC5EOETIIU089VONPY>I*$.8.A /+'#4T1D
MC5P<7Z-09XP 6R1VB-3CGHG8Z"FNR$,--OPB3KK1 WX(^[]<_A5-("4@ZY%K
MBZ+%O AB>.;\J"'Z_,NYZIX8P@X MR#>3DHD29E DZ$[:%&G(Z(/@A/=LW]P
MM!/X1A$<J/5PJS$_^'OS"39$=GD6"GQ'+T<B=JGXC*VF8Y&)$68T@$\*)[;O
M$FW:>=$)=B4<&J<5G.VS&?J9&KC@2RY?;LH:-?6Z\[QTDF#'B9CA%A&C;G.F
MF9Z>S"Z#_K&QSB<,W,[;=GHO-8U'('N^![Y)V@AJ1HC_F3E:!G.3-->WOWC]
MM#\K$=,S-;J5VS:>J=>XQV]YB(K*8?:BX/:6J]^/?HRS1*OF?C$)%GZSOPJ$
M]BZYM3=)D\_>\O@/^TK9V3$MMRQ;Y]NQ5TAK(0I\]C(1<#.:%OG5!@X]Y7?%
M*$=AEZ\J2 /<60.-K_%1KN T9_8;"O(5O9_*3K>70<88;. 22;M,0J0K2['3
MC1]+..ZI<.](5K\[P^(;762&Q08CCZ1JMT3WS $NZRE;C6N0$N'O[']'U-1_
MHOOH]1.):T=:0!P; K&+B  2V.^VQ3I''%50"3=OPJA*7AXSEB7>9_Q>K5AH
M=R(?(U0XJ,3P;;']7YV6H^4X!E7/62'V?DLNG;RCW;(EWC*6;.,W-\[B"6ZZ
M2>E(!!3B:B6B+R''R=$U/YQ+6.IRTPAEZ([D9RZQRE3PO:/HAN*8/ +E:OG(
MES@MAQ"KRBJ69:-N;9RY2S[RUE%JIQ&HL\Y7L.LA 2@B$\H-!GQ(#^ G%NAQ
M1'FXW@(EJL=-HAA\M,F^_ZVLZ$(3,:X>*A9LZJLW_%/:T =WN6DDG-=7@&4@
MCAB?"S7H;ZE/EYU^OTRLIG</@GKN7;ADE3PA$UU+;4<^0(O=;(:0\3$=3=1X
MV&M<JT8?VZ[%[CQ."L2Z5<<L$-.-0HZDGVD>*^.(C1/^9-D4M59[7/,Y A1H
M7.C03GVU,K09I/L\2]F-PLMUI&;;OM+]R,VH#_!J?CV>IIA_L,SMDN/3F(HS
MKOC2ZJS[<3Y8"[SD4(G=)DW+VCCUY CEO52OR>MNFL[58'LK^=%IA^ "7.#6
M&#IMKG&1K]!C)T@3FH!*W.N@(\^<8"6H) 91E9=,6[4S6-2'N UIF?IU:=_I
ME5KF_?A%*\"]$[T?S.B2JXH+>PW=MZ2^/PJ+AE"Z:UYC&W![396(55L?FO(M
M$!6FR3CIV;I]>?<-,S"WVD.^T<S7 J*D[DZ5T5SCHXKD;]==GGZ0TCFX1R"B
M"6E_-I6OD(T"]5B<']%]Q#^T!,U70#/N>?#$D;=%C0PL<0=I=[(<^P#LCJ"(
M7K<P[LW(,.F28T\47BL,VO<D(<JBP]"U!KRHFV7K\JO"O=/69"1;(U6_SK2K
M!Q(?EI*Y'$78I>/O8]Y;"C&*",VPS;\9@O#RT'?0ZBZPH=FF[M)-.U;D5N67
M[>>K*?MR).5TMNFK6Z%Y*:'/OHYT6%W^@:1NBTU.+PQV09BH>=]DCC][?75I
M 3(5V+7536,;G&Z5P7,WO9LY;L]+@YHR<T/2J&3JXV8I8,6M3F7Q"6PMJZ0G
M_J7SE?'&6S,SY\)3Z,X3\YMKCB(PN@U2><=!_WFC51Z6=_H,)THHZ<V)8=$3
M:"1YPEY H9-9]@"A #)\AHR>%X^Y=S"WQ5(WUN5,[FT4SR[-[OY(L+TV"E?&
MO%[9*NM,EYY"Q!"IA$TV"=0-Y"M0N>9O/T8?_OW2R!5(@A=Z=?'U\IU<\<=P
M9T#I<F,S1RFV"D?S.3(%JQ"@4**@KV-<*F?.^'@'%:IRPA%_T#C9]-/Q67X+
M%(T+5><+LM14LLJCS!**XN(-/7W@WJ(5D0!3&%).!W1_!OEC[:;&R,Z*2SH.
MAN:NWDJVQED6N&R2OJ:;_'S96L55[80T?WVC6CNUA+:KQ7!?]5)-*0?=\"*4
M9+FG?=1=IP[7?);.U*CP>1 U5H@43JE<C]D6VRD$DWDWA /WTN/@Q%*14MA=
MU:I+,'W'D2ZD1+(*+I>?]ZOC*&:5+A>J3X1\KGUC9G'G[<MM,<R22FM6^=3,
M4D[W,'>8+<^_ YX3+;3(\3QJB)[RW0.DIQ*O&DV2YGM2X<=>!#&A\:W'\=MB
M;,L%$-W1E- ML4K9,)*?Y!\?@5ORSH!_.J+W@-=5^[ GW7EV/;EU'YR6MU8N
MFF5;A'\DC^$_6.T8S@\U/^GGGQ*[\/[@X6,1H6_P;ET.;JF2\AQS'5:%Z^L%
M%=<5%J;/:WF\S)Y5_:;++8^QX$HLM[==E],_#=>Z.UP,32KQ].,\Z1PIV_G9
M0OZ8JRQ-&;T501V8 W5(:]^)\P5(,?Y)3AM!&WE@\#%")P@I;1W7DT9GH56=
MJ_"X+N%?*O\9I[.D.3U,Z4:^!MU?V"_\3\(@CTCB?FWM^_=R= SF"W^)J^WB
M[3K:7U SZM;W@2<[]\QY#8M95,Q;?;GP05&(-2ETZ_^WP9YX&@F$*?&?!3)P
M/ N<&''Y+?CV\ALZQL$C.'SY:-/;!L>8@@M'^RT\*N?$8ZGO/^1[%:C0-)4]
M35Z5*"D?GKCN+8DG]X^6&:)7/PW*'7!Q+C-W*<JZRG$YR<[-#'"@6=S.5*T+
MO96;>?GE][]$&S(>/;-YZ5P$5K39)P64;R%55].BHA[#("EA9^!R?SU5+LI%
M3BD49^OX!^#_M;H6?J77]A_L)V( #C1$MV^+I4"5]>G724S_^9PNR"2)&S\6
M\>RGCUX[7<&-O<E0LBBM4$\TBFTV([)/NS.$.SGH^&8_]G]@D<W#X>OR?/,A
MN-GI>E-'+WS'INM$>(CN.C>RC?A=$SPA[$+MVQ9;>CE /T"<IR-KZ0^%IM$=
MLZ? +L.'F&TQ*7]N6+HMAQY#\ S!RJXX@E?1^S'W<&GP$Y'1288EP,9 PFL?
M_(.I$_7&V'OJ>?</I(>\SZ&J><6[/J;H6XHGMK%J'.*/=;\B7SW*4CPB7^$?
MU&]F@Y*R=*&:CY<YY6AD?KJV5!YA?KPW(NR&J=S4^%;#"=6X8F_)MX?<8CD1
MKW6&.L93W@:L5HQE8G2Z*1)6#@<WR,YA%9!/N7J<,I;2&H.C 04U&F)XF*7O
M7Q''P<9YW-3$I5&J-B>KJOAU4*L&IX?AX_"CK8FRF;@6'H(^.UHU[39J(I5J
M[>*#]!C1>OKMBUN:]RU""1C#4N(KG!)*3O,"\)H=OC#!8^+5]$="$V#@87%0
MH0K8L[ MEJB4SB)*+D,/:-<VCC8[^@.#%SF0-?%YZ0MX:X;Q[+1G;XP3YTO5
M#_FFUJ81Z;6T M-G*?#77Y[QJY0HWH94VVR-E^E:NN&A"IS)X .]=7F7BN.R
M"%+%%K3#10Y5VN+V[YLXP<8;8S?H?SYS<2PZ>-]BMC>SK-^1?6NT.BO4_*AU
M]@ER4LE>;U+M)5<UN.'QFS)<V42!Q1#ZR7^E(TXO+(BOH=E$YKMYZIH!BQ@O
ME 1Y/"."*VX/5L6:86#4N05-B$!+]IN2BZ:#/WK@WW6U'A\S-"SB:,=MK-/0
M[>4]5[=\R:R6;.,^O4^^P<(98B.JB_Z05"^2F,X\[>A!A!H8P4Y/1-?WI!E"
M4N?8NY^P?6[/M9,DPZ=YJO9VG4T1Z?%P-$OJ,0U:6Y8481=%.?M%V![2K$V4
MF[PP7/DDX$#8>&^0<V:PW:F[1.Z-%]-EOB>S]K"#1A<Q1T=*SHQ6)&925A6A
M,LJ\G_GVEW]AKD<$6X5GHPZ&U^UQ2=>Z>*+-IJ,R</>W,C?? ?-K:QOIE7X%
MI@N^><2*<+DTE-AMFS7+Z*AML79G(H;!TXKNF%./UEUJJO1"I=[D&VD_0*C8
MB*AK%LGA$3M@+V<Q_PQFOFL&/BDU"HVC;C_5J0$^_UMKQ;'4*-2_J<4RIG$D
MU8?#YP6IJM^;P$0:"I*0;&N/DO%U^7IV*".,+)]Q3^W91>1XC8DQ?W8 IFOI
M4CZV<#9IL^*J;O#3DH1795Z5>2E^#K*9)0=*)WK0=8%\I3]9@VM*O+!@8NTN
M:OOTG 1H=XF#ZAS<13 "5R(6?E1@2+($.X!UK0E[%*X%?6C"LY<UVK_D%KF5
MEF?,&:C1][T>%PBK:9J@#$,^,87ZB%/"SD)]P5/Z?":]VF@M<=[C9CTQ#5F7
MTTF!<&,XJYQ7W,W40,X/'Z"[X@JS\LF%.GVAZKNA: 6\P_?9"U/7ZIK&QMF6
MYX,^"^E""8(',-A#%!'1WF@3O*E[3L>VF'RS%"M=[>M+)U)00RW'\ FFG!*W
MW/W]L%=\_J:1W^N_#Q/KYKPO_^U1?[WE+LMUK]9E>-E:W<'D8]GG"B;LGA9J
M'JA^1@C9>^-0M$>E>WWWI7^+]S@F<.\+\@,0]UJOA1HVZ&9KY*O!WUFT#YJ]
M7S);TSXGO3?DAM9E_>6C9?=<B'4UCJZ?:J3]Y^#,I))S (^]R5=ZQ_A="1YG
MC^(>YT2N?OX7'W@.[&(AXW+GNA<X68?2[4;X]H9Q\L+C;P YOGZ XKVCXUU=
MW_)$W%T=6%^7ZS*J,'45^C&5*$&D&:VRB1CT]*)0RHPEL&B;!1DL:H?]N07<
MP^8WS2MO-@;CO=;;UP+='G7 U/WGL @)G"(^>MC\\9-OL*".^!N:Q,NBD$.A
MF/NFN<6"Y&VQ0%*J7K@A#2=+.#7T<TX)>O++4Z.#H VZ(]HDS?W)OWEA8(;E
M:-75$^_LM.J!BZNS5_S?9QM5 N.N*90J?_@^]V?L<JQP)'9 Q]\8#.[=3U/1
M3?-[<KTFWW^/3;.]:@EJ4KOU=#/B_C._)9\KBJ=.]%4#P7V0Y-Z 1UTNK\KM
M<DLB'[<%>NB<L0UIOX)]K_/6-3,:^[N-TN]@:#XI8IRAC]&RE^V "J&267*K
M_K)0*Y[1H</9$:V^+1: #^O(]@I;GM5\,V;]B!_^0V18!KV'POM.GZZOL'S'
ML]SH#98,GV@DK<U-^2_T\$UZ5J>!*&[LMEBLNW _%?16WS$,#Q6YT73N(O\P
M:1+*K#:9FR**3-?D%H1+?=*(FR;6A,^9G>0=QG<1=4B <QM2-+ET-.!,3/E.
M[.QCE?'EUKD$0*D-LF-P<S6'O9G:JA7D"/8*/QUL%Q25W"]C1\;33-,C.GH"
M7\ I*I42Z"$B7Y8A='S+4R=._0FD"__IN_R$C-P(,_T@LM[3\L:>\9)NCEL-
MZ&=.;.N<GDE8Y,8G1>><0$F/U[T5:0A=F9*$T%>89,$L-J9C>#/(.3[@85<7
M;YCR_(K.K0%M!;/3+H@R;WCG9X<"Y:-1%Z5M7!UHGXB'6T6+U=Y&JB=UZ]GC
M7,'?Q2?3P05.\M\?87VD?<N%?X%HCE)/*WQH-2(JB/TFQ'1;[!)0MDJK]/18
MMAI@CP-+FTIZX=D3;C_DC]FITM%W14IM"RP"LGE6XT3L'*A5MN;(,^5KC^$"
MA^BL*W/V[--GOZ'VM^9%$4N"FJR2.2=8D';(OA6ER)?==V]>0:LST4Q,]@0S
MJXI$SC.K%]G(F$#DO^/TH&TQGH4:3O37H3O=?YY<H/X!(MFXF&8[411!XG^F
M*X':W2JGOSUD$_>NC%]:5K&BO0J6,3%S<V_(J+ ^?#/U[<&0;(GLD_/XQ:23
M2D-=P]G2CMQ+)4D5\$;][J-7 YRR=&FA4]?E5'6="W:7V>KB$YWC/,C?O6!:
M5N4IKP=*5LO]0W].D^,9'P?";LC??Y3J.5+TH#_40S=$=Y-+&6%T#<CF:SF>
M/ M;LBD?^HS8P[\%NO.L^,< :C?JT>RQD>9(8+'[SFW?((3&B-.WF>N\TYT-
MD0WNS#LE(0'E2RH->5$[N1:EZ16>GL'W0E9EF;-,QO'C[A7NWT4$O?-,AJO@
M.?(F'3Q*Y,O-1%3PZ E"<8YI#4>*-9M3_O[+Y>EI$-N5[2LKG'1^(D(&&5"S
MLU7,XE.1E]YS$P.$1\K?,F8;:K;E14[Q/NGM3=1=>0&3-P9W5WSGX1VI@Q+#
ME/??W@YU#E$M'4Q=_1Q@+GYK)S7[4=/#U&=7CCGDU]QU0[3Z))$M[29=*ZQ,
MEJTHZ@'*MT>+O%)*\_W?NXZ6J0=UG'AB*>^VN_W_)RTO_UM^R]8AX?_2R_+#
M)$O(KU-O4+S]B\2MZT_X73^;ML4RS-*VQ6J$EMMB9 6(Y,LD/<%Y9._?_\^K
M VR1N,<$F00<#Q/]L5 *E)[/&UR%KJTW+@L-.+3NA(H5IO4#N,R+:=BW%G:!
M[XA-LK#%!++/>SER:]^3*OR<+] 8MTZP%DT=9TV>!JX_+_Q3JR_T5RLFL>Q1
MW^T/1S35TKK&OMQBL&[5EWBU>%K)%-A\=X[-C3-W>#53Y""77ZST-<#3UZ_P
M^MUH^TQ6L'\8?$0YH>V*<>9;UXM61@IN)D%.*>6VO_-#0AU*;#H*S&<CM/=8
M.:%?D0!+*JAMQH<A.R?I0<0DIEE<!'V*,;^85/4S>4X"GTIL0+(P?/MZ0%!*
M*<5[+9RI'PTAD"1!I% 6LA<<[#)3UXY?9PAU!Y[,GV$-*@9MS:5> ZC<Z<OB
M'7-Q=$BT!/\T4-9!BD/(#S?+ +QV%9=[9O&$$\76NDP/+_W:3Y_L85T?&I6V
M"BO(<Y]\EIG?WE7XS&&C#XVOTZ3#+H_"I-&76EI(=.IW[:YUN1]0>;"V-<+'
MK>/S ?/!78PIEW\I#_JRK)$8+_G/NJAC/;:3*?>#>HMO<ST\QLEQ[2P7Y!1D
M-U^O#WZ$I:*LKC;4%6C^_IQ:Y]UZC?5GUV_FQI1916BJ5!BT68&$IMAB^Z,6
MDV^'RI*[V9^/)QVE]D'&_^>J_B+ ^J5+JE,29$H@-S1!XO^HZO_?\F/^MZKZ
M*Q/??_Y]ZU)+)!.7()U-O_N+<G+XA>X=.)[V5H[P'[[=_^:(4PRA;=G:J=^I
M.4C!!>%?[O_5>.'_+C_F?SG/ZW<BC<ZVV%-WZN\\FC'BQD&@Y+\Z+_RW5J;_
MW]7@H+)_"/>)0"&#"?J(H*%FGB3P1JNN\,Y1/^"F[802EKQ3PAFT?#TTF:C(
M#^04,UH/ ^L/3.@)IF[H?03+^?N:YW/.#\,MV50Y;Q\?;WP>:S!Y?<Y5I,.5
MEB\-PBTR%5,QNU)")[M,W)64D'5X2/<OI03A7WY@\N/EJYB ^N_-@Q(Z+./A
M+C?N9'GX@HVN8^A-@ZX?ML(ED#3\Y\.PWP6<3W4"$]+.'6/]NE^F? UENJ_Z
MQQ:OWLH*M.@?SWWJY/CT<RK5, '8@69"^:I%VV)'[#C6P@%2]]P6.7K/[U?/
MOT9WTG^Z$(.)?(/6WWUE_J&.D"8;N0:@-T^2;S#1*DLX/-%,9!M)@\D]6V6=
MV.FYQ\RRA(C[-PUP[L!Z'.%$&!8;QA+%Y]EVDU?50'R>R7[[TL$[C6%S-EH_
MJ_MPN!#>8+HZ'$]DBR> A6JL3U88]^,5N0'/WE@K9;MV#''-O6H+W)9[;]O:
MV-SNGOWQEL_[2=Q"@HFLB<?/;FJQ+YNZVNF597YY=G)0/->I:]RU)IS<G>3B
MMZ=1D3U:0KS3,Y'I:$G<#YUI1_>EKVJ9_)>=J./^!(T6GLLR+@E>5L)]%GY7
MB<QQJ"EM.4*OPA!5;M2OF5H9E_2E2ZT@M'\4)^D4GB))H:>?2S$_#!,=QT">
M2'V<%6E$SQ[>+9MY8LJVV&[$(1O@%/<=>%JMB7\2S%/@-I9@<EOB"X@(6G&0
MK\88WZ06S&"X6RBVA)I26215\/:$XU@S$C9;)O>5.1IYASCE?+9L],=%]6M+
MHQ2K Q<G]+J=7V56.+<''K!,H"0SAC-?5+"-(S"7* =/D2$AENYENU=LDR*=
M\D.?WS$RS+HP5'#1RN<92_M4N5//9W-2I=_7JT<R"^ (C8*+ELKVUI^H</BR
M2]E9V*OH=O=V$9^E\^7-YDFK#SFGYI7:!P^"D6Q<6NMAX="L!GH?7JI#9$N1
M>\$$U[JG/EA+8*.T@NWM0^Q&R.<RK.ACM#=K^H;AX 8V.7N$%J-6:O(K[)=U
M"=]#)*)R$ <Q(^ ?"]PK@FPAW)Y5T>]_(6'!C<Q&)GCY%B_T!=%4V_W8'B9K
M)[B)X$D_7*!!<;L@76U;K"-=?+G,(;Z_V;KH2#TS,6>2[H<&M8@]][6Y:<3I
M'J$DDI-L"W)X*.\I[VF^!=#]>,$1"&0<*!FY4UJD7W8&F$U0I!>IV;F-U!M)
M@IJ,;/7=0&'1$3([]80K!U%'\5Q6@5BI9P9?_>I0XN78%^222K@Q?:N3#2S#
M#AKC=>4<J9)@[I,RR:S@X91;]?]^&KWVZ>L/-[*Y'[;;I/2'2OUG:PD'4W)\
MT>.,%*VD3O9?,\I^0+E3Q9ZS!+!L)YD\/>4BR!]&P/C*'&@G;C__X,=H \*Q
MB58#T*F=AE3@ZPW#[[)\G-EF\?75)OW,A,<$2&#Y(#M$I<VPL?CFN]'Z=]A;
ML/LGCE\53O3S16K@D>A,M9] 7D4K1W?3Z]7+6(-3(_.1'5!5O#B+*E+A(E6J
MS4#&ST) #!6CK@-HQ]'H^SVWQ; KB+W#X:<* AGWGCUB,WR&8.]A:AI!AO'E
M#7J4)2]$L=\BJ;&1+\?@YJ1SBX!-OKR[4&*(/;@'Q')S/O+A6T:=<_'J,%,W
M7V5PNF@I]U)M0S7M72M-V&6Q^3B\P@#9OM65D 1#2RVY*]YI@C[^25?#:W9&
MJR8[C;;Z@^D 52@U(0H.:6!F</4SSQ*OQXT0)$7O I^L_@N2%G!_!C/1CVGK
MRG@?F(^)+X@8O AL=I-2+6:+;FE"*DM3&DE[ZU'[&667O_IJ<#J](GB8R-D(
M6X50$.J7@!7/<RUQEO:B8 1>:4HR!^U=XWI8-:2]P,?BU3#)2ZDV5Y?<4B_"
ME\[2:[F%62H_J\U!M\I93?VX&Z:'SF8&>)5J)!4[>.0K:DO(+ZYE>;*-G3*7
M]&'!)[A#&<6ZS?1B)&")2IV312!$*V\AW ..L*LH1#92<<D9W].6RD[UBNKK
M]^]L0CXB.)._6BB2*X.5ANU#R<N))=/>F!SFJSH[T^+0LI:93[5H^_ U;ME:
M&!G,L!)D;HMA"M#M_1;X1EMP!R?9$>ACUFGU8KEH"-PR[-7INE?_-#GD<-H^
M-MG)53[TO&:U(WYSE0- VZ!U2NVH!.2.:*6IF2D0RB(EA/"1Q6IG(YK&8.*R
M_5'EV'M=HZ'>C-!*++-E1D@K[\.%8(,G-C>AU^KK:?NG+5>53,<W&R84(V]9
MAF$B=S9,N(UTU[:'XN A\A_MY1X]M=2_.?1>]5%5BNO#G4EK[ L],,\N??UB
MX71\)VMIG*Q\%E8^QK"-K<G"=)G9K;CFU[ABSL LQ[+,C[Q(VZ>>^7UPM>E-
MTDT0;KG7CD&V<DC5Q6?Y%DK"Y$+)&U[P-Q?&6LIU;:,N\,U%L'#GYZ"$)[$=
M1E"]R^H<Z:ZK)#B!%5$+[PT4=]P1'HWIE"B=JBH?LGI*^S=:N@9X\>!R_=.J
MW'&M@W\/Z8+K?"7M,T"10$1.\QF^VD_TV9Q>X83*D9A C9*7RTJM<D1E@M$H
MS"0;=0RW6#>\$3OL-;/3>8K97S%S[.DXMLM[T+Q>D("<)R.!BZBD.1DJ??Y9
MP]SO7 SB5 9[\_$&4N8<#TEPG0A?,^8?'S<\;\44AG/<TX4':!^:'/*D&^-^
M#LKAW=D7<].3ZM_9P3B;,5](9S["/)H9[$6^W(I0\AW/EG]+\ \=2V*Z370(
MM<$85CI3J>U>-A6 LJC)!(F7! O!<X0XB.TL/, Y4G./PC8Z$,*Q3MX07)^X
M]&;L"I"3B#B\O%[R]=[Y2%\=CI3]JZ^M\M\\<N^FA3'>9MZM=KGUO%'2M?M^
M\"C'7.+*2L ;N*7D,8=0RAF84]8-'Q7:+9/CULE4M/*@O2.E;U4KY_-;KN2V
MF#<YL2WTO#':_?)H377/T(=0>5V7C&VQ2/*>\12R'_:,/_:+"0 &FT>LN=X[
M101\DG&IT=J_;]WGG[=*@=8+1I($).?^;!'Y$T&%0^S4BXH:_ ,D+J@7<<0[
MQIG1Y$I/-![;/:X$P465X8^8NRVT;S&3R:OGO!PH/%+DME@\5K3SF<2EO^BU
M4*%,M,*VV%<-:K-H>#(:</"&@$>1'5#I27Q@5S7!!-P$DCW?<7#MZ,<9)6R/
MJ>!-&6_5];U@TJ9-DD^D/<!M"2W#*!E4!3E^6A8JCYL4Z*%K1R(R:YL^TG#]
M:R=ZD$ 8)(Z@9]2>"2KPS,'Q%0>5LAA](D: ZB1)+7)<9^IS)MQ4<)VO*X^
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M'M'G#)C#-0-UJH3_03>05JG )C=J]"=I_R<0TGYO,XX BV)#]V4L&,EH)]Z
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MMWU7Z 8$9_!W/N /T:(G?#W'#1>\X,OP$-%=I#_X?W-_$"YQ2 \C!)H>H_
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MDW:GP?==U.$B>X=BJ\S2.U,YU45V%&O_;I<2-FWKHZ[=#ZN-)78_O/9_\K(
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M)RV,!25?C8JY@+R'9W=H ,T-MF%*>P3U65*]W\,!5E>/V%[]ML!7J.GP&.W
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M<7YA*3A,RR;BHS&K#-X5"&C')5CLJZE],E3IAG 0\:O<,(D0T"W$V#7WZGL
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M](Y&5NQ^/%<GY>D\--&Q,)=[-B\R=#[,H'"@:^JG@R#Q3"V"G6XCNF&_0_!
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M]XD?1R__\6Q ]VO=!T_;OJK'1E>CS@Z3#G$$:P^#O(**P!SS"<KC^YQA3L.
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M1Z-!ND&4N&_34!V@0G*&Y#,2^?;%(=&CF3..7C88QH*RT<<OZ]M'2FC A7/
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MK\1''6.[%G[O5&S*4W3KH$R^?S_?A".N=]&Q4LSHU <6!9AB L?,B*VC=,'
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M%PXCE/D)U'"A)>= ?DBX:<$,-0D=U3YB',B<AH7;GZZK;02FFF,?^J/M;7*
M269\,I][^*P(1K<R83XO-'R^4^N1"):8/W=U;[9]LR#_Q#NKA_5'=;%&Z9OU
M]%[>_W009;S_7:72X[S#5T[._)PC0D-&2U#!A_.<A6]HC4\%U7'P"4TV(E%H
M (:RS)8W4?G1-$[[31OR0]!WI4/J$2:2.;NJ;-;ECT:W/AV,$\$4PRXMX'2&
MVPP?UQ0K)D:MDN!A"J->3;WK]H@E><Y-Y S533A-Z21)T9@N3L!9K"5:2BH8
MX@#U6YNL-:43N65E>+JJM;X@E_O7!,H:\]='P7T"#UYT_P33MS3E+VWW$C7W
MCL^J\7ZR*"GI4S8[LT/H5U/@AF3G)T<]'M9ZE(>L'M*V"")O22UZX7,2T](Z
M4E\X7!;@SBGP^G6HU/K$LUJEPI\)<C.U/EF.M9?OE7MPC2.#*T[G$&O)!B=M
MCQU,^P0-Q$LB&+_,JH?&=6O?V-W40PT3S9</8'B^@&JJ)-8LYU1S6\FT"QC)
M4T,OGA^VR)YV\$/^,B&1,7*\[V%$_K6@G<P[!ON:;O]QVE*8C>]PAU &D89N
M1BS=9$5O,##39S/1<$RO+X=XL^UX9#G_Q'"C0)-Q:!P3ZNOL*-3-Z)?"A':U
M5GQT_N5>P\G5\*"[9_6&)BG]Z-_":?4)!&L/WFXPDNL&#@4^!LM^*YHQ3&J7
MQO[6/&AP,9N$/W!GIEJ7<:U8!".LJ3S7U065I\\\M:00XGT:>/K'WLY)2!U?
M:FJ^E%KVS4,\YQ58F-X08])"(1A=D-+NS0V:G[7PL'BEO;@TCU(\9NZ8ZWLQ
MY\E<J4V UX+ET^P81N/L&Z"A)>%([Z&1WY^5[)KSH1@RN)5Z^WWOIY^>P*:9
MUH3BZ-=(!!/\>PK7D09D^#430@0/<)(]CR6"'FL%-X(W_O1UCDRZ>T:U*?\@
M*C)FL\7=*=:NW^_IU;9FZZ(%U1 9BGXNV" AZ%O(G80T9%AT(DT2BX]B(R3?
M@\'=HP=!>_\<V^<#<9^B%2-P2HW >?*-:.JTS\2+QP1JQ-BE#UU7ZOQ"4>T0
M<<P6(J#>.@LE%#Y$RB@ U.=MPW<<;5>9GZX_\O%K;3D8?!Q\]>A&?O>4+$0L
MTN>X_O9V@[N$XMC@Q&/>"G$OBGP!LS1KQ=!J3.&*)\==71IX6XDW<EHOW5BE
M!MWY"GB<NPG$LYV.LXMCV6+=U$R;/2A%[ 6PEV7^M3H>H1SI^4.YNKL@,I(2
M$-$Z._*XF/RJ)E(QUG_!LKVZ)G+]:VW58F%36=T*:C NVLDL2X][=>WJ2)[L
M]@)FO:U+TI\B6(-"8(%S]P/?N>)M,X!XS=[JB+:AJX3Z,A3<6J=BT3Y1/_ZR
M[]4CRG&CNHKYK#K>J&O[5A\<NE=[..='I"!:;=OI+!U3$2RHW+)]/"A7>S__
M+P@7(3+T.W5"C%LO*,+:LX@WH<'NCL^>KJNF)MMH1K:K<;PZ$"E<VHZ4W$<+
MW^9]#Y2%LEZQ@?[E30#KM8.U!P4E=XS#/Z1ZM_^A__LB7L_0N1TW2GF.T(V5
M;/;US$AHB6 7D* !,5L#](EA15GJ6R##_:*N8C<A,_-ZW4@.V:]P6L*Q1$8=
MIB#N2WQ!PZ<_3"OT'@Y_:E(_YB^S2NJF@AJ4Y?U !C>5$[U\'(ITE:#<F#I.
MZT+*FEQ=X>.!'):D8C_PXO-(V=A7DX].J+N3=-I.XZ@$1\O'9*D50CL"[&6F
MU(8R_;U.CZSU2X&TD]E#1]\9KX%7H9O=%CP5P<+Z,TO$-C:$W').4-T GY X
M"MJ7OU^PV02J 26#45;,IN8;(6:3K!%KGU_5?P&=F,N'"I>*CEP;LP.OWJ""
M/0Y$U- :6G5\WO*<K_&:<FU/[V;7TSYXO<.S!4.=;[U)%<,,>[BDQ]GVAW-Y
M@1:MESIGAH-3DL4;;V3FZGAKOU$SN[G^0<."7:;-)N>[,[0"9U-3]L9_/I9G
MJKYT4.?!^2]!9,T #Z;3A/W$<-=1I(:@[D(^$ZH'T<+M\O$<>*<#"P&;Q.X'
M5B U!\?0YS[XA9?L!>]LF<[&FFVM__4,*CXJ.K8*S.@D25.Q3QIUP:7ITT/C
MLYAC9U$":_\/?KZ^'SX&]$F]*&YL&U-,4)2N/;JEX5!#3I]UC8=&BE;NE(/:
MK8>Z1CLVF0 (OIR]<#L3:!:*JP$9#H!8I@F4F80I<\"TVBRU78[O^2[NN;^7
M-V#:&!NE5BUH:STWYNNW&* X&MS\]$8L8W1]E*"_/'KGX;1?!%>QU8-,QP5\
M00/.)%#/ONN(D;. A(1T'*@UG6R"&I?M;7S'#XX&7DL\[\]&[+"6(#NK/0-*
MFMEJ3DSX+>P9*[#_N.Q\B?8(UHWCUG,PI>VN?X(]>/-BW?C'F0K/KM\K0T:.
M9%F?_9XI@AU.,53\M>[UL-$;]T,C$4&!28GERN\=<S4=:]1+$!/!\\=DZ%K?
M="X].U-F+TOH)FL'EMW]5.!Q]H#"MZYWE3FGRV^5J5IU]MF]T LQ<"R9J@ZK
MDIOTSC^#C#+($$KU/0/65E[B)UC?Z7N\Z GX)LVLK]B#.Y[O!I:$LD!FJY;=
MW:G!8V7.D;^3EZ,>9"HT)\V9"--TOQ&%VP_QMF!/0+B!X^N!XP"[9Z*?(?"=
M[$&KQ:^D!FPC,KG-K.HK8PZ \VCBGU\*#7)K_,%ZNE"IW?_*J+Y:WOQN9]_W
ME%Q-;N,;ZF[TR.NIMG+'DK-/7K<QG3282R8<:ZI<1>!EO>=2GDH4!>9:87RX
M2XE&;@LOK#^W\?P<J3$^=OMHIH9K>VQ)$+KNHCM9U3,FN].M6-M!VS'7,3[8
MTO6N:]RLXKZB<+S>=./Y<HJPDP:@5_Z8;J!UJK08HQ(A-!+!_KC0MJ<"[/7
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M\S8O&W/+W42P?53TQM3R"DB-6S =_^6(DH[_E+LH@G%/FZ %]M;:_Z"A__A
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MW>X7%#^<G\+NO=II]-'?'Q5*#O>\EMWX9+XUZO/Z4>%;$6R3C;H0>L8M_,T
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M13_!Z<);?=7K"+Z"!KNDG"<KI).V0A++,,FRH5UM%+<G[!J:OFWMAOF+FK)
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MMKHL,2N@;VLJL0[K:?T%GT0+4QT('2:(?5X'G;(C<:M7!(Y6AT"AC^SH/:0
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MKB6HGNZ/R:QR:M$6+3>/#!=(K<([A.G&]BHS+>C3QS' DU!)WVZN:<8<UDE
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M5@OB[1@Z^K?'E_(/=C75&>#N8ZT S-L+?>>;0O6?AIT-[P6O5.%!0>FG:O#
M4(X=;2@-WBN?_+C2_LV76;^TRK)TZC!U[GS$^7#,4<03,*ZG&8C>3/=0EM.
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M\X_\+WZPBA%'?/K*1*R8\G'98J[%=ZGA9=Z5:2->[Y84[X4#XL>J'5,^0(M
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M74H2\=WYC>LS1%*MP%J C4Q/ 6=0PK=UQ\\9]&;WT=O-/G_@*?,8*7:$RXV
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M948<1Z/<@+3JJC7C9^Y0\Q=K79.X+\'MJ(2\$\@>^;CBA45@Z\^]%_M\-_1
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M]*OF6HT9[9+2-_TJUUY*=17F!(IDG6X;CJA U:MJ:50]_D@>(2T]VN=K4LH
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M+A58]61=X[@@[G(#Z.]_$DD#7WB&KM_"+I7L2Y_M[)M%I"OXV1C-%+8EA A
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MDO_ Z,&SGDZ);2%7?AX4$FW!R@G/R3,K[9)UK+;UCO74_$.CSR;#JV*SZ]O
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MF+-_S<I%U 16BYYV""C;0#2RUN^$"4 _8<Y:0&2PE]C$>&U7EOB38B"K<ZF
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MGCSY Z$9E9-0,V?C#.CZ>/E)9$SH(R2W18C"[_$=O^'I5H#:5\YO +P"0-D
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M\CZ5/%O:TGA6&UAW?D#&D9],F7M(>7&K1IC4\GD/O0!'YI$@2S:XBR8/%#D
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MZ9T(J3(6AQX^L33<U13EIE6#<0F\6FI5<G)\T]]DHI<] !':DZA5I$L);%>
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MQI?%F)GH-_5+G@3 HB7;P_/W'X(#V5M0UFF5(9I=NBDH%"7=8XBT 4H9ASV
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MX73;,/@>CO%C?869 ,#Z":<2E(%1FF;J&88!T2[UA^DY %>+2'2E+Y.8D,/
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M<Y/OE&O3)(TTHD]LOQ[5'+SA+WTQV'<U[IK)6144/B/LRE:,R^2!:V_/Z;?
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M05A</'.;,>/&*"<PCR'#IA/D #OV*3@D!/:RO5\5+0%<BE97=4\E+D##D[N
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M!PF$G9],)/NC1^KZ6Z82M!_%:^8/(8'3;/Y!!%(^23XVCQ$M:$!46'1-!\Y
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MD+XHK2@ICM>[>ITXD:VB52ZOT4L--71\F'5V0W6ZUKZFLK/J<^XR6"0"<8U
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M%8K&W&L>S)/>^R'*&#[RYNJ1RD?&78]Y3AKBJFC.TM#$!2'?",+K06H'3FO
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M1_QEXS;&]V1@I]8R<&RT\%],Q]16 U<W9M#-(0D8>AE7)G;O&CJ_A*,X0F"
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M";1IG2R+.Y%-+-DR4)E8"5/FVMP@;:1\#1H!1-.RQ*F^_R!$&<*X7+X?<N<
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M[]V<X<W&S7DAB;UCXOO1>($SIB>Z6[W?3!V@K@8@39 #FN#[4R0RTVTN7@F
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MV1[7Z9\V-Z3DF)-%OA1(ROZ#"AC2)^YU8"@@/[GK2H1%34AO/1\4WNS7G$.
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M5=H3.829$.U?%>VNT*&<5!3]/^04TGPZK%T]&=RFD&9XA&*!7EZ"0P?E!!I
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M_9 G$R6NLY.Y+UI8J%.8H(WA0R4;V&_/%!U!I^E(0R2 3E=BVTSV<U.?UU#
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M#K.=<-C5<#OY%&BC2 ^>*L)^;WN &]4QC3U;A3%8())7K0:\3@/F=[HDN"H
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M/W^7T=-0]&WZBO1$:&UF1!W+]4&-Q<(-<- P[9+CXV6$3UPZ\G3?^:<(."+
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M+6.<;#NQ$N230AT9')P^7KL:%,3,$,,<N?C$]((3-$< D48L9*'$NH[AIGY
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M-ZQWTKKA2A-ZJU)6+%Q-S;*<G'Y[(:_N8?'K<BNEC+\:YN=I1UNI^*_F*U*
MB5#Y-Q%7\H 8.B+=[@HK(;%DJ9V8_%3RFR*X'HONFS\ZC?6,*=::*NR;)AA_
MMD<39@Q.?XF2^M)F<#-*SCG*('1$>_$;S/35#768!)EK[A#/?-GAE#Z\O* >
MNE2D_JCAH9."ZW/;4[FHC+!>[QS1MSWV[(QL%8,4KZFI.&"$,(RI(L\A[BY\
MW<<X#KS!R*6&8Z^=ELBD7YSJK8 1)38JS?6*Q!2F57?2G1/V[K];8N:$:%99
M]70Q.XU'41875X6.P8Y=8!1GOS]?J66RX\PMEAS#)<TG]P>Y"#+14A,B\<0_
M-ZH>25OF'Z64U4^7OVWN\5JBF?E'*"&9[E/7OVIZ)\Q/4QPFUVEOC;B+/"'A
M6'@@@&P34E9"BC--MDL5'&#N)=11,5'F0+.">1S,9&'5@-SPQ4AOOCAF#SJH
M!A3QFI)U+RBT9[N_EG.YO*I]Q?W&-N(0>":TB;%'&AQQ[2-/=I9Y^&KN41_L
M4K>[RS8,#I2J0.:HYWAX1F<'.M2L^!C:5UF6TIVA#X$C"^]8XJ)SMS:^ 'SE
M^,"IT&>[G"/#WCWX-B 15P4[B]3[_#8KNWJJRJQ%/=W>L<2^H&H4.E@JU-:=
MPK5\KL-8N-XEL(XLTDK%PN>N/2B4?YL#IA,NP[T.$!,W>!*77V0&M25V'5GB
MGYSN4 N(K44FUT9X>J^O1H\8MV5\"%!X&J:71FO%-U2LI@(_V*.@QSP"",I9
M3-1[+_E-7&Z@:.>4MD_G)$R5:!789B%ME'8":5K[&1EGYA9Q-MI80V)5_LJS
MC&7K\0T-*]ZIT1$AEB4"B"Q<%JO 2^=K^>/T")<24% NG 4EVR;B)%&'="*)
M^Y<5CN8[_Q51>$8J56?WZ[  XI*<A?3-=M]R@N3/Y*CPBNZPGW<%D%]5 #:)
M'K*#/TF0USNNO<J5.@J7&'MZ]&:*HI:/"^!5R*#M6^;\D;?#=TR7%V.19G.Q
M=;O[0\_4E]T(US??^-(,DK@A(:W^T2&3NRRWG7YWR1\V ,.GII8'^C1M='8G
MUMZIL21IP<P.I\-,LI<O5V"F+P<Z5I+EY#9'PK-"1^5 EP>L:9&[]7,R!0N&
MJ=MS?*5O<)V/E4LD'6>>Q&AJ>< "&(YJ4U4)F#?6%E=#UUW63BW51QZRE,]W
MA-?PGB,6GAKYK?QDSA+^I&W#[D>S8IB^':T*UXB1.&KAP%VN&B/(\E/O%[Z4
M-?0<!_Z"N2;M@1QYB_JB<(SX>-8_/Z&XW$V_H1J=2UU+6!_-P^X0SOD"\"?
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MW*G>I:KUY@;WPK=-1[20VLX]2]'[GB:M%&BI;5>6Q@9J=GL726P>)<:3%IY
MFQ<S\7\09N91J?B]NIF[T%Y';!4Q/N2K0_W3"B-E3V(3D=86=67Z5%D2_84
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M<Q:.948W>LSVI;$D^[SAVR9)"T1"6T5W)XI,;5M5Y!SR]Y(';*K"*I&U"67
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MB?:3;79$9/Z7<H[83S2])/1+K#K+L*N7)$!GGL)-JCBGM><&Y[]4_7FAN\C
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M+M:4/ 5_M#YQ'K0'HISCCEF<D#]BD7%^E&S.FYE<[#Y3=>X0M.X [@A7"^7
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M!]]X+ZW \\". W7JME#Q[_G3<=F31X[!G^58"=:<ND"4T;]V^&O;I=P+::8
MIX0G8H\7ZO1Z$1#V-6!]"2;/1HZP+],(P6U.->Y?.Y3IAW#45.F-GR]'!NOA
M311/^]W)+OW;]I;I7T@A:\93>H)/!8!:'BQX@#"?\OF/WZ=OT4[PU?PY1GP5
MIK^*N(K^D_.,O,ASU1OTF# *.7WWTR[D?@UWX1#!M)RQ?W$J#GV ;J6A\SM
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MPG>F%5I<BU'?3KK<WP.ILH59-[&=/5A1M!15,PDCQ&/@-TV0G5Q#^F0BC<?
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MXS:OM8T#5+QJE^=Z/SB*[7^!-N?UF<G <JLTXR38^2[;>7N@ R=X?5X!TO=
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ML>T:U;;QPK%(LT%O3H:\JO9?E?I],^3%$C+=$7P8\SLNRZ)K#Y32L8^.8VN
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M&\2T*L5G9EYI&\4=CU2YTH WK##*#AT;^<JM.F22??PA3"7F@08 4VAZZ(B
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M@>DTW!$@>RP:DIPR88B!H7V)Q\=V7(X.!"1ODN--U!5WFR$QH5;;)PGF<DU
M,E/H<;C'L+HMX"=N)/0VK!&"8[1]9 EBH"?M5E'1H04,M?\!O0X33SY"47&[
M9]#R[S+;*-W$6F;<EBV5A0UBB4O(TB.K,;DLN-"1#PU3#PI@ZU-"O[\3R#M-
M?HC_?SU]AK41\39R-2O#!.-"=.H@WVZ<YM.OGZO8_RCQ9I70^YZAZ):?OIN-
M#A7UJ?T4.$-K-'Y6^NUNFB19SONCJ_+5&Z]\)$*M:[2E4@NCBX">R$YV,/^"
MH5AC?$;?&?DHSPIY)\+4*EU$[-]=P@5@D'?X;T";_I 7-8FS@%Y16ZIS[W[]
MQM[?SK5>"98#[DUC[8BF642/IJ.V(!P(YKIW >^,7]:JG:+!%0U,LP.VG7,&
M3[O).]]4R*Z%^J 7C#;RGW@T>G:8CE+'*E:[,:-7=B0<: LV@-IFI63=$XS4
M8+%2>TPH?7SU^.F(SNS2MJ+B6QT546ZA1+<G(-YW;'/+Y+4AY-QC-O(EAKJ8
MB6__9V\[3]&<TR7VDW[ R)(A;-!R9",A*[01TY\L+*I[;_'S(!7<$%P,,OX,
M%_N/@?$PW"P$9Q.$"6Y7!]8Q-ZAI>:Y ;N8_P$Y!87-5U'2P"EC)=M4K2_!J
M47&M3&R?JRE).JP7<W3VK.$^.N=\@=5?KTA3G,,MP-=8OP-CE>Z7(BYI9M&9
M:^ZD  0T_9.OA$>U$UJ1.V=1C_#6]_2['[+\.L#TJ/X^IZCVDWW.4EFEM>.[
M/0$RM$MUXZ3UY'_'!QSD[4M])RN'/:6LBBH.O"VPY4@V(9P%L".?[B'716L%
ML)6].^U^Y9H"V(.;?7#.WDG\USN)P';N=[F/!(ZA4)BMFGJ."[4Q95&(/#TI
M 8QX$8\0RK6K([R_'0;(7*L?(\!7GX$NJ H4X(?Z;I^P@1? +O<B=W2 #5RB
MD#";D5_"X"K4]35L^'_<L66*2\7WAN"7E1FM A@_;Z\ -D&DMWYFDWF9-Z6X
M&C>V^&'7SS 9WP^_%<">D8\+8%-Y"CAUJ#?X5R'*AW!CA*;I%PQ)7)\5HQ<Y
MZ[#HVXL2D_IYA2!#,0Q<6?B5K;WQ$RO0Q==?76_"Y)2U)].W_[,)51SCX&DW
M&M--%@.O6>[83_P,TOM]CZ\FPN\B'?&+#Y# >?P<G)/+1@UNS3IPAH&IS,>X
M<7RSYNL"2GM#I$I\X_W8)0DMB3.H@VO?;'X=-4DHHC6M[2+O-6P8:DPC5/D%
M3*-#*S;:8QJC".L028)A17VRK1 @^(QCR,5B9-.NK=SU2JR^?\;OF2I_7T,X
MD$<0U>=AE\MO:Q2''XU[^.\7R_ KVMOA')@ EK\E#)D[?OULNP V_HTVM,.6
M@HS?C>L\*8CRRY*27ZJ;;MAB!8<^[#1=RJAP7TE+,Y+V:*ECZCBLOJVT>%LA
M%E5Z!<+=;1=?GBTP>C=!S&9>55?)UAX^DQ-4_"8N++5.C1T?P60ZB2L'#76O
MV<>/U]20/'=M.5^%L?T3&FO"C2;Z\F27(-%QX-OO[.D-YUJ,/]:3C60Y9#YN
M+^DEP'A'ZR-KIZRZV^;RI^:.@NFNK5,F<(7A.DR9*5G"_W02DWIP%CS)@M_'
MABJD5V()2UNJ^-X7R*>W_HSGV@NEZUVN%6Z.L*];$3X'Z0JUJ'UN!09_ ?AV
MQZ#1 -VZI1H09674:W0']VOS\_&6-><R*S5/USR69F[ZM%=)'^Y7,*$^HMAE
M>;.$?9C:[- O] S.D'@8-Y&G"_AND(7\9P0677\(MMNQX?0GO/.[@WWH_8&S
M&,G589J$>2I%FZ?3]5!"CYY8^&?C8*A61=V@)N5!_ W]=(Y7^_UOX=G4Q2QX
MFQKU+C80V8<'#7,W]$3H,UC31N<E4G=,#-O>:'__(OAUN(:M7VZ0%\0G*_[N
M)J&5911X(?EBMD%<;QSZWU:9Z;NI!9C+LSZ1ZDZ8[A%#:(KS"#IG+SG9I%3@
M=(<>-%9YES96O:/[[#HQJ\&C 'NA]J:;E&[P3KS][;93AOGAON)%H:3EA\2[
MGRHR2+IQQYO)]_Q2*CUJM)5U&0'T7E>*3*K5(ZQQMMWA,Z1=6_8(9UK=0KAY
M_EAG?COR"ES6C?G>?GO1M8&]YT5 S^;?S/?1G@#^_M?O]H3:B-TWN75ST9!*
MUQ1/IW$^JGA_4WA\=&UDNOOX)J(R'OWAE0#V$-FL.$ %#8MX<IY,D3\@0VB$
MJFHC"HT0)+M/5*] L"E>(/L4K5RBBZT]B#_\^=[=08;T5[[6]*)BG_71<^,&
MIND$VZ?C)J>,]D;$.H9KYH?Z3!BT!@X;5>S 9[F]\&9SWB$\1Z@^@6FA.,%O
M^"X&PM.I2J:YDKP 0+XM-889^"2^[+9AO('(.9O#[,$^:]V;C]?N>F5\B<"Z
MQ/Y"*?XHVA"CD=)G\Z-EWK$53F("3X;+<<T96#AUN0,@9IF*3AW_K9 C@+'P
M.89D0U4-Z N+Y5!XYKAXTR]B7Y>=)0X/6_=Y>)8KBJK+-_S9.Q%?Z29Q_Q5<
MUJ?!]1GII:>T4_9!@PO[$F_RWYA5'7^THC/1>['6<SO45WI'OS#5]2QK;9H5
MA7GEE*W<;2]N>%M"Q3-7VUK7HOAYJ;VBHLN +B;@YN B:\56]GZE[T?\?!(D
M]A,WB#!7(C2)@,O6CS\U4K#*+-2<L0#VHC.X@QV^E)"S4=$!;-&<#6XZ93"[
MG???[W01<230B\,XN4O6SAYLPP=+!C9Q4U_18A%X*81W8U2ASTE>+OO3 !ZX
MGKLNOV@I@$4R,O%PY!7R7#C3@;[V+YRE2&=(8I"T-0G*W7K]8GV;7Z?'G4$U
M0'7 I7(E8*"B!EFR2% >J9U9-?:+4AG(3F:*NTD_HI3R251T[GSF4OA&Q=((
MJ%W$DT4)%R[1;<GZX7$56R=QQKA1@GR*+T=]S_,NE'B4_1K=*FR#TOSX=%@E
MI8L(>GI"8X!V'Q_=I]+6^D0 "\4XV#T%ZB&M+M"-L\,OPB\V3J&:&(/H>_AV
M!YY<.),_2(>GJRNV3YHPT@2P/5_%@V2D,HO;NDASF&CH$%J=\1DOA0P_1K"E
M%'DT<24)=0YLW3><[X_HS+/D?]K*\=IK\I%A=28U3-&I'#WXP5M6I>KBJF<L
MAC9E>L,>I)ZUW7/01$%*7$SIML\KO3,WJH,;CUPGINW\>B:_:>++R]J"7QTO
M/I6_[A>0AUFWCGITSD27'WTBO](TEQQ0V3<9OT9=;[6HMU/RK-;QY9?R'PM@
M,4;R:P3 D: (S0M@/Z$_@3>7#-"+R'2<%L8FJ<1("M.XU-NYV4"*\.FL^=NT
MD5JUBE.;^C#:V&CJHE8]8>)OL'D.&65F-BZ? 1]"SU9R_A:"^+W0G%)$,;)]
MA&<"6#8DS1,%VO\PN8>U7"+,R2Z9IW6K2;9R3V,]VXT=63L (\UD)(4ATVW]
M&'2CL;ZYC%\EG 9O,N=/E7 -[)US%1E1N22,+0WJ%3IKW5$C?O%K(E2/B?X:
M#AWX1 *=/847C(!>&F-,6[9#P@&6B[E/KMMQ^?3^3OR]UBZT4C7KM$9Y<(71
M?4_/SB[_C#=?+MS^8E\>U9 (=AOH^C,4W3-(.Q?:9?,\>D-"/:I"SU1?2% 8
M\Z[V_'NZ3.EM+ZW@*A(1R5KCGVDTC*^\2SQ#SKO;-TG* QHB;_!#3] ^-O>S
MM ^T^QSO!5H37(\_JVDRK@NN^CP56_IT)O+*<?J9@G.>9(<E*J@]R)-SYC2V
M\4GQ*%#;G">'[^TTR^3:^W^V(M^CJ&!]W^I_?:U]#NRHCIR:3F2;FZFKIS%Z
M=^]/8$^%UZ\NJ+/-[ZYCS6M:A7LM)0[>I<V%9YOTN#1VY<YF<CKXC[M/"27Z
M17XM/@0UY\!"4"R 6Q5,/YPN;MC7JBBE>P^SI.$4_:<-GJUY:@.Z6Y&).O@>
M_'N<'GRD^UDYM\^H;J&*<+!5M'#9T+!5U! *XE,_-K-1/,6[D&@>,W?/L"K(
MI4&J;5/=T6:E<]CVPH5#=X/86_<8YR8ZTC["$">J,90OSDE=Q <F/6&&7[EJ
MWVPW^%L\A1*['GX)SAK7*ZP5GG"QE;PT4(T=-<C$#Y2\-WY=U4T! UG?#;7O
M6)^)D,7Z.%:-L!7IA]Y=*,SD.@QT!CUF^8=D7#AN&AIT?2$T,UO7_=7)P\)J
MLRU_S+Y<Q;/<RM_'NT]/8M\!=]+!-_[Q>Y^^]2*=R0FQ2?+I<RIR-<SZ/((<
MODY9J'_:X6K7]_W&M]I+Y(/FG!JD5LZ1+V1/*91(VJNCB<_J?*J=0+\ATZ/V
M93I\'6$0[_#)% MH)%B:7XJ3@H86=._2""W$C=/L83H$ X)K(76 FE$]CC5%
M6U<3[J$5?V?C[K,,).V>3W7;,JT-G4MZM$+184E/W&(T9%\T.^Q^>QR FHF8
M<\FIJWW=N%H8$)9:4]WP+M#?_UVT.6>JR?9V[4ADS;S_RE1SE**HYKLVCL*M
MPO.(U_(-+8?T8XVVWP-4=_P\ 1+/6R+?_VOO%.['T%@$)->_R-@3]9=&WN=.
M0C]>?64K)CZY)W-N&#.^MF"9Y/Q(Z8K43YA;')-A!U/\[P5*F*%R[[0Z'Z,U
MY38]Y1*',G-=2[3)C7<U*4<]=IX.M1ZD-,;XI))T1DQ3:L=OIGBIW1ZH"?4H
M4R:='SZ..4=Q+7V8BJ6UX%M/BHU[E1"#F%!/ZK".3VFMJ]1/P2;\,JO<.3EW
MN],A_U]K50,*B]'>(7X:-4S((XOFF=C;;"H3S]-:T!O#&48O2(_OH$ 7RA$0
MO0ZI/P70?[26N"#7;:39M^[6#"]'!4 --SD=ZQ\H>1NX<T5&>Q5&;7>1J:6H
M0@"IX#'2'*6T;B]9+J*:&O=EU2_Q>9&G[ %["2%+TCP^N!J5=0XY!HP^V$6G
ME$86 (I*[JR#2U*Y?8ND97!=GQ36\G2GR;5&ZU"VY;%+37Y6%^[W;[?[.^K=
M&'#8CK?#1Z. %3BH3>6K?H/"T-D,WI<(H4\]*]QW:P'L,X.ZK8>])H!]RD.-
MH]C&/%$![$RY@0!&.T@0P B#.PX\%^UT >RK]A*<9_Z!P#]$Z#>0YS?@Z57X
MQ7+AYVC&]P**.7[[926D=E08GV\"6"5. 'O5P.X2P,I=X/^7GQ0FKZPC4VAL
M1,%!(75^%S+^[]ILY__\.AUXYZ@_X]\2,_' 7>&7/P'XOC&,T%*=P9T0P.@X
M1P%L5)3G,8J:F^99.4"B0KM@SQ? _@Y<2A# $,5(YA@2<,/OFF_QAABJU.\?
M1H7K,7I!^*K#8O!^>2F ?>?!V2;E< 'L+2$+#S >XK^>P<NU^'*$7DSR@9 <
MDH2_3\5_] '?"V C6KE@7"Y/E@%E<P4PX_:!+>BV";YO&-#FBV&$_N2 ,1["
MB_QW!/]_$4$6?#V0*X<IH:'$]9'1J PKA>I_AEG627:CT/X5WX0Q_Z H=>5I
MK.F2*,)YB8^B"V 7G?/'X[O.MF1*I1>9%]?'KG;:#=Y'_ ZI/Q]KA?^,*?ZT
M.T?.Q$=OJ)X%MGK=]H%X^JY/246$BF)FMV5E1+%6=FAT3:2*V8,:C%O?5,"U
M@NK(-O?38<3(SOC\0W-^,W.V$@W5]2<"Y_L/NS^6:JG[;I0-4H\OX8X,A,^F
M=VS<O@[JZX=9>KQ8_GJ8TI!:5:TS]VZ;'-0_8!H;SY:?^'7CMB^;H1Y;'C98
MZIS#.CSXCO/N.7:_C'$I*>Q[C(A1+5-'Y\VM=L0:Z_"%$%]EE.R]\^EML79R
M[B@-[/7_9*.D_[Z1ZW_[1BYYWGU\;QP574*]QSBDS<^&%*+GJHE_V"BNIO"N
M44=W-A0^T1DRT"\: >IU5:#3Y5'<;+)6$9"VJU<7<]-Y,KXDXB-8OIM:T[XX
M[X)BXM-,N=2I$5!?:F,[DJN!%>L$8P%N\)@ QJRP,8U,S$WO1H9$DZ,341F4
MPUCDE,D&VFD:9SR+3+<92:Z)*@[;Z?P,E]R\ML.0>(G,,M1FFV4M:+: \:R&
MG]V8-.HS**M<+CFJ!RESDF<*S/A/$FDSY^Q4!RB&1K.3(\DK7X:4+'5GKOY<
MID-N3#H78^G1<(?N5<3.'4OJ)]0R5S$Q?UV*N=]/*W#5[6>NSOEA-:A)SD>^
MA;Q67CKRF16[*7\1(JX#WJ$^A>:RKII"!+XC D_^'^\K_5^V:UI\_7_3WBEH
M"<4K;K00P)HT47SKW_G.O<CO5N\DA YL"+E[I8E?X&XG#YV'KQW_7U[K)4$=
M&4*>C>;\S<:5+8UD"V#BPM":L8/SF%W( RN[9)X60QIKSL%+^44E#C1'$OGI
M-!O#MW&SV 9GU&0C;MJZM&@LF?SRX?+BG;ECN.;'7<_6QT\.G=!3SO^HM$Y6
MJK"*EB^ZQ%;2=R*Z:UKH@E'YM4]<-(CRAOX:C7\S"C]VU+AD^+TC& \N^\W0
MXI8RAV,?94GJ>#YY2'*Y=+Q5Q_M\L:.K+O:9XTTMW'5A"?\_UT5R/;0'>L,0
M05Y!'XBRV0/^NBB @6>P.G68A]O]<VD% IBH2 ;6D9-[B+%2;).=\"2YJW]N
MH8=D]W&E<W]>#.>LT=&FW/7RN%LO$=^,7V_$^58^8J/D/H+A=U\_ST.^ FZ4
MZCJ+/_JDG&-^<-4S(>7]0=<C#=H6YAC' 79B3:Z;,0O2?W.=O*\TUD'ZRG,=
M5WG-E%?-]<-JJ05.U[ZN(FST9'WR2E6OR5S_F#EE($RNX)^V*_YG+ZJ+A"QU
MF?^C%Q6E%2Z#-2U9_-9'O3L73M\0I]\*&,S0 (LBZV<QODR?=(,W#94CBVMH
M\=X:4\:?K9%'BT<&?+_9+RRYWGKF>*4C;7R'EA$76)&19@P?(*8.+K(6FCB6
M.6K,)IW!^C+M".=U9^_K!.J9-G44O1%X]J0PNUO]E,0C]^:5JZXRF47;IYU4
MS^I].<4:69=FIP\2 !_J[ AG>PSA"$S-,T5H\)0YPI\(9^9K9S_V[T@9=&O2
M^STLJ$#^37KE'&BU35>TBGJ'_6VTW)',"ZD).A#3:A9HCHD)[>''/LZX$=>D
M=-4+F9E:>,2K9,J\_V+L[?C@, XY;6#:'?)_/H*9T>:^,C,7-5I< AC>?9I5
M949H!VGABH?G0E8H8:.F$SPAT]_)Q?=J#6[$"ZN0.&Z<T,P8, CG1/')D'JD
M0=@_V#-C&I,;<6@E>O5,E".SYV1?0&ZZT=5N1Z:$Q] J$!FYM"55TY$0PPQL
M<'"81,!9_X:.'AF%$&QMGJPO)&[*]0F8Q6KPVZF+%0+8045.'*4[C3LPY_"B
M3$P/J0C6+/P;@C!-#G_,DP!50^L_[Y;>.*>!D@>+^JSV%Y'Z:\ [Z'U@SC?G
MYCO(E:B,-P46'D1=Q(.ZU/BZ2SZ2G1SP+*OI)*> +5WA6:P^UNKM6NW7-4JR
M,GFW@DQVK7T33U1YXT&\GZWBAVYPQPW*ZYLJU<8]_=(@[ORPS";Q_,-6OS-5
M$U%:I$X\#!O.O_<U$K]8)H =0H;@9SOGZ9#X^!9.,@IYD (WSS)5\[!6F>/L
M]+^:&\DTS=9SF-J)W-Q)=G)^CPJ:V#!QGB_I<=W]N*S_1]&PZSPDNL-%@-.<
M\_P<F_VX$92T*5)\S<8$#&.^1YV=;D7N6UB=RTW=W$3S EEJB8IC1O&O9>G%
M#7WBX76!#GK!$6TRXOEE"MKW0XO=GD4TWO>ILWJT.UY2=F&H1JS1\.:4M^Y%
MS;^'4J:_M.LSE%8#EVZDO;O7ZTY4NDBBB1T:7EG2":E4K1;#+!?ILI.V(PN8
MEJI3B.;)[>8O2.;6NBS[+@T%^**$Q:A]JI+EEM:,50>+@*1S8'(%YMJP$(4$
MF0W3$B,QGN[;Y8[)EML\M1@FQF2@"S!KT+CI#PY!G^??1;Z9<M2?/CZ72.3)
MNW%.@P7<6.A?=2T^ 9*-+M\/?,MJ)2N!JGUFG80^%V?4&/:D6E%:?-4$F?6\
M&YA.PP;6-DR\U7'^/=>^4$>3]MJZ$[NS:VEW8[)2;$:?^I/) EP_347)J\33
MG7;%^/6Q[>';K1DE-WHZ*B)B2).N+2NL6(OG\_.75KBZK^OZZ5S='+?-P74J
MZ3Q15:@,^U:OK>,NXT;Q@(M1.KZ5L6X'Y''\P'%2MNP 592BCA$_!Z3W&^VC
MJQ-O+H[<HT@#:KFIACLQNM97AEV>LZ7NM"9E1AZ9YIDF=NZ%-$9]9A]NT8-_
M;1[=:5#<=IK_C_/-^^;;@'I\\RL4X$%-;<*]B;R.5:+H!B9?<\MQQQK%1'SR
M2+^ OR.  >7DC$MO9UJIZ8J<U)P#[J% '/+0K\ 7S2_X<_F^=K?YX;*/6'H#
MIK^67*K.>@4\[.H-C97))&[HA6P-O8MPJE&V>$X-\8G[L+QIL3V:/@F !ZT5
M=6\, :.TL)DGLY> N*.:R'#[GHZ.L "YM59-S0W20)578)$YC0"XC<R(,^$\
MV?'%8JP.&'/S-@LOO39=N/ +6,$V]V]N;YK&_0(^T]-HYH8\;2]<M=Y#5[F
M2Z:F\#0EH$K)/\-B;WP+J&DG1P5\NF>:NUP)B1*Y2M!;JFKKUKPXYRY?")Y(
MYZW980X!M./^CLFE6<GMOA(E\73!]$6R_(4UQ<[V5-ROD0858/E)^?**2'3C
MBF]B>DIW;)5A1:A0&R W3,<0+DSJIAC5C+I81@7<T.!%##7B+)4IM!JT:0$L
ME<UVH6AN"F I(M A%&B78%A%G7DN?#L]@)Q_!(V.< KC\#M(-I,[\L"J(/IC
M?-/.ZD2JWP>_5UJJLHZUGM49I.+K(TT53B8/LZW<=%]\E+.T+J;5FVBF/G1J
MT/6T+K.R$+.P,JFP,G[S=*;>1[V6D[_*#"V*%6DG>4_$O'$[,7"QUER9'SKO
MY;W2LN):C4RA'!0Z(J'BBW++HK:(_"&,@!&H.[WA7 &-[C)Z>YST&*D$$4AE
MUCD4Z#0X0TN6]1SK/DW^:9&<NFM0ZN#U]#;6C@F7PIJVY V<7+%1ZF2[Y9C&
M''G#I27@/7!3A*>^ U*Y2,!=:B:/TP:DW[=1C:1*(J_\6X:X^1B3Y\>V(V2W
M>LQMDFJEP-^_OC_9.S>0BK4929*!;^3*1#B\\5=4_?E? :QAPGN@GC0U%.V1
M;86<>?[]XR,5+]* 7&ANG6LUPEZK18:_<\&W-7_M3>6-T@*3TL@QHJNLE5/U
MX:%4?Z_:Y@L';[P+<\K+K^V6MVJJ<Y!R<G,Z_P^KTO&,CKUAS,+-4L8PLNU3
MKY0";HSP##7(^&-AWP3"N@JDLHCTAG":C?I$MW\"R0^\-N(Q@25H)5_9=AB+
M?^^ZT(]MV[[\;'1'>?IH6/-V;JG- =P 7 ZG(HRG7C@_/?Y]T@MSO((FOPPR
MQFJ@#JU8$>\1P5L(![:DE%K_XX6R@&W:E+H&U->*EIU1\_B .<MX\6LW5ZLD
M,33E JYX]$)K!*T1?H+V&AE6[$%S[Z_:T+'=YV9"M'T8V/OD([APA:*MBX:"
MZG8\&JPL2JF*XDE7GS5JM<FW8DBLU;#6Z)N#D43].M&AL@ZO**.VC>]PKAZN
M%ZED(X+OU>5%<R7 YCZ"1#P\TT8##./^#AH/]MFH32'<$X!- T_6)YX6 <@>
M2:B+"I8<0S@5*J" !S,"6,RP5 KQ>=N71DIO-.EJ^@@R##VCO23R8@O41&7C
M0Z@*F#QF8R4[O(]PD!I!V.\'IM,[!S,,(;7^6NP%(<K'(>F.S9T8Y]XYA_L>
MM&%(YA1\HR,$R/^FL. ]/6,0;_#7=P&L4<X'[$ D<-K;I[G1^U)?A'8D+URU
MD5U3[_=L!SY2FGV+G39]?<%S3ZGKA-GR0;?UK''%THO?>S8O7#$OFN\D;'\I
M6;[0\CX_B5" ;T+S9$<\07>A#Y[!SYSDY$_P3K!"6=9PUF!:=S2)IS_56I>M
MQX6SC.YWGZX+",(D^+/-4WF6)+OZ%9_BUH97)X/!F^M3G?V/"7KG6W-/0M'8
M$T)M$2[<XVO(R\F*[J I]Q?AF]^@?;: B/-48RMR[QS6%> ]!.^\L?98F(IQ
M54)8L@A_$ YO\*0NS3WI+L4DT!:0W0"_?WVZ7%/A5L ;:ET_:GQ#WKMV@IS9
MMQ1NJ?O\E0U<(B-+-?NPG;Y&M;YNG=.F<9RF1_/=\8#Q&Q^C2E(\B&)^41@_
MFF'9X6!MY3.>3MX1TP-.'OU6WBH?[Y Q Y'6H:[%/LW4+^\KA6L30T91]T#C
M^&:CC:O(Z* ]G/O@H%#R9E*4P6SN;T)+H+K%0__C1HJ@*'0!MI'J*N#MY/W9
M;%_?Z<UZDS)D_]QA*T)&JY'X2AW1;G$^69L^MZ^U8..9T'J:N'MO5.\$6!P;
M*$,8JE.T>L1,5@:D'[//TSW++&Y4\?-UF,?.E%Y>UGC\CJCCY!$]JWVO7/<&
MR5/65RJ=/D7VN%&ZYB".^%U8A[YRBOHFW!Z<.5RK<]J__?N&D(WL^'F4(] \
MJJF]3VIVB>G3NDB6 L?[$[_]$>]RR@N\^V2MTS>5V0Z0L[ZBI:-$DY*8(Y(8
MLD].9'W+]\?-?B;.^0]7'CM^:$\MC^/5 >;K: %,1)YG!J!2A&QIQ/G"_^LK
M2@14I ? 4Q!Z57B:T>-5Y"Q.#?A8$E,5,9? 26O@*J"BBABAX_4;&]#TDX4%
MU(7;N)C)5]M=0XRQ#?D1>YO>2Y.6+K:J]ZNS^CQOYA$1=H<-$&JZI47+/59R
MWW^9NV8SUJX7/&8_&;91KCR1=1AXE/@H0-;=J>J8=]^(O,=A 4R>&( =<ZPV
M=$IP&;^+>NU"X$F/<UC\1D@'<W2  'A3YY%TO")V#T 1P-R> ULTHSO%5]ML
MX.RPQV4^6QYW?1XRA,3=2SV(T>)L0BZZPX%LR2)  .M?,&*C4FTFF:,LO%C9
MR=\FKE*KAE7UK(V'1ES&&V+6X_@V4PM# T-C&C^Z! F?YZ;F#A2$IBTL'!@[
M=BG;^VBVO/29/W0GY;MJ^0\K#HQ7VWD5)+AF6XQGG_N=J>35YQUYT[O!=-_M
MB?P.S]B:"I%_0]?'ZS8^Z19$Z[K3:?'A.IT8C.,;DTCMS?&::KW6O:7?([D.
MR'"WHCYJ)#IM;FL -3N^-$TS.A@4:::N 58#T2PTG2K%B!Y?"/A\*W$Z&Z'8
M@+GIW#EE&,=5\X 8SNV4B8N%4)+!R?-=&9.:24FJI()?\,7XQ4?P9[E];C-$
MCAD8ST5@/:>PBF1PFF8UF&LJX>P%XI^L%9-3/Z7WJYM,==L1&[*W[G5;,ET"
M'$.>3?R3P0X?-7AXJJK@UZ1[WMKXMU9Z5BZCA<;G1Y>>+ )@YEHB1F4FRVX?
M?#FJ1K<N#R43Z\8T:>#N8JR\;0[OUY/-HL_;UUT")H""4L)<9J6K[@G\0;)A
M!2H/"?@9S2!9WWAR4AP\F  0%Z?O0:I@>%^P##A8R;.=(..T5B'MT1;_KT%(
M&L[P;4UKTW. ?)<7GJSU9#J17_K UJ8L)F)J]%W70A5)[B2NV=T3O1"RRJ\W
M/+DOIWK6]\6ESTO7-YTW['SIXS=SQC)BDXK'&JR,2RLN?[*532^8%, 2,NB3
M=._VDNJ **/UH9$* ,F3DV6*;-QDMW-"IH1$]2_E!!@(; ^4V[3ETG!6;$8?
M6@9#_2WY*'/G38D!^=XZ0ED[A;=G*:F9C"EP^OQLU??\"KHJHBB@X,W?5FO&
M,^]7YH5JC#!#[$4]#5\?763\N:!D%D"\+XUD"K=SZ52$B@XBE@WW;FL+2O+?
M[\=Z'J3U*G#^,TZY];E=\0B],[A$;:B'&_S.C;,L'T?41<Y)PM7#/:40WO9D
M'R^@-GA85(P@=]RII5R'Z<DQ[A? 6IYSO5_=J#WN]6Q.A7NXMB# SRGA6ZCN
M:*HE2XNRH#?CF:/FB]NE+V1_5\L=$OIY709/-FT$$I,% G\?[U:K_6QS@%]!
M45B+%4JY3WTN-V+<W,;K7[_O?PSFTBA')DT,S'VG#1#6#8&! :OGWZ\DAFU6
M5(%%O[_=$?<+GHFZ5<0(@X9VD1N*3.J?-C!@9,.WEF?-UA[8.KAR",3WXXZ#
MX8V8]"!@*SNM0"4@$C+LR.M;D 3L*XA@;F!+SJE<F15@16:EKI[?^.U<9\X;
MCH&YZZY"AE=@A;/\&0(0B\G #.57;]DK=<;Q,_O<\6HZ/I51\2LTI]1PI:DR
MQ?L9]9'^28G/H[8A,X44X"E)31.A_VG#6VR86:?BC;:2UX3'.%IZI'JGX_[5
M8Z]QA*;WSBF>'K\.I[W":$FG(3,H5OP'U*C75JPQ?QLSK'[@;$YG3(-!RY,=
MJ4,8O L;?C?>CFU7F+IWSO!O%ED,'*05Y_D'O92ZK]BOT%8<5)V^;B!?2AKP
M/C;YK3)0RM0C->I&@55+34.]]O[J\+#7^]]I/?3,>MA4%>5TO,[-T;-!Q+7!
M<L!49^*N2\#YXOQ WVNR[=:626_SPZ[@S<6YFOC>0;, 8]"##HEI<HW?12@4
M7P1V"BN??.;<P#Q+5A='K<\GS6_)7,#]:U64H<&6:SN;]SXZ#WPL@*&2'<NA
M(-R:N\&3EU\=UO.$Q&X/1@*!2W:Y&TCN.6P"6,V-A,82S<AA]>#-08:L86NR
MN=VHT== :Y41VN[DP ,22!Z =-EN&3R#_7^;YN368HB#Q81T@[@5D]&0Q9Y3
MWF];7@<8S>_JU10DYD?5G[/$/:=^M*3)]#.*3WIFAZN.D53N3Z8&Z);Y>94N
M*]=5=:RZIP9<2^DHE"?9+2Y9UNNE=,@2K2Z,S'DLIUS\/'FSVF+ 9DSV^MW<
MCU(\N5Q(]/ZB%'C,+'TQZ)J1VAI^+V2-U: &;J4*8,H\TQ MTNVJP+;*2-+[
MB.*%W/UDYEJ/TXO@V<':"/-=]#V3(#2M_,C9UFQC*-"QM4PVD#<K] YW<$(*
M2(2TP#/#B^@!-U!'NY>OMUC80%Q9D&>G=2P&)@=Z@8T+,DT9QPY+20=B]X-!
M2P2E**M\A=$Y,,,@8<GP@7EF@V&\'EHNNKA4):U"?NOK2[L;X]6NA^KL>KUH
MON2=XN>Z#2,B"-O(B;IUPTK1J=8UJVN'=PZO108W!#2OE 7D%5C5NI9K99O:
MYQ@7G^\?KU:+'/=^V%WI*(")>GER(NVE6RT&Q)G(._BG!#IA-H$CI*?U N 7
MDT@R*,Z2+(AGC2B\@V](*6!_8X^DH4VB1Y0PG5OGFHI>^F]J/&W_8O+:S.]K
MF;C;L_%Z_<U]^9>NB4"BI[FJ/%=^*O)RMOFB=O_KA!>X(^Q40BXOFD6*-TJW
M(MPSQ4N8$5B.ZV%-::=&9#$HFDI%S_V8RXJQ;3E/?]7Y\,Y57)ZO^[@SN0?5
M<,7BI5LQ)?(.+0RLF?"RJ?NS'Q&L4* 2ZYYZ8)04X9DJ%#A6AU+%KJ=:V.N5
MS'CL4O:(50X[&/2SFIY?+BVE-&?1DWVE/5H=+;W(NBU;EF_JJSWBJZTFM:T>
MYA,^I+5S]_(N3E 7R<%2?.H_;&WZ9=!22-MW%9&29(2I81,K%?S;L-T\I=O]
MGX;)QJQRR3S:2+7XZVMC]N4H9=M;!I7/8R^%G646-0GW^H%PKT\@?A+JH_UO
M>>(-_4L]Z$7"(#FE:"T9H"XAT^HU)HU,,F]-Q)B>:I -'%V<Y%D+O8OXO,6.
MRWX!S(6]/[,!].QS5&BJ00U'FC4_CL83)WQ-2 ->Q^.,CNE3&H]0)!LL+7SI
M4WT?+=;'J@/B0[=T^-$G^HV6"]4KZ5[93L:EVJ/*SZ?ZIULNL]]6N,F[QGI6
M!I?#C7J7_R):>;C*W*4M'G_WDKQD.V\W\#BKDO?Z';X7B5_LP<MB?PT#S)>T
M>7)YBU !X.PS_G5+#*1?  PH#;587[2H7[^<I,B]!LH>K"%[),M4S4D\8@-K
MI]#%+CI;TC]59%70GF'ZVE7"]GS&-\XVQX3_%TX.1V?\C# %%)D'55(ZM1[$
M)M2O04>G/J2A#PF5XMR3N]SH?JNO;:.GKQH9[6MMJ&ZHKI(.B"QVR2FK"=3)
M>'T97WNLL3HX-D?3[LS) :?2IH*EO4U*K8[;'L3@=K:N1ZH;(^G4$]=V3:>,
M&Q7I<1W+]C)EHC;A!W5).TZ2-S!8_=K^,PU.<H'7L_W'LR*X/F5G1SV(KN=3
M U9)_G,]59UI>;5^9_YM#EZ9;GM@4EUH^O#CG)][E6YC[QX+0V^U.Q]20WM'
M'W?HC:9II5ZU]GIO];76_4E>\_4Z$=&J71O_4S:YGH_+'#U(KO4&(ZZQ)-6Z
MQ@A')_,@[[&W/((0"4B(AE=$+A(8S2-]1BE4980=\*F/<I0=/C!R"'MVG(Q3
MCH*TIN+.QEG[]D(B +^G>F,D _OKXO#GG<L]P"2O^?3^DIM7VI[-6:$<]?-L
M1288[8072"5H O],:A _*X QH6IF WP )8<X3%%_:XI46H@JQJ==W;)OKH[2
M"KJT;3?:?;IV?NZ[PDE#KH'J^:+7$=/_SOB/K]7J71B$Y'6\*S*_D:9>C T3
M7VZ:IU7>(1;U:K41)E=.6VY^NGV-+FIYL4FZ[^U8_8G)FWL_=%3N9,QT+%W9
MX)4O5!7G#)EE?[5QXJ=0]F"HG(O\OZ ]V)_8G$IF#VH *=XMJYC&.TW"G-GV
MH@*OE[]$)6:O%#ET3[7@I5:+%,J]/T1I](RV?._NOWY13'[^ VKV+D<4[ 4\
M(3%?;A@T:Z,KS, 86V;NAC1SIB5W7T0P7&A[XY=>&RZ;(O<M%+%=BYZ IYP
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M*:S6*&0#J@SV,Q0@:>SUL?76'ZTE**;-792Q*K8OG60$R?-0X^O5;(.RLJJ
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M%<_0 4_,9)EX>P</ZSL6(2HB[!.8@U_YD^ W@.(PCCC."<3E=SXLXNDX@_Y
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M:P.9*,5XS"Y\!!>6H3\:GW=LS@VMBC_.FM$<L[P'8] .M7>DLCKW%S0&%:B
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MT_9>53DL]P1C'T:(X>_C92Z*]V87.+MM#$SIQOV'1JFK8?=ONLG#^Z-^[95
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M   1              "  3#W  !C8FEO+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0
M   ( !EHJ51"NW5:7@H  /]_   5              "  0,' 0!C8FEO+3(P
M,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    "  9:*E4_K;#B> 7  "P>0$ %0
M            @ &4$0$ 8V)I;RTR,#(R,#,S,5]D968N>&UL4$L! A0#%
M  @ &6BI5*D ->?;20  >W\$ !4              ( !IRD! &-B:6\M,C R
M,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !EHJ507 Z4NV2L  &LZ P 5
M          "  ;5S 0!C8FEO+3(P,C(P,S,Q7W!R92YX;6Q02P$"% ,4
M"  9:*E4$A@#)#$(  !C-P  $               @ '!GP$ 8V)I;RUE>#,Q
M,5\V+FAT;5!+ 0(4 Q0    ( !EHJ539 H>"-P@  &HW   0
M  "  2"H 0!C8FEO+65X,S$R7SDN:'1M4$L! A0#%     @ &6BI5-O,E,#8
M!   S24  !               ( !A; ! &-B:6\M97@S,C%?-RYH=&U02P$"
M% ,4    "  9:*E4X)(>A]L$  #3)0  $               @ &+M0$ 8V)I
M;RUE>#,R,E\X+FAT;5!+ 0(4 Q0    ( !EHJ52CPM)D8EL& ).<!P 6
M          "  92Z 0!G>G5Q<'EP9#)G:FXP,# P,#$N:G!G4$L%!@     +
-  L R@(  "H6"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
